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In memory of my father.
Abstract
Previous observations had suggested that the reduction in glucagon-stimulated 
adenylyl cyclase activity that was elicited by challenge of hepatocytes with phorbol 12- 
myristate 13-acetate (PMA) may have been mediated by the action of protein kinase C.
In order to gain further insight into the nature of the protein kinase species which 
conferred such an inhibitory effect in these cells, I used a model system consisting of 
COS-7 cells transiently transfected so as to overexpress glucagon receptors. In these 
cells glucagon elicited a profound, dose-dependent, increase in the intracellular cAMP 
concentration with an EC50 of 1.8±0.4 nM glucagon. This value was comparable to 
those reported previously for the response observed in intact hepatocytes. In the 
transfected cells, levels of cAMP accumulation were maximal after approximately 
10 minutes of stimulation with glucagon and thereafter remained stably elevated. These 
studies were undertaken in the presence of the non-selective phosphodiesterase inhibitor, 
IBMX, which elicited an inhibition of >96% of total cAMP phosphodiesterase (PDE) 
activity in these cells.
Glucagon challenge of the transfected COS-7 cells failed to elicit a significant 
stimulation of IP3 production. However, in the presence of 0.3% (v/v) butan-l-oi, the 
hormone elicited an increase in the level of [^Hj-PtdOH, although not of [^Hl-PtdBut, 
suggesting that the hydrolysis of PtdCho by PEG, but not by PLD, was stimulated by 
glucagon in these cells.
Intriguingly, in contrast to previous observations made using hepatocytes, 
treatment with PMA did not inhibit the ability of glucagon to increase intracellular cAMP 
levels in these transfected cells. Furthermore, PMA-induced inhibition of the response 
was not conferred by varying the quantity of transfected DNA or by treating with the 
potent protein phosphatase inhibitor, okadaic acid. Nor was it observed following the 
co-transfection of the cells with cDNAs encoding various protein kinase C isoforms 
(PKC-a, PKC-(3II and PKC-e) or the PMA-activated G-protein receptor kinases, GRK2 
and GRK3.
A striking PMA-induced inhibition (51%) of the glucagon-stimulated cAMP 
accumulation was, however, observed in COS-7 cells which had been co-transfected 
with a cDNA encoding the novel diacyl glycerol/phorbol ester-stimulated protein kinase, 
protein kinase D (PKD). This PMA-induced inhibitory effect in these co-transfected 
COS-7 cells was dependent upon the catalytic activity of the kinase since PMA failed to 
elicit a reduction in glucagon-stimulated cAMP accumulation in COS-7 cells which had 
been co-transfected with the glucagon receptor and a kinase-inactive form of PKD. 
Moreover, the effect appeared to be directed at the level of cAMP synthesis rather than its
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degradation as studies of homogenate cAMP PDE activity showed no change in total 
PDE activity and IBMX was able to inhibit a similar fraction of the total activity. In the 
transfected cells, treatment with PMA did not inhibit either [l^^I]-glucagon binding or 
GTP-induced glucagon dissociation. Furthermore, the intracellular cAMP accumulation 
elicited by either cholera toxin or forskolin was not reduced by treatment with the phorbol 
ester.
No statistically significant PMA-induced reduction in the isoprenaline-stimulated 
cAMP accumulation was detectable in COS-7 cells transfected with PKD and either the 
PzAR or the I33AR. This is consistent with the possibility that, in the co-transfected COS 
cells in which the inhibitory effect is observed, PKD phosphorylates the glucagon 
receptor itself.
PKD transcripts were detected in RNA isolated from hepatocytes but not from 
COS-7 cells. Transcripts for GRK2 were present in hepatocytes but not in COS-7 cells, 
whilst transcripts for GRK3 were not found in either cell type. Immunoblotting studies 
indicated that PKC-a, PKC-pII and PKC-e were expressed both in hepatocytes and in 
COS-7 cells, although the level of PKC-piI appeared to be lower in the latter cell type.
Such studies also indicated that the levels of PKC-a, PKC-pll, PKC-e and PKC-^ 
in hepatocytes isolated from streptozotocin diabetic rats were 1 .4-2.0 fold higher than in 
hepatocytes obtained from healthy control animals. In contrast, the level of PKD-specific 
transcript in hepatocytes and adipose tissue appeared to be markedly reduced in diabetic 
rats, and was restored by insulin treatment. It is suggested that PKD may play a role in 
the regulation of glucagon-stimulated adenylate cyclase activity in vivo and that the loss, 
in the diabetic state, of such a regulatory mechanism might constitute an important factor 
in the pathogenesis of hyperglycaemia.
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CHAPTER 1 
Introduction
1.1. G-protein-coupled receptors
1.1.1. Structure
1.1.1.1. General features
Thi'ough electron microscopy imaging studies, the three-dimensional structure of 
the first membrane protein, namely the light-activated H+ translocator, bacteriorhodopsin, 
was deduced in 1975 (Henderson and Unwin, 1975). Intriguingly, the primary sequence 
of the first G-protein coupled receptor (GPCR) to be cloned, namely the P-adrenoceptor 
(pAR) showed seven similar hydrophobic stretches of amino acids (Dixon et al, 1986). 
Each of these stretches was of a length sufficient to form a single transmembrane a-helix, 
as deduced for the structure of bacteriorhodopsin. Thus it was by analogy with the 
transmembrane protein, bacteriorhodopsin, that the subsequent proposal of the likely 
structure and orientation of the purified and sequenced P-adrenoceptor, was formulated 
(Dixon et al, 1986).
By vii'tue of the widespread application of molecular cloning techniques, the 
nucleotide sequences of over 300 GPCRs have been elucidated. The subsequent 
comparison of their deduced amino acid sequences has revealed that, despite the diversity 
of the ligands which activate these receptors, the receptors themselves share a surprising 
degree of structural homology, both at the primaiy and tertiary level. Thus, all of these 
receptors contain seven domains of 22-28 predominantly hydrophobic amino acids, 
which are each postulated to form a-helices that span the plasma membrane and which 
ai*e connected by hydrophilic extracellulai’ and intracellulai' loops (Houslay, 1992). It is 
in the membrane-spanning regions that the majority of the amino acid sequence homology 
resides, with greater diversity in the hydrophilic regions. These regions extend out into 
the extracellular space at the amino-terminus and between helices 2-3, 4-5 and 6-7, 
whereas those hydrophilic loops which are located between helices 1-2, 3-4 and 5-6 
extend intracellulaily and the C-terminal tail is found at the cytosolic surface of the plasma 
membrane (figure 1.1). Such a tertiary structure was also indicated by a more recent low
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resolution projection map, obtained by two-dimensional electron crystallography, of 
bovine rhodopsin (Schertler et al, 1993). This also implied that while four of the helices 
are almost perpendicular to the membrane, the otlier three are tilted (Schertler et a l ,
1993).
Primary sequence data for various GPCRs has led to their further classification into 
three sub-families: the rhodopsin/p-adrenergic receptor sub-family, the 
secretin/vasointestinal peptide receptor (VIP) sub-family and the metabotropic glutamate 
(mGlu) receptor sub-family.
1.1,1,2. Ligand binding site structure
The rhodopsin/p-adrenergic receptor sub-family, which contains the majority of the 
GPCRs identified to date, has been the subject of the most extensive studies done 
concerning structure-function relationships. Owing to the difficulty in obtaining high- 
quality crystals for the stmctural determination of membrane proteins, however, there is a 
paucity of structural data relating to the tertiary stmcture of GPCRs. Therefore, computer 
moleculai’ modelling, based upon the three-dimensional structure of bacteriorhodopsin 
and the primary sequences of GPCRs, has been combined with biochemical, 
pharmacological and genetic analyses in order to identify the key structural elements of 
these receptors. An important obsei-vation was that the periodic distribution of 
hydrophobicity within the seven relatively hydrophobic regions was consistent with an 
a-helical conformation in all cases (Rees et al, 1989). Thus, the structure of 
bacteriorhodopsin has been used as a template ar ound which to orient the hydrophobic 
regions in the GPCRs (Strader et al, 1994). Such modelling has directed subsequent 
mutagenesis studies, leading to the identification of key residues in the pAR that form the 
ligand binding site. Thus, by the systematic mutagenesis of negatively charged residues, 
Asp^i3, which is located near to the extracellular end of the third transmembrane helix of 
the pAR, has been shown to constitute an important contact point for the basic amines in 
the agonist molecules (Strader et al, 1988). Although this ionic interaction is a major 
source of binding energy between the ligand and the receptor, however, it does not
appear to be critical for agonist activation of the pAR (Strader et al, 1988).
Subsequently, from analyses of the interactions of differing analogues of isoproterenol 
with mutant forms of the receptor, it was inferred that the catechol ring of the agonist 
interacts with Phe^^o transmembrane helix 6  (Strader et al, 1989). In addition, these 
studies indicated that the catechol hydroxyl groups of the agonist appear to form 
hydrogen bonds with the side chains of two Ser residues at positions 204 and 207 in 
transmembrane helix 5 (Strader et al, 1989). Thus it appears that the ligand binding site 
of the pAR is formed by a juxtaposition of amino acids residing in at least three helices, 
defining its specificity and affinity for agonists.
Many members of the rhodopsin/p-adrenergic sub-class of GPCRs interact with 
peptide ligands, which range from 3 to 40 amino acid residues in length. As discussed 
above, catecholamines and related biogenic amines bind primarily within the 
transmembrane domains of their receptors. However, as most peptide ligands are 
significantly larger than catecholamines, it might be envisaged that the former are less 
able to fully enter the helical core of the receptor. It is not surprising, therefore, that the 
binding of one such ligand, substance P, has been shown by site-directed mutagenesis of 
its receptor, the NKl neurokinin receptor, to be dependent upon residues located in both 
the extracellular and transmembrane regions of the receptor (Fong et al, 1992).
1,1.1.3. Residues which are involved in mediating the agonist-induced 
conformational change in GPCRs
The binding of agonist to a GPCR causes a confoimational change allowing the 
formation of an agonist-receptor-G protein complex with a low affinity for ligand 
(Gilman, 1987). It has been difficult, using mutagenesis techniques, to distinguish 
between residues which participate solely in the initial binding step and those which are 
involved in the subsequent conformational change. However, two amino acids in the 
NKl neurokinin receptor have been identified whose substitution leads to a complete loss 
of the ability of the receptor to mediate a signal transduction response but only a modest 
reduction in the binding affinity for agonists (Strader et a l , 1995). These two amino
acids, Glu78 in transmembrane helix 2 and Tyr^ OS in helix 5, therefore, appear- to be 
crucial for the receptor activation process rather than for ligand binding per se.
1.1.14. Identification of the G-protein coupling site
Site-directed mutagenesis studies of the pAR have indicated that regions of 
approximately 8 and 12 residues, located at the N- and C-terminal ends of the third 
intracellular loop, respectively, determine the specificity of interaction with G a subunits 
(O’Dowd et al, 1988; Kosugi et al, 1992; Baldwin, 1994). Thus, the reduction in 
length of this loop in the m3-muscarinic acetylcholine receptor, from 239 to 22 amino 
acids, did not appear* to affect the function of the receptor, provided that the charged 
residues near either end were preserved (Baldwin, 1994). Additional studies of the 
contribution made by the thir d intracellular* loop have included the transfection of Chinese 
hamster ovary cells with the cDNA which encodes the rat thyrotropin (TSH) receptor 
resulting in TSH-stimulated cAMP and Ins(l,4 ,5 )P3 responses (Kosugi et al, 1992). In 
this system it was found that the substitution of Ala'^ ^^ , which is located at the C-terminal 
end of the third intracellular loop of the receptor, results in the loss of TSH-stimulated 
formation of inositol phosphate but not that of cAMP (Kosugi et al, 1992).
It appears, in addition, that the C-teiminal tail of the GPCRs may also influence 
coupling. For example, in the pAR, this region contains a number of residues, including 
Thr384  ^Ser396^  Ser^oi and Ser^o?, whose phosphorylation by P-adrenergic receptor 
kinase (pARK) leads to an attenuation of the signalling by the receptor (Roth et al, 1991; 
Inglese et al, 1993; Fredericks et al, 1996). In addition, a highly conserved cysteine 
residue, that can be post-translationally modified by palmitoylation, is located in the C- 
terminal tail of a large number of receptors (O’Dowd et al, 1989; Baldwin, 1994). This 
is found approximately 12 amino acids from the end of helix 7 (O’Dowd et al, 1989; 
Baldwin, 1994). Mutation of this residue reduced coupling, implying that it is 
functionally important (O’Dowd et al, 1989). It is conceivable that the lipid moiety 
associated with this residue inserts into the bilayer allowing the formation of a small
fourth intracellular loop. This may be expected to engender a structural change which 
may enhance the interaction of the GPCR with its appropriate G-protein.
Significant differences exist in the structure of the G protein binding site between 
members of different GPCR sub-families. This is perhaps not too surprising, 
considering the range of G-protein a-subunits to which different GPCRs are able to 
couple. For instance, activation of G proteins by members of the metaboti'opic glutamate 
receptor sub-family appears to be determined by regions in the second intracellular loop 
(Pin et al, 1994) rather than in the third loop, which, as discussed above, appears to be 
an important determinant of G-protein coupling for the receptors of the rhodopsin/p- 
adrenergic sub-family. There is still, however, no clearly defined primary sequence 
motif that appeal's to determine the specificity of a particular GPCR for an individual G- 
protein. Indeed, the implied degeneracy in the structure of the G-protein coupling site 
might be envisaged to account for the ability of an individual receptor, when over­
expressed, to activate non-cognate additional G-proteins (Milligan et al, 1991; Chabre et 
al, 1992; Gudermann etal, 1992; Zhu etal,  1994).
1.1.2. Receptor-G-protein coupling
Activation of GPCRs by agonists such as light, odorants, hormones or 
neurotransmitters causes a conformational change that leads to their ability to couple to 
their cognate G-protein. The association of the receptor with a G protein was originally 
demonstrated using a number of different approaches. These included the reconstitution 
of Gs in plasma membranes isolated from cells deficient in adenylyl cyclase activity (Ross 
et al, 1978) and the agonist-induced apparent increase in receptor size as assessed by 
both radiation inactivation (Houslay et al, 1977) and gel filtration (Limbird et al, 1980). 
The activation process, which is now known to involve the replacement of GDP by GTP 
on the Ga subunit (Gilman, 1987), was shown in early studies to require the presence of 
divalent cations such as Mg2+ or Mn^+ (Pohl et al, 1971). This activation of Gg, by 
agonist-bound receptor, is considered to be a catalytic event, as the foimation of the 
receptor-Gg complex is transient (Levitzki, 1988). It was suggested that during this
encounter, the guanine nucleotide exchange is brought about by an “opening” of the GTP 
binding site i.e. a conformational change in the protein that allows the replacement of 
GDP with GTP (Cassel and Selinger, 1978). Support for this hypothesis was later 
gained from the demonstration, by a kinetic analysis of the (3AR system in turkey 
erythrocytes, that the Gg protein can, indeed, attain an open and a closed state (Braun et 
al, 1982). The GTP/GDP exchange and the activation cycle of the G a subunit are 
described in section 1.2 .1 ,
Although binding of GTP, or one of its non-hydrolysable analogues, by Gg, causes 
this protein to dissociate rapidly from the PAR (Limbird et al, 1980), a temporal 
amplification of around 100-fold is achieved owing to the relatively low GTPase activity 
of the G protein (Levitzki, 1988). Moreover, since the receptor-Gg interaction is 
transient, a single receptor can activate several Gg molecules within the lifetime of the 
ligand-bound (occupied) receptor, thus leading to a further tenfold amplification in the 
system (Levitzki, 1988). In the rhodopsin-transducin system the potential for such an 
amplification is even greater, with up to 300 molecules of cGMP phosphodiesterase 
becoming activated by activated rhodopsin within the first 500 milliseconds following a 
flash (Yee and Liebman, 1978; Fung and Stryer, 1980).
It is the case, generally, that the addition of GTP and related analogues decreases 
the affinity of binding of a hormone or neurotransmitter to specific receptors in isolated 
membrane preparations (Rodbell, 1980). One of the first receptors for which this was 
demonstrated was the glucagon receptor, where the binding of -glucagon was 
found to be markedly reduced by GTP (Rodbell et al, 1971c). Thus, it was suggested 
that, in the presence of GTP, the receptor-G protein complex has a lower affinity for 
ligand than the free receptor (Limbird et al, 1980). Following the occupation of the G 
protein by GTP, the ligand is released from the receptor, permitting the cycle to be re­
initiated (Limbird etal, 1980).
1.1.2.1. Conformational equilibrium of GPCRs
There is now evidence that GPCRs, even in their unoccupied state, elicit a 
significant basal level of signal transduction. For example, the activation of membrane 
adenylate cyclase by unoccupied transfected receptors has been demonstrated in NGl OS- 
15 cells expressing either the human p2 adrenoceptor (Adie and Milligan, 1994) or the 5- 
opioid receptor (Mullaney et al, 1996) and also in Chinese hamster ovary cells 
transfected so as to over-express the histamine H2 receptor (Smit et al, 1996). This 
phenomenon appears to relate to the abnormally high expression levels of GPCR in these 
transfected cells. Thus it has been postulated that GPCRs exist in an equilibrium between 
Ri, an inactive conformation that is unable to couple to G proteins, and R ,^ an active 
conformation which can couple (Mullaney et al, 1996). Ligand binding stabilises the R  ^
state. However, even in the absence of ligand, an increase in the concentration of 
GPCRs will lead to an increase in the number of unoccupied receptors which adopt the 
active conformation and lead to signal transduction. Studies using cell lines stably 
transfected with the P2AR have demonstrated this to be the case (Samama et al, 1993; 
Adie and Milligan, 1994).
According to the model, an agonist stabilises the active conformation, while an 
inverse agonist reduces the basal activity of the receptor by stabilising the inactive 
conformation of the receptor (Milligan et al, 1995a). It could be envisaged that an 
antagonist would not stabilise either conformation. Like agonists, inverse agonists may 
cover a range of efficacies, and may thus be termed “paitial inverse agonists”. For the 
P2AR, a rank order of inverse efficacy has been described of timolol > propranolol > 
alprenolol > pindolol (Chidiac et al, 1994).
1.1.2 2. Receptor-G-protein selectivity
Activation of multiple cellular signalling cascades is a frequent outcome of the 
exposure of cells to a single agonist. The mechanisms by which a single GPCR species 
may initiate more than one signalling cascade include (i) the ability of one receptor to 
couple to a number of G protein types and (ii) the capacity, described in sections 1.2.5 
and 1.2.6, of the a  and py functional subunits of a G-protein to regulate distinct effector
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enzymes. A laige number of studies have been reported to demonstrate the first of these 
mechanisms. Many of these studies, however, have involved the analysis of receptors 
that have been over-expressed following transfection of their cDNA, thus limiting the 
physiological implications of the data. It is clear from these and other studies, however, 
that certain GPCRs do have the intrinsic capacity for coupling to alternative G-protein 
types. For instance, the agonist occupation of the p-adrenoceptor leads, in turkey 
erythrocytes, to the activation of a phospholipase C, in addition to that of adenylyl 
cyclase (Rooney etal, 1991; Vaziri and Downes, 1992). While the activation of 
phospholipase C could, as discussed in section 1.2.6, result from the action of Gpy, it 
has since been demonstrated that antibodies directed against the C-terminus of G an, 
which is the Gaq-like G protein expressed by these cells (Maurice et al, 1993), 
abrogated the phospholipase C response without affecting the activation of adenylyl 
cyclase (James et al, 1994).
The ligand occupation of another GPCR, the glucagon receptor, has been shown, 
in hepatocytes, to lead not solely to a stimulation of adenylate cyclase, but also to the 
production of diacylglycerol (Bocckino et al, 1985; Pittner and Fain, 1991), an increase 
in inositol phosphates (Wakelam et al, 1986; Whipps et al, 1987) and a marked 
elevation of intracellular calcium (Charest et al, 1983; Mauger et al, 1985; Sistai’e et al, 
1985; Blackmore and Exton, 1986; Mine et al, 1988). It remains to be demonstrated, 
however, whether this apparent phospholipase C activation is mediated by Ggpy or by the 
coupling of the receptor to one of the members of the Gq family.
1.2. Guanine nucleotide-binding proteins
Since the early observation by Rodbell, Bimbaumer and colleagues that GTP is 
required for the hormonal activation of adenylyl cyclase (Rodbell et al, 1971a), it has 
become clear that guanine nucleotide-binding proteins (G proteins) mediate the regulation 
of a variety of other enzymes, ion channels (Bimbaumer et al, 1990b; Krapivinsky et 
al, 1995) and vesicular transport processes (Helms, 1995) by seven-transmembrane 
domain receptors which have been activated by hormones, neurotransmitters or sensory 
signals (Gilman, 1987; Bimbaumer et al, 1990a; Houslay, 1990). G proteins consist of 
three polypeptides, aixanged in two functional units: an a  subunit which binds and 
hydrolyses GTP, and by the nature of which the G proteins aie defined, and a py 
heterodimer which functions as a single unit (Sternweis, 1994). The heterotrimeric G 
proteins constitute pai t of a larger superfamily of proteins possessing GTPase activity 
that includes the small GTP-binding proteins such as Ras, Rho, Rab, Rap and Arf 
(Bokoch, 1993; Takai et al, 1995). Numerous heterotrimeric G protein monomers have 
been cloned in recent years, resulting in the identification of at least 20  different a, 5 
different p and 12 different y subunits (Hamm and Gilchrist, 1996). Although, in 
theory, the existence of such numbers of isoforms would permit the generation, by 
random association, of over a thousand different heterotrimeric G proteins there is 
evidence that the number of distinct G protein complexes is actually more limited, owing 
to preferential association of individual monomers (Pronin and Gautam, 1992). For 
example, while the Gpi subunit can form a dimer with either Gyi or Gy2, the Gp2 
subunit can interact only with Gyi (Pronin and Gautam, 1992; Schmidt et al, 1992).
This is likely to be at least partly due to the thiee-dimensional structural characteristics of 
the isoforms (Lee et al, 1995).
1,2.1. The G protein activation cycle
The activation state of the complex is determined by a GTPase cycle (Gilman, 
1987). Briefly, in the inactive state, GDP is bound to the G a subunit, and the
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heterotrimeric complex is stabilised. Agonist occupancy of the receptor, however, and 
the consequent adoption of an “open” confoimation by the Got subunit, cause a reduced 
affinity of the G protein subunit for GDP (Brandt and Ross, 1986). This nucleotide then 
dissociates and is replaced by GTP, since the concentration of GTP in cells is much 
higher than that of GDP (Gilman, 1987). The binding of GTP causes the Ga subunit to 
adopt its activated conformation, with two consequences: (1) the G-protein coupled 
receptor adopts a conformation with a lower affinity for its agonist, thus encouraging 
agonist dissociation and permitting the re-instigation of the cycle (Rodbell et al, 1971c; 
Rodbell et al, 1974; Limbird et al, 1980) and (2) each of the G protein functional units 
(a  and py) becomes free to activate target effectors (Gilman, 1987). This active state is 
maintained until the GTP is hydrolysed to GDP by the intrinsic GTPase activity of the 
Ga subunit, with the consequent re-association of the Ga subunit with the Gpy dimer.
In fact, while all Ga subunits possess the ability to hydrolyse GTP, the rate of this 
intrinsic activity varies between the G a subunit types (Carty et al, 1990).
1.2.2. Covalent modifications of G-proteins
The activation of G proteins can also be effected experimentally by non- 
hydrolysable GTP analogues such as GTPyS and Gpp[NH]p. The activation can, in 
addition, be effected by fiuoroaluminate (AIF4 ) (Gilman, 1987), which, together with 
GDP, forms a non-covalent complex that mimics GTP in the binding site of Ga 
(Antonny and Chabre, 1992). In addition, bacterial toxins, which covalently modify G a 
subunits by catalysing the transfer of the ADP-ribose moiety from NAD to Ga, can be 
used to alter the functioning of these G-proteins. Thus, cholera toxin, produced by 
Vibrio cholerae, ADP-ribosylates Gag on Argl®'^  which is located in the GTPase domain, 
causing the loss of its GTPase activity and the consequent constitutive activation of the G 
protein (Moss and Vaughan, 1977; Cassel and Pfeuffer, 1978; Gill and Meren, 1978; 
Gilman, 1987; Hamm and Gilchrist, 1996). In contrast, pertussis toxin, from Bordetella 
pertussis, by ADP-ribosylating Ga^-l and Gai-2 on Cys^^i and Cys^sz  ^respectively, at 
their extreme C-termini, causes the uncoupling of these proteins from their receptors,
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thereby preventing their activation (Katada and Ui, 1982b; Katada and Ui, 1982a;
Gilman, 1987).
The role of covalent modification of G proteins in disease is not, however, limited 
to the ADP-ribosylation reactions effected by these bacterial toxins. The observations 
that GOi can be phosphorylated in vitro by protein kinase C (Katada et al, 1985) and that 
Goti-2  is phosphorylated in intact hepatocytes in response to a number of agonists 
(Bushfield et al, 1990b), have been shown to have pathophysiological relevance. Thus 
the induction of diabetes in rats by streptozotocin is associated with the phosphorylation 
of Goti-2 and the consequent inactivation of this G protein subunit (Bushfield et al,
1990a). A similar phosphoiylation was observed in obese Zucker rats (Bushfield et al.
1990c). This modification has been shown to occur at the protein kinase C 
phosphorylation site (Morris et al, 1996) and is considered to be the principal change 
underlying the observed aberrant functioning of Gi in these animals (Houslay, 1994). 
Interestingly, in transgenic animals where the expression of Goq-2 was oblated solely in 
the liver, hyperglycaemia was evident (Moxham and Malbon, 1996). This indicates that 
Gai-2  is important in glucose homeostasis.
1.2.3. G protein subunit structure and lipid modification
The G protein a  subunits are a family of proteins of 39-52 kDa, which can be 
divided according to their amino acid sequences into four classes, named Gag, Gai, Gaq 
and G a i2-
Differential co- and post-translational processing occurs on these monomers, 
including myristoylation and palmitoylation (Wedegaertner et al, 1995). Thus those G 
protein a  subunits belonging to the Gi subfamily are co-translationally myristoylated at 
an amino-terminal glycine residue (Buss et al, 1987; Jones et al, 1990; Mumby et al, 
1990) and most are also palmitoylated at the cysteine residue nearest the amino terminus 
(McCallum et al, 1995; Wedegaertner et al, 1995). Such lipid modifications, like the 
association with Gpy, are believed to contribute to the membrane attachment of Ga 
(Milligan et al, 1995b). It has been suggested that the palmitoylation of Ga, which is
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known to be reversible, may, by changing the affinity of the subunit for the plasma 
membrane, modulate its signalling (Bigay et al, 1994; Grassie et al, 1994). It is 
interesting to note in this connection that agonist-induced activation of the p-adrenoceptor 
can alter the palmitoylation status of the stimulatory G-protein Gg (Degtyarev et al.
1993).
Crystallography, primaiily of Gat and Gai, has revealed that the G a subunit
I1
consists of two domains. The first is a GTPase domain composed of five a-helices 
surrounding a six-stranded P-sheet (Noel et al, 1993; Coleman et al, 1994; Lambright 
et al, 1994; Sondek et al, 1994; Mixen et al, 1995). This domain contains not only the 
binding site for the guanine nucleotide, but also the sites for the interaction with the 
receptors, effectors and the py heterodimer (Sondek et al, 1994). The second domain is 
entirely a-helical and is considered, on the basis of its structure, to function as a 
molecular “lid” that encloses the guanine nucleotide (Noel et al, 1993).
The approximately 36 kDa Gp subunit consists of an amino-terminal amphipathic 
a-helical region followed by seven repeating units of approximately 43 amino acids each, 
which are examples of the sequences known as WD motifs (Neer et al, 1994). Crystal 
structure analysis has shown that these seven WD repeats foim a “p propeller” 
comprising 7 p sheets (figure 1.2.) (Sondeketal,  1996).
The Gy subunits share less homology at the level of primary structure than their GP 
counterparts, which suggests that it may be these subunits which determine the functional 
specificity of the Gpy complexes. The y subunits aie only 6-9 kDa in size and have been 
shown to undergo isoprenylation at a carboxy-terminal cysteine residue that is part of the 
CAAX-COOH sequence (Kalman et al, 1995). This isoprenylation can take the form of 
either farnesylation or geranylgeranylation depending on the identity of the X residue. 
Thus it has been shown that a C15 farnesyl group is added to proteins in which a Ser or 
Met residue is found in this position, while proteins which end with a Leu residue 
undergo, instead, a modification with a C20 geranylgeranyl moiety (Kohl et a/., 1991; 
Seabra etal, 1991). Such isoprenylation appeal's to be necessary for the interaction of
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the Gy subunit with the lipid membrane, the Got subunit and also with effector molecules 
(Higgins and Casey, 1994).
1.2.4. Structural characteristics of the heterotrimer, and its interaction 
with receptors
The crystal structures of GotuPiyz (Wall et al, 1995) and GottPiYi (Lambright et 
al, 1996) suggest that the Gy subunit lies extended along one side of the p propeller with 
the G a subunit located on the opposing side. Extensive non-covalent interactions 
between the P and y subunits, including the formation by their a-helical amino termini of 
a coiled-coil, results in a tight association between these two units (figure 1.2 .)
(Garritsen et al, 1993; Sondek et al, 1996). The sites of lipid modification of the a  and 
y subunits are located on their amino- and carboxy-termini, respectively. Since these 
sites are both located on the same face of the complex, it has been postulated that the Upid 
moieties may serve to orientate the heterotrimer with respect to the plasma membrane 
surface (Lambright etal, 1996).
Synthetic peptides have been used previously to map the sites of interaction 
between the receptor, rhodopsin, and the G a subunit, transducin (Hamm et al, 1988). 
More recent studies, using the transducin-py subunit complex, have however, indicated 
that the receptor-G protein interaction is not mediated solely by the G a subunit, but also 
by Gpy interactions (Phillips and Cerione, 1992). Furthermore, there is now evidence, 
from peptide studies, that the carboxy-temiinal region of the Gy subunit is a significant 
determinant of the ability of the heterotrimer to couple to receptors (Kisselev et al,
1994).
1.2.5. Stimulation of effectors by G protein a  subunits
The initial demonstration that Gg is required for the hormonal stimulation of 
adenylyl cyclase under physiological conditions (Ross et al, 1978), was followed by the 
findings that the hormonal inhibition of adenylyl cyclase could be abolished by treating 
platelet membranes with pertussis toxin and that a subsequent restoration of the hormonal
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inhibition could be effected by reconstituting the membranes with purified pertussis toxin 
substrate (Katada et al, 1984a; Katada et al, 1984b). This protein is now termed Gi.
Much has been learned regarding the functions of individual G proteins since these 
discoveries. The four classes of G a subunits mentioned above are now known to 
stimulate a variety of effector molecules, including a number of second messenger 
enzymes and ionic channels (table 1.1). It is believed that the effector-binding region of 
Gag comprises the a  helices 2, 3 and 4 (Neer, 1995) and there is evidence from peptide 
studies which suggests that the specificity of the interaction may be conferred by the a4 
helix (Rarick et al, 1992).
1.2.6. Effector stimulation by Py heterodimers
For many years it was considered that the activation of effector molecules by G 
protein heterotrimers was attributable solely to the Ga subunit, and that the Py dimer 
functioned merely as a negative regulator. Although the py released from an activated 
heterotrimer can, indeed, deactivate the G a subunits of other G proteins by forming 
heterotrimers (Gilman, 1987), this paradigm was fundamentally changed in 1987 by the 
finding that the Py dimer could activate the muscarinic K+ channel (Logothetis et al,
1987). Subsequently, the py heterodimer has been shown to be a positive regulator of a 
large number of other effectors, including adenylyl cyclase II (Taussig et al, 1993; Chen 
et al, 1995b), phospholipase C-p2 and p3 (Camps et al, 1992; Smrcka and Sternweis,
1993; Murthy and Makhlouf, 1995; Stehnobittel et al, 1995), phospholipase A2 (PLA2)
(Jelsema and Axelrod, 1987; Kim et al, 1989), phosphoinositide 3-kinase (PB-kinase)
(Morris et al, 1995a; Zhang et al, 1995) and p-adrenergic receptor kinase (pARK) M
(Pitcher et a l , 1992b).
In addition, evidence is accruing which supports the ability of the Py dimer to 
mediate the activation of the mitogen-activated protein kinase (MAPK) pathways by Gi 
(and possibly Gq) -coupled receptors (Faure et al, 1994; Inglese et al, 1995; Coso et al,
1996; Sadoshima and Izumo, 1996). The mechanism of this activation is poorly defined, 
but may involve the Gpy-induced tyrosine phosphorylation of She, leading to an
15 is
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increased functional association between She, Grb2 and Sos (Touhara et al, 1995; Van 
Biesen et al, 1995; Sadoshima and Izumo, 1996). It has recently been proposed, on the 
basis of studies involving the expression of a dominant negative mutant form of PI 3- 
kinase gamma, that this enzyme mediates the activation of the tyrosine kinase by Gpy 
(Lopez-Ilasaca et al, 1997). The identity of the tyrosine kinase remains to be ascertained 
but it has been suggested that it may be the recently discovered protein tyrosine kinase, 
PYK2 (Lev et al, 1995). Such a mechanism is speculative and is unlikely to represent 
the only route by which this Gpy-induced She phosphorylation takes place, especially in 
view of the fact that PYK2 is expressed almost exclusively in the brain (Bourne, 1995). 
In fact, other tyrosine kinases such as Btk and Tsk have also been shown recently to be
py-stimulated (Tsukada. et al, 1994; Langhans-Raj asekaran etal, 1995). Finally, the 
MAPK pathway activation by GPy may occur via a more direct mechanism, as it has been 
demonstrated by yeast two-hybrid analysis, and by co-immunoprecipitation, that Py can 
interact with Raf, localising this Ser/Thr kinase to the plasma membrane (Pumiglia et al,
1995).
■I
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1.3. Adenylyl cyclases
1.3.1. Structural features
The diterpene forskolin has been shown to activate all forms of adenylyl cyclase 
through an interaction with the catalytic unit of this enzyme. Such a property was 
exploited to purify adenylyl cyclase to homogeneity through the use of a forskolin affinity 
resin, and led to the isolation of the full-length cDNA encoding the type I isoform 
(Kmpinski et al, 1989). Subsequently, the cDNAs encoding a number of other 
isoforms, types II-IX have been isolated by homology cloning under low-stringency 
conditions (Bakalyar and Reed, 1990; Feinstein etal, 1991; Gao and Gilman, 1991; 
Katsushika et al, 1992; Fremont et al, 1992; Yoshimura and Cooper, 1992; Cali et al, 
1994; Watson et al, 1994; Volkel et al, 1996). Based on sequence homology, the 
isoforms have been classified into three principal subfamilies: the type I-like group (types
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I, III and Vni), the type Il-like group (types H, IV and VII) and the type V-like group ■
(types V and VI) (Mens and Cooper, 1995). The more recently characterised type IX 
isoform has been ascribed to an independent sub-class on the basis of the degree of 
divergence of its sequence from the other members of the family (Fremont et al, 1996).
While aU adenylyl cyclases isolated to date appear to be expressed in neural tissue, 
many of the isoforms appear to exhibit region-specific expression within the nervous 
system. Thus, while the type III enzyme is expressed principally in the olfactory 
neuroepithelium (Bakalyar and Reed, 1990), the recently isolated type VII adenylyl 
cyclase is expressed in the retinal pigment epithelium (Volkel et al, 1996) and type IX is 
predominantly expressed in hippocampus, cerebellum and neocortex (Fremont et al.
1996).
Adenylyl cyclases are large transmembrane proteins of 1080-1248 amino acids
(Cooper et al, 1995). Interestingly, all the isoforms characterised to date exhibit the 
same inferred topology. This is proposed to consist of two regions, each comprising a 
transmembrane (Ml and M2) domain that crosses the plasma membrane six times and a
large cytoplasmic (Cl and C2) domain (Cooper etal, 1995; Whisnant etal, 1996;
Zhang et al, 1997). The regions containing the highest degree of homology between the 
isofoi*ms are the cytosolic domains, in contrast to the GPCRs where it is the 
transmembrane domains that are the most highly conserved regions (Zhang et al, 1997). 
The complex deduced double motif structure of adenylyl cyclases is reminiscent of that 
proposed for membrane transporters such as the P-glycoprotein and the cystic-fibrosis 
transmembrane conductance-regulator (CFTR) chloride channel (Riordan et al, 1989). 
There is, however, no evidence to date which suggests that the mammalian cyclases 
might also serve as either channels or transporters.
It is believed on the basis of sequence conservation and expression studies, that the 
Cl and C2 domains represent the catalytic regions (Tang and Gilman, 1995). Consistent 
with this is the observation that point mutations in these regions leads to a severe 
impairment of enzymatic activity and an increase in the for substrate (Tang et al,
1995). Furthermore, an interaction between these two cytosolic domains appears to be a 
pre-requisite for catalysis, since the independent expression of either of these domains, 
even in the additional presence of one of the transmembrane regions, is insufficient for 
the detection of significant enzymatic activity (Tang etal, 1991). However, the co­
expression of both a Cl and a C2 domain, tethered by a linker, permits regulated high- 
level catalytic activity (Tang and Gilman, 1995). It has been observed that within the Cl 
intracellular domain is a less conserved region named Clb (Taussig and Gilman, 1995). 
Although deletion of this region did not prevent the assembly of Cl with C2 to form a 
catalytic enzyme that responded to Gas and forskolin (Whisnant et al, 1996), point 
mutations in Clb did interfere with the activation of type I adenylyl cyclase by calmodulin 
(Wu etal,  1993).
The complex transmembrane nature of adenylyl cyclases has hitherto prevented the 
elucidation of the three-dimensional structure of these molecules. However, very 
recently, the C2 -catalytic region of the rat adenylyl cyclase type II has been crystallised in 
complex with forskolin (Zhang et al, 1997). Stmctural analysis of the complex, to a 
resolution of 2.7 Â, indicates that the catalytic region forms a dimer in which alpha
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helices and p-sheets are arranged in a wreath containing a central cleft (Zhang et al,
1997). It is in the hydrophobic pockets situated at either end of this cleft that forskolin 
appears to bind (Zhang et ai, 1997).
1.3.2. Regulation o f  adenylyl cyclases
All adenylyl cyclase sub-types that have been characterised are positively regulated 
by both forskolin and GTP-bound Gas and are inhibited by the adenosine analogues 
termed P-site inhibitors. Individual isoforms reveal differing regulatory effects by other 
means, including G-protein py complexes, calcium/calmodulin, PKC-mediated 
phosphorylation and intracellular calcium levels. These are shown in table 1.2.
The marked inhibition of type I adenylyl cyclase by G protein py subunits that was 
observed in SF9 cell membranes (Tang et al, 1991) was later shown, using highly 
purified proteins, to be due to a direct interaction of adenylyl cyclase with the py subunit 
complex (Taussig et al, 1993). Intriguingly, this inhibitory effect appeared to be specific 
for the type I isoform, with the demonstration of stimulatoiy effects elicited by py, 
paiticularly in the presence of Ga^, upon the type II (Tang and Gilman, 1995) and type 
IV (Gao and Gilman, 1991) isoforms.
It has also been shown that calcium has a stimulatory effect upon types I and VIII 
(Tang et al, 1991; Cali et al, 1994) but inhibits the activity of types V and VI (Ishikawa 
et al, 1992; Katsushika et al, 1992; Yoshimura and Cooper, 1992). Recently, it has 
been demonstrated that elevated calcium also inhibits type III adenylyl cyclase in vivo 
(Wayman et al, 1995), and that this is mediated by activation of the calmodulin (CaM)- 
dependent protein kinase II (Wei et al, 1996). This mechanism was deduced from the 
demonstration that not only is this isoform phosphoiylated in vivo when the intracellular 
Ca2+ concentration is increased, but that both the calcium-stimulated phosphorylation and 
the inhibition of adenylyl cyclase type III were abrogated by the site-directed mutagenesis 
of the CaM kinase II consensus site of this isoform (Wei et al, 1996).
The regulation of adenylyl cyclase isoforms by protein kinase C is discussed in a 
great deal of literature, much of which is contiadictory. One prevailing conclusion is,
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however, that in intact cells, type II adenylyl cyclase can be stimulated by PKC 
(Jacobowitz et al., 1993; Lustig et al, 1993). However it is not yet clear whether this 
activation is a direct or indirect effect of PKC.
In addition, earlier evidence from in vitro studies that PKC activation leads to a 
stimulation of the activity of type V adenylyl cyclase (Kawabe et al, 1994) has recently 
been confirmed in stably transfected intact cells (Kawabe et al, 1996). The evidence 
with regal'd to type I adenylyl cyclase is less clear. Thus while some workers have 
reported enhanced forskolin- (Choi et al, 1993) or calmodulin- (Jacobowitz etal, 1993) 
stimulated type I adenylyl cyclase activity in response to activation of protein kinase C, 
others have been unable to demonstrate such an effect (Yoshimura and Cooper, 1993).
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1.4. Receptor desensitization
During the continuous exposure to stimuli, a number of biological processes 
involving cell surface receptors undergo a regulatoiy process which results in the 
attenuation of their function despite the continuous presence of the stimulatory agent.
This phenomenon is termed desensitization and has been observed in such diverse 
biological systems as visual light adaptation (Hargrave and Hamm, 1994), bacterial 
chemotaxis (Stock, 1994) and yeast mating behaviour (Liggett and Lefkowitz, 1994). It 
is also widespread amongst GPCRs, having been demonstiated in both intact tissue and 
cell culture systems. In the case of GPCRs, desensitization can occur by one or more of 
three principal mechanisms. These ai'e: (1) phosphorylation of the receptor, leading to its 
functional uncoupling from the G-protein, (2) receptor internalisation (sequestration) to a 
pool where it cannot generate a signal and (3) a reduction in total cellular' receptor number 
(down-regulation) (Liggett and Lefkowitz, 1994).
Receptor internalisation involves the removal of receptors from the cell surface into 
endosomes, where the receptors may be dephosphorylated prior to their return to the cell 
surface or, in the case of prolonged receptor stimulation, where they may eventually be 
degraded (Von Zastrow and Kobilka, 1992; Pippig et al, 1995). In the human A431 
carcinoma cell line internalisation of the P^-adrenoceptor has been shown to occur at a 
slower rate, with a half-life of approximately 10 minutes, than was seen for the 
phosphoiylation-induced uncoupling of the response, which has a half-life of between 15 
seconds and 2 minutes (Lohse, 1990; Lohse etal, 1990; Roth et al, 1991).
In those systems where it occurs, the even slower process of down-regulation is 
evident only after 30-60 minutes of receptor stimulation (Hadcock and Malbon, 1991). 
This reduction in receptor number is achieved, it appears, by agonist-induced lysosomal 
degradation of the receptors, in combination with reduced receptor mRNA levels, 
resulting from both reduced transcription (Hosoda et al, 1995) and a shorter half-life of 
the mRNA (Hadcock et al, 1989).
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Phosphoiylation of G-protein coupled receptors is now known to be mediated by 
serine/threonine kinases of two categories: (a) the non-receptor-specific effector kinases 
(such as protein kinase C and protein kinase A), for which such receptors are likely to 
form only one of many classes of substrate, and (b) the G-protein coupled receptor 
kinases (GRKs) whose only known cellular substrates are GPCRs (Lohse, 1993). The 
characteristics of both of these groups of kinases will be discussed in this section.
1.4.1. Protein kinase C
1.4.1.1. Introduction
Protein Kinase C (PKC), when first discovered in 1977, was considered to be a 
proteolytically activated serine/threonine kinase whose proteolytic cleavage yielded the 
active molecule termed Protein Kinase M (PKM) (Inoue et al, 1977). Subsequently, 
however, a “phorbol ester receptor” was identified and demonstrated to have properties 
similar to those of PKC (Leach et al, 1983; Sando and Young, 1983). It was later 
shown that intact PKC possessed kinase activity but its activation was found to require 
calcium and the presence of the cofactors 1,2-diacylglycerol (DAG) and 
phosphatidylserine (PS) (Nishizuka, 1984). The requirement for DAG, a product of the 
phospholipase C-mediated hydrolysis of phosphatidyl inositol 4,5-bisphosphate (PIP2) 
(Berridge and Irvine, 1984), suggested that PKC might play an important role in lipid- 
mediated signalling pathways.
PKC activity is now known to be provided by a family of structurally related 
serine/threonine kinases. All known PKC isoforms contain 3 or 4 highly conserved and 
thus presumably functional amino acid stretches (C1-C4), separated by regions of greater 
variability (V1-V5) (Nishizuka, 1988) (figure 1.3.). These kinases are involved in a 
variety of signal transduction processes which include proliferation, differentiation and 
secretion. A total of 12 members of the PKC gene family have been identified to date. 
The members show differences in their structure, mode of activation, substr ate specificity 
and patterns of expression. They are classified (Asaoka et ai, 1992) on the basis of their
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requirement for calcium and DAG into three groups: (1) the "classical" PKCs (cPKC-a, 
pi, pil and y) which are dependent upon calcium, PS and DAG for their activation; (2) the 
calcium-independent "novel" PKCs (nPKC-5, e, q/L and 0); and (3) the more recently 
identified calcium- and DAG-independent "atypical" PKCs (aPKC-i, Ç and X). PKC-p 
will be discussed separately in connection with protein kinase D (see section 1.4.4).
I.4.I.2. Structural features of PKC isoforms
The Cl region, which is common to all known PKC isoenzymes, is the putative 
binding site for the physiological activators (diacylglycerol and phospholipid) and also 
for the activating phorbol esters, which ai*e structural analogues of DAG. In both the 
conventional and novel PKC isofoims this region contains two cysteine-rich zinc finger­
like sequence motifs, whereas in the atypical PKCs, such as PKC-Ç, only one such 
sequence is evident (Ono et al, 1989). Motifs of this kind are known to mediate the 
DNA-binding of transcription factors such as GAL4, although DNA-binding to PKC 
remains to be demonstr ated. It does appear, however, that the presence of two of these 
cysteine-rich sequences forms a so-called “zinc butterfly” between His^^  ^and Cys^^  ^
which is necessary for the binding of both DAG and phorbol ester to PKC (Bell and 
Bums, 1991; Quest etal, 1994).
Classical and novel PKC isoforms show selectivity for binding of phorbol esters 
with an order of potency for PKC-piI, PKC-y and PKC-e of sapintoxin A (Sap A) > 12- 
deoxyphorbol-13-O-phenylacetate (DOPP) > 12-tetradecanoylphorbol-13-0-acetate 
(TPA) > phorbol-12,13-dibutyrate (PDBu) (Dimitrijevic et al, 1995). While both DAG 
and phorbol esters do bind within the cysteine-rich region of the Cl domain, it has been 
suggested that these two classes of activator may bind rather differently. This conclusion 
was reached as a consequence of the observation that the activation of PKC elicited by 
both DAG and phorbol ester together is in excess of that which can be achieved by either 
of these aetivators alone and also by the finding that butanol inhibits DAG-induced PKC 
activity but not that induced by PM A (Slater et al, 1994).
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The Cl region also contains, near to its NH2"terminus, a "pseudosubstrate" 
sequence. This, owing to its similarity to the postulated PKC phosphorylation site motif, 
occupies the substi'ate-binding site in the catalytic domain of the enzyme in its non­
activated state (House and Kemp, 1987). Since the serine or threonine in the substrate 
motif is substituted by an alanine, the pseudosubstrate sequence cannot itself be 
phosphorylated and thus the enzyme is retained in an inactive state (Orr and Newton,
1994). Consistent with such a function is the observation that synthetic peptides based 
upon pseudosubstrate sequences, can, indeed, act as inhibitors of activated PKC (House 
and Kemp, 1987). This activation of PKC by DAG is envisaged as occumng thiough a 
conformational change which removes the pseudosubstrate from the active site of the 
enzyme.
The C2 region contains the putative calcium-binding site of the cPKC isoenzymes. 
Although it does not contain any classical E-F hand (Van Eldik et al, 1982) calcium- 
binding motif, it does consist of many acidic amino acids which are likely to paiticipate in 
calcium binding (Ohno et al, 1987). Analysis of divalent cation binding using GST- 
PKC fusion proteins suggests, however, that the Cl region alone can bind Mn^+, Mg^+ 
or Ca^+ and that it is only Ca^+ specificity that is conferred by the C2 region (Luo and 
Weinstein, 1993). The C2 domain must, nevertheless, contribute to the Ca^+ 
dependency of the cPKCs, since the nPKCs, which possess no C2 region, can be 
activated in the absence of this cation (Koide et al, 1992; Ogita et al, 1992).
The conserved region C3 contains the ATP-binding site while the phosphate 
transfer and substrate-binding regions are contained within the C4 region (Hug and 
Sarre, 1993). Contained within the centre of the phosphate transfer region is the central 
sequence DFG, which is highly conserved amongst protein kinases (Kemp and Pearson,
1990). Within this amino acid motif, it is the Asp residue which is believed to be directly 
responsible for phosphate transfer (Kemp and Pearson, 1990).
The C-terminal catalytic domain is separated from the N-terminal regulatory domain 
by the variable V3 region. The V3 region is a stretch of amino acids which has been 
demonstrated to be susceptible to proteolysis by trypsin and by the calcium-dependent
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neutral proteases calpain I and II, both in vivo and in vitro (Nishizuka, 1988). In fact, 
proteolytic cleavage of the molecule at this site produces the constitutively activated C- 
terminal catalytic fragment mentioned above, termed PKM (Inoue et al, 1977).
It has been shown that the deletion of the regulatory domain from PKC~a leads to 
not only the constitutive activation of this kinase, but also its nuclear targeting (James and 
Olson, 1992). Furthermore, it is inferred from the properties of other deletion mutants 
that such targeting is mediated by the V3 region, which only becomes exposed upon 
activation of the kinase by DAG or phorbol ester (James and Olson, 1992). Thus, it is 
conceivable that, in vivo, proteolytic cleavage of activated PKCs may lead to the nuclear 
targeting of the catalytic domain, allowing the latter to phosphorylate nuclear transcription 
factors.
14.1.3. Expression of PKC isoforms
1.4.1.3.1. Tissue distribution of PKC isoforms
The tissue-distribution patterns of individual PKC isoenzymes have been elucidated 
by the use of Northern and Western blot analyses. It appeal's that PKC-cx, 6 and Ç are the 
most ubiquitous iso-enzymes (Dekker and Parker, 1994) and it has been suggested that 
these PKC iso-enzymes may serve "house-keeping" functions while other PKC 
isoforms, which are expressed in only particular differentiated tissues, serve more 
specialised functions. For example, PKC-y is found predominantly in the central 
nervous system (Wetsel et al, 1992), PKC-rj is preferentially expressed in skin and lung 
(Osada et al, 1990) and PKC-0 is expressed predominantly in skeletal muscle (Osada et 
al, 1992). In addition to tissue-specific expression patterns, it is appaient that within a 
given tissue the PKC isofoim expression patterns vary according to the developmental 
stage (Nishizuka, 1988).
1.4.1.3.2. Regulation of PKC gene expression
Only limited information is currently available regarding the mechanisms which 
regulate PKC isoenzyme expression. The promoter regions of the rat PKC-y (Chen et 
al, 1990) and the human PKC-p (Niino et al, 1992; Obeid et al, 1992) genes have.
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however, been cloned. Both promoters lack a TATA box but possess binding sites for 
the API, AP2 and SPl transcription factors. Interestingly, the DNA-binding of API can 
be induced by the phosphoiylation of this tianscription factor complex by MAP kinase 
(Meek and Street, 1992), which, itself, is involved in a cascade of phosphoiylation that 
can be initiated by the PKC-a-mediated activation of Raf-1 kinase (Kolch et al, 1993). 
This implies that PKC-|1 and PKC-y transcription may be positively regulated by PKC-a 
and, possibly, by other PKC isoforms. The PKC-y promoter contains, in addition, a 
cAMP response element while tlie PKC-p promoter contains a CAAT box.
PKC gene expression is regulated not only at the transcriptional level but also by 
differential splicing. Thus in any given tissue or cell line one of the two PKC-p splice 
forms, which differ at their 3' ends, is preferentially expressed (Kubo et al, 1987), and 
differential splicing also plays a role in PKC-e expression in brain and lung tissue 
(Schaap et al, 1990).
1.4.1.4. Activators and substrates of the PKC isoenzymes
A great deal of information regarding the biochemical features of the PKC 
isoenzymes has been obtained by detailed analyses of individual recombinant isoforms 
purified from transfected COS cells or baculovirus-infected insect cells.
1.4.1.4.1. Activation of PKC isoforms
A pre-requisite for the effector-dependent activation of PKC isoforms is the post- 
translational phosphorylation of key residues within the catalytic domain by a non-PKC 
kinase (Pears et al, 1992). Thus PKC-a, when purified from rat brain, is a functional 
phosphoprotein (Kikkawa et al, 1982) that can be completely inactivated upon treatment 
with the serine/threonine-specific protein phosphatase 1 (Pears et al, 1992). More 
recently, site-directed mutagenesis has been used to map the phosphoiylated residues in 
PKC-a to a region in the catalytic domain which contains Thr^ 94^  Thi-^ s^ and Thi-497 
(Cazaubon and Parker, 1993). Phosphorylation of Thi-497, in particular, appears to be 
critical for the generation of functional PKC-a although ThH^s ^^ay also be involved 
(Cazaubon et al, 1994).
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In addition to the trans-phosphorylation of residues within the catalytic domain 
PKC-pII has been shown to undergo auto-phosphoiylation on the C-terminal residues 
Thr^34 and Thr^^i (Dutil et al, 1994). In contrast to trans-phosphorylation, this auto­
phosphorylation is not a pre-requisite for the generation of the functional kinase but rather 
is dependent upon the presence of the activators of the kinase (Newton and Koshland,
1989).
The cuiTent model for the mechanism of activation for the cPKCs envisages that 
activation is initiated by the binding of calcium to the C2 region of the PKC with the 
consequent translocation of the protein to the plasma membrane. In this model, DAG and 
phosphatidylserine (PS), being constitutively present in the membrane, complete the 
activation process by binding to the Cl region (Bell and Burns, 1991; Gschwendt et al,
1991). This results in the stabilisation of the conformation in which the pseudosubstrate 
site is not bound by the catalytic domain. In addition, it is possible that the phospholipids 
which activate PKC may bind, by virtue of their acidic nature, to the released 
pseudosubstrate site. The latter contains basic sequences which have been shown to bind 
these phospholipids in vitro (Mosior et al, 1990).
The presence of calcium is not necessary in achieving the activation of cPKCs by 
phorbol esters. These agents mimic the effect of DAG in stimulating the activation of 
both the cPKC and nPKC isoforms. However, they persist for a greater duration in the 
cellular membrane than DAG (Gschwendt et al, 1991) and lead to a more prolonged 
activation of these isoenzymes (Nishizuka, 1995).
The nPKC isoforms, as discussed above, lack the calcium-binding C2 region that is 
a feature of the cPKCs, and can be activated by DAG and the co-factor PS without the 
requirement for calcium (Osada et al, 1990; Koide et al, 1992; Ogita et al, 1992).
It is now accepted that DAG is not produced solely by the action of PLC on PIP2 .
It appeal's that the PLC-mediated hydrolysis of PIP2 gives rise only to an "early", 
transient, phase of DAG production and that a more sustained, "late", phase of DAG 
production can occur largely as a consequence of the action of phospholipases C and D 
on phosphatidylcholine (PC) (Billah and Anthes, 1990). This PC-derived DAG is likely
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to be important physiologically as current evidence supports the hypothesis that the 
sustained activation of PKC is an essential requirement of signal transduction pathways 
which lead to cell division or differentiation (Aihara et al, 1991; Asaoka et al, 1991). | |
In contrast to the cPKC and nPKC isoforms, PKC-Ç, which is a member of the
aPKC class, is not stimulated by calcium, DAG or even phorbol ester (Nakanishi and 
Exton, 1992). Instead, this isoform can be activated by phosphatidic acid (Liscovitch 
and Cantley, 1994), ceramide (Müller et al, 1995), PS, unsaturated fatty acids such as 
arachidonic acid and by phosphatidyl 3,4,5-trisphosphate (PIP3) (Nakanishi etal,
1993). Thus the signal transduction pathways in which PKC isoforms might be involved 
in vivo are not limited to those leading to the generation of DAG. They include, for 
example, the insulin signalling pathway, which leads to the activation of 
phosphatidylinositol 3-kinase (PI-3-kinase) and the generation of PIP3 (White and Kahn,
1994).
1.4.1.4.2. Substrate-specificity of PKC 
The cPKC isoforms are relatively non-specific Ser/Thr kinases in vitro. They can 
seemingly phosphorylate a wide range of proteins and peptides provided that these 
contain a motif of the type K/RxxS/TxK/R or K/RxS/TxK/R (Kemp and Pearson,
1990). In contrast, members of the nPKC group display a relatively poor kinase activity 
towards several efficient substrates of cPKC isoforms, including histone IIIS, myelin 
basic protein, protamine and protamine sulphate (Hug and Sarre, 1993). There is I
evidence which suggests that the limited kinase activity of nPKCs towards these
:substrates may be due to a restrictive effect exerted by the regulatory domain of these 
kinases rather than an intrinsic property of their catalytic domains. For example, upon 
the proteolytic removal of the regulatory domain of PKC-e (Schaap et al, 1990) or of 
PKC-T) (Dekker et al, 1993) by trypsin treatment, the catalytic fragment displays a much 
enhanced capacity for histone phosphorylation. Furthermore, a chimaeric enzyme, 
formed by the fusion of the regulatory domain of PKC-e to the catalytic domain of PKC- 
y, exhibited a substrate specificity similai* to that of PKC-e (Pears etal, 1991).
A large number of putative physiological substrates have been revealed by 
labelling of cells treated with PKC stimulators. The substiates can be divided aibitrarily 
into the following classes: (1) ion channels and pumps (Winkel et al, 1993; Hell et al, 
1994; Torchia et al, 1994) (2) the family of myristoylated alanine-rich C-kinase 
substiates (MARCKS) which mediate the attachment of cytoskeletal actin to the plasma 
membrane (Aderem, 1992; Blackshear, 1993) and whose ability to bind calmodulin is 
abrogated by PKC-mediated phosphorylation (Blackshear, 1993) (3) proteins which 
regulate gene expression and mitogenesis, such as Raf-1 kinase (Kolch et al, 1993) (4) 
cell surface receptors such as the epidermal growth factor, insulin, serotonin, nicotinic 
acetyl choline and p2-adrenoceptors (Ido etal, 1987; Houslay, 1991; Hsieh etal,  1991) 
and (5) GTP binding proteins such as Gi-2ot (Morris et al, 1996).
It has been proposed that PKC-a can phosphoiylate and activate Raf-1 kinase 
(Kolch et al, 1993), which, in turn, initiates a protein kinase cascade that culminates in 
the activation of mitogen-activated protein kinases (MAPKs). Consistent with the 
activation of this growth factor signal transduction pathway by PKC isoforms was the 
finding that PKC-e, when stably overexpressed in fibroblasts, functions as an oncogene 
(Cacace et al, 1993). The action of this isoform in fibroblasts appears to be mediated by 
its activation of Raf-1 kinase since its oncogenic activity was blocked in fibroblasts which 
were transfected so as to express a dominant negative Raf-1 mutant, but not in clones 
which instead expressed a dominant negative Ras mutant (Cacace et al, 1996). In 
contrast, in T-lymphocytes, PKC appears to activate the MAPK cascade by inhibiting 
GTPase-Activating Protein (GAP) and thus stimulating the activity of Ras (Downward et 
al, 1990).
Other recent studies have, in addition, indicated the potential for inhibition of 
endothelial nitric oxide synthase (NOS) activity by the PKC-mediated phosphorylation of 
this enzyme (Hirata et al, 1995) and the enhancement of the activity of G protein coupled 
receptor kinase upon the phosphorylation of the latter by PKC (Chuang et al, 1995) (see 
section 1.4.5.3).
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1,4,2, cAMP-dependent protein kinase (PKA)
1.4.2.1. The structure, regulation and distribution of PKAs
The cyclic AMP-dependent protein kinase (PKA), a serine/threonine kinase, exists 
in its inactive state as a tetrameric holoenzyme comprising two regulatory (R) and two 
catalytic (C) subunits (Taylor, 1989). Activation of the holoenzyme, consequent upon 
the binding of two cAMP molecules to each of the regulatory subunits, results in the 
dissociation of the latter from the catalytic subunits, thus permitting the free diffusion and 
activity of the C subunits (Krebs and Beavo, 1979; Taylor, 1989). Two major isoforms 
of PKA exist, type-I and type-II, classified according to the nature of theh regulatory 
subunits. These subunits exist in two forms, RI and RII, which are distinguished by 
their amino acid sequence, molecular weights, immunoreactivity and affinity for cAMP 
analogues. In addition, two alternative isotypes of each of these R subunit isoforms 
exist, namely RI (a  and p) and RU (a  and p). Moreover, the catalytic subunit exists in 
three forms, C(a, p and y) (Showers and Maurer, 1986; Uhler et al, 1986a; Uhler et al, 
1986b; Beebe et al, 1990). Of these, the a  and p species are the mostly highly 
homologous, with 93% identity at the amino acid level (Showers and Maurer, 1986; 
Uhler et al, 1986a; Uhler et al, 1986b). The y form exhibits only 83% amino acid 
identity to a, and 79% to p (Beebe et al, 1990).
The different forms of these regulatoiy and catalytic subunits do appear' to possess 
distinct properties. For example, while the RI isoform exhibits a wide tissue distribution, 
RH is only expressed in a limited number of tissues (Rubin et al, 1972; Corbin et al, 
1977). The RI and RQ isoforms also display differences with regard to their intracellular 
locations. Thus, while RI isoforms are found predominantly in the cytosolic 
compartment of the cell, the RII isoforms are generally associated with cellular str-uctures, 
including the golgi apparatus and the cytoskeleton (Nigg et al, 1985; Salavatori et al,
1990). This localisation is, at least in part, mediated by A-kinase anchoring proteins, as 
discussed below.
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The catalytic subunit isoforms, like the regulatory monomers, differ with respect to 
their tissue distribution, with the y species being restricted to testis and the a  and p forms 
being widely expressed (Beebe et al., 1990), Furthermore, the a  and p isoforms appear 
to differ from the y isoform with respect to then- substrate specificity. For instance, the 
latter, unlike the a  and P isoforms, more readily phosphorylates histone than the 
heptapeptide substrate, Kemptide (Beebe etal, 1992). In addition, the histone kinase 
activity of the y catalytic isoform is inhibited by the protein kinase inhibitor (PKI) protein 
to a much lesser extent than is that of the a  isoform (Beebe et al, 1992).
I.4.2.2. A-kinase anchoring proteins (AKAPs)
It is now known that the type-II PKA holoenzyme is localised to specific 
subcellular regions by binding to specific A-kinase anchoring proteins (AKAPs) (Scott 
and Carr, 1992). The high affinity interaction of PKA-RH with these adaptor proteins 
requires the prior dimérisation of the RII monomer (Luo et al, 1990; Scott et al, 1990) 
and appears to be mediated by the NH2-terminal 5 amino acids of each RII subunit, of 
which the isoleucines at positions 3 and 5 serve as the principal sites of contact (Hausken 
etal,  1994).
AKAPs contain additional binding sites which mediate their interaction with cellular 
structures. Such domains, for example, taiget AKAP95 to the nucleus (Coghlan et al,
1994), AKAP75 to the cytoskeleton (Glantz et al, 1993) and AKAP79 to post-synaptic 
densities (Faux and Scott, 1996). Fmthermore, it has been shown that AKAP79 binds 
not only PKAII, but also the Ca^Vcalmodulin-dependent protein phosphatase 2B, 
calcineurin (Coghlan et al, 1995) in addition to PKC-a and PKC-|3 isoforms (Klauck et 
al, 1996). The formation of such a signalling complex may pei*mit the concerted action 
of the thiee co-localised multisubstrate enzymes, PKA, PKC and calcineurin, on 
individual substrate molecules, in response to the distinct second messenger signals: 
cAMP, Ca^+Zphospholipid and Ca^+Zcalmodulin, respectively.
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1.4.2 3. The substrate specificity of PKA
PKA is the prototype multisubstrate enzyme. This feature, which it shares with 
many other kinases including PKC and casein kinase II, distinguishes it from such 
kinases as phosphorylase kinase, which exhibit a higher degree of selectivity with respect 
to their substrates (Walsh and Van Patten, 1994). The activation of PKA, therefore, 
results in the phosphorylation of numerous protein substrates. For example the 
mechanism by which an increase in the rate and force of cardiac contr actility results from 
P-adrenergic stimulation of heart muscle, involves the PKA-mediated phosphorylation of 
several proteins, including troponin I, phospholamban, sarcolemma p27, phosphorylase 
kinase and glycogen synthase (England, 1975; England, 1976; Walsh etal,  1979; 
Huggins and England, 1983; Angelos etal, 1987),
The activity of PKA towards potential substrates is, however, influenced by several 
factors including not only the localisation of PKA and its substrate, but also the 
conformation of the substrate and the amino acid sequence surrounding the candidate 
phosphoacceptor residues. Thus most PKA substrates contain the amino acid motif 
RRxS*x, where S'*" represents the phosphoacceptor serine (Kemp and Pearson, 1990).
A conformational change induced by covalent modification of a protein may affect its 
ability to undergo PKA-mediated phosphorylation. An example of such a phenomenon, 
termed hierarchical phosphorylation (Roach, 1991), is the requirement for 
phosphorylation of one site on phosphorylase kinase by PKA for the subsequent 
phosphorylation of another site on the same enzyme by PKA (Ramachandran et al, 
1987). The efficacy of substrate utilisation by PKA has been shown, by extensive 
studies of the phosphorylation of pyruvate kinase, to correlate with the occurrence of a 
pair of arginine residues at positions -2 and -3 relative to a potential phosphoacceptor 
serine (Kemp et al, 1977; Feramisco et al, 1980). In fact the heptapeptide, Kemptide 
(LRRASLG), is as efficacious a substrate for PKA as is pyruvate kinase, the protein 
from which it was derived (Pilkis et al, 1980).
In addition to phosphorylation of enzymes which are involved in metabolic 
processes, PKA is known to phosphorylate both hormone receptors and DNA-binding
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proteins. The catalytic subunits of PKA also possess the ability to enter the nucleus and 
thereby to modulate gene transcription. The mechanism by which this occurs involves 
the phosphorylation of transcription factors such as the cyclic AMP-responsive element 
binding protein (CREB), which are also known as members of the activation 
transcription factor (ATE) family (Karin and Smeal, 1992). Although such 
phosphorylation does not increase the ability of these BZip proteins to bind to cyclic 
AMP-responsive elements (CREs), it does potentiate their ability to promote 
transcriptional activation, by causing a conformational change that enhances the 
interaction of CREB/ATF with TFIID, the TATA-binding factor (Meek and Sti'eet,
1992). The ability of PKA to phosphorylate membrane-bound receptors will be 
discussed below.
1,4,3, G-protein coupled receptor desensitization by PKC and 
PKA
An important gi'oup of substrates of the second-messenger activated kinases, 
protein kinases A and C, aie the G-protein coupled receptors (GPCRs). G-protein 
coupled receptors, upon phosphorylation by the action of these kinases, become 
functionally uncoupled from G-proteins. The phosphorylation of such receptors 
constitutes part of a negative feedback mechanism (Benovic et al, 1985).
The prototypical receptor used in studies of this type of desensitization has been the 
p2-adrenergic receptor, whose phosphoiylation has been studied extensively (Sibley et 
al, 1984; Benovic etal, 1985; Bouvier etal, 1987; Bouvier et al, 1989; Hausdorff et 
al, 1989; Johnson et al, 1990; Okamoto etal, 1991; Roth et al, 1991; Pitcher et al, 
1992a; Chuang et al, 1995). This receptor contains two consensus phosphorylation 
sites for PKA: one in the N-terminal part of the C-teiminal tail region and one in the C- 
teiminal region of the third intracellular loop. The latter is the preferred phosphorylation 
site (Bouvier et al, 1989; Clark et al, 1989) and its phosphorylation is sufficient to 
impair the activation of Gg by the receptor (Pitcher et al, 1992a). PKC also 
phosphorylates the p2-adrenergic receptor, at the same sites utilised by PKA, again with
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a preference for the site in the C-tenninus of the third intracellular loop (Bouvier et al, 
1987; Johnson et al, 1990; Pitcher et al, 1992a). Neither PKA nor PKC-mediated 
desensitization appears to involve the binding of P-aiTestin, which interacts at an equally 
low level with p2-adrenergic receptors phosphorylated by either of these kinases as it 
does with the control receptors (Lohse et al, 1992; Pitcher et al, 1992a).
The use of heparin and PKI to inhibit GRK2 and PKA, respectively, has permitted 
the analysis of the rate of desensitization of the P2-AR that is mediated by each of these 
two kinases in human A431 carcinoma cells (Roth et al, 1991). It was determined by 
this means that PKA-mediated desensitization was considerably less rapid than that 
mediated by GRK2. In these cells, in the presence of 10 |J,M isoproterenol, the ti/2 for 
each process was 2 minutes and <15 seconds, respectively (Roth et al, 1991). These 
values are, however, likely to differ in other cell types, where the expression levels of 
receptors, kinases and other proteins will be different.
While PKA mediates the desensitization of a number of other GPCRs such as the 
PGEl receptor (Clark et al, 1988) and the peripheral DAl-dopamine receptor (Bates et 
al, 1991), the occurrence of such a process is not observed in other systems, such as the 
p3-adrenergic receptor, which contains no PKA consensus phosphorylation site (Nantel 
et al, 1993). In an analogous manner, many receptors which lead to the activation of 
PKC can undergo desensitization mediated by the latter kinase, in addition to GRK- 
mediated desensitization, which is discussed below. Such receptors include the Hi- 
histamine receptor (Leurs et al, 1991; S mit et al, 1992), the thrombin receptor (Brass,
1992), the 5HT2 -serotonin receptor (Kagaya et al, 1990), the parathyroid hormone 
receptor (Dunlay and Hruska, 1990), the angiotensin II receptor (Sakuta et al, 1991; 
Oppermann etal, 1996) and the glucagon-like peptide-1 (GLP-1) receptor (Widmann et 
al, 1996).
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1,4,4. Protein kinase D
Protein kinase D (PKD) is a serine/threonine protein kinase with several similaiities 
to PKC but which possesses, in addition, several distinct structural and functional 
characteristics which distinguish it from PKC isofonns (figure 1.3).
1.4.4.1. Cloning of PKD and its expression in mouse tissues
The use of PCR oligonucleotides specific for conserved regions within the coding 
sequences of tyrosine kinase family members (Wilks, 1989) led, fortuitously, to the 
identification of a product of a novel putative serine/threonine kinase. The entire coding 
sequence, elucidated from cDNA clones isolated from a mouse lung cDNA libraiy was 
found to encode a protein of 918 amino acids with a predicted molecular weight of 102 
kD (Valverde et ai, 1994). This protein was named protein kinase D (PKD) (Valverde et 
ai, 1994). Northern blotting of RNA extracted from mouse tissues demonstrated that the 
expression of PKD is highest in lung and brain, with intermediate levels of expression in 
skeletal muscle, testis, heart and kidney and low levels in liver and spleen (Valverde et 
al, 1994). In addition, Western blotting was undertaken following the 
immunoprécipitation of the kinase from Swiss 3T3 cells and mouse embryo fibroblasts 
with a polyclonal antiserum raised against a synthetic 15-residue peptide corresponding to 
part of the C-terminal region of the protein. The results showed that PKD migrates as a 
single band with an apparent molecular weight of 110 kD (Valverde et al, 1994).
1.4.4.2. Structural features of PKD
The protein possesses a modular stmcture, consisting of catalytic and regulatoiy 
domains (figure 1.3). The former encompasses the region between residues 589 and 
845, which conforms to the protein kinase consensus composed of 11 distinct sub- 
domains (Hanks and Quinn, 1991; Hanks and Hunter, 1995). Sequence comparisons 
indicate that PKD is distantly related to Ca^+-regulated kinases but is not a member of any 
of the recognised protein kinase sub-families (Rozengurt et al, 1995). For example, the 
PKD amino acid sequence exhibits the unusual featui e, of the substitution in PKD of a 
cysteine for the arginine residue that is highly conseiwed in many protein kinases in the
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HRDL motif of subdomain VIB (Rozengurt et al, 1995). The PKD catalytic domain is 
most highly homologous to that of myosin light-chain kinase (MLCK) of Dictyostelium 
(41% identity), but is also homologous to calcium/calmodulin dependent protein kinase 
(CaM kinase) types II and IV, PKA, and phosphorylase B kinase, in decreasing order of 
homology (Valverde et al, 1994). It is notable, however, that the catalytic region of 
PKD exhibits only a low level of homology with the conserved regions of PKC 
isoforms, with marked sequence differences in subdomains I, II-III, VI and VII. 
Interestingly, several differences between PKD and a PKC consensus are apparent in a 
motif, xxDLKxxN/D, within subdomain VI, which has been shown to be invariant in all 
cPKC, nPKC and aPKC isoforms (Rozengurt et al, 1995). This motif is believed to 
play an important role in orienting the peptide substrate in order to permit subsequent 
catalysis (Knighton et al, 1991; Rozengurt et al, 1995). An implication of these 
differences is that PKD may have a substrate specificity that is distinct from the members 
of the conventional, novel and atypical classes of PKC isoforms.
I.4.4.3. Functional differences between PKD and PKCs
It has been demonstrated that PKD isolated from transfected COS cells (Van Lint et 
al, 1995) and a bacterially expressed fusion protein containing the catalytic domain of 
PKD (Valverde et al, 1994), both display only low levels of kinase activity towards a 
vaiiety of substrates utilised by PKCs, including histone, protamine and a synthetic 
peptide (BRMRPRKRQGS VRRRV) based upon the sequence of the PKC-e 
pseudosubstrate region. PKD is also unable to phosphoiylate either myelin basic protein, 
which is a substrate both of PKCs and of CaM II, or G peptide, which contains a PKA 
consensus site (Valverde et al, 1994). In marked contrast, PKD catalyses a high level of 
phosphorylation of a synthetic peptide, syntide 2 (PLARTLSVAGLPGKK), which is 
phosphorylated by PKD exclusively on the serine residue (Valverde et al, 1994). 
Intriguingly, PKD is unable to phosphorylate a syntide-2 variant 
(PLAATLSVAGLPGKK), which contains an alanine residue instead of the arginine at 
position 4 (Van Lint et al, 1995). Thus it is possible that a requirement for
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phosphorylation by PKD is a basic residue upstream of the phosphoacceptor serine. 
Additional requirements are likely to be important, however, since an arginine was 
present in the same relative position in the PKC-e-derived pseudosubstrate peptide, 
which PKD was unable to phosphorylate (Valverde et ai, 1994; Van Lint et al, 1995).
I.4.4.4. Regulatory domain of PKD
A prominent feature of the amino-terminal, regulatory domain of the deduced amino 
acid sequence of PKD is the presence of a cysteine-rich repeat sequence (H-X12-C-X2-C- 
X13-C-X2-C-X4-H-X2-C-X7-C-). This sequence is homologous to the tandemly 
repeated zinc finger-like cysteine-rich sequence which is present in the regulatoiy region 
of all known classical and novel PKCs and which confers phorbol ester sensitivity on 
these iso-enzymes (Ono etal, 1989; Gschwendt etal, 1991; Hug and Sarre, 1993). 
However, the length of the intervening sequence between the cysteine-rich domains 
varies greatly. It ranges from 28 amino acids in conventional PKCs to 35-36 amino acids 
in the novel PKCs and as much as 95 residues in PKD. As in PKCs, the zinc finger-like 
domains confer high affinity phorbol ester binding on PKD (Valverde et al, 1994). 
Furthermore, as with PKCs, the activity of immunopurified PKD can, in vitro, be 
stimulated by either DAG or phorbol ester in the presence of phosphatidylserine (Van 
Lint et al, 1995). Very recent work in Rozengurt's laboratoiy (Zugaza et al, 1996) has 
demonsti'ated that PKD activation can be effected by phorbol esters in a variety of cell 
types, namely transfected COS cells, Swiss 3T3, NIH3T3 and Rat-1 cells and in 
secondary mouse embryo fibroblasts.
Besides the spacing of the zinc finger-like domains, there are several other 
important structural differences in the NH2-terminal domain of PKD which distinguish 
this kinase from members of the PKC family (figure 1.3.). These include the presence at 
the NH2-terminus of a highly hydrophobic stretch of amino acids, constituting a putative 
transmembrane domain, and also a pleckstrin homology (PH) domain which is found 
between the cysteine-rich regions and the catalytic domain. PH domains are regions of 
approximately 100 amino acids which consist of a beta-barrel capped by an alpha helix
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(Yoon et ai, 1994). These are present in a variety of signalling and cytoskeletal proteins 
(Gibson et al, 1994) but aie not found in PKCs. It has been shown that PH domains 
can bind both to PIPg and to GjJy heterodimers (Pitcher et al, 1995b). In fact it has been 
suggested that it is this binding which mediates the association of the p-adrenergic 
receptor kinase with the plasma membrane (Pitcher et al, 1995b).
Especially conspicuous is the absence in PKD of any of the typical pseudosubstrate 
sequences, which are found on the NH2-terminal side of the cysteine-rich domains in all 
known mammalian (House and Kemp, 1987; Hug and Sarre, 1993) and yeast (Toda et 
al, 1993) PKCs. Such sequences consist of an alanine residue, instead of the substrate 
serine residue, flanked by basic amino acids. These mediate the intra-peptide regulation 
of PKCs by blocking the access of exogenous substrate to their active sites (Orr and 
Newton, 1994).
1.4.4.5, The similarity between PKD and PKC-p,
The 912-amino acid kinase termed PKC-|I was isolated from a human cDNA 
library and shown to be expressed constitutively at a relatively low level in normal 
tissues but at elevated levels in tumour cell lines (Johannes et al, 1994). In each of the 
normal human tissues examined by Northern blotting the PKC-|i-specific transcript was 
present, albeit at very low levels in comparison to other genes. The highest steady state 
levels were detected in lung and kidney, followed by heart, liver, skeletal muscle, 
placenta, pancreas and brain (Johannes et al, 1994).
The deduced amino acid sequence of PKC-p. displays a homology to PKD of 92% 
overall (extending to 98% in the catalytic domain) and exliibits very similar structural 
features. It was originally believed by Johannes et al. that PKC-p, exhibited neither 
phorbol ester binding nor phorbol ester-induced activation and it was thus concluded that 
it is a member of the atypical class of PKCs (Johannes et a l , 1994). These authors noted 
that the level of phorbol ester binding was only 1.2-fold greater in PKC-|Ll-transfected 
COS cells than in control cells. In apparent contrast, the corresponding increase in 
phorbol ester binding in PKD-transfected COS cells observed by Rozengurt's group was
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4.8 fold (Van Lint et al, 1995). It should be noted, however, that the experiments 
performed with PKC-jii used stable COS transfectants whereas those done with PKD 
utilised a transient transfection strategy. Thus the different levels of expression may have 
contributed to some extent to the apparent differences in phorbol ester binding. In fact, 
very recently, it has been shown, by in vitro studies using baculovirus-expressed PKC- 
\i, that this kinase is, under these conditions, activated by phorbol ester (Dieterich et al, 
1996). In conclusion, it is highly likely, that PKD and PKC-|I are murine and human 
functional homologues, and that on the basis of stmctuial characteristics and their 
sensitivity to phorbol ester, neither of these kinases can be classed strictly as an atypical 
PKC isoform.
I.4.4.6. Implications of the properties of PKD for cellular signalling
The discoveiy (Valverde et al, 1994; Van Lint et al, 1995) that PKD is a novel 
kinase that can be activated by phorbol ester suggests that certain effects of phorbol esters 
are not mediated by PKC alone. That its activity can also be stimulated by DAG indicates 
that PKD may mediate some of the effects of extracellular stimuli which promote the 
hydrolysis of membrane phospholipids by phospholipase C. The activation of 
phospholipase C can be elicited through both the receptor tyrosine kinase-mediated 
activation of PLC-y and through the activation of PLC-p by the GPCR-stimulated release 
of Gqa (Rhee and Choi, 1992). Thus there are many extracellular stimuli which could be 
envisaged as being capable of eliciting the activation of PKD.
1,4.5, G-protein coupled receptor kinases
The G-protein coupled receptor kinases (GRKs) constitute a group of kinases 
whose only known substrates are the GPCRs (Lohse, 1993). In contrast to the effector 
kinases which, as described above, are known to phosphorylate either the agonist-bound 
or the agonist-free forms of the receptor, the phosphorylation of a GPCR by a GRK 
requires agonist occupancy of the appropriate receptor itself (Hausdorff et al, 1990).
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Phosphorylation of GPCRs by GRKs occurs in response to a conformational 
change in the receptor that results from agonist-induced activation. Such a change has 
been proposed to involve a lateral reaixangement of the tiansmembrane helices brought 
about by a charge neutralisation resulting from ligand binding (Oliveira et al, 1994).
The GRK-induced phosphorylation of a particular receptor causes an increase in the 
affinity of the receptor for a family of cytosolic inhibitor proteins, tenned arrestins, 
which, upon binding to the phosphoiylated receptor, cause the uncoupling of the 
receptors from the G proteins (Lohse et al, 1992; Ranganathan and Stevens, 1995). The 
arrestin family comprises at least six members which include arrestin-1, arrestin-2  (p- 
arrestin), arrestin-3 and their splice variants (Premont et al, 1995). Although multiple 
arrestin forms have been identified, the functional specificity of particular somatic (non- 
retinal) ai’restins remains to be demonstrated.
Intriguingly, it has been shown very recently that the binding of p-arrestin to the 
pAR promotes an association of the receptor with the protein clathrin. Such an 
interaction is believed to facilitate the endocytosis of the receptor and thus the interaction 
of p-arrestin with the pAR may be pivotal not only for receptor-G protein uncoupling but 
also for receptor sequestration (Menard et al, 1996).
1.4.5.1. The family of GRKs
Six G-protein coupled receptor kinases have now been cloned (Benovic et al,
1989; Benovic etal, 1991; Ambrose etal, 1993; Benovic and Gomez, 1993; Inglese et 
al, 1993; Kunapuli and Benovic, 1993). Based on their sequence and functional 
similarities, these can be grouped into three sub-families: (1) rhodopsin kinase (GRKl); 
(2 ) the P-adrenoceptor kinase sub-family comprising p-adrenoceptor kinase 1 and 2 
(pARK-1 and 2, or GRK2 and GRK3) and (3) the GRK4 sub-family, consisting of 
GRK4 (ITl 1), GRK5 and GRK6 . Rhodopsin kinase mRNA is found almost 
exclusively in the rod and cone photoreceptor cells (Lorenz et al, 1991). In contrast to 
the limited distribution of this kinase, expression of the other GRKs has been 
demonstrated in a variety of tissues. This is particularly true of GRK2, GRK3 and
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GRK6  (Benovic et al, 1991; Benovic and Gomez, 1993), while GRK4 mRNA is found 
predominantly in testis (Ambrose et al, 1993) and GRK5 mRNA levels are highest in 
heart, lung and retina (Kunapuli and Benovic, 1993; Premont et al, 1994).
Although, in vitro, all six GRKs appear to possess the ability to phosphorylate the 
PAR, only two have been shown to regulate the function of this receptor, namely GRK2 
and GRK3 (Inglese et al, 1993).
I.4.5.2. Membrane attachment
All six GRKs cloned to date possess the same general structure, consisting of a 
central catalytic domain flanked by relatively well conserved amino and carboxy termini. 
The approximately 185 residue amino-terminal region is thought to be important for 
recognition of the activated receptor substrate (Premont et al, 1995). An additional 
common feature is that the C terminal domain mediates membrane association (Inglese et 
al, 1993; Pitcher et al, 1995b), which is possibly a pre-requisite for substrate 
phosphorylation. However, the mechanism by which this region confers membrane 
attachment is one characteristic which distinguishes the members of the GRK family. 
Thus, while GRKl (rhodopsin kinase) is isoprenylated at a CAAX motif at its C- 
terminus (Inglese et al, 1993), which presumably confers membrane association, GRK2 
and GRK3 both possess a C-teiminal 125 amino acid region that contains a pleckstrin 
homology domain (Inglese et al, 1993; Gibson et al, 1994). This domain confers 
plasma membrane association upon these kinases by virtue of its ability to bind to G-Py 
heterodimers and phosphatidylinositol 4,5-bisphosphate (PIP2) (Pitcher et al, 1995b). 
Thus, it is likely that the membrane translocation of GRK2 and GRK3 which occurs 
upon receptor activation is triggered by the release of the Py heterodimers from the 
activated G proteins.
Recently, it has been shown that GRK2 exists not only in cytosolic and plasma 
membrane bound pools but also in association with internal microsomal membranes in a 
variety of tissues and cell lines (Garcia-Higuera et al, 1994). Furthermore, the kinase is 
anchored to these internal membranes by both an interaction with G protein components
41
as described above, and by a postulated association with a membrane anchoring protein 
by the N-terminal region of the kinase (Murga et al, 1996). The functional role of this 
pool of GRK2 remains to be determined.
Like GRK2 and GRK3, GRK5 is able to bind membrane phospholipids.
However, for GRK5 this is proposed to occur through an interaction of its highly basic 
C-terminal 46 amino acids with head groups of acidic phospholipids (Premont et al,
1994).
In contrast, GRK6  is targeted to membranes by the palmitoylation of a cluster of 
three C-terminal cysteines (Stoffel et al, 1994).
GRK4, the only known GRK to exist in multiple splice forms, appears to be 
membrane associated, even in unstimulated cells (Premont et al, 1995). The mechanism 
by which membrane attachment is confeiTed on this kinase, however, remains to be 
ascertained.
1.4.5 3. Regulation of GRK activity
In the vertebrate retina, the level of active rhodopsin kinase is regulated by the 
association of this kinase with a 24 kDa acylated protein known as recoverin (or S- 
modulin) (Dizhoor et al, 1993). This protein, in the presence of Ca^+, binds to 
rhodopsin kinase and prevents it from phosphorylating light-activated rhodopsin 
(Dizhoor et al, 1993). Since the intracellular Ca^+ concentration is highest in the dark 
(Yarfitz and Hurley, 1994), this may constitute a molecular basis for dark adaptation, in 
that, under dim light conditions, recoverin-mediated inhibition of GRKl would permit 
longer signalling by any light-activated rhodopsin (metaihodopsin II) molecules. In view 
of the existence of non-retinal recoverin-like proteins (Chen et al, 1995a) it is 
conceivable that similar regulatoiy mechanisms modulate the activity of other GRKs.
As described above, the activities of GRK2 and GRK3 are enhanced by their 
membrane translocation, which is promoted by the release of Gpy. It is now known, 
however, that a further mechanism by which the activity of GRK2 (and possibly GRK3) 
is regulated is the PKC-mediated phosphorylation and activation of this kinase both in
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vitro and in vivo (Chuang et al, 1995). Whether this phosphorylation potentiates the 
interaction of the GRK with G protein py or phospholipid remains to be ascertained.
1.4.5 4. Receptor specificity
Perhaps as a consequence of the technical difficulty of isolating pure receptor 
proteins, the ability of individual GRKs to phosphorylate specific G protein-coupled 
receptors has been assessed for only a small number of such receptors. Those that have 
been tested as GRK substrates have been members of the largest sub-family of GPCRs, 
P2-adrenergic receptor-related proteins. While some members of the gastrointestinal 
hoimone receptor sub-family such as the glucagon receptor (see section 1.5.4) and the 
glucagon-like peptide-1 (GLP-1) receptor (Widmann et al, 1996) have been shown to 
undergo an agonist-dependent desensitization process, these receptors have not yet been 
tested as GRK substrates. From the rather limited studies which have been undertaken 
so far, it appears that there is no clear specificity of any individual GRK for any particular 
receptor or class of receptors. Thus, GRK2, the p-adrenergic kinase, has been found to 
phosphorylate not only the p2-adrenergic receptor, but also the a 2-adrenoceptor when its 
cDNA was co-transfected with that encoding GRÏC2 into COS cells (Kurose and 
Lefkowitz, 1994). In addition, purified GRK2 has been shown to effect the 
phosphorylation of the rat substance P receptor (SPR) after the partial purification of the 
SPR from recombinant baculovirus-infected Sf9 cells and its reconstitution in 
phospholipid vesicles (Kwatra et al, 1993). More recently, this kinase has also been 
found to phosphorylate the rat type lA angiotensin II receptor, expressed in transfected 
293 cells (Oppermann et al, 1996). It is possible, however, that differential tissue- 
specific expression of individual GRKs determines which GRKs catalyse the 
physiological phosphoiylation of any paiticulai- receptor in vivo. While roRNAs 
encoding several GRKs have been found to be present in heai't tissue (Inglese et al,
1993), the levels of expression of the individual kinases in the distinct cell types wliich 
constitute that organ remain to be determined.
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With regard to the nature of the phosphorylation sites on receptors that aie 
phosphorylated by the GRKs, only in the cases of rhodopsin and the human p2- 
adrenergic receptor have the precise sites of receptor phosphorylation been determined. 
Both in vitro and in vivo, GRKl phosphorylates rhodopsin on specific residues located 
at the distal portion of the caiboxy-terminal tail, principally Ser^^  ^and Ser^ -^^
(Palczewski etal, 1991). Although GRKs 1, 2, 3 and 5 all phosphorylate these two 
serines of rhodopsin, GRKl and GRK5 preferentially phosphorylate Ser^^s whereas 
GRK2 and GRK3 favour Ser^43 (Palczewski et al, 1995).
From studies undertaken with model peptide substrates, it appears that 
phosphorylation by GRK2 is favoured by the presence of several acidic residues on the 
amino-terminal side of the putative phospho-acceptor residue (Onorato etal., 1991). At 
present, a meaningful GRK consensus phosphorylation site cannot be defined owing to 
the dearth of data regarding the phosphorylation sites in receptors other than rhodopsin. 
Very recently, however, the phosphorylation sites in the human P2-adrenergic receptor 
have been identified (Fredericks et al., 1996). In a manner analogous to GRKl-mediated 
phosphorylation of rhodopsin, it is cleai’ that phosphorylation of this receptor by GRK2 
and GRK5 takes place at multiple serine and threonine residues, all of which were found 
to be contained within a peptide comprising the carboxyl-terminal 40 amino acids of the 
P2AR (Fredericks et al., 1996). Moreover, in keeping with the implications of the 
peptide studies mentioned above, both rhodopsin and the P2AR possess pairs of acidic 
residues located on the amino-terminal side of the most amino-terminal phosphorylated 
residue (Fredericks et al, 1996).
44
1.5. The glucagon receptor
1,5,1, The glucagon receptor gene
Glucagon, a hormone that is secreted by the a-cells of the islets of Langerhans of 
the pancreas in response to hypoglycaemia, is a key regulator of hepatic glucose 
production (Sneader, 1996). The glucagon receptor (GR) is a member of the secretin 
sub-family of G protein-coupled receptors (GPCRs). The rat hepatic GR cDNA, was 
isolated by expression cloning (Jelinek et al, 1993) and by low-stringency homology 
cloning using degenerate primers whose sequence was based on consensus cDNA 
sequences (Svoboda et al, 1993a; Svoboda et al, 1993b). The open reading frame of 
1455 nucleotides encodes a 485 amino acid protein with the seven predominantly 
hydrophobic putative trans-membrane domains which aie characteristic of the GPCR 
superfamily (Houslay, 1992). Interestingly, although the rat hepatic glucagon receptor 
shares no significant sequence homology with the majority of members of the GPCR 
super-family, the amino acid sequence of the receptor displays a 47-57% identity, in the 
core region that excludes the amino and carboxy-teimni, with the deduced amino acid 
sequence of other members of the secretin receptor sub-family (Jelinek et al, 1993; 
Svoboda etal, 1993a; Svoboda et al, 1993b).
More recently, the receptor has also been cloned from a human liver cDNA library. 
This was achieved both by the use of degenerate PCR primers (Lok et al, 1994) and by 
cDNA hybridisation using the rat glucagon receptor cDNA as a probe followed by the 
technique of rapid amplification of cDNA ends (RACE) (MacNeil et al, 1994). The 
isolated cDNA was found to encode a protein of 477 amino acids with 80% identity to the 
rat glucagon receptor (MacNeil et al, 1994). In addition, as a prelude to future 
transgenic studies of glucagon receptor function, the murine glucagon receptor gene has 
now been sequenced (Burcelin et al, 1995). Its cDNA, like that of the rat, encodes a 
485 amino acid protein, and the two homologues shaie 93% identity at the amino acid 
level (Burcelin et al, 1995).
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Genomic DNA sequencing (Burcelin et al, 1995) has revealed that while the 
murine GR promoter region lacks both TATA and CAAT boxes it does, however, 
possess putative binding sites for transcription factors API, AP2, SPl and HNFl, the 
latter possibly conferring high transcriptional activity in liver (Xanthopoulos and 
Mirkovitch, 1993). In addition, the promoter region was noted to contain the c-fos 
ti'anscriptional regulatory serum response element (c-fos-SRE) (Treisman, 1992). The 
transcriptional start site was mapped by the RNase protection assay to lie approximately 
175 bp upstream of the start codon (Burcelin et al, 1995). Similarly, the promoter 
region of the human GR which, like the murine gene, lacks TATA and CAAT boxes, 
contains binding sites for SPl and AP2 in addition to the liver-specific LF-Al factor 
(Buggy et al, 1995a). Identification of the transcriptional start point of the human gene, 
by primer extension analysis, determined that it lies approximately 475 bases upstream of 
the start codon (Buggy et al, 1995a).
In contrast to the genes which encode the adrenergic and muscarinic receptors, 
which are devoid of introns, the rat hepatic glucagon receptor gene contains 11 introns 
and stretches over 3.8 kb of genomic DNA (Svoboda etal, 1993a; Christophe, 1995). 
Similarly, the human glucagon receptor gene spans a genomic region of 5.5 kb and is 
interrupted by some 12 introns (Lok et al, 1994). Southern blot analysis of rat, murine 
and human genomic DNA revealed a hybridisation pattern that was consistent in each 
case with the existence of only a single copy of the glucagon receptor gene (Lok et a l , 
1994; Burcelin et al, 1995; Christophe, 1995).
Despite the existence of multiple exons in the glucagon receptor gene, Northern and 
rtPCR analyses of rat and murine tissue RNA, respectively, have detected the presence of 
only a single glucagon receptor-specific transcript of 2,3 kb with no evidence for 
alternative splicing (Yoo-Warren etal, 1994; Burcelin etal, 1995). Interestingly, 
Northern blot analysis of rat glucagon receptor expression indicated that the gene was 
expressed in both kidney and heart (Yoo-Warren et al, 1994). Although no transcripts 
were detected in this particular study in fat, brain, lung, heai't and muscle (Yoo-Warren et 
al, 1994) the control, ribosomal RNA probe showed that the quantity of RNA loaded in
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each lane was markedly different. In particular, significantly weaker control signals were 
detected in the fat and heart RNA samples, thus calling into question the authors’ 
inferences of tissue specificity from these results.
1.5,2. Structural aspects
A notable feature of the rat hepatic glucagon receptor is the N-terminal region. This 
contains a hydrophobic sequence which constitutes a putative signal sequence and also 
four potential asparagine-linked glycosylation sites at positions 47, 60, 75 and 79. In 
fact, the hypothesis that the receptor is glycosylated is supported by the observation that 
the apparent molecular weight, on denaturing gels, of the intact glucagon receptor is 7 
kDa greater than the predicted value of 54.9 kDa. It is also indicated by the finding that 
its size is reduced by treatment with endo-N-acetylglucosaminidase F (lyengai* and 
Herberg, 1984). Another feature of the primary sequence of the GR is the presence of 
eight cysteine residues (C-8 , 20,44, 59, 6 8 , 82, 101 and 122) which could foim intra­
molecular disulphide bonds.
The regions of the glucagon receptor which determine glucagon binding specificity 
have recently been delineated by the analysis of a series of chimaeric receptor constiircts 
formed by replacing various domains of the human glucagon receptor with the 
homologous regions of the glucagon-like peptide I receptor (Buggy et al, 1995b). 
Binding studies performed following the expression of these mutants in COS-7 cells 
revealed that the ligand binding specificity is determined by the membrane-proximal half 
of the amino-terminal region, the sixth trans-membrane domain and one or more of the 
following regions: the first extracellular loop, and the third and fourth transmembrane 
domains (Buggy et al, 1995b). A separate study has been undertaken since then in 
which chimaeras were constracted by the transposition of the amino-terminal domains of 
the human calcitonin and glucagon receptors. It was observed that neither of these 
mutant receptors, when stably transfected into BHK cells, led to specific glucagon 
binding or to a glucagon-induced elevation of intracellular cAMP (Stroop et al, 1995). 
This lends further support to the implication that the amino-terminal extracellular region
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of the glucagon receptor is necessary but not sufficient to confer specific glucagon 
binding upon the glucagon receptor.
More recently, polyclonal antisera have been raised against peptides corresponding 
to the first extracellular loop and the membrane-proximal region of the amino-terminal tail 
of the GR (Unson et al, 1996). Each of these antisera, when incubated with rat liver 
membranes, was found to block the binding of glucagon to its receptor and to attenuate 
the hormone-stimulated adenylyl cyclase response (Unson et al, 1996). These findings, 
which suggest that these two regions of the GR contain important deteiToinants of 
glucagon binding, are thus consistent with the conclusions of the studies using chimaeric 
receptor constructs (Buggy etal, 1995b) mentioned above.
In addition to the construction of chimaeric receptors, the delineation of the ligand 
binding site of the glucagon receptor has been approached by other techniques involving 
the mutagenesis of the receptor. Site-specific mutagenesis has thus been used to mutate 
Asp^4 in the amino-terminal extracellular region of the rat glucagon receptor to Glu, Asn, 
Lys or Gly (CaiTUthers et al, 1994). Asp^^ was chosen on account of its alignment with 
Asp^o in the hypothalamic growth hormone releasing factor (GRF) receptor, which is 
mutated in the little mouse phenotype (Lin et al, 1993). The finding that any of the 
above replacements of Asp^ in the rat glucagon receptor led to a complete inability of the 
receptor to bind glucagon, was interpreted as an indication that this residue may directly 
interact with the horaione (Cairuthers et al, 1994). The possibility, however, that such a 
mutation caused a conformational disruption of the extracellular domain of the receptor, 
can not be excluded.
Another method by which the determinants of the glucagon binding site of the 
receptor have been analysed is the creation of a series of deletion mutants of the glucagon 
receptor cDNA (Unson et al, 1995). The deletion of a lai'ge part of the amino terminal 
region abrogated glucagon binding. In addition, however, deletion of any of the seven 
putative transmembrane segments led to a similar failure to bind glucagon (Unson et al,
1995). It is conceivable, however, that any such deletion could have caused gross 
conformational changes in the tertiary structure of the receptor.
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The cytoplasmic carboxyl terminus of the GR contains three cysteine residues, one 
of which may be palmitoylated and thus mediate the attachment of the C-terminal tail to 
the plasma membrane (Svoboda et ai, 1993a). Interestingly, a deletion of all but the 
proximal ten amino acids of the caiboxy-terminal tail of the glucagon receptor failed to 
prevent glucagon-stimulated cAMP accumulation, implying that while the C-teiminal tail 
may regulate the coupling efficiency, the greater part of this region is not directly 
necessary for Gg activation (Unson et al, 1995). That the third intracellular loop is likely 
to play an important role in mediating the receptor-Gg interaction is supported by the 
presence, at the carboxy-terminal end of this loop, of the amino acid motif R-L-A-R, 
found in the rat and murine sequences (Jelinek et al, 1993; Svoboda et al, 1993b; 
Burcelin et al, 1995) and R-L-A-K, found in the human sequence (Lok et al, 1994). 
Such a motif, Basic-(L/A)-(L/A)-Basic, matches the sequence K-A-L-K which is present 
at this location in the P2AR and whose basic residues have been shown to be important 
for coupling to Ggoc (Okamoto et al, 1991). It is unlikely however, that this short motif 
is the only region of the receptor that is required to effect coupling to Gg. In this respect 
it is notable that the C-terminal half of the seventh trans-membrane domain and the 
beginning of the intracellular C-terminal tail of the receptor conforms to the consensus 
sequence F-Q-G-Hydrophobic-Hydrophobic-V-A-X-Hydrophobic-Y-C-F-X-N-X-E-V- 
Q/R which is found at this position in all of the receptor sequences of the secretin receptor 
sub-family (Loketal, 1994).
Another region that is highly conserved among the members of this receptor sub­
family is the first intracellular loop. At the time of writing, the structure-function 
relationships of these regions of the GR remain to be investigated. In the calcitonin 
receptor, however, it appear s that the structure of the first intracellular loop is a 
determinant of whether the receptor is able to couple to Gq/n. The calcitonin receptor, 
which, like the GR, is a member of the secretin receptor sub-family, exists as two 
isoforms, calcitonin receptor 1 (CTRl) and calcitonin receptor 2 (CTR2) (Gorn et al, 
1992). While both isoforms can stimulate the production of cAMP, only CTR2 can also 
stimulate IP3 production (Gorn et al, 1992). It has therefore been suggested that a
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supplementaiy stretch of 16 amino acids that is present in the first intracellular loop of 
CTRl, but not in that of CTR2, inhibits the formation of IP3 production (Nussenzveig et 
al, 1994). Indeed it has been found that the insertion of the nucleotide sequence 
encoding this stretch into the corresponding position in the CTR2-encoding cDNA results 
in the loss of the ability of this isoform to stimulate IP3 production (Nussenzveig et al,
1994). Like CTR2, the GR can stimulate the production of IP3 (see section 1.5.3.). The 
absence of such a 16-residue stretch from the first intracellular loop of the GR (figure
1.4.) is thus consistent with the possible importance of this loop in the coupling of the 
GR to Gq/11.
1,5.3, Effector systems o f the glucagon receptor
Glucagon binding causes the glucagon receptor to interact with Gg, the alpha 
subunit of which, upon dissociation from beta/gamma subunits, subsequently activates 
adenylate cyclase. The consequent elevation of intracellular cAMP leads, in liver cells, to 
the stimulation of both gluconeogenesis (Exton et al, 1969; Johnson et al, 1972) and 
glycogenolysis (Exton et al, 1970). From analyses of the signalling consequences of 
glucagon exposure, however, evidence is accruing that glucagon may elicit cellular 
responses through the activation of at least two G protein-mediated signal pathways in 
hepatocytes. For example, like PTH (Abou-Samia et al, 1992) and calcitonin (Chabre et 
al, 1992), both of which bind to receptors closely related in structure to the glucagon 
receptor, glucagon has been demonstrated to cause not only an increase in cAMP 
production but also a significant increase in the level of intracellular calcium (Charest et 
al, 1983; Mauger etal, 1985; Sistaie et al, 1985; Blackmore and Exton, 1986; Mine et 
al, 1988). The elevation of intracellulai* Ca^+ is likely, however, to be principally due to 
a cAMP-dependent calcium influx rather than a release of calcium from intracellular 
stores, as although glucagon has been shown to cause an increase in inositol phosphates 
in hepatocytes, the degree of elevation is small (Wakelam et al, 1986; Whipps et al, 
1987; Unson etal, 1989).
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In addition to eliciting the elevation of intracellular calcium and inositol phosphates, 
glucagon has been demonstrated to elicit the generation of DAG (Bocckino et al, 1985; 
Pittner and Fain, 1991) and to effect a stimulation of protein kinase C (Pittner and Fain, 
1991; Tang and Houslay, 1992). Glucagon has also been shown to stimulate the 
hydrolysis of the membrane lipid phosphatidylcholine (Pittner and Fain, 1991). In such 
studies, in which rat hepatocytes were exposed to 10 nM glucagon, it was observed that 
the release of choline was greater than that of phosphocholine or of 
glycerophosphocholine, indicating a predominant phospholipase D activation with a 
possible additional activation of phospholipases C and A2, albeit to a lesser extent (Pittner 
and Fain, 1991).
In conclusion, glucagon does not merely elicit an elevation in the level of 
intracellular cAMP. The hormone also stimulates the hydrolysis of both 
phosphatidylcholine and PIP2 and the activity of PKC. In addition, the honnone is 
known to elicit an elevation in the levels of DAG and intracellular Ca^+. It is likely, 
therefore, that the GR couples not only to GgOt, but also to other G-proteins such as Gq 
or Gii.
1,5,4. Glucagon receptor de sensitization
1.5.4.1. The timecourse for glucagon-stimulated intracellular cAMP 
accumulation and its implications
Glucagon binds to specific receptors on the external surface of hepatocytes (Rodbell 
et al, 1971c; Sonne et al, 1978) and exerts its cellular effects through the activation of 
adenylate cyclase (Birnbaumer etal, 1971; Pohl etal, 1971; Rodbell etal, 1971a; 
Rodbell et al, 1971c; Rodbell et al, 1971b; Houslay et al, 1980). Exposure of rat 
hepatocytes to glucagon causes an increase in intracellular cAMP accumulation which is 
rapid, reaching a maximum value of 10-20  fold above basal levels within 6  minutes 
(Johnson et al, 1972; Pilkis et al, 1975) and is dose-dependent with an EC50 for
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glucagon of 1-2 nM in the presence of PDE inhibitors (Christoffersen and Berg, 1974; 
Sonne et al, 1978; Heyworth etal,  1983).
This increase in the intracellular level of cAMP is, however, short-lived. In the 
presence of the phosphodiesterase inhibitor, IBMX, a gradual decline in cAMP levels to 
approximately 50% of maximal stimulated values occurs subsequent to the peak of cAMP 
accumulation (Heyworth et al, 1983; Murphy et al, 1987). Similar results were also 
obtained in preparations of parenchymal liver cells in the presence of the PDE inhibitor, 
theophylline (Christoffersen and Berg, 1974). The decline in intracellular cAMP is not 
thought simply to reflect an increased rate of loss of cAMP to the extracellular 
environment as only a small proportion of the total cAMP is detectable in the incubation 
medium (Christoffersen and Berg, 1974; Heyworth et al, 1983) and the rate of exit of 
cAMP actually decreases after the observed maximum intracellular cAMP accumulation 
(Pilkis et al, 1975). Nor is it thought to be due to hormone degradation as further 
additions of glucagon could not overcome the desensitization (Murphy etal, 1987). 
Rather it is believed that it reflects an underlying profound attenuation of the activity of 
adenylate cyclase (Heyworth and Houslay, 1983; Newlands and Houslay, 1991; 
Houslay, 1994).
In the absence of PDE inhibitors, although the cAMP accumulation is again 
maximal at 5-6 min after glucagon addition, the magnitude of the cAMP increase is 
reduced by 3-5 fold, and the cAMP level returns fully to basal levels within 20-30 min 
(Johnson etal, 1972; Heyworth etal, 1983). The additional decline observed when 
PDE inhibitors are absent reflects an increased metabolism of cAMP by 
phosphodiesterases and the activation of type m  PDE by a protein kinase A mediated 
mechanism (Heyworth et al, 1983; Houslay, 1994).
I.5.4.2. Glucagon receptor desensitization elicited by pre-exposure to 
the hormone
The glucagon-stimulated adenylate cyclase activity in membranes isolated from 
hepatocytes exhibits a profound inhibition of the response if the cells have been pre­
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exposed to glucagon (Plas and Nunez, 1975; DeRubertis and Craven, 1976; Gurr and 
Rub, 1980; Heyworth and Houslay, 1983; Noda et al, 1984; Murphy et al, 1987; 
Murphy and Houslay, 1988; Premont and Iyengar, 1988; Murphy etal, 1989; Savage et 
al, 1995). The desensitization was dose-dependent with an observed maximum 
reduction of 30-40% following a pre-treatment period of 5 minutes with a concentration 
of 10 nM glucagon (Heyworth and Houslay, 1983). Furthermore, treatment of 
hepatocytes with glucagon has been shown to reduce the elevation in intracellular cAMP 
that is elicited by the subsequent challenge of the intact cells with this hormone (Savage et 
al, 1995), This supports the hypothesis that the transience of the glucagon-stimulated 
intracellular cAMP accumulation described in section 1.5.4.1 reflects the rapid 
desensitization of the response of adenylate cyclase to glucagon stimulation (Newlands 
and Houslay, 1991; Houslay, 1994).
Although the glucagon receptor was one of the first adenylate cyclase-linked 
GPCRs for which agonist-dependent receptor desensitization was described, there are 
several other receptors of this type for which the phenomenon has been documented. For 
example the desensitization of both the p-adrenergic receptor-stimulated adenylate cyclase 
system (Benovic etal, 1989; Lefkowitz, 1996; Lohse etal, 1996) and that of lutropin 
(luteinizing hormone) (Dix and Cooke, 1982; Dix etal, 1982) have been studied in 
detail. Moreover, very recently, an agonist-dependent desensitization process affecting 
another member of the secretin receptor sub-family, the glucagon-like peptide-1 (GLP-1) 
receptor, has been described (Widmann et al, 1996). In insulinoma cell lines, following 
the pre-exposure of the cells to GLP-1, the intracellular cAMP accumulation in response 
to GLP-1 was reduced by 20% and the dose-response cuiwe shifted 3-5 fold rightward 
(Widmann era/., 1996).
I.5.4.3. Evidence for phosphorylation of the receptor
Studies have been undertaken to investigate the mechanism by which the 
desensitization of the glucagon-stimulated adenylate cyclase response occurs. It is 
evident that phosphorylation of a membrane protein is pivotal to the process of
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desensitisation as alkaline phosphatase treatment of membranes causes a striking reversal 
of the desensitization of glucagon-stimulated adenylate cyclase (Savage et al, 1995). 
Earlier studies have also shown that in the desensitised state, neither NaF-stimulated 
adenylate cyclase activity, which depends upon Gg-cyclase coupling, nor ^^H-glucagon 
binding is reduced (Santos and Blazquez, 1982; Heyworth and Houslay, 1983). This 
implies that the mechanism of the desensitization involves the uncoupling of the glucagon 
receptor from the stimulatory G protein, Gg.
I.5.4.4. The potential role of PKC
In hepatocytes, a similar reduction in the ability of glucagon to stimulate adenylate 
cyclase activity to that which is induced by pre-exposure to glucagon, can be induced by 
tieatment of the cells with a variety of other agents. Thus, in hepatocytes, activation of 
lipid signalling pathways by hormones such as vasopressin and angiotensin II (Murphy 
et al, 1987) and challenge of cells with either the tumour promoting phorbol ester, PMA 
(Heyworth et al, 1984; Garcia-Sainz et al, 1985; Heyworth et al, 1985; Murphy et al, 
1987; Refsnes etal, 1989) or the synthetic diacylglycerols 1-oleoy 1-2-acetyl glycerol 
(OAG) and dihexanoyl glycerol (DHG) (Newlands and Houslay, 1991), have been 
demonstrated to lead to a profound reduction in the ability of glucagon to stimulate 
adenylate cyclase activity.
In contrast to TP A, DAG and DAG-elevating hormones, the use of permeant cAMP 
analogues, such as dibutyryl cAMP, did not induce desensitisation, implying that the 
cAMP-dependent kinase (PKA) cannot mediate such an effect (Heyworth and Houslay, 
1983). Similaiiy, the rate of the onset of desensitization by glucagon was not enhanced 
by IBMX, despite the fact that this PDE inhibitor greatly enhanced cAMP accumulation 
(Heyworth and Houslay, 1983). Furthermore, treatment of hepatocytes with the calcium 
ionophore A23187 was unable to elicit a reduction of either the adenylate cyclase 
activation or the intracellulai' cAMP accumulation stimulated by glucagon (Savage et al,
1995), implying that calcium entry is, in itself, insufficient to cause desensitization.
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As discussed above, glucagon has been demonshated to elicit the elevation of not 
only intiacellular cAMP but also the level of intiacellular calcium (Charest et a l , 1983; 
Mauger etal, 1985; Sistare etal, 1985; Blackmore and Exton, 1986; Mine etal, 1988). 
It has been shown, however, that the increase in intracellular calcium concentration is not 
necessary for the desensitization as the latter was blocked neither by treatment of cells 
with EGTA, to chelate calcium, nor by the addition of La^+, which blocks the entry of 
calcium across the hepatocyte plasma membrane (Barritt and Hughes, 1991).
The ability of glucagon to stimulate the generation of DAG (Bocckino et al, 1985; 
Pittner and Fain, 1991), together with the evidence described above that treatment of 
hepatocytes with DAG analogues or hormones which increase cellular DAG levels can 
attenuate the ability of glucagon to stimulate adenylate cyclase activity, suggests that the 
mechanism of glucagon and vasopressin-induced glucagon desensitization in hepatocytes 
is likely to involve a DAG-activated protein kinase. The obvious candidate to propose for 
such a kinase was protein kinase C (PKC). In this regard it is interesting that the dose- 
dependence observed for the glucagon-induced desensitization of glucagon-stimulated 
adenylate cyclase activity in hepatocyte membranes (Ka of 0.45 nM) (Heyworth and 
Houslay, 1983; Murphy et al, 1987) closely matches that observed for the glucagon- 
induced stimulation of inositol phospholipid hydrolysis (Ka of 0.25 nM) (Wakelam et 
al, 1986). Furthermore, glucagon-stimulated PKC activation has been demonstrated in 
rat hepatocytes (Pittner and Fain, 1991; Tang and Houslay, 1992) and compounds 
known to inhibit PKC such as chelerythrine, calphostin C and staurosporine have been 
found (albeit to differential extents) to block the vasopressin and glucagon-induced 
desensitization (Savage et al, 1995). These observations lend additional support to the 
conclusion that a DAG-activated kinase, such as PKC, is likely to mediate the 
desensitization of glucagon-stimulated cAMP accumulation in hepatocytes.
The work described in this thesis aimed, using a model system in which the GR 
was transiently expressed in COS cells, to address the possibility that PKC does, in fact, 
trigger the desensitization of glucagon-stimulated cAMP accumulation.
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Class M embers Modifying toxin Functions R efs .
CCj « S *  « o l f Cholera Stimulates AC 
Stimulates Ca^+ channels
(a)
(b)
ai «il-3> « 0 » «gust»
« Z
Pertussis (except a j Inhibits AC; Stimulates Ca2+ and K+ channels; 
Stimulates PLC (ao)
(a), (b), 
(c)
« t l - 2 Pertussis Activates cGMP PDE (d)
CXq «q» «11» «14-16 Activates PLCp ((31+|34 > 
(32 and (33)
(e), (f), 
(g)
« 1 2 «12» « 1 3 Stimulates Na+/K+ exchange
(h)
Table 1,1. The functions of the G protein a  subunits.
Cholera toxin and pertussis toxin catalyse the ADP-ribosylation of an Arg residue 
and a Cys residue, respectively, of the indicated a-subunits (Gilman, 1987; Birnbaumer 
et al, 1990a). The references cited in the table are: (a) (Gilman, 1987), (b) (Birnbaumer 
et al, 1990b), (c) (Moriarty etal, 1990), (d) (Fung etal, 1981), (e) (Cockcroft and 
Thomas, 1992), (f) (Sternweis and Smrcka, 1992), (g) (Grand et al, 1996) and (h) 
(Voyno-Yasenetskaya ef a/., 1994)
AC First
described
G i inhib. (37 effect Stim by 
PKC
Ca2 + 
effect
R efs.
I 1989 Yes Inhib. Stim. (a), (b), (c)
III 1990 No No Stim. (d), (e)
VIII 1994 No Stim. if)
II 1991 No Stim. Yes No (b), (c), (g), 
(h)
IV 1991 Stim. No No (i)
VII 1994 Stim. Yes No (i), (k)
V 1992 Yes No Yes Inhib. (1), (m), (n)
VI 1992 Yes No No Inhib. (m), (o), (p), 
(q)
IX 1995 No No (r), (s)
Table 1.2. The regulation of mammalian adenylyl cyclases.
The table shows the regulatory properties of the currently identified adenylyl 
cyclases as deduced largely from the study of the regulation of these isoforms following 
the expression of their cDNAs in intact HEK293 cells. The references cited in the table 
are: (a) (Krupinski etal, 1989), (b) (Tang and Gilman, 1991), (c) (Taussig etal,  1993), 
(d) (Bakalyar and Reed, 1990), (e) (Sunahara et al, 1996), (f) (Cali et al, 1994), (g) 
(Feinstein etal, 1991), (h) (Lustig etal, 1993), (i) (Gao and Gilman, 1991), (j)
(Watson et al, 1994), (k) (Vdlkel et al, 1996), (1) (Ishikawa et al, 1992), (m) (Premont 
et al, 1992), (n) (Kawabe et al, 1996), (o) (Yoshimura and Cooper, 1992), (p) 
(Debernardi etal, 1993), (q) (Katsushikaa/ . ,  1992), (r) (Paterson etal,  1995), (s) 
(Premont et al, 1996)
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Figure 1.1. Structural features of G-protein-coupled receptors.
This model of the structure of a G-protein-coupled receptor (GPCR) is based on the 
presumed structural analogy between the GPCR, rhodopsin, and the photoprotein, 
bacteriorhodopsin, whose structure was elucidated by electron diffraction. It is assumed 
that other GPCRs, which share a high degree of primary sequence homology within their 
7 hydrophobic regions with rhodopsin, adopt similai' tertiary stmctures.
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coiled coil
Figure 1.2. Schematic illustration of the GPy heterodimer.
This diagram shows the overall structure of the G-protein py heterodimer, as 
determined by the recent crystallography of rod transducin (Sondek et al, 1996). The P 
subunit (lighter shading) is composed of an amino-terminal a  helix followed by a 
repeating module of seven similar P-sheets, each comprising four anti-parallel strands. 
The arrangement of the modules is such that each one forms a single “blade” of a 
propeller-like structure. The outer strand of each sheet, with the inner three strands of the 
following sheet, together constitute the structural unit that corresponds to the “WD” 
sequence (Neer et al, 1994).
The y subunit (darker shading) comprises two a  helical regions, but unlike the p 
subunit possesses no inherent tertiary structure. The N-terminal helices of the p and y 
subunits together form a coiled coil, whereas the remainder of the y subunit interacts 
extensively with the p-propeller domain of the Gp subunit.
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Figure 1,3. Structural comparison of the members of the PKC family.
The isoforms are depicted in four groups: conventional (cPKCs), novel (nPKCs), 
atypical (aPKCs) and the more divergent PKD/PKCp. The conserved (C1~C4) and 
variable (VI-V5) regions of PKC are indicated in the regulatory and catalytic domains. 
Conserved domain structure, where present, is indicated by identical shading.
1
Figure 1.4, Sequence comparison of the first intracellular loop of the 
glucagon receptor with that of the two calcitonin receptor isoforms.
In this figure, the primary sequence of the first intracellular loop of each of the two 
human isoforms of the calcitonin receptor (CTRl and CTR2) has been aligned with the 
corresponding regions of the human and rat glucagon receptors (GRs). It is appaient that 
the 16-residue stretch that is present in the human CTRl (Gorn et al, 1992), and which 
is believed to inhibit coupling of the receptor to Gq/11 (Nussenzveig et al, 1994), is 
absent from the CTR2 sequence and from that of the glucagon receptor.
RKLTTIFPLNWKYRKALSLGCQRVTLH human CTRl
RSL  GCQRVTLH human CTR2
SKL----------------- HCTRNAIH human GR
RKL----------------- HCTRNYIH rat GR
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CHAPTER 2
Materials and Methods
2.1. Materials
2,1.1* Radiochemicals
Amersham International
Amersham,
Buckinghamshire, U.K.
[8'-3H] adenosine 3', 5'-cyclic monophosphate 
[5', 8'-3H] adenosine 3', S'-cyclic monophosphate 
(3_[125i] iodotyrosyllO)glucagon 
[3H]-palmitic acid
D-myo [3H] inositol 1, 4, 5-trisphosphate
2,1,2, General reagents
BDH, MERCK Ltd
Poole, Dorset, U.K.
Gibco BRL
Paisley, Scotland, UK
Sigma
Poole, Dorset, U.K.
Citric acid
Ethylenediaminetetra-acetic acid (EDTA)
Glucose
Glycine
HEPES (N-2-Hydroxyethylpiperazine-N’ -2- 
ethane-sulphonic acid)
Methanol
T ris(hy droxymethyl)aminomethane
2,2,4-trimethylpentane 
Acetic acid 
Butan-l-ol
CHAPS (3- [(Cholamidopropyl)dimethylammonio] 
-1 -propane-sulfonate)
Ethyl acetate
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Fisons Scientific Equipment
Loughborough,
Leicestershire, U.K.
Boehringer Mannheim
Lewes, East Sussex, U.K.
Ethylene glycol-bis (p-aminoethyl ether)-
N,N,N',N'-tetra-acetic acid (EGTA) 
Triton X-100 
Tween-20
CaCl2
Dimethyl sulphoxide (DMSG)
Glycerol
KCl
KH2PO4 
MgS04  
NaHCOg 
Sodium acetate 
Sodium citrate
Sodium dodecyl sulphate (SDS)
Sucrose
Keyhole limpet haemocyanin (KLH) 
Triethanolamine hydiochloride
2.1,3* Biochemical reagents
Rhone Merieux
Harlow, Essex, U.K.
Worthington Biochemical
Freehold, New Jersey, U.S.A.
Sigma
Poole, Dorset, U.K.
Sagatal
Collagenase
3-isobutyl-1-methylxanthine (IBMX)
12-O-tetradecanoyIphorbol 13-acetate (TPA, PMA) 
Alkaline phosphatase
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Antipain
Aprotinin
ATP (adenosine 5’-triphosphate) 
p-mercaptoethanol 
Benzamidine hydrochloride 
Bromophenol blue 
BSA (bovine semm albumin)
Cholera toxin 
Collagen
Cyclic-AMP (adenosine 3’:5’~cyclic 
monophosphate)
Cytochalasin B
DowexlX8-400 (chloride form 200-400 mesh)
Glucagon
Glutathione
GppNHp (5 ’ -guanylylimidodiphosphate)
GTP (guanosine 5’-triphosphate)
Insulin 
Pepstatin A 
Phosphatidic acid
PMSF (phenylmethylsulphonyl fluoride)
Ponceau stain
Snake venom (from Hannah ophiophagus)
Sodium pymvate
Streptozotocin
TEMED (N,N,N’ ,N’ -tetramethylethylenediamine) 
Theophylline
Peptide Research Foundation Leupeptin 
London, U.K.
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Lipid products
Surrey, U.K.
BDH, MERCK Ltd
Poole, Dorset, U.K.
Calbiochem-Novabiochem
Nottingham, U.K.
Boehringer Mannheim
Lewes, East Sussex, U.K.
Miles Ltd
Slough, U.K.
Bio-rad Laboratories
Hertfordshire, U.K.
Eli Lilly & Co. .
Basingstoke, Hants, U.K.
National Diagnostics
Buckinghamshire, U.K.
May & Baker
Dagenham, UK.
Gibco BRL
Paisley, Scotland
Phosphatidyl butanol
Charcoal (Norit Gsx)
DTT (dithiothreitol)
Universal indicator
Forskolin
Inositol (l,4,5)“trisphosphate 
NP-40 (Nonidet"P40)
Creatine kinase
Creatine phosphate
Diabur-Test 5000 test strips
Nicotinamide adenine dinucleotide (reduced form)
Dextrostix test strips
30% acrylamide/bis-acrylamide mix (29:1) 
Bradford reagent
Humulin Lente (insulin zinc suspension)
Ecoscint, scintillation fluid 
Ammonium persulphate 
Pre-stained molecular’ weight markers
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Amersham Life Science
Amersham,
Buckinghamshire, U.K. 
SAPÜ
Carluke, Lanarkshire, 
Scotland, U.K.
MERCK
Darmstadt, Germany
ECL (enhanced chemiluminescence) reagents
Horseradish peroxidase-conjugated anti-rabbit IgG
Pierce
Beijerland, Holland
Pharmacia Biotech
Herts., U.K.
Agar
Peptone (tiyptone) from casein (pancreatically 
digested)
Yeast extract
Freund's complete adjuvant 
Freund's incomplete adjuvant 
Sulfo-MBS
Glutathione sepharose 4B beads 
Protein-A-sepharose
2*1*4, Molecular biology reagents
Boehringer Mannheim
Lewes, East Sussex, U.K.
Pharmacia Biotech
Herts,, U.K.
National Diagnostics
Buckinghamshire, U.K.
Sigma
Poole, Dorset, U.K.
Agai’ose
First strand cDNA synthesis kit
Sequagel-6 aciylamide mixture
Agarose (low melting point)
DEAE (diethylaminoethyl)-dexti’an
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Promega
Southampton, U.K.
Stratagene
Cambridge, U.K.
Invitrogen
San Diego, CA, U.S.A.
IBI
New Haven, CT, U.S.A.
DEFC (Diethyl pyrocarbonate)
Ethidium bromide 
Mineral oil 
Tri-reagent
Deoxyribonucleoside trisphosphates (dNTPs) 
MgCl2
Molecular weight markers 
Restriction enzymes 
T4 DNA ligase 
Taq buffer 
Taq polymerase
Wizard Mini, Maxi, PCR and Clean-up preps 
“Perfect match” PCR additive
MC1061/P3 strain of Escherichia coli
Ammonium persulphate (sequencing grade)
2*1,5, Plasmid DNA
Dr. M. Svoboda
Brussels, Belgium
Dr. P. J. Parker
London, England
cDNA encoding the rat hepatic GR (gift)
cDNAs encoding PKC-a, pll, and e (gifts)
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Dr. J. L. Benovic
Philadelphia , U.S.A.
Dr. E. Rozengurt
London, England
Dr. A. Katz
Pasadena, U.S.A.
Prof. G. Milligan
Glasgow, Scotland
BRL
Bethesda, U.S.A.
cDNAs encoding the bovine GRK2 and GRK3 
(gifts)
cDNA encoding the wild-type and mutant murine 
PKD(gift)
cDNAs encoding the G protein sub-units p i and y2 
(gifts)
cDNA encoding the p2 and p3 adrenoceptors 
pSV-Spoitl vector DNA
2,1,6, Tissue culture
2.1.6.1. Media
Gibco BRL
Paisley, Scotland, UK
2.1.6 2. Plastic ware 
Costar UK
High Wycombe, 
Buckinghamshire, U.K.
Dulbecco’s modification of Eagle’s medium
( 10%)
Foetal calf serum 
L-Glutamine (200 mM) 
Penicillin/Streptomycin (10000 lU/ml) 
Sodium bicarbonate (7.5%)
TiypsinÆDTA
50 ml centrifuge tubes
Falcon tissue culture flasks: 75 cm^
Filters (0.22}xm)
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Multi-well plates 
Tissue culture pipettes
2.1.7, Animal resources
Male adult Sprague-Dawley rats were purchased from commercial sources with 
weights ranging between 200 and 250g. Euthanasia was effected by the intraperitoneal 
injection of a lethal dose of Sagatal, and was confiimed by testing for the absence of eye 
reflexes and respiratory movement.
2.1.8, Cell lines 
COS-7 ceils
These cells were derived by the transformation of simian CV-1 cells with an origin- 
defective SV40 genome (Gluzman, 1981). They constitutively express wild-type SV-40 
large T antigen, and therefore permit the replication and expression of plasmids which 
contain an SV-40 origin and promoter region.
P9 cells
This is an SV40-immortalised hepatocyte-derived cell line described first by 
Livingstone et al. (1994). These cells express several enzyme activities that are 
characteristic of hepatocytes, including glucose-6-phosphatase, glycogen phosphorylase, 
and bilirubin glucuronyltransferase (Livingstone et al, 1994).
HEK 293 cells
This cell line was derived from human primary embryonal kidney cells by 
transformation with sheared human adenovirus type 5 (Ad 5) DNA (Graham et al, 1977; 
Harrison et al, 1977; Graham et al, 1978).
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2.2. Methods for genetic manipulation
2.2.1. Water purification
The water used for work involving DNA or RNA was purified by reverse osmosis 
and subsequently autoclaved.
2.2.2, Plasm id purification  
L-broth
171 mMNaCl 10.0 g/1
Bacto-tryptone (Casein/Pepsin) 10.0 g/1
Bacto-yeast extract 5.0 g/1
pH to 7.5 with NaOH, sterilise
SOB medium
8.56 mMNaCl 0.5 g/1
Bacto-tryptone 20.0 g/1
Bacto-yeast extract 5.0 g/1
2.50 mM KCl 10 ml of 250 mM KCl
pH to 7.0 with NaOH, sterilise
1 mM MgC12 (added before use) 0.5 ml of sterile 2M solution
For the large-scale purification of plasmid DNA for cell transfection, a single 
colony on an agar plate containing antibiotic was used to inoculate 5 ml L-broth or SOB 
medium containing an appropriate antibiotic, which was incubated in an orbital shaker at 
37 “C overnight. Following confirmation by plasmid mini-prep (see below) and 
restriction digest (see section 2.2.4.) that the plasmid of interest was indeed present in the 
cultured bacteria, a 2 litre conical flask containing 500 ml of culture medium was then 
inoculated with 500 jxl of the mini-culture. An overnight incubation was perfoimed as
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above, and the bacteria were subsequently pelleted, resuspended (in 50 mM Tris-HCl 
pH 7.5, 10 mM EDTA, 100 |lg/ml RNase A ), lysed (in 0.2 M NaOH, 1% SDS), and 
neutralised (in 1.32 M KAc pH 4.8). The DNA was then purified by a DNA-binding 
resin supplied in a Promega plasmid Maxi-Prep kit. All steps were performed according 
to the manufacturers' instructions except that 0.6 instead of 0.5 volumes of isopropanol 
were added, in order to improve yield. Additionally, following elution of the DNA in
1.5 ml water, phenol/chloroform extraction (see section 2.2.2.1.) and ethanol 
precipitation (see section 22.2.2,) was undertaken to remove any contaminating 
endonuclease co-purified from the endA positive MC1061/P3 strain of E. coli. The purity 
and concentration of the DNA solution was then assessed by UV absorbance as described 
in section 2.2.3.. The total yield from a 500 ml culture was typically 1-2 mg of plasmid 
DNA.
When a lower yield was acceptable (eg. less than 10 |xg), a Promega Mini-prep kit 
was used to purify plasmid DNA from 3 ml of an overnight culture. Again, all steps 
were performed according to the manufacturers' instractions, and the composition of the 
resuspension, lysis and neutralisation solutions was exactly as described above for the 
Maxi-prep kit.
2.2.2.1. Phenol/chloroform extraction
An equal volume of phenol was added to the DNA solution in a microcentrifuge 
tube and vortexed briefly. Subsequent phase separation was achieved by centrifugation 
at 12,000 gav in a benchtop microcentrifuge for 15 seconds. The aqueous (upper) phase, 
was then transferred to a new microcentrifuge tube leaving the interface layer containing 
the protein and the organic (lower) phase. Phenol addition and phase separation was 
repeated until no protein was visible at the interface. An equal volume of chloroform was 
then added and the tube vortexed briefly and centrifuged as above. The upper phase was 
again transferred to a fresh tube. Chloroform extraction was repeated once prior to 
ethanol extraction of the DNA.
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2,2.2.2. Ethanol precipitation
The DNA solution was divided in order that the maximum volume did not exceed 
400 pi per microcentrifuge tube. The solution was briefly vortexed and 0.11 volumes of 
3M sodium acetate (pH 5.2) were added. The tube was vortexed and 2 volumes of ice- 
cold absolute ethanol (analytical grade) were added. Following mixing, the tube was 
stored at -70 “C for at least 30 minutes, to allow full precipitation of the DNA. The tube 
was then centrifuged at 12,000 gav at 0 °C for 10 min, and the supernatant carefully 
discarded. In order to wash the pellet, 1 ml of 70% (v/v) ethanol was added, and the 
centrifugation performed at 12,000 gav at 0 °C for 2 min. The supernatant was carefully 
removed and discarded, and the wash was repeated once. The tube was then stored open 
on the bench to allow evaporation of any remaining fluid. The DNA pellet was 
subsequently resuspended in purified water.
2.2.3, Determination o f DNA concentration and purity
Using a Bio-Rad UV spectrophotometer, the absorbance, or optical density (OD), 
of a 5 pi sample of the DNA solution, diluted to 1 ml in H2O, was determined at 
wavelengths of 260 nm and 280 nm in quartz cuvettes. Following the subtraction from 
these readings of the OD of H2O alone, the purity of the DNA was determined by the 
division of the OD260 by the OD280» yielding, ideally, a result of 1.8 to 2.0. The 
concentration was determined by the multiplication of the OD260 by the dilution factor 
(200) and by a constant (50 pg/ml). Alternatively, when measuring the concentration of 
a solution of oligonucleotide primer, the constant used was 33 pg/ml.
2.2.4, Restriction Digest
Restriction enzymes were stored at -20°C and were kept on ice during the 
prepai'ation of digests. Typically, reactions were prepared in a microcentrifuge tube by 
adding 7 pi deionised water to 10 pi DNA solution (containing approximately 1 pg 
DNA), 2.0 pi lOx restriction enzyme buffer and 1 pi restriction enzyme. The buffer 
composition was chosen carefully in order to provide the optimum conditions for the 
activity of the individual restriction enzyme. The contents of the tube were mixed gently
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and centrifuged briefly. Incubation was performed at 37 °C in a water bath for 2 hours. 
In some cases, the digestion of DNA with two enzymes simultaneously was performed, 
and in such cases the buffer was chosen so as best to suit both enzymes. Confirmation 
of digestion of the DNA was obtained by running a sample (at least 0.3 pg) on an 
agarose minigel.
2,2,5. Agarose gel electrophoresis
TAE (Tris-acetate/EDTA electrophoresis buffer)
40 mM Tris-acetate (in Ix) 242 g/1 (for 50x stock)
5.71 % (v/v) glacial acetic acid 57.1 ml
1 mM EDTA, pH 8.0 100 ml 0.5 M EDTA, pH 8.0
DNA samples were separated by electrophoresis through an agarose gel of a 
selected concentration ranging from 0.8% to 2.0% (w/v), depending on the lengths of the 
DNA fragments to be resolved. Typically a 2% agarose minigel was used. Thus 0.4 g 
of agarose was mixed with 20 ml of TAE buffer and heated in a microwave oven until 
the agarose had dissolved completely. Subsequently, 1 pi of 10 mg/ml ethidium 
bromide was added, and, after allowing the gel to cool to about 60 °C, the gel mixture 
was poured into a casting tray assembly with casting blocks and an 8-well gel comb in 
place. Each DNA sample to be loaded was prepared by mixing a 10 pi DNA sample 
with 2 pi loading dye (Promega). In each minigel, one lane was also loaded with DNA 
markers, specifically À/HindlII (Gibco BRL), d>X174/HaeIII (Promega) or a 1 kb ladder 
(Gibco BRL). After allowing the gel to set at room temperature, the comb and casting 
blocks were removed and the gel and electrodes submerged in the electrophoresis tank in 
a volume of 200 ml TAE. The samples were then carefully loaded into the wells and the 
electrodes connected to a power supply. Electrophoresis towards the anode was then 
undertaken at a constant 75 volts at room temperature until the first dye front reached 2
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cm from the end of the gel. Visualisation of the DNA was then performed using an 
ultraviolet light, and photographs were taken using a digitising camera.
2.2.6. Purification of DNA from  an agarose gel
Where DNA was to be excised from an agarose gel, DNA fragments were separated 
on a gel consisting of low melting point agarose. Following electrophoresis, the 
fragment was visualised with ethidium bromide under ultraviolet light and a slice of the 
gel containing the entire DNA fragment excised with a scalpel blade. The agarose slice 
was subsequently melted at 70 “C for 2 min in the presence of 1 ml Promega PCR prep 
resin. The mixture was vortexed and the DNA purified on the columns supplied with the 
Promega PCR prep kit as described in the manufacturers' instructions.
2.2.7. Phosphatase treatment o f  DNA
Prior to ligation of an insert into a vector cut with a single restriction enzyme, the 
plasmid DNA was tieated with calf intestinal alkaline phosphatase (CIAP). The CIAP 
removes the 5' phosphate groups and thus prevents recirculaiization of the vector during 
ligation. The following were added in a microcentrifuge tube: 2 pg vector DNA 
(equivalent to 2 pmol ends for a 3000 bp plasmid), 10 pi CIAP lOx buffer, 1 pi CIAP 
and H2O to a total volume of 100 pi. The contents were mixed gently, centrifuged 
briefly and incubated for 1 hour at 37 °C. The reaction was terminated by the addition of 
2 pi of 0.5 M EDTA. Prior to ligation of the phosphatase-treated vector to the insert 
DNA, removal of the CIAP was effected by the use of Promega's DNA Clean-up resin, 
as CIAP can interfere with efficiencies of ligation and transformation reactions.
2.2.8. DNA ligation
Prior to ligations, the vector DNA was digested (see section 2.2.4.), if necessary 
treated with alkaline phosphatase (see section 2.2.7.) and purified with Promega’s Clean­
up resin. The insert DNA, was prepared by digestion of either plasmid DNA or PCR 
DNA, and purified in the same way. Ligation reactions were prepared by the addition of
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vector DNA and insert DNA, in varying ratios, prepared as above, to 0.5 pi T4 DNA 
ligase (3 units/pl) and 1 pi of lOx ligase buffer (300 mM Tris-HCl pH 7.8, 100 mM 
MgCl2, 100 mM DTT, 10 mM ATP) in a total volume of 10 pi. Additional reactions, 
serving as controls, were also prepared and incubated, containing, in the absence of 
insert DNA, vector DNA which was either phosphatase-treated (testing the phosphatase 
efficiency) or not (testing the ligase efficiency). The reactions were left overnight at 
room temperature and subsequently used to transform competent E. coli.
2.2.9. Preparation o f competent E. coli 
RFl buffer
100 mMRbCl 2 0 ml/dl 0.5MRbCl
50 mM MnCl2.4 H2 0 5.0 ml/dl 1.0 MMnCl2
30 mM potassium acetate 3.0 ml/dl 1.0 M KAc
10 mM CaCl2 1.0 ml/dl 1.0 MCaCl2
15 % (v/v) glycerol 18.8 ml/dl 80% glycerol
pH to 5.8 with 0.2M acetic acid.
Filter sterilise (0.22 pm) and store a t4 T .
RF2 buffer
10 mMRbCl 2 .0  ml/dl 0.5MRbCl
10 mMMOPS 2 .0  ml/dl 0.5 M MOPS
75 mMCaCl2 7.5 ml/dl l.OMCaCL
15 % (v/v) glycerol 18.8 ml/dl 80 % glycerol
pH to 6.8  with 0.2 M NaOH.
Filter sterilise (0.22 pm) and store at 4 °C.
Bacteria of either the JM109 or MC1061/P3 strain of E.Coli were grown overnight 
in an orbital shaker at 37 “C after inoculating 10 ml L broth or SOB medium 
(respectively) from a glycerol stock of E, coli. 5 ml of this culture was then used to
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inoculate the 500 ml of the appropriate medium and this was incubated at 37 °C until the 
culture reached mid-log phase (OD550 = 0.5-0.55). It was then poured into 250 ml 
centrifuge containers and allowed to cool on ice for 30-60 min prior to harvesting the 
bacteria by centrifugation for 10 min at 7,500 gav at 4 °C. From each 250 ml container 
the supernatant was decanted and the bacteria resuspended in 20 ml sterile ice cold RFl 
solution. The suspension of cells was incubated on ice for 15 min and then centrifuged 
for 20 min at 1,500 gav at 4 “C. The supernatant was again discarded and the pellet 
resuspended in 3.5 ml per tube of sterile ice cold RF2 buffer. The suspensions were 
pooled into one tube and again incubated on ice for 15 min. Aliquots of 225pl were then 
snap frozen in liquid N2 in sterile microcentrifuge tubes and stored at -80°C.
2.2.10, Transformation
100 pi of competent cells were mixed with 5 pi of each of the ligation reactions, 
and incubated on ice for 30 min. For additional controls, aliquots of competent cells 
were incubated with undigested vector (testing transformation efficiency), digested but 
unligated vector (testing digestion efficiency), or no DNA (testing the ampicillin in the 
agar and confirming that the untransformed E. coli were not ampicillin-resistant). The 
bacteria were then placed in a 42 °C bath for exactly 2 min and returned to ice for 5 m in. 
To each tube, 1 ml L-broth was then added and the mixture incubated, with shaking, at 
37 °C for 1 hour. From each tube, 100 pi was then streaked onto selective 1.5% (w/v) 
agar plates containing 50 pg/ml ampicillin. In addition a plate of agar without antibiotic 
was streaked with untransformed E. coli to check the viability of the bacteria. Where the 
MC1061/P3 strain of E. coli was used instead of the JM109 strain, SOB medium was 
used in place of L-broth, and tetracycline at 7.5 pg/ml was added in addition to 
ampicillin. The culture plates were subsequently incubated at 37 °C overnight and 
examined for the presence of colonies.
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#2.2.11. Transient transfection
TE buffer
10 mM Tris.HCl (pH 7.4) 1.21 g/1
1 mM EDTA (pH 8.0) 2 ml 0.5 M EDTA, pH 8.0
Exponentially growing COS-7 cells, 40-60% confluent, were transfected, where 
indicated, with expression vectors encoding the glucagon receptor (in pCDM8 ), PKC-a 
(in pMT2), PKC-PII (in pC02), PKC-e (in pMT2), pARKl and PARK2 (each in 
pBC12BI), p2"adrenoceptor (in pcDNA3), pg-adrenoceptor (in pcDNA3-RSV), and both 
mutant and wild-type PKD (in pcDNA3) using the DEAE-dextran method as described 
previously by Al-Molish et al. (Al-Molish and Dubes, 1973). Briefly, for each 75 cm  ^
flask to be transfected, 5 pg plasmid DNA was diluted with TE to a total volume of 
250 pi and mixed with 200 pi of 10 mg/ml DEAE dextran solution. This was left at 
room temperature for 15 min and then added to 5 ml DMEM containing 10% (v/v) 
newborn calf serum and 100 pM chloroquine. The medium was aspirated from the COS 
cells and the above mixture added. Following an incubation period of 3 hours at 37 "C, 
the cells were shocked by replacing the medium with 5 ml dimethylsulphoxide (DMSO) 
10% (v/v) in phosphate-buffered saline (PBS). This was aspirated after exactly 2 min 
and the cells washed with 10 ml PBS before 10 ml DMEM containing 10% (v/v) foetal 
calf semm (FCS) was added. After an incubation at 37 °C for 2 days the cells were split 
into 6-well plates and subsequently grown to confluence in DMEM supplemented as 
above. Cells were stimulated approximately 72 hours following transfection, as described 
in section 2.4.14.1..
2.2.12. RNA extraction
Total cellular RNA was exti'acted by the acid guanidinium thiocyanate-phenol- 
chloroform extraction method (Chomczynski and Sacchi, 1987) from confluent 
monolayers of COS-7 cells, suspensions of isolated hepatocytes or from fresh samples of 
rat tissue. Briefly, approximately 100 mg tissue was homogenised in 1 ml Tri-reagent
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using a sterilised glass homogeniser. Alternatively a confluent monolayer of COS cells in 
a 75 cm^ flask was washed with sterile PBS (10 ml) and then harvested using a cell 
scraper into 1 ml Tri-reagent. Where hepatocytes were used, 5x10^ cells were pelleted 
by centrifugation at 1,000 gav for 5 min followed by resuspension and lysis by repetitive 
pipetting in 1 ml Tri-reagent. In each case the lysate was stored at room temperature for 
5 min and 1 ml subsequently transferred to autoclaved microcentrifuge tubes. In order 
to remove the cell membranes and high molecular weight DNA, the tubes were 
centrifuged at 12,000 gav for 10 min at 4 °C and the supernatant transferred to fresh 
tubes. To separate the RNA from DNA and protein, 0.2 ml chloroform was added, and 
the tube vortex-mixed. After storing the tube at room temperature for 3 min, phase 
separation was performed by centrifugation at 12,000 gav for 15 min at 4 °C, and the 
aqueous (upper) phase transferred to fresh tubes.
To precipitate the RNA, 0.5 ml of isopropanol was added. The mixture was then 
stored at room temperature for 5-10 min, and centrifuged at 12,000 gav for 10 min at 
4 °C. The supernatant was removed and the pellet washed by adding 1 ml of 75% (v/v) 
ethanol, vortexing for 15 sec and centrifuging at 7,500 gav for 5 min at 4 °C. Finally, 
the RNA pellet was dried in vacuo and re-solubilised in di-ethyl pyrocaibonate (DEPC) 
treated water by repetitive pipetting and incubating for 10-15 min at 55-60 °C. The RNA 
concentration was then determined as described below (section 2.2.13.).
2.2.13. Determination o f RNA concentration
Using a Bio-Rad UV spectrophotometer, the absorbance, or optical density (OD), 
of a 5 111 sample of the RNA solution, diluted to 1 ml in H2O, was determined at a 
wavelength of 260 nm in a quartz cuvette. Following the subtraction from this reading of 
the OD of H2O alone, the concentration was determined by the multiplication of the 
OD260 by the dilution factor (200) and by a constant (40 pg/ml).
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■I2.2,14, First strand cDNA synthesisFirst strand cDNA was prepared by the use of the Moloney Murine Leukaemia 
Virus (M-MuLV) reverse ti'anscriptase and oligo-dT primer, provided with the Pharmacia 
First-strand cDNA Synthesis Kit. Briefly, 5 pg of RNA, as determined by its 
absorbance at 260 nm, was diluted in DEPC-treated water to a total volume of 20 pi and
denatured by heating it for 10 min at 65 °C then chilling on ice. The solution was then 
added to 11 pi of "Bulk First-strand cDNA Reaction Mix", containing cloned M-MuLV
reverse transcriptase, RNAguard, BSA, and dNTPs in an aqueous buffer. To this was 
then added 1 pi of 200 mM DTT, and 1 pi (0.2 pg) of the supplied poly (dT) primer 
(Notl-d(T)is), the solution was mixed gently by pipetting, and the mixture incubated for 
Ih at 37 °C. In the complete reaction mixture the buffer and dNTP conditions were:
45 mM Tris (pH 8.3)
68 mM KCl 
15 mM DTT
I9 mM MgCl]0.08 mg/ml BSA 
1.8 mM each dNTP
After synthesis, cDNA was used immediately as a template for PCR or stored at 
-80T.
2.2.15. Polymerase chain reaction (PCR)
2.2.15.1. Design of oligonucleotide primers for PCR
Oligonucleotide PCR primers were designed using the GeneJockey II program. 
Typically primers were of approximately 20 bp in length, and members of each primer 
pair were designed so as to have approximately equal melting temperatures. The extreme 
3' ends of each oligonucleotide contained at least two C or G nucleotides and were 
checked for complementarity with the other member of the primer pair in order to reduce 
the likelihood of "primer-dimer" formation. Sequences that could potentially form 
significant secondary structure or which contained sti’etches of polypurines or
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polypyrimidines were avoided. To identify regions with homology to other sequences, 
sequence alignments were undertaken with the aid of the GeneJockey II and Lasergene 
software packages. In addition, prior to oligonucleotide synthesis, the specificity of each 
primer sequence was verified by performing a BLAST (Basic Local Alignment Search 
Tool) computer search of the Genbank nucleotide sequence database.
2.2.15.2, Preparation of PCR oligonucleotide primers
Synthesis of the primers was performed by Dr. Veer Math of the Institute of 
Biomedical and Life Sciences of the University of Glasgow. Synthesized primers were 
supplied in an aqueous solution of ammonium hydroxide and, before use, were purified 
by ethanol precipitation (see section 2.2,2.2.), quantified (see section 2.2.3.) and diluted 
to the required concentration in H2O.
2.2.15.3. PCR conditions
PCR was performed, unless otherwise stated, in the presence of 1 x Taq buffer 
(50 mM KCl, 10 mM Tris.HCl, pH 9, 0.1% Triton X-100), 1.5 mM MgCfy, 40 \iM of 
each dNTP, 1.5 pM of each primer, 3 pi of first-strand cDNA synthesis reaction, 5 units 
of Taq polymerase and 0.5 units of Perfect Match® DNA polymerase enhancer in a total 
volume of 50 pi. 35 thermal cycles were undertaken, each consisting, typically, of a 
1 min dénaturation segment at 95 “C, a 2 min annealing step at 52.5 “C and a 3 min 
extension time at 72 °C. PCR products were resolved by electrophoresis on a 2% agarose 
gel with ethidium bromide and visualised under UV light. Prior to the use of PCR 
products as substi'ates for further enzymatic reactions, the DNA was purified from the 
other constituents of the PCR reaction by the use of Promega's PCR Prep resin, 
according to the manufacturers' instructions.
2.2.16. Site’•directed mutagenesis
The strategy used to perform site-directed mutagenesis was essentially that of 
overlap extension PCR (Ho et al, 1989). Briefly, two pairs of PCR oligonucleotide 
primers were designed with complementarity between the 3' primer of one pair and the 5'
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fprimer of the other pair. Thus, PCR reactions were used to generate two DNA products 
with overlapping ends. The novel DNA sequence containing the desired specific 
nucleotide substitutions was incorporated into the region of overlap. In a subsequent 
'fusion' reaction, the overlapping ends were permitted to anneal, allowing the 3' overlap 
of each strand to serve as a primer for extension, with the other member of the
the resulting product DNA.
sequencer linked to a Macintosh H computer mnning the SeqEd data collection and
template DNA 8.5 pi
primer (SP6  or T7) 2  pi
5x buffer 4 pi
dNTP mix 1 pi
dideoxy GTP 1 pi
dideoxy CTP 1 pi
dideoxy TTP 1 pi
dideoxy ATP I pi
AmpliTaq® DNA polymerase 0.5 pi
3.2 pmol
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overlapping primer pair serving as template. The product of this fusion reaction was then 
amplified by successive rounds of PCR, thus incorporating the mutant sequence into all
2.2.17. Automated DNA sequencing
The determination of DNA sequence was undertaken using an automated ABI
analysis program. I'l;
2.2.17.1. PCR reactions
DNA samples to be sequenced were first purified by mini-prep or maxi-prep. In 
addition, subsequent ethanol precipitation was found to improve markedly the quality of 
the data obtained. The purified DNA was used as a template for a PCR reaction 
containing dideoxyNTPs in order to generate a mixture of prematurely terminated single 
strand DNA products of varying lengths. Each PCR reaction was prepared as follows:
1.5 pg
I
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The mixture was overlaid with 40 pi mineral oil and transferred to a thermocycler 
with the following preset programme, with the ramp rate set at 1 “C per second, for a 
total of 30 cycles:
Dénaturation 96 °C 30 seconds
Annealing 45 “C 50 seconds
Extension 60 °C 4 minutes
2.2.17.2. Sequencing gel preparation
The glass plates were washed with the detergent, Alconox, and then rinsed with 
water followed by absolute ethanol. The spacer, casting comb, and sharkstooth comb 
were washed in a similar fashion but with the exclusion of ethanol. Once dry, the plates 
and spacers were assembled and the lower edge sealed with tape. Using Sequagel-6  
(National Diagnostics) pre-mixed acrylamide solutions, 48 ml solution A was added to 
12 ml solution B, and 480 pi of freshly prepared 10 % (w/v) ammonium persulphate 
was added. This mixture was then poured slowly into the gel assembly with the latter 
inclined at an angle of approximately 30% taking care to avoid the introduction of air 
bubbles. When almost completely filled, the plates were laid flat and the casting comb 
inserted. After allowing the gel to cure for two hours, the tape was removed and the gel 
placed in the ABI sequencer. The upper and lower reservoirs were filled with running 
buffer and the casting comb removed. Prior to sample loading, the gel was scanned for 
contaminants and pre-mn according to the instructions in the user manual.
2.2.17.3. Sequence sample purification and loading
The samples were removed from the thermocycler and 80 pi water was added 
beneath the layer of mineral oil. The aqueous (lower) phase was transferred to a fresh 
0.5 ml tube, to which 100 pi phenol/chloroform/water was then added. After vortexing 
briefly, the mixture was centrifuged for 30 seconds at 12,000 gav in a microfuge. The 
aqueous (upper) phase was then ti'ansferred to another tube and the phenol/chloroform 
extraction repeated. Ethanol precipitation was performed as described in section 2.222.
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and the pellet diied by heating to 85 “C for 1 min. Finally, the pellet was resuspended in 
4 pi deionised formamide, and, prior to loading onto the gel, the samples were heated to 
90 “C for 3 min and placed on ice. With the sharkstooth comb in place, the samples 
were loaded and the sequencer switched on.
2.2.17.4. Data collection and analysis
Data from the sequencer was collected continuously during the electrophoresis of 
the samples and stored in a computer file by the SeqEd program. When electrophoresis 
was complete, the file was opened from within the GeneJockey H program and the mis­
reading frequency examined (see fig. 2.1). All stretches of sequence with an error 
frequency of 10 % or more were discarded prior to exporting the sequence into a 
GeneJockey nucleotide file for subsequent analysis.
I
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2.3. Methods for antiserum production
2.3.1. Generation o f peptide antisera
Polyclonal antisera used for immunoblotting were raised in New Zealand White 
rabbits against synthetic peptides. Where the peptide sequence itself did not contain a 
cysteine, these were synthesised with an additional cysteine at the C-terminus in order to 
facilitate conjugation to keyhole limpet haemocyanin (KLH).
2.3.2. Coupling peptides to KLH  
2.3.21. Solutions for coupling
Sodium phosphate
50 mM NaH2PO4 .H2 0  6.85 g/1
0.04 M NaOH 40 ml/1 IM NaOH
N-ethylmaleimide
300 mM N-ethylmaleimide 38 mg/ml
Sodium phosphate/sodium chloride
20 mM NaH2P0 4 .H2 0  2.75 g/1
135 mMNaCl 7.85 g/1
pH to 5.6 and to 8.0 with 1 M NaOH
2.3.2.2. Coupling method
Prior to conjugation, the KLH was prepared as follows: 20 mg KLH was 
dissolved in 2 ml 50 mM sodium phosphate and dialysed overnight against this buffer to 
remove amines. To the dialysed KLH was then added 17 pi of 0.3 M N-ethylmaleimide 
(5 pmol). After 30 minutes 6.2 mg (15 pmol) sulfoMBS was added, and, after a further 
30 minutes, the pH was adjusted to 6.0 by adding IM HCl (approximately 50 pi). The 
solution was then dialysed overnight at 4 “C against 20 mM sodium phosphate.
85
135 mM NaCl pH 5.6 to remove unreacted or hydi'olysed sulfo-MBS. Subsequently, an 
equal volume of 20 mM NaPO4/150 mM NaCl, pH 8 , was added at room temperature. 
The pH was checked and adjusted to pH 6 .6 ~6 .8 .
The peptide (9 mg) was then added immediately and dissolved by vigorous 
vortexing. Following re-adjustment of the pH to 6.7 with 1 M NaOH, the solution was 
incubated for 4 hours, at room temperature.
2.3.3. Expression and preparation of GST fusion protein
Protease inhibitors (lOOOx stock)
0 .1 % (w/v) aprotinin 
0.1  % (w/v) antipain 
0.1  % (w/v) pepstatin 
0.1  % (w/v) leupeptin 
1 mM beiizamidine 
1 mM PMSF 
solubilised in DMSO and stored in aliquots at -20°C
2.3.3.1, Induction of E. coli
Previously, using a pGEX vector, an in-frame GST fusion protein construct had 
been generated using PCR, that encoded GST linked to the C-terminal portion of the rat 
glucagon receptor. Glycerol stocks of bacteria tr ansformed with the recombinant plasmid 
were frozen at -80 "C. In order to generate the fusion protein, 15 ml of L-broth 
(containing ampicillin) was inoculated with 2 0  pi of the glycerol stock, and the culture 
was incubated at 37 °C overnight. A 500 ml culture was then inoculated with the 15 ml 
overnight culture and incubated at 37 °C for 2 hours. Filter-sterilised IPTG was then 
added to a final concentration of 0.1 mM and the culture incubated for a further 5 hours. 
The bacteria were then pelleted by centrifugation at 4,000 gav for 15 min at 4 °C and 
resuspended in 20 ml PBS containing protease inhibitors. The suspension of bacteria 
was then divided into aliquots of 1 ml and frozen at -80 °C until use.
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2.3.3.2. GST fusion protein extraction
Aliquots of frozen bacteria were thawed and sonicated for 4 x 10 seconds or until 
the cells had lysed. Unlysed cells and debris were then pelleted by centrifugation in a 
microfuge for 5 min.
2.3.3.3. Verification of induction
In order to confirm that induction of expression of the fusion protein had taken 
place, following centrifugation, 10 pi from the supernatants of both the bacteria 
containing the hision protein and of bacteria containing only the original GST vector, 
were boiled with 10 pi Laemmli (Laemmli, 1970) buffer and loaded onto an SDS 
polyacrylamide mini-gel. Following electrophoresis the gel was removed from the glass 
plates and stained for protein.
2.3.3.4. Gel staining, destaining and drying
This procedure was carried out as described previously (Sambrook et ah, 1989). 
Following electr ophoresis, gels were soaked, with gentle shaking on a rotary shaker, for 
1 h in 45% (v/v) methanol, 10% (v/v) acetic acid containing 0.25% (w/v) Coomassie 
Blue R-250. Gels were destained hy washing with 45% (v/v) methanol, 10 % (v/v) acetic 
acid with frequent changes of the wash solution, and finally re-hydrated by immersion in 
water. Gels were subsequently dried down onto Whatman 3MM paper under vacuum at 
60°C for two hours.
2.3.3.5. Fusion protein purification
Pre-swollen glutathione sepharose 4B beads were prepared by adding an equal 
volume of PBS containing protease inhibitors followed by pelleting for 10 sec in a 
microfuge. This wash was performed three times, and the beads subsequently 
resuspended to give a 50% (v/v) slurry. Binding was carried out by mixing 1 ml of 
supernatant containing the GST fusion protein (obtained as described in section 2.3.3.2. 
above) with 100  pi of the bead slurry, and incubating the mixture, end over end, for 
60 min at room temperature or overnight at 4 “C. The beads were then subjected to three 
washes, each consisting of a 10 sec centrifugation, aspiration of the supernatant, and a
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5 min incubation with 1 ml PBS containing protease inhibitors. At this stage an aliquot 
of beads was assayed for protein content by the method of Bradford (Bradford, 1976). 
In order to release the bound fusion protein, the washed beads, after pelleting, were 
incubated for 10 min with an equal volume of 10 mM glutathione in 50 mM Tris-HCl 
pH 8.0, centrifuged as above, and the supernatant removed and retained. This was 
performed three times and the retained supernatants combined.
2.3.4. Immunisation
Prior to immunisation, 200 pi of the solution, containing approximately 250 pi 
conjugated peptide, was mixed with 200 pi sterile PBS and 600 pi Freund's complete 
adjuvant. One month later the immunisation was boosted with the same peptide solution 
but mixed instead with Freund's incomplete adjuvant, and the first test bleed was 
performed after a further ten days.
2.3.5. Preparation o f anti-serum
5-10 ml blood was obtained from the ear vein of rabbits and left overnight at 4°C 
to allow clot formation and contraction. The blood was then centrifuged at 1000 g for 
5 min, the serum was removed and re-centrifuged at 1,000 g for 5 min. The supernatant 
was retained and then divided into 50 pi aliquots and stored at -80
-
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2.4. Methods for biochemical analysis
2.4.1. SDS polyacrylamide electrophoresis
Resolving gel mix (8%) for two gels 
27.8 ml water
16.0 ml acrylamide mixture
15.0 ml resolving gel buffer 
0.6 ml 10% (w/v) SDS
0 .6  ml 10% (w/v) ammonium persulphate 
36 pi TEMED
Stacking gel mix (5%) for two gels
13.6 ml water
3.4 ml acrylamide mixture
2.5 ml stacking gel buffer 
0.2 ml 10% (w/v) SDS
0 .2  ml 10% (w/v) ammonium persulphate 
20 pi TEMED
Resolving gel buffer
1.5 M Tris, pH 8.8  181.7 g/1
Stacking gel buffer
1.0 M Tris, pH 6.8  121.1 g/1
Electrophoresis buffer
191 mM glycine 14.4 g/1
25 mMTris 3.0 g/1
0.1 % (w/v) SDS
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Laemmli sample buffer (for 20 ml)
3.5 ml water
2.5 ml stacking gel buffer
5.0 ml glycerol
8.0 ml 10% (w/v) SDS
0 .0 0 1  % (w/v) bromophenol blue
1.0  ml p-mercaptoethanol
The gel appar atus, consisting of two glass plates (measuring 160 mm x 180 mm) 
separated by 1.5 mm plastic spacers was assembled and clamped in place in a casting 
stand, after the plates and spacers had been thoroughly cleaned with ethanol and H2O. 
The assembly was subsequently checked, by filling with distilled water, for leakage. 
Following the addition of the TEMED and 10% (w/v) APS to initiate polymerisation,
25 ml of 8 % resolving gel mixture (see above) was introduced between the plates, 
overlaid gently with distilled water, and allowed to set. The water was then poured off, 
and, with a 10-well gel comb in place, the stacking gel mixture was added, taking care 
not to introduce air bubbles. After polymerisation of the stacking gel, the comb was 
removed and the assembly transferred from the casting stand to an electrophoresis tank, 
containing the anode submersed in 4.5 litres of running buffer. The remaining running 
buffer was poured into the upper reservoir, thus immersing the cathode. Samples were 
prepared by adding to each an equal volume of freshly prepaied 2x sample buffer and an 
appropriate volume of H2O to bring the total volume of each sample to 50 pi, unless 
otherwise stated. All samples were then placed in a boiling water bath for 3 minutes, and 
loaded into the appropriate wells. Pre-stained molecular weight protein standar ds (see 
section 2.4.2.) were loaded in one well for comparison. Electrophoresis towards the 
anode was performed at a constant current of 7 mA overnight or 60 mA for 
approximately 3 hours with constant cooling, until the bromophenol blue dye front 
reached 1 cm from the lower edge of the plates.
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2.4.2. Protein molecular weight markers
Pre-stained protein molecular weight standards comprising myosin H-chain (200 
kDa), phosphorylase B (97.4 kDa), BSA (68  kDa), ovalbumin (43 kDa), carbonic 
anhydrase (29 kDa), p-lactoglobulin (18.4 kDa) and lysozyme (14.3 kDa) were 
purchased from Gibco and were made up as described by the manufacturers. Briefly,
500 pi 1 mM dithiothieitol (DTT) was added to the vial of standards. The contents were 
boiled for 5 minutes, vortexed and then aliquoted into 20 pi aliquots and stored at -20 ”C. 
When required, an aliquot was thawed and an equal volume of sample buffer added. The 
vial was boiled for 3 minutes with the rest of the samples, then 20 pi was applied to the 
gel.
2.4.3. Western blotting
Electro-blotting buffer
191 mM glycine 14.4 g/1
25 mMTris 3 .0g/1
2 0  % (v/v) methanol
Tris-buffered Saline (TBS)
0.5 M NaCl 29.2 g/1
20 mM Tris, pH 7.5 2.42 g/1
Protein transfer from the SDS gel to nitrocellulose was performed in electro-blotting 
buffer in a Transblot apparatus (Hoefer Instruments) using a 1 h transfer time at a 
constant current of 1 amp. The blots were blocked for 2h at room temperature in 5% 
(w/v) skimmed milk powder in TBS, to prevent any non-specific antibody binding.
After washing twice with TBS/0.05% (v/v) Nonidet P-40 and twice with TBS, each for 5 
minutes, the nitrocellulose was incubated with the designated antiserum, diluted 1:100  in
TBS containing 1% (w/v) skimmed milk powder, for 2 h at room temperature. The
blots were then washed four times for 10 min each with TBS/0.05% (v/v) Nonidet P-40
91
and probed with horse-radish peroxidase-linked anti-rabbit IgG antiserum at a dilution of 
1:500 in TBS containing 1% (w/v) skimmed milk powder, for 30 min at room 
temperature. Following a further four washes for 10 min each with TB S/0.05 % Nonidet 
P-40, the blots were finally rinsed in TBS and immuno-detection carried out using an 
Amersham enhanced chemiluminescence (ECL) kit. This procedure was undertaken as 
per the manufacturers’ instructions, using both photosensitive Amersham film and X-ray 
film with various exposure times.
The isoform-specific PKC antisera were generated and characterised previously in 
our laboratory (Tang et al, 1993; Spence et al, 1995). The PKD-specific polyclonal 
antiserum (PA-1), raised against a 15-residue peptide contained within the C-teiminal 
region of mouse lung protein kinase D (Valverde et al, 1994), was a kind gift from Dr E. 
Rozengurt.
2.4.4. De-hybridisation o f antibodies from  nitrocellulose 
membranes
De-hybridisation solution
100 mM p-mercapto-ethanol 0.781 % (v/v)
2 % (w/v) SDS
62.5 mM Tris-HCl pH 6.7 62.5 ml IM Tris pH 6.7 per litre
The nitrocellulose was incubated at 50“C in the pre-warmed de-hybridisation 
solution for 30 rain, with agitation every 10 min. Subsequently, the membrane was 
washed 6  times for 5 min with TBS/0.05% NP40, and then processed again with the 
ECL immuno-detection kit to verify the complete absence of signal prior to re-blocking 
and re-probing.
2.4.5. Immunoprécipitation
The source material for the specific immunoprécipitation of -glucagon binding 
activity was a hepatocyte membrane fraction (1.75 mg of starting material) solubilised by
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CHAPS detergent. The solubilisation mixture comprised 25 mM HEPES pH 7.5;
137 mM NaCl; 2 mM EDTA pH 8.0; 6  mM CHAPS; and Ix protease inhibitor 
"cocktail" (see section 2.3.3.). After a period of 30 min on ice during which the 
constituents were agitated every 10 min, any unsolubilised membranes were pelleted by 
centrifugation at 245,000 gav for 30 min at 4“C. Antisemm was added to each sample of 
the supernatant at a dilution of 1:50 and the samples briefly vortexed before being left 
overnight at 4°C in order to allow conjugation to occur. Pansorbin (2% w/v final) was 
then added and the resultant suspension gently mixed at 4°C for 2h. The preparations 
were then centrifuged at 14,000g for 2 min and the pellets were resuspended in the 
immunoprécipitation buffer (25 mM HEPES pH 7.5; 137 mM NaCl; 2 mM EDTA pH 
8.0; and Ix protease inhibitor "cocktail") before being recentrifuged as before. The 
resultant pellets were then washed twice more. The final pellet was resuspended in 
binding assay buffer and assayed immediately.
2.4.6. Induction and treatment o f diabetes in rats
Adult male Sprague-Dawley rats were injected, by the intraperitoneal route, with 80 
mg/Kg streptozotocin dissolved in 0.3 ml O.IM sodium citrate, pH 4.5. After 4 days, 
the presence of glucose in the urine was tested using Diabur-Test 5000 (Boehiinger 
Mannheim) test strips, to confirm the induction of diabetes mellitus. Animals which were 
treated with insulin, received 10 units of a long-acting insulin prepar ation (Humulin 
Lente), every 12 hours, for 7 days. Urine was checked as above to confirm the absence 
of glucose. At the time of dissection of killed rats, the level of blood glucose, detemiined 
using Dextrostix, was found to be 15-20 mM for untreated diabetic rats and to be 
approximately 5 mM both for control animals and for those diabetic rats which had been 
treated with insulin.
2.4.7. P^^I]-glucagon binding
This was done using a modification of a procedure described previously (Houslay 
et al, 1977). Briefly, membranes were incubated at a final concentration of l(X)-200pg
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protein/ml in a final reaction volume of 100 |xl containing 0.1% (w/v) BSA, 1 mM 
EDTA, 20 mM Tris-HCl pH 7.5 (binding buffer), and 0.2 nM [l^^I]-glucagon. Non­
specific binding was determined by the addition of unlabelled glucagon to a final 
concentration of 1 )iM. Incubations were done for 20 min at 32°C. The reaction was 
stopped by the addition of 3 ml ice-cold binding buffer and the diluted samples 
immediately filtered through 0.45~|im cellulose acetate filters which had been soaked in 
10% BSA overnight and washed with 2 ml ice-cold binding buffer. The tubes were 
rinsed twice with 3 ml ice-cold binding buffer and the rinses filtered. The filters were
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then finally washed with 6  ml ice-cold binding buffer and the radioactivity bound to them 
was measured using a y counter. Results were expressed in fmol [l^^Ij-glucagon- 
specific binding per mg membrane protein.
i
2,4*8» Protein determination
Protein was routinely measured by the method of Bradford (Bradford, 1976) with 
BSA as a standard. Briefly, in order to construct a standard curve, a set of tubes were 
prepared containing, in duplicate, 0, 1,2, 5, 10, 15 and 20 |Ltg BSA dissolved in 800 jxl 
distilled water. To each was then added 200 p.1 of Bio-Rad reagent, the tubes were 
vortexed and the absorbance (A 5 9 5 ) read against a blank cuvette containing no protein, at a 
wavelength of 595 nm. The protein concentrations of the unknown samples were 
determined, in duplicate, in a similai' manner, diluting 5 p,l of the sample in 800 pi 
distilled water, adding Bio-Rad reagent and reading the absorbance in the 
spectrophotometer as before. Protein concentrations were determined by plotting the 
standard curve, with the protein concentration (mg/ml) represented on the y axis and the 
A595 on the X axis. Using the Cricket Graph software package, the equation of the best fit 
line was obtained and subsequently used to calculate the protein concentration by 
substituting the absorbance reading for "x" (see fig. 2 .2).
■
2,4,9* Preparation o f hepatocytes
Hepatocytes were kindly prepaied by Dr. L. Zeng by a modification of the method 
of Beriy and Friend (Berry and Friend, 1969) as described previously (Hey worth and 
Houslay, 1983) from 220 - 250 g fed male Sprague-Dawley rats.
2*4*10, Isolation o f adipocytes by collagenase digestion
Low-phosphate Krebs
114 mM NaCl 6.92 g/1
4.7 mM KCl 0.32 g/1
1.18 mM MgS0 4 .7 H2 0  0.29 g/1
50 pM KH2PO4 6 .8  mg/1
25 mM NaHCO] 2.10 g/1
25 mM HEPES 5.96 g/1
3 % (w/v) BSA 30.0 g/1
1.0 mM CaCl2 1 ml of 1 M CaCl2 per litre
adjust to pH 7.4
Incubation buffer
Add 20 mg collagenase to 10 ml of low-phosphate Krebs buffer.
Epididymal fat pads were dissected and excised, rinsed with low-phosphate Krebs 
buffer at 37°C and cut into small pieces which were then washed using a tea strainer. 
Subsequently, the pieces were incubated in a shaking water bath at 37“C in 10 ml 
incubation buffer in a siliconised conical flask for approximately 1 h with continuous 
gassing with air. The adipocytes were then washed 5 times by centrifuging the 
suspension at 600 rpm (72 gav) for 2  min, aspirating the buffer below the floating 
adipocytes, and adding 20 ml low-phosphate Krebs buffer (minus the BSA). Finally, 
the buffer was aspirated, and the adipocyte layer was either fractionated as described in
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section 2.4.11., or added to an equal volume of Laemmli sample buffer and then placed 
in a boiling water bath for 4 min.
2.4.11, Preparation o f membrane and cytosol fractions
Cells were homogenised in 1 mM EDTA, 20 mM Tris-HCl pH 7.5 buffer 
containing a 'cocktail' of freshly added protease inhibitors diluted fr om a 100 0-fold stock 
(see section 2.3.3.). The cell suspension was homogenised in a glass dounce 
homogeniser, on ice, using 50 strokes and finally passed through a 25G syringe needle 
10 times. The homogenate was subsequently centrifuged at 1,000 gav for 10 min at 4°C 
to remove nuclei and intact cells, after which the supernatant was spun at 100 ,000  gav for 
40 min at 4“C. The pellet, representing the membrane fraction, was then resuspended in 
homogenisation buffer, while the resulting supernatant, containing the cytosol, was 
divided into aliquots and stored at -80 “C until subsequent use.
2.4.12, Lactate dehydrogenase (LDH) assay
This assay was used to provide a measure of the effectiveness of homogenisation. 
The level of LDH was ascertained by measuring the rate of oxidation of NADH. As 
NADH absorbs light of a wavelength of 340 nM, the rate of decrease of optical density at 
340 nM is a measuie of enzyme activity.
Free LDH in the homogenate was measured first, then Triton X-100 was added to a 
final concentration of 2% v/v in order to lyse any intact cells and the total LDH measured. 
The difference between the total and the free LDH levels gives the occluded LDH in the 
cells under investigation. Each reaction comprised 1.35 ml Tris-HCl (0.15M) pH 7.4,
50 pi sodium pyruvate (10 mM), 50 pi tissue sample (diluted so as to yield a 
measurable rate of change), in addition to 50 pi p-NADH (2 mM), added as substrate. 
The rate of change in A340, at 30°C, was determined before and after the addition of 
Triton, reflecting free and total LDH activity, respectively.
% Cells broken = Free LDH/Total LDH xlOO
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2.4.13. Membrane cyclase assay
Adenylate cyclase activity was determined by a modification of an assay described 
previously (Houslay et al, 1976). Briefly, this involved using an assay mixture 
containing 10 pi of membranes (10-20 pg protein) and 50 pi of buffer/ATP 
regenerating system with final concentrations of 1.5 mM ATP, 5 mM MgS0 4 , 10 mM 
theophylline, 1 mM EDTA, 1 mM dithiothreitol, 25 mM triethanolamine 
hydrochloride/KOH (pH7.4), 7.4 mg/ml phosphocreatine, 0.2 mg/ml creatine kinase and 
0.8 mg/ml BSA. Where indicated, 10 pi of GTP (100 pM final concentration) or 10 pi 
of glucagon (10 nM final concentration) was added. The volume of each incubation 
mixture was made up to 100 pi with water. The membranes were incubated at 30 “C for 
10 minutes prior to the addition of an equal volume of 4% PGA to stop the reaction. The 
samples were then centrifuged, the supernatants neutralised, and the cAMP content 
determined as described in section 2.4.14.6..
2.4.14, Determination o f intracellular cAMP production
This was done using a modification of the procedure described previously (Savage 
et al, 1995). The assay involves the measurement of intracellular cAMP production by 
the use of the cAMP binding protein, cyclic AMP-dependent protein kinase (Brown et 
al, 1972). While the details of the assay are given in sections 2.4.14.1.-2.4.14.8., the 
basic outline is summarised below.
Briefly, following stimulation of the cells for the desired time, the cells were lysed, 
thus releasing the cytosolic cyclic nucleotides. After neutrahsing the extiact, an aliquot 
was incubated with fixed quantities of [5', 8'-^H] cyclic AMP and cyclic AMP binding 
protein, allowing competition of labelled and unlabelled cyclic AMP for a limited number 
of binding sites on the binding protein. Activated charcoal was then added to the sample 
to bind any free cyclic nucleotide and the chai’coal pelleted by a brief centrifugation step. 
The radioactivity of a proportion of the supernatant was then determined, seiwing as an 
indication of the labelled nucleotide that was not displaced from the cAMP binding 
protein by the unlabelled cAMP. A standard cmwe was constructed by incubating a range
97
of known concentrations of unlabelled cyclic AMP with the fixed amounts of binding 
protein and radioactive cyclic AMP. Thus it was possible, thereafter, to detennine 
unknown cyclic AMP concentrations from the radioactivity counted by reference to the 
standard curve.
2.4.14.1, COS cell stimulation
When confluent, approximately 72 hours following transfection, cells 
(approximately 5 x 10 )^ in individual wells of a 6-well culture plate were incubated at 
3TC  with serum-free DMEM containing 1 mM-IBMX (unless stated otherwise), and, 
where appropriate, ligands were added to the indicated final concentrations after a further 
15 min. When PM A was present, it was added to a concentiation of 1 jxM in the pre­
incubation medium.
2.4.14.2, Extraction of cyclic AMP
After the indicated period of incubation with ligands, incubations were stopped by 
the aspiration of the medium from the cells and the addition of 500 |al of 2% perchloric 
acid (PCA). Following incubation for 15 min on ice, the cells were then scraped and the 
precipitated protein pelleted by centiifuging the samples in a microfuge at 13,000 gav for 
2 min at room temperature.
2.4.14.3, Neutralisation of the sample
To the supernatant 5 pi universal indicator solution was added, which turned pink. 
Neutralisation was achieved by the gradual addition of approximately 100 pi 2M 
KOH/0.5 M triethanolamine until the solution turned green, and the potassium 
perchlorate precipitate sedimented by a further centiifugation for 2 min at 13,000 gav. 
The cyclic AMP content of the supernatant was determined using a cyclic AMP-binding 
protein prepared from bovine adrenal glands as described below.
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2.4.14.4. Preparation of cAMP binding protein 
Adrenal cortex homogenisation buffer
0.25 M sucrose 85.6 g/1
50 mM Tris, pH 7.4 6.06 g/1
25 mM KCl 1.86 g/1
5 mM MgCl2.6H20 1.02 g/1
The cAMP binding protein was prepared by the method of Brown et al. (Brown et al, 
1972) from bovine adrenal glands. All steps were performed at 4 °C. From 30 fresh 
adi'enal glands, collected from a local abattoir and kept on ice, the surrounding fat was 
dissected and the gland hemisected to expose the pale inner medulla and daik outer 
cortex. Using a scalpel, the medulla was removed and discarded. The cortex was then 
scraped from the adi’enal capsule using a scalpel blade and placed in beaker of buffer.
One volume of tissue was homogenised in one and a half volumes of homogenisation 
buffer in a Waring blender. The homogenate was filtered through muslin and the muslin 
washed with a small volume of buffer. The filtrate was then centrifuged at 27,000 gav 
(eg. at 15,000 rpm in a JA20 rotor) for 15 minutes at 4°C. The supernatant was 
subsequently decanted through filter paper, and the filtrate was aliquoted into 0.25 ml 
fractions which were stored at -20^C. Separate samples were thawed and diluted for each 
assay.
2.4.14.5. Reagent preparation for the cAMP binding assay
The following solutions were prepared freshly on the day of the assay:
cAMP assay buffer
50 mM Tris 6.07 g/1 
4mMEDTA 1.49 g/1 
pH to 7.4 and store at 4 °C
Binding protein: the binding protein was prepared as described in section
2.4,14.4., then diluted 30-fold in cAMP assay buffer, and stored at 4°C until required for 
use.
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[S', 8’-3H] cyclic AMP: 13 |xCi (13 |ll) [5', 8'-% ] adenosine 3', 5'-cyclic 
monophosphate was added to 15 ml cAMP assay buffer, and stored at 4°C until required
for use.
Charcoal solution: the required volume, consisting of 2% (w/v) activated 
charcoal and 1% (w/v) bovine semm albumin in assay buffer, was stirred, on ice, for at 
least 15 minutes before it was used.
cAMP standards: these were obtained by making a series of two-fold dilutions 
from the most concentrated standard, 16 pmol/50 pi. The latter was obtained by diluting 
an aliquot of 32 pM cAMP by 100 fold in assay buffer, to a concentration of 320 nM (16 
pmol/50 pi).
2.4.14.6. Assay procedure
A standard curve was obtained for each assay performed by including a set of tubes 
containing, in duplicate, quantities of cyclic AMP varying between 0.0625 and 16 pmol. 
These tubes, together with the 50 pi experimental samples were set up as follows:
Tube no. cAMP
(pmol/50pl)
Buffer
(111)
[^H]-cAMP
(hi)
Binding protein
(hi)
1,2 200 100
3,4 - 100 100 100
5,6 0.0625 50 100 100
7,8 0.125 50 100 100
9, 10 0.250 50 100 100
11, 12 0.500 50 100 100
13, 14 1.00 50 100 100
15, 16 2.00 50 100 100
17, 18 4.00 50 100 100
19, 20 8.00 50 100 100
21, 22 16.0 50 100 100
23- samples 50 100 100
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The first two tubes, to which no binding protein was added, were included to 
detennine the quantity of cyclic AMP that remained after nucleotide binding by charcoal. 
The results from tubes 3 and 4 indicated the maximum cyclic AMP bound in the absence 
of any unlabelled cAMP and tubes 5-22 were prepared with a range of known cyclic 
AMP quantities in order to constmct the standard curve, thus permitting the subsequent 
calculation of unknown cyclic AMP values to be calculated.
The tubes were set up as described above on ice, adding binding protein to the 
tubes last. The tubes were then vortexed and incubated at 4 for 2 hours. After this 
time, 250 pi charcoal solution was added, and the tubes were immediately vortexed and 
spun in a microfuge at 12000 gav for 5 minutes. An aliquot of 300 pi was removed from 
the resulting supernatant, added to 2 ml Ecoscint, and the radio-activity determined by 
counting for 3 min in a scintillation counter. Curve-fitting software was used to calculate 
pmol unlabelled cAMP per vial.
2.4.14.7. Calculation of cyclic AMP levels
After correction for the sample volume and for the cell number per well (see section
2.4.14.8.) the results were expressed as mean pmol cyclic AMP produced/10^ cells 
±SEM.
2.4.14.8. Determination of cell number and viability
For each experiment, COS cells were divided into 3 additional wells which were 
then incubated together with the other 6-well plates of cells, but were reserved for cell 
counting. From these wells, the cells were trypsinised, pelleted and resuspended in 
500 pi DMEM. Subsequently, an aliquot of 100 pi was mixed with an equal volume of 
Trypan Blue solution (0.4%) and the number of viable cells was determined. This was 
performed by viewing the cells under a light microscope in a heamocytometer and 
counting those cells that excluded the Trypan Blue dye; that is the cells whose membranes 
remained intact, thus remaining white under the microscope. The cell number was 
calculated by using the grid on the slide, which ensured that the same area was counted
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for each determination. The number of cells per ml suspension was calculated by 
multiplying the mean number of intact cells in the cential grid by 1 x lO"^ .
2,4,15, Cyclic AMP phosphodiesterase assay
Cyclic AMP phosphodiesterase activity was determined by a modification 
(Marchmont and Houslay, 1980) of the two-step procedure of Thompson and Appleman 
(1971) (Thompson and Appleman, 1971). Briefly, [8-^H] - adenosine-3',5'- cyclic 
monophosphate was hydrolysed by the PDE to form labelled nucleotide mono-phosphate 
which was then completely converted to the coiresponding labelled nucleoside by the 5’- 
nucleotidase activity of snake venom. Unhydrolysed cyclic nucleotide was subsequently 
separated from the nucleoside by incubation of the mixture with Dowex-1-chloride, 
which binds charged nucleotides but not uncharged nucleosides.
2.4.15.1. Stimulation and lysis of cells for the PDE assay
Incomplete KHEM buffer
50 mM KCl 3.73 g/1
10 mM EGTA 3.80 g/1
50 mM HEPES, pH 7.2 13.0 g/1
1.9 mM MgCl2.6H20 0.390 g/1
Complete KHEM buffer
Add, immediately prior to use, to incomplete KHEM buffer:
1 mM DTT 0.1 % (v/v) of 1 M stock
protease inhibitor mix 0.1 % (v/v) of lOOOx stock
20 pg/ml cytochalasin B 0.1 % (v/v) of 20 mg/ml stock
TEA/KCl
150 mM KCl 11.2 g/1
10 mM triethanolamine 
pH to 7.2 with HCl
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Transfected COS cells, grown in 75 cm^ flasks, were incubated at 37 “C with 
serum-free DMEM containing either 1 |iM PMA or 0.1% DMSO for 15 min. Glucagon 
was then added to a final concentration of 10 nM and the incubation continued for a 
further 10 min. The flasks were then placed on ice, and the culture medium aspirated and 
discarded. 2 ml complete KHEM (ice-cold) was then added and the flasks incubated at 
4 °C for 45 min. All subsequent steps were carried out at 4 °C. The KHEM was then 
removed and 5 ml ice-cold TEA/KCl added. After 10 min, the TEA/KCl was aspirated 
and the cells washed with incomplete KHEM. The latter was then replaced by 2 ml 
complete KHEM, which, after a further 2 min, was removed. Using a cell scraper, the 
cells were then harvested and the suspension was transferred to a glass on glass dounce 
homogeniser. Following homogenisation with 20 strokes, the homogenate was 
centrifuged at 4 °C for 5 min at 1500 rpm in a benchtop refrigerated microfuge to pellet 
nuclei and cell debris. The supernatant was then divided into aliquots of 10 pi, ‘snap’ 
frozen in liquid nitrogen and stored in the -80°C freezer until required.
2.4.15.2. PDE assay reagent preparation
3',5'-cyclic AMP was prepaied at a concentration of 1 mM in 20 mM Tris-HCl, 
pH7.4, containing 5 mM MgCla and frozen as stock. The concentration required for the 
assay was obtained by diluting the stock on the day of each assay. 3-isobutyl 1- 
methylxanthine (IBMX) was freshly prepared on the day of the assay as a 500 mM 
solution in DMSO and subsequently diluted to the desired concentration in 20 mM Tris- 
HCl / 5 mM MgCl2 buffer, pH7.4. A maximum concentration of 0.2% DMSO was 
employed in the assays, and such levels of DMSO did not significantly affect the PDE 
activities. Snake venom was prepared by dissolving the venom of Hannah ophiophagus 
in distilled water at a concentration of 10 mg/ml. This stock solution was frozen down in 
aliquots and was diluted to 1 mg/ml in distilled water for use in the assay. Dowex 1X8- 
400-chloride was prepared as described previously (Thompson et al, 1979). Briefly, at 
4°C, 400g of Dowex 1-chloride was washed with 4 litres of IM NaOH for 15 minutes.
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The resin was then washed repeatedly with distilled water, until the pH of the eluate fell 
to 7.0. Subsequently, the resin was washed with 4 litres of IM HCl for 15 minutes, 
followed by further washes in distilled water until the eluate pH rose to 3.0. The resin 
was stored at 4°C, mixed with distilled H2O (1:1). For use in the assay, the 
Dowex: water mix was further diluted with ethanol, to a final ratio of 
Dowex: water :ethanol of 1:1:1.
2.4.15.3. Assay procedure
A 10 pi sample of cell extract was added, in microcentrifuge tubes on ice, to 40 pi 
of 20 mM Tris-HCl, pH7.4, 5 mM MgCl2 , containing, where indicated, either DMSO 
or IBMX at 2.5 times the deshed concentration. Blanks were included with every 
experiment done, replacing the cell extract with 10 pi KHEM buffer (see section
2.4.15.1.). Following the addition of 50 pi of 2 pM cAMP containing 0.15 pCi cAMP, 
and mixing the tubes by vortexing, the tubes were placed in a 30°C waterbath and 
incubated for 10 minutes, unless otherwise indicated. After this time the tubes with 
placed in a boiling water bath for 2 minutes to teiminate the phosphodiesterase activity. 
The samples were then allowed to cool on ice. 25 pg snake venom was added to the 
tubes and they were incubated for a further 10 min in a 30°C waterbath. The tubes were 
then placed on ice, and to each tube, 400 pi freshly prepaied slurry of 
Dowex:ethanol:water (1:1:1) was added. During this addition, the Dowex was stirred 
gently, in order to ensure that a homogeneous suspension was being added. The tubes 
were vortexed twice over a 15 minute period, and then centrifuged at 12,000 gav to pellet 
the Dowex resin. An aliquot of 150 pi supernatant was removed and mixed with 2 ml 
Ecoscint, before being counted in a liquid scintillation counter for 1 minute per sample.
2.4.15.4. Calculations
The cpm values obtained with the blank for each condition was subtracted from 
each cpm result to give the corrected cpm per sample. Calculation of specific activity 
(pmol cAMP hydrolysed/min/mg ± SEM) was performed after determining the protein 
content (see section 2.4.8.) of each sample.
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2.4.16, COS and 293 cell culture
Stock cultures of COS-7 cells were maintained in DMEM supplemented with 
penicillin (100 units/ml), streptomycin (100 pg/ml), 2 mM glutamine and 10% (v/v) 
foetal bovine serum. Cells were grown in an atmosphere containing 5% CO2 at 37 °C in 
a humidified incubator. Cells were routinely split 1:3 by trypsinisation and confluence 
was attained within 3-4 days.
2.4.17, PtdCho-PLC and PtdCho-PLD measurement
The measurement of PtdCho-PLD and PtdCho-PLC activities was performed using 
a modification of a method described previously (Cook et al, 1991). COS-7 cells were 
transfected with the GR-encoding plasmid and subsequently grown in 24-well plates. 
When 80% confluent, the culture medium was replaced with 0.5 ml DMEM containing 
1% (v/v) foetal calf semm (PCS) and 2 pCi [3H]~palmitic acid/ml. After an incubation 
period of 24 hours the cells were then washed in 0.25 ml semm-free DMEM at 37 °C 
for 30 minutes prior to incubation for a further 5 min in 0.25 ml of semm-free DMEM 
containing 0.3% (v/v) butan-l-ol. Incubations were commenced by the addition of 28 pi 
glucagon in DMEM/0.3% (v/v) butan-l-ol giving the desired final concentration and were 
continued at 37 °C for a further 10 minutes unless otherwise stated. Incubations were 
terminated by aspiration of the medium and the addition of 0.2 ml of ice-cold methanol to 
each well. Samples were harvested on ice and transferred to glass vials. Each well was 
then rinsed with a further 0.2 ml methanol which was combined with the first. Lipids 
were extracted for at least 15 min at room temperature with 0.4 ml of chlorofonn. The 
solvent mixture was evaporated in vacuo and the lipids re-dissolved in 100 pi of 
chloroform/methanol (19:1, v/v) by vortex-mixing. Subsequently, 10 pi of the sample 
was transferred to a scintillation vial for counting in order to measure total lipid labelling 
and allow normalisation of sample size. The remainder of the sample was applied to a 
Whatman LK5D TLC plate which was developed in the organic phase of 2,2,4- 
trimethylpentane/ethyl acetate/acetic acid/water (5:11:2:10, by vol.) using an unlined 
chromatography tank, until the solvent reached 1 cm from the top of the plate. pH]-
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PtdBut and [^Hj-PtdOH, identified, upon iodine-staining, by their co-migration with 
authentic PtdBut and PtdOH standards, were excised from the plates and their 
radioactivity determined by scintillation counting.
2,4,18, Measurement o f  inositol phospholipid hydrolysis
Transfected COS cells, grown for 48 hours in DMEM containing 10% (v/v) ECS 
were incubated in 0.5 ml DMEM containing 1% (v/v) ECS for a further 24 hours. The 
cells were then washed in 0.25 ml semm-free DMEM at 37 “C for 30 minutes. 
Stimulations were performed by the addition of 11 pi glucagon diluted appropriately in 
DMEM to give the desired final concentrations. Reactions were terminated after 10 
seconds by the addition of 25 pi ice-cold 10% (v/v) perchloric acid. Samples were 
harvested on ice and neutralised in the presence of a trace of Universal Indicator by the 
addition of approximately 25-30 pi 1.5 M KOH/60 mM HEPES. A sample of 110 pi 
was taken for Ins(l,4,5)P3 mass measurement.
2.4.18.1. Ins(l,4,5)P3 measurement by binding assay
Ins(l,4,5)P3 assay incubation buffer
4 mM EGTA 1.52 g/1
4mMEDTA 1.17 g/1
0.4% (w/v) BSA
100 mM Tris 12.1 g/1
pH to 9.0
Ins(l,4,5)P3 mass was quantified using a stereospecific radioligand binding assay 
(Palmer and Wakelam, 1990). All procedures were undertaken at 4°C. 110 pi 
neutralised cell extract was added to 110 pi incubation buffer, 110 pi [^H]-Ins(l,4,5)P3 
(approximately 7,770 dpm) diluted with distilled water, and 110 pi of binding protein 
(approximately 3 mg), prepared from bovine adrenal cortex as described in section
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2.4.14.4.. A standard curve using 0-256 pmol Ins(l,4,5)P3 (diluted in DMEM, to which 
PCA, KOH, HEPES and Universal Indicator had been added) was conducted in parallel 
(fig. 2.3.).
Samples were incubated on ice for 30 min, then centrifuged at 12,000 ipm at 4 °C 
for 3 min, and the supernatant aspirated. Each pellet was mixed with 1 ml of scintillant 
and the associated radioactivity determined by scintillation counting. As a precaution, 
samples taken from the 1 pM and 30 nM dilutions, and from water, were diluted to 
110 pi without DMEM to determine whether the phenol red contained within the medium 
interfered with binding. However, a comparison of these results with those obtained 
from the standards in which DMEM had been used to dilute the samples, indicated that no 
such interference took place.
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Figure 2.1. Analysis of DNA sequencing error frequency
A typical analysis of the mis-reading frequency, within an 842 bp DNA sequence 
file, imported from an automated ABI DNA sequencer into the GeneJockey II software 
package. The error frequency is indicated on the vertical axis, while the horizontal axis 
represents the position within the entire length of the sequence. Only the region with an 
error frequency of 10 % or less, corresponding to nucleotides 42 to 425 of the sequence, 
was extracted for subsequent analysis.
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Figure 2.2. Standard curve for Bradford protein assay
The samples for the standard curve were prepared as described in section 2.4.8. 
BSA concentrations of 0-20 pg were used as protein standards as indicated, and the 
absorbance was read at 595 nm after zeroing the spectrophotometer using the sample to 
which no protein was added. Each point represents the mean of duplicate samples. This 
experiment has been carried out at least twenty times.
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Figure 2.3. Standard curve for the Ins (1,4,5) P3 assay
This standard curve represents the specific binding of [3H]-Ins(l,4,5)P3, using a 
range of concentrations of unlabelled Ins(l,4,5)P3 as the competing ligand. The standard 
curve is plotted as %B/Bq versus pmol/sample of unlabelled Ins(l,4,5)P3. B represents 
the specific binding (i.e. dpm bound - NSB) at a given concentration of unlabelled 
Ins(l,4,5)P3; Bq is the maximum specific binding i.e. dpm bound in the absence of any 
unlabelled Ins(l,4,5)P3 - NSB; and NSB is non-specific binding. Similar calculations 
were performed to determine the specific binding for the unknown samples. Thus, from 
the standard curve, the value of pmol Ins(l,4,5)P3 present in each sample was 
determined. This assay is sensitive to changes in Ins(l,4,5)P3 mass of approximately 1- 
30 pmol.
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CHAPTER 3
Approaches towards the construction of a 
full-length cDNA encoding the glucagon 
receptor, and the incorporation of an 
epitope tag at its amino-terminus.
I l l
3.1. Introduction
A pre-requisite for the intended study, in transfected COS cells, of the mechanism 
by which the glucagon receptor (GR) is regulated, was the acquisition of the full-length 
cDNA encoding this protein. Unfortunately, we had hitherto been unable to obtain this 
cDNA from the authors of the two papers in which the cloning and sequencing of the 
receptor cDNA had been described (Jelinek et al, 1993; Svoboda et al, 1993b). It was 
deemed necessary therefore to obtain the receptor-encoding cDNA by another means. In 
fact, it appeared that another researcher in our laboratory. Dr. S. Griffiths, had 
previously isolated from a rat hepatocyte cDNA library, a partial cDNA for the GR, 
corresponding to the C-terminal region (nucleotides 505-1458 of the coding sequence). 
This cDNA species was isolated by screening the library with a 517 bp RT-PCR product 
that had been generated using PCR primers specific for regions 119-142 and 612-635 of 
the published rat GR nucleotide sequence. I therefore decided to use RT-PCR (utilising a 
polymerase possessing 3'-5’ exonuclease proof-reading activity) to amplify the cDNA 
encoding the amino-terminal region of the GR, with sufficient overlap to perniit the 
subsequent digestion of the product and its ligation to the existing C-terminal cDNA. The 
PCR and the subsequent analyses of the GR-encoding cDNAs are described in this 
chapter.
In addition, with the intention of examining the expression, intracellular' 
distribution, disease-related changes in expression, and phosphorylation of the GR, it 
was considered necessary to develop a means by which the receptor could be both 
immunoblotted and immunoprecipitated. In previous years, when GR-specific antisera 
were not yet available, the identification of the receptor protein was undertaken by 
techniques such as electrophoresis of proteins following the binding and cross-linking of 
radio-labelled iodo-glucagon (Iyengar and Herberg, 1984). Such studies showed the 
receptor to migrate under denaturing conditions with an apparent mobility of 63 kD.
Later, the partial purification of the rat hepatic receptor led to the development of GR- 
specific monoclonal antibodies (Iwanij and Vincent, 1990) which recognised both protein
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and carbohydrate antigenic determinants. Such antibodies detected an immunoreactive 
species migrating with a Mwt of 62 kD (Iwanij and Vincent, 1990).
In our laboratory, using the amino acid sequence of the rat hepatic GR deduced 
from the cloning and sequencing of the cDNA encoding the receptor (Jelinek et al, 1993; 
Svoboda et al, 1993b), five peptides corresponding to various extracellular or 
intracellular regions of the receptor were synthesised. These peptides were individually 
coupled to KLH and used to immunise a series of rabbits.
An alternative strategy for the generation of polyclonal antisera involves the prior 
construction, and expression in bacteria, of a plasmid encoding a fusion protein 
comprising a hapten (the peptide sequence of interest) fused, in frame, to a carrier 
molecule such as glutathione S-transferase (GST). This method had been used 
previously in our laboratoiy (Huston et al, 1996) to permit the generation of 
phosphodiesterase-specific antisera. Such a strategy, in addition to that of peptide 
immunisation, was employed here with the aim of raising an antiserum specific for the 
carboxy-terminus of the GR.
The testing of the antisera subsequently obtained from both the KLH-coupled 
peptide and the GST fusion protein techniques is described in the Appendix. 
Unfortunately, none of the antisera appeared to be able to detect the transfected glucagon 
receptor.
An additional method used to permit the immunodetection of a protein is to 
mutagenize the cDNA which encodes it by the technique known as epitope tagging. In 
this method, a foreign epitope, or epitope tag, for which a specific monoclonal antibody 
is available, is incorporated into the amino (N) or carboxy (C)-terminus of the protein of 
interest. This is achieved by the insertion of the appropriate nucleotide sequence, in 
frame, immediately 5' to the termination codon or immediately 3' to the stait codon of the 
cDNA which encodes it. The incorporation, by a PCR-based strategy, of such a 
sequence into the N-terminal region of the cDNA encoding the GR is described in this 
chapter. This technique has been undertaken in a number of instances, using as an 
epitope, peptides such as substance P (Munro and Pelham, 1984; Albers and Fuchs,
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1987) or c-Myc (Munro and Pelham, 1986; Munro and Pelham, 1987; Pelham et al,
1988). However, since such epitopes are derived from cellular proteins, such as neuro­
transmitters or proto-oncogenes, there is a significant chance that the resulting antisera 
will cross-react with a cellular protein other than the one of interest. To minimise this 
risk, the epitope tag chosen for the tagging described in this chapter, was composed of a 
viral epitope, corresponding to the peptide sequence of part of the C-terminus of the 
vesicular stomatitis virus G protein (Kreis, 1986; Soldati and Perriard, 1991).
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3.2. Results
3.2.1. RT-PCR of the 5' region of the cDNA encoding the GR
The first step of the strategy outlined in figure 3.1. was to amplify the coding 
sequence corresponding to the N-terminal region of the glucagon receptor. In order to 
amplify this cDNA with sufficient overlap with the existing C-terminal fragment to permit 
subsequent digestion and ligation, PCR oligonucleotides were designed so as to amplify 
a region corresponding to nucleotides 1 to 932 of the open reading frame (ORF) of the 
published receptor sequence. The antisense primer matched a sequence within the ORF 
that contained a unique BamH I restriction site, while the 5' oligonucleotide was 
designed so as to anneal to the first 12 bases of the ORF, with in addition, a 9 bp 5' 
extension containing an Spe 1 site. As no Spe 1 site was present in the entire coding 
sequence of the GR, as deposited in Genbank, it was included in the 5’ primer in order to 
facilitate subsequent ligation of the 5' end of the GR cDNA to the Spe 1-cut cloning site 
of the expression vector, pSV-Sport 1. The primer pair designed was, therefore:-
5’ sense oligonucleotide ET-GR-sl; GCGACTAGTATGCTCCTCACC (Spe I 
site underlined)
3' antisense oligonucleotide ET-GR-asl; GGGATACGCAGGATCCACC.
(BamH I site underlined)
Such primers would be predicted to amplify a specific 941 bp product 
corresponding to nucleotides 1-932 of the open reading frame of the rat hepatic glucagon 
receptor (Genbank accession no. M96674) with the additional 9 bases incorporated at the 
extreme 5' end.
The reaction conditions chosen were designed with an initial low annealing 
temperature cycle, in order to permit the 12 complementaiy bases of the 5' primer to 
anneal effectively. Thus, the first cycle consisted of a dénaturation step of 95 “C for 2 
min, an annealing segment of 37°C for 2 min, and an elongation step of 55°C for 2 min. 
This was followed by 35 cycles, each comprising a dénaturation step of 95°C for 1 min.
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Ian annealing segment of 55“C for 2 min, and an elongation step of 72°C for 3 min. A final elongation step of 60“C for 7 min was also included,
RNA was extracted from rat hepatocytes by the method described in section 2.2.12. 
and subjected to reverse transcription and PCR using the primers described above. In 
addition, serving as a positive control, a PCR reaction was undertaken using cDNA and a 
pair of primers known to amplify a sequence of approximately 400 bp.
It was found that although no RT-PCR product could be detected, the control 
reaction yielded a DNA product of the predicted size (figure 3.2.A). It was concluded, 
therefore, that the reverse transcription reaction, itself, must have been ineffective, 
perhaps as a result of a defective reverse transcriptase enzyme. When this was replaced 
in a subsequent experiment with fresh enzyme, the RT-PCR did indeed yield a product of 
the predicted 941 bp size (figure 3.2.B), An additional DNA product of approximately 
1030 bp was also visible, however, which may have reflected the amplification, by RT- 
PCR, of an incompletely spliced transcript.
In order to confirm that the species of higher mobility was indeed that resulting 
from amplification of the desired fully spliced GR transcript, this product was purified 
from an agarose gel and digested with the restriction enzyme Pst 1. This restriction 
digest resulted in two products (figures 3.3.A and 3.3.B), with mobilities corresponding 
exactly to the predicted lengths of 683 and 258 bp, respectively (figure 3.3.C).
3.2,2. Preparation and analysis of cDNA fragments of GR prior to 
ligation
In order to permit the subsequent ligation of the 5' DNA fragment prepared as 
described in section 3.2.1 to the previously isolated 3' fragment, and the insertion of the 
product into pSV-Sport 1 (figure 3.1.), it was necessary to subject all three DNA species 
to double restriction digestion. The 3’ fragment, inserted in pUC-18, was thus digested 
with both BamH I and HinD III. It was calculated that the product of such a double 
restriction digest would be a 2.7 kb linearised vector fragment and an excised insert of
116
858 bp (figure 3.4.A). Surprisingly, however, the products of this reaction, comprised 
the 2.7 kb DNA fragment corresponding to the linearised pUC18 vector, and, instead of 
a single 858 bp insert, two fragments of approximately 560 bp and 600 bp, 
respectively, (figure 3.4.B.). I considered that such digestion products might have been 
obtained if the insert had contained an additional region of DNA, of approximately 
300 bp, and if such a region was, itself, to contain a BarnH I or a HinD III restriction 
site.
Intriguingly, the published genomic rat hepatic GR sequence (Svoboda et al, 
1993a), includes 4 introns, the most 3' of which, is located 1221 bp downstream of the 
start of the open reading frame, and thus 311 bp from the exonic BamH I site. In 
addition, this intron is 300 bp in length, and does indeed contain an additional BamH I 
restriction site, at a position 250 bp from its 5' end. If it is assumed that this intron is 
indeed present within the 3' GR DNA fragment then, based upon this data, the species 
predicted to result from a BamH I / HinD III double restriction digest would be 561 bp 
and 597 bp, respectively (figure 3.5.), in addition to the 2.7 kb vector. In view of the 
proximity of these predicted sizes to those actually observed, it was considered that the 
presence of this intronic DNA was a likely explanation for the aberrant digestion 
products. This hypothesis was tested by digesting the DNA with either BamH I or HinD 
m, independently. The resulting fragments were found to correspond to the predicted 
species of 3703 bp and 561 bp (BamH I) and 4264 bp (HinD III) (figure 3.6.).
3.2.3. Design of PCR oligonucleotides for the amplification of the entire 
GR coding sequence
It has been reported that the transfection of GR-encoding cDNA which contains one 
or more introns does not lead to the expression of functional receptors (Svoboda et al, 
1993a). Therefore, in view of the apparent presence of intronic DNA within the 3' GR 
fragment, to which it had been planned to ligate the 5' fragment obtained by RT-PCR, it 
was considered that a preferable approach would be to use RT-PCR to amplify the entire
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GR coding sequence. The successful utilisation of such a strategy has been described 
previously (Tung et al, 1989) with respect to the isolation of the entire coding sequence 
of a South Aiuerican bat salivary protein. I thus designed oligonucleotide primers which 
would direct the amplification of the entire coding sequence of the glucagon receptor and, 
in addition, would possess the appropriate restriction enzyme sites to permit the 
subsequent insertion of the product into an expression vector. The choice of restriction 
enzyme was governed by the following criteria: such restriction sites should be absent 
from the coding sequence of the receptor itself, and should occur only once in the entire 
expression vector sequence, at the multiple cloning site.
As the 5' (sense) oligonucleotide primer described above had already been shown 
to direct the amplification of GR cDNA effectively, and as it contained a suitable 
restriction site, this primer was used again as the 5' sense PCR primer. The 3' 
oligonucleotide was designed so as to anneal to the GR-encoding sequence, downstream 
of the termination codon at the position 1496-1507 relative to the stait of the open reading 
frame. A HinD HI site (underlined) was incorporated into the 5’ end of this antisense 
primer. The sequence of this 3’ antisense oligonucleotide, ET-GR-as2, was: 
5-GCGTGAAGCTTTCTTGTGAGGCC-3'.
As the sequence to be amplified was relatively long (1527 bp), a proof-reading Pfu 
polymerase was used, to reduce the rate of errors. Unfortunately, no product of this size 
resulted from the RT-PCR, although it remained possible to amplify the 941 bp product 
with the primers ET-GR-sl and ET-GR-asl, indicating that the Pfu polymerase, its 
buffer, and the first-strand cDNA preparation were functional (figure 3.7.). The desired 
PCR product was not obtained in subsequent reactions, despite varying the amiealing 
temperature, using the "hot start" technique (Chou et al, 1992), increasing the primer 
concentrations, preparing fresh RNA and, in addition, employing the following 
alternative 3' antisense oligonucleotide sequences:
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Name______Sequence_________________________  Position in QRF_____
ET-GR-as3 5’-GCATGAAGCTTTTGGCTGGAGTC 1469-1480
ET-GR-as4 5'-CGGAAGCTTCTTCAGCCTTGGC 1528-1540
ET-GR-as5 5’-CGGAAGCTTTGCTGCTTTGCC 1542-1555
ET-GR-as6 5 -CGGAAGCTTCAGTTGAGGAAACAG 1203-1215 (tmncating)
ET-GR-as6 was designed so as to effect a C-temiinal truncation of the GR and 
therefore represents the complement of a sequence located within the ORE. The other 
oligonucleotides were designed so as to anneal to sequences located downstream of the 
1458 coding sequence and should, therefore, have led to the amplification of a product 
encompassing the entire ORE.
Eortunately, we subsequently received the kind gift of an intron-free, hill length 
GR-encoding cDNA (Svoboda et al, 1993b) which was used successfully for the 
transfection studies described in chapters 4 and 5, and as a template for the epitope 
tagging PCR described in section 3.2.4..
3.2.4. Epitope tagging the glucagon receptor
In view of the difficulty in obtaining a GR-specific antisemm (see Appendix 1), it 
was considered worthwhile to attempt to engineer an epitope tag onto the receptor 
molecule. The tag chosen was the 12-residue epitope sequence of the VSV G protein C 
terminus, the successful use of which had been reported previously (Soldati and Perriard, 
1991). It is recognised by the monoclonal antibody, P5D4. As Soldati and Perriard 
reported that it was not possible to truncate the epitope without preventing 
immunoprécipitation of the tagged protein by the monoclonal antibody, the full sequence 
was used here to tag the glucagon receptor.
As the addition of an amino acid sequence such as an epitope tag within the receptor 
sequence might be envisaged to cause a conformational change in the receptor, it was 
decided to place the tag at one or other of the termini of the molecule. It was considered,
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however, that its addition to the C-teiminus might interfere with the coupling of the 
receptor to Gs. Furthermore, tagging of the C-terminus could reduce any propensity of 
this region for phosphorylation, an effect which it was intended to analyse subsequently 
using the tagged receptor. Thus it was considered expedient to introduce the tag at the 
amino terminus of the protein. A PCR-based strategy was employed (figure 3.8.), in 
which the nucleotide sequence encoding the 36-base tag was incorporated into a 5' sense 
oligonucleotide primer, immediately 3' to the start codon. Both this sense primer and the 
antisense primer were so designed as to permit their subsequent cleavage by restriction 
enzymes and the ligation of the product into the appropriately cut vector containing the 
wild-type GR sequence. The sense primer, therefore, comprised a HinD III site, close 
to its 5' end, followed by the sequence ACCATG, serving as an optimal Kozak sequence 
(Kozak, 1986) and start codon, which, in turn, was followed by the tag-encoding 
sequence and the coding sequence of the amino-terminus of the GR. The 3' primer was
designed so as to anneal to a region of the GR sequence that contained the unique
restriction site, Esp I.
The PCR conditions, which included an initial low-temperature annealing cycle to
permit the 3' portion of the sense oligonucleotide to anneal to its complementary
sequence, were as follows:
1 cycle comprising:
95”C 2min 
62°C 2 min 
70“C 8 min
35 cycles, each comprising:
94“C 1 min
7 rC  8 min 
1 cycle comprising:
72“C 10 min
The Pfu polymerase with 3'-5' proof-reading exonuclease activity was used in the 
reactions in order to minimise the error rate.
The PCR reaction gave rise to the predicted 832 bp product (figure 3.9.A, lane 4). 
This species was excised and purified from the gel. Following restriction digestion with
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HinD III and Esp I, attempts were made to ligate it into the vector pCDM8~GR which 
had been similarly digested and purified. Notably, the fragment excised from this vector 
by the HinD IIE Esp I digestion (figure 3.9.A, lane 1) was considerably larger (at 
950 bp) than the PCR product which was to be used to replace it, indicating the presence 
of additional 5' untranslated sequence in the vector, located between the HinD IE site and 
the start of the sequence encoding the GR. Following ligation and transformation, 
several colonies were identified on the selective plates. In order to verify that these 
colonies had resulted from the desired ligation, their plasmid DNA was isolated and PCR 
was performed with the GR-specific primers ET-TAG-sl and ET-TAG-asl. The cycling 
parameters were set so as to exclude the initial low-annealing temperature cycle, in order 
to minimise amplification from unmodified pCDM8-GR plasmid. The results from the 
analysis of 5 typical colonies aie shown in figure 3.9.B.
Unfortunately, these PCR reactions failed to discriminate between unmodified and 
recombinant pCDMB-GR plasmid (figure 3.9.B, lanes 1-6). In addition, however,
HinD IE/ Esp I double digests were undertaken on the same DNA samples and on 
unmodified plasmid DNA as a control. It was subsequently found, by these restriction 
digests (figure 3.9.B, lanes 8-13), and by subsequent DNA sequencing reactions, that 
the plasmid DNA isolated from these colonies did not contain the tagged receptor 
sequence. Thus, the digests yielded either no detectable excised fragment or only the 
950 bp fragment corresponding to the unmodified pCDM8-GR constmct (figure 3.9.B). 
The confirmatory sequencing reactions were perfoimed using as a sense oligonucleotide 
not only the T7 primer, complementary to the T7 bacteriophage sequence present 
immediately 5' to the multiple cloning site of pCDM8, but also using an additional sense 
primer designed for this study so as to anneal further upstream. This was done to permit 
the sequence determination of the putative tag region with a reduced error frequency. 
Such sequencing reactions indicated, however, that several of the colonies arose from 
bacteria which contained no vector DNA, while others were derived from E. coli that 
contained only the original, unmodified pCDM8-GR vector, suggesting re-circulaiisation 
of the plasmid.
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3.3. Discussion
3.3.1. The attempted construction of the entire coding sequence of the rat 
hepatic glucagon receptor
The products resulting from the BamH I / HinD III double restriction digest of the
■previously isolated C-terminal cDNA fragment led me to predict that this cDNA may 
contain the 300 bp intron 4 of the glucagon receptor. This was confirmed by subsequent 
single digests of this cDNA. It is likely, therefore, that although this cDNA species was
Iisolated from a cDNA library formed from poly-adenylated mRNA, a number of the 
mRNA molecules had not been fully spliced prior to polyadenylation. In fact, this 
phenomenon has been described previously for the glucagon receptor (Lewin, 1985; 
Svoboda et al, 1993a). The rat hepatic glucagon receptor gene is known to contain four 
small introns of lengths 95, 89, 85 and 300 bp, respectively (Svoboda et al, 1993a). 
The persistence of introns in some poly-adenylated mRNA species is unlikely to be due 
to anomalous splicing signals, as the 5' and 3' splice sites of each of the four introns 
present in the GR genomic sequence do conform to the consensus dinucleotide sequences 
GT and AG, respectively (Ohshima and Gotoh, 1987). Interestingly, a number of other 
receptors of the secretin receptor sub-family of GPCRs possess at least four small 
introns, including the calcitonin receptor (Lin et al, 1991), the secretin receptor (Ishihara 
et al, 1991), the vasoactive intestinal polypeptide receptor (Ishihara et al, 1992), the
parathyroid hormone receptor (Juppner et al, 1991) and the glucagon-like peptide 1 
receptor (Thorens, 1992).
It is possible that the DNA product of approximately 1040 bp which was visible in 
addition to the predicted 941 bp N-terminal GR RT-PCR product may have reflected the 
amplification, by RT-PCR, of a partially spliced transcript. According to the reported 
genomic sequence of the GR gene (Svoboda et al, 1993a) such a transcript, containing 
intron 1, intron 2, or intron 3, would, indeed, be predicted to be of 1036, 1030, or
1026 bp in length, respectively. Alternative explanations for the appearance of this extra
product include the non-specific amplification from a related sequence and RT-PCR from 
a mature mRNA of a genuine splice variant. It is unlikely that the RT-PCR product of 
approximately 1040 bp was due to the presence of a mature mRNA from a splice variant 
of the GR as there is no documented evidence for the existence of more than one splice 
variant of the glucagon receptor. Particularly notable is that Northern blotting, using a 
GR cDNA probe, of RNA isolated from a variety of tissues, revealed only a single band 
(Yoo-Warren era/., 1994).
The subsequent inability to amplify the entire 1527 bp sequence may reflect a 
limitation of the first-strand cDNA preparation, perhaps with sufficient integrity of the 
cDNA species to perniit the amplification of the 941 bp product but not that of the longer 
sequence. Alternatively, the amplification by PCR of the long target sequence may have 
been compromised by the preferential amplification of shorter non-specific products. In 
this respect, the lengths of the designed primers aie unlikely to have been the cause of 
such a difficulty, as they were designed so as to have balanced melting temperatures of 
approximately 65°C. This is considered to be sufficiently high to ensure the level of 
reaction specificity that is required for long PCR (Cheng et al, 1994).
3,3,2. Incorporation by PCR of an N-terminal epitope tag into the coding 
sequence of the glucagon receptor
Although the 832 bp PCR product was amplified as predicted using the primers 
designed so as to incorporate an amino terminal epitope tag, it was not possible to then 
insert this fragment into the expression vector containing the remainder of the coding 
sequence of the GR. This difficulty may have been due to a failure of efficient restriction 
digestion of one or both extremities of the PCR product. Such incomplete digestion, 
which in the case of the 5' end could occur as the result of the proximity of the restriction 
site to the end of the DNA, would be difficult to detect using agarose gel electrophoresis. 
It is known that restriction enzymes cut less efficiently when a restriction site is located at 
the extreme terminus of a DNA sequence (Doyle, 1996). In fact, it was for this reason 
that an additional six nucleotides were incorporated into the design of the sense
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oligonucleotide on the 5' side of the HinD III restriction site. It is, however, conceivable 
that the exonuclease activity of the proof-reading polymerase may have caused 
subsequent restriction (and therefore ligation) difficulties by degrading the ends of the 
amplified products during PCR.
Another possible explanation for the difficulty encountered in ligating the product 
into the vector was that the cut vector may have re-circularised without the inclusion of 
the insert. This is less likely to occur when employing a strategy such as that used here 
in which the vector is cut with two different restriction enzymes, than when the vector is 
only cut with a single enzyme. The possibility remains, however, that one of the two 
enzymes failed to cut efficiently, potentially leaving cohesive ends. To combat this, 
following restriction digestion, the plasmid DNA was treated with phosphatase, in order 
to remove the 5' terminal phosphates and thus prevent re-circularisation. In addition, 
following phosphatase-treatment, the cut vector was separated from uncut vector by 
electrophoresis on a low melting point agarose gel, and was subsequently excised and 
purified prior to ligation to the cut PCR product. It appears from subsequent digests and 
DNA sequencing, however, that despite these precautions the original unmodified GR 
vector resulted from the ligation process.
The genetic manipulations were hampered by the additional difficulties created as a 
result of the nature of the vector containing the GR sequence. This vector, pCDM8, is 
one which necessitates the use of the MC1061/P3 strain of E. coli (Seed, 1987). As this 
strain is Endo A positive, it contains an endonuclease which makes purification, and 
subsequent manipulations difficult. In addition, it depends on an antibiotic selection 
process involving the suppression by a plasmid-encoded suppressor tRNA of premature 
stop-codons in the antibiotic resistance genes of the P3 episome. This system, however, 
may yield false-positive colonies (F. McCaUum, personal communication), possibly due 
to read-through of the amber non-sense mutations (Lewin, 1985). Furthei*more, very 
few unique restriction sites were available at the 5' and 3' ends of the GR DNA 
sequence.
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Consequently, in order to facilitate further studies, it would be desirable to sub­
clone the coding region of the glucagon receptor from pCDM8 into a more easily 
manipulated mammalian expression vector such as pc DNA3 or pSV-Sportl.
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N-terminal GR PCR product C-terminal GR cDNA clone in pUC 18
Spe BamH
I Spe I + BamH I
BamH I HinD ill
BamH I + 
HinD III
HinD
FINAL STEP:
Ligate Spe i/BamH I 
and BamH l/HinD Ml 
fragm ents together into 
the  cloning site  of 
pSV -Sport i
INITIAL DIGEST: 
Spe I + HinD III
CL
MultipleCloningSite
pSV-Sport 1
Figure 3.1. Strategy for the construction of the full length glucagon 
receptor coding sequence
It was intended to obtain the full glucagon receptor coding sequence by digesting 
the 941 bp RT-PCR product with Spe I and BamH I, and the pre-existing cDNA clone 
with BamH I and HinD III. These digestions would have permitted the subsequent 
ligation of these N-terminal and C-terminal coding regions, respectively, together into the 
multiple cloning site of the mammalian expression vector, pSV-Sport I following the 
excision of the Spe I/HinD III stuffer fragment.
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Figure 3.2. The use of RT-PCR to amplify the S' region of the sequence 
encoding the rat hepatic glucagon receptor
(A) Ethidium bromide stained 1.2% agarose gel electrophoresis of the RT-PCR 
amplification products from 2.5 pg (lane 1) and 5 pg (lane 2) hepatocyte RNA with the 
GR-specific primers ET-GR-sl and ET-GR-asl; 5 pg positive control RNA with 
appropriate primers (lane 3); and 5 pg of a different hepatocyte RNA preparation with 
the GR-specific primers (lane 8). Lane 7 represents PCR of positive control cDNA with 
appropriate control primers and lane 5 contained lambda / HinD El DNA markers. The 
sizes are indicated in bp. Lanes 4 and 6 were not loaded. The predicted amplification 
product was detected only in lane 7, suggesting that defective first strand synthesis was 
the cause of the RT-PCR failure.
(B) Ethidium bromide stained 1.2% agarose gel electrophoresis of the RT-PCR 
amplification products of 5 pg rat hepatocyte RNA after reverse transcription and PCR 
with the GR-specific primers ET-GR-sl and ET-GR-asl (lane 1), with lane 2 containing 
(()X174 / Hae IE DNA markers. While the PCR reagents were as used in the reactions 
represented in figure 3.2A, the reverse transcriptase was taken from a fresh stock. The 
941 bp predicted product was detected, in addition to a weaker signal of approximately 
1030 bp, which is discussed in the text.
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Figure 3.3. Pst I digestion of the 941 bp RT-PCR product.
(A) and (B) Ethidium bromide stained 1.2% agarose gel electrophoresis of the 
Pst I digestion products (lane 2) of the 941 bp RT-PCR product, following the excision 
and purification of this fragment from a low-melting point agarose gel. Lane 1 contains 
the (^X174 / Hae El DNA markers. The marker fragment sizes are indicated in bp. The 
gel was photographed with two alternative exposures (A and B) so as to reveal the 
683 bp fragment (arrow in A) and the 258 bp fragment (arrow in B).
(C) This shows the predicted Pst I digestion pattern of the 941 bp PCR product. 
Amplification of the 5' region of the cDNA encoding the rat hepatic glucagon receptor by 
RT-PCR using the primers ET-GR-sl and ET-GR-asl containing Spe I and BamH I 
sites, respectively, was predicted to yield a product of 941 bp. Excision and purification 
of this fragment from a low-melting point agarose gel and subsequent Pst I digestion 
should yield the two products of the lengths indicated. The translation initiation codon is 
separated from the 5' end of the 941 bp cDNA by 9 bp, containing the Spe I restriction 
site, ACTAGT, incorporated into the product by the sense primer. The Pst I and 
BamH I sites are located within the sequence which encodes the glucagon receptor.
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858 bp
5 ’ t
BamH I
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3'Î
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1353
1078
872
603564
Figure 3.4. Restriction digestion of the cDNA clone encoding the C- 
terminal region of the glucagon receptor
(A) The cDNA clone corresponding to the C-terminal region of the glucagon 
receptor had been previously isolated and inserted into the cloning site of the vector 
pUC 18. Double digestion of this construct with BamH I and HinD III was predicted 
to yield a single 858 bp product in addition to the cut vector.
(B) Ethidium bromide stained 1.2% agarose gel electrophoresis of the
BamH I/HinD III double digestion products (lane 1) of the C-teiminal glucagon receptor 
cDNA clone. To permit more precise determination of the size of these products, two 
different sets of DNA markers were used: lambda/HinD III (lane 2) and (|)X 174 /
Hae in (lane 3). The marker fragment sizes are indicated in bp. The digest resulted in 
two fragments of approximately 560 bp and 600 bp, respectively, rather than the 
predicted single 858 bp product.
129
Bam H  I
300 bp I
A
5’
311 bp 547 bp
cDNA clone in pUC 18BamH I HinD III
3’
B
5'
561 bp
250 50
597 bp
3’t
BamH
300 bp 
intron t
BamH I
t
HinD III
Figure 3.5. Hypothesis for the rationalisation of the digestion products 
of the C-terminal GR cDNA clone
The finding of two digest products, with a total length of approximately 1160 bp, 
led the author to speculate on the presence of additional sequence within the cDNA clone, 
such as an intron. In fact, intron 4 of the rat hepatic glucagon receptor genomic sequence 
is exactly 300 bp in length (Svoboda et al, 1993a). In addition, it contains a single 
BamH I site at 250 bp from its 5' end and no HinD III sites (A) . The presence of 
such an intron, located at 311 bp downstream of the exonic BamH I site would, indeed, 
be predicted to give rise to two products, of 561 bp and 597 bp, respectively, upon 
digestion with BamH I and HinD III (B).
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Figure 3.6. Confirmation of the presence of intronic DNA by individual 
BamH I and HinD III digests of the pUC 18 -  GR construct
(A) The two BamH I sites which would be present if the cDNA did contain an 
intron are sepai'ated by 561 bp. A BamH I digest would therefore be predicted to yield 
this fragment in addition to a 3703 bp vector fragment. A HinD III digest, however, 
would only give rise to a single fragment of 4264 bp, corresponding to the entire 
linearised vector.
(B) Ethidium bromide stained 1.2% agaiose gel electrophoresis of the HinD III 
(lane 1) and BamH I (lane 3) single digestion products of the vector containing the C~ 
tei-minal glucagon receptor cDNA clone. The DNA mai'kers used were lambda/HinD III 
(lane 2). The marker fragment sizes are indicated in bp.
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Figure 3.7. Attempted RT-PCR of the full-length cDNA encoding the 
glucagon receptor
Ethidium bromide stained 1.5% agarose gel electrophoresis of the reaction products 
following the synthesis of first strand cDNA from rat hepatocyte RNA and the 
subsequent PCR using the primers ET-GR-sl and ET-GR-as2 (lane 1). The predicted 
amplification product was 1527 bp in length. Despite the use of the proof-reading Pfu 
polymerase, and, in addition, a number of reaction modifications including the use, in 
subsequent PCR reactions, of the alternative anti-sense primers ET-GR-as3, 4, 5 and 6, 
no product of this length could be detected. The DNA markers used were (j)X 174 /
Hae in (lane 2) and the fragment sizes are indicated in bp. As a control, the pair of 
primers shown previously to yield a 941 bp product, ET-GR-sl and ET-GR-asl, were 
used in a parallel reaction in order to test the PCR reaction constituents (lane 3).
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Figure 3.8. Strategy for the incorporation of a VSV epitope tag into the 
coding sequence of the glucagon receptor by PCR
The oligonucleotide primers were designed so as to add the tag onto the amino 
terminus of the protein. In the PCR-based strategy employed, the nucleotide sequence 
encoding the 36-base VSV tag was incorporated into a 5' sense oligonucleotide primer, 
immediately 3' to the start codon. Both this sense primer, ET-TAG-sl, and the antisense 
primer, ET-TAG-asl, were so designed as to permit the subsequent cleavage of the 
amplified product by restriction enzymes and the ligation of the fragment into the 
appropriately digested vector containing the wild-type GR sequence. The sense primer, 
thus, comprised a HinD III site, close to its 5* end, followed by the sequence ACCATG, 
serving as an optimal Kozak sequence (Kozak, 1986) and start codon, which was then 
followed by the tag sequence and the amino-terminal GR sequence. The 3' primer was 
designed so as to anneal to a region of the GR sequence that contained the unique 
restriction site, Esp I. The predicted length of the product amplified by these primers was 
832 bp.
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Figure 3.9. Analysis of epitope tag incorporation by PCR amplification 
and restriction digestion
(A) Ethidium bromide stained 0.9% agarose gel electrophoresis of the PCR 
amplification products following PCR from glucagon receptor-encoding vector cDNA 
template (lane 4) or, as a control, in the absence of DNA template (lane 3), with the GR- 
specific primers ET-TAG-sl and ET-TAG-asl. The DNA markers were (j)X 174 /
Hae III (lane 2) and the fragment sizes are indicated in bp. Lane 1 shows the products of 
a HinD III/ Esp I digestion of the unmodified pCDM8 -GR construct. Notably, this 
digestion excised a fragment of 950 bp, whereas the PCR product that was to be inserted 
in its place was only 832 bp.
(B) Ethidium bromide stained 1.5% agaiose gel electrophoresis following PCR 
amplification using primers ET-TAG-sl and ET-TAG-asl, from the DNA of 5 of the 
colonies which appeared after the ligation (lanes 2-6), and HinD III/ Esp I double 
digests of these samples (lanes 9-13). As a control, the same PCR and restriction digests 
were performed on unmodified pCDM8-GR plasmid (lanes 1 and 8 , respectively). It 
was observed that with none of the DNA samples did the HinD m / Esp I digest excise a 
fragment of a length corresponding to the PCR-generated insert. Rather no detectable 
product was excised (lanes 11 and 13), or the digest yielded only a product 
coiTesponding to that obtained from digestion of unmodified plasmid (lanes 9, 10 and 
12).
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CHAPTER 4
Glucagon stimulation of COS-7 cells 
transfected with cDNA encoding the 
glucagon receptor and PKC isoforms
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4.1. Introduction
Glucagon, a hormone that is secreted by the pancreas in response to 
hypoglycaemia, is a key regulator of hepatic glucose production. Glucagon binding 
causes the glucagon receptor (GR) to interact with the stimulatory G protein, Gs, the 
alpha subunit of which, upon dissociation from beta/gamma subunits, subsequently 
activates adenylate cyclase. The consequent elevation of intracellular cAMP leads, in liver 
cells, to gluconeogenesis (Exton etal,  1969; Johnson etaL, 1972) and glycogenoiysis 
(Exton et al, 1970). The glucagon receptor, however, like several other hormone 
receptors, undergoes a rapid regulatory process during continuous exposure to an 
agonist, that attenuates its response to subsequent hormonal challenge. This phenomenon 
is known as desensitisation.
4.1.1. Evidence for rapid glucagon receptor desensitization
Subsequent to the binding of glucagon to specific receptors on the hepatocyte 
surface (Rodbell et al, 1971c; Sonne et al, 1978), an activation of adenylate cyclase 
ensues which results in the rapid accumulation of intracellular' cAMP, reaching a 
maximum value of 10-20 fold above basal levels within 6 minutes (Johnson et al, 1972; 
Pilkis et al, 1975). This response is dose-dependent with an EC50 for glucagon of 1-2 
nM in the presence of phosphodiesterase (PDE) inhibitors (Christoffersen and Berg,
1974; Sonne et al, 1978; Heywoith etal,  1983).
The increase in the intracellular level of cAMP is, however, transient, as following 
the peak cAMP accumulation at 6  min after glucagon addition, a gradual decline in cAMP 
levels, to approximately 50% of maximal stimulated values, is observed in the presence 
of the PDE inhibitor, IB MX (Hey worth et al, 1983; Murphy et al, 1987). Similar 
results, have also been observed in preparations of parenchymal liver cells in the presence 
of the PDE inhibitor, theophylline (Christoffersen and Berg, 1974). The decline in 
intracellular cAMP is unlikely to simply reflect an increased rate of loss of cAMP to the 
extracellular environment as only a small proportion of the total cAMP is detectable in the
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incubation medium (Christoffersen and Berg, 1974), and the rate of exit of cAMP 
actually decreases after the observed maximum intracellular* cAMP accumulation (Pilkis et 
al, 1975). Nor is it likely to be due to hormone degradation since the desensitization can 
not be overcome by further additions of glucagon (Murphy et al, 1987). Rather it is 
believed that it reflects an underlying profound attenuation of the activity of adenylate 
cyclase (Newlands and Houslay, 1991; Houslay, 1994).
In the absence of PDE inhibitors, the decline in intracellular cAMP is even more 
pronounced. Thus, although the magnitude of the peak cAMP increase is reduced by 3-5 
fold, the cAMP level returns fully to basal levels within 20-30 min (Johnson et al,  1972; 
Hey worth et al, 1983). This accentuated decline, observed when PDE inhibitors are 
absent, is believed to reflect an increased metabolism of cAMP by phosphodiesterases 
and the activation of type III PDE by a protein kinase A mediated mechanism (Hey worth 
etal ,  1983; Houslay, 1994).
4.1.2. Glucagon receptor desensitization observed upon repeated 
glucagon administration
It is well established that the glucagon-stimulated adenylate cyclase activity in 
membranes isolated from hepatocytes is profoundly inhibited if the cells have been pre­
exposed to glucagon (Plas and Nunez, 1975; DeRubeitis and Craven, 1976; Gurr and 
Ruh, 1980; Hey worth and Houslay, 1983; Noda et al, 1984; Murphy et al, 1987; 
Murphy and Houslay, 1988; Premont and Iyengar, 1988; Murphy etal, 1989; Savage et 
al, 1995). This desensitization displays a maximum reduction of 30-40% following a 5- 
minute pre-treatment with 10 nM glucagon (Heyworth and Houslay, 1983).
Furthermore, treatment of intact hepatocytes with glucagon has been shown to desensitize 
the ability of a subsequent challenge with the hormone to elevate the level of intracellular* 
cAMP (Savage etal, 1995).
These observations support the premise that the rapid desensitization of the 
response of adenylate cyclase to glucagon stimulation underlies the transience of the
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glucagon-stimulated intracellular cAMP accumulation described above (Newlands and 
Houslay, 1991; Houslay, 1994).
4.1.3. The potential involvement of PKC in the mechanism of 
desensitization
It is evident that phosphorylation of a membrane protein is pivotal to the process by 
which the desensitization of the glucagon-stimulated adenylate cyclase response occurs, 
as alkaline phosphatase treatment of membranes causes a striking reversal of the 
desensitization of glucagon-stimulated adenylate cyclase (Savage et al, 1995).
Moreover, since in the desensitised state, neither '^sf-glucagon binding nor NaF- 
stimulated cyclase activity, which depends upon Gs-cyclase coupling, is reduced (Santos 
and Blazquez, 1982; Heyworth and Houslay, 1983), the mechanism of the 
desensitization is likely to involve the uncoupling of the glucagon receptor from the 
stimulatory G protein, Gs.
In hepatocytes, a similar degree of inhibition of glucagon-induced adenylate cyclase 
stimulation to that which is induced by pre-exposure to glucagon, can be elicited by 
ti'eatment of the cells with a variety of other agents. Thus, a profound reduction in the 
ability of glucagon to stimulate adenylate cyclase activity has been demonstiated 
following the activation of lipid signalling pathways by hormones such as vasopressin 
and angiotensin II (Murphy et al, 1987) and after challenge of these cells with either the 
tumour promoting phorbol ester, PMA (Heyworth et al, 1984; Garcia-Sainz et al, 1985; 
Heyworth et al, 1985; Murphy et al, 1987; Refsnes et al, 1989) or the synthetic 
diacylglycerols 1-oleoy 1-2-acetyl glycerol (OAG) and dihexanoyl glycerol (DHG) 
(Newlands and Houslay, 1991).
In marked distinction to the agents which mimic the action of DAG, permeant 
cAMP analogues such as dibutyryl cAMP do not induce desensitisation, implying that the 
cAMP-dependent kinase (PKA) cannot mediate such an effect (Heyworth and Houslay, 
1983). Similarly, calcium entry appears, in itself, insufficient to cause desensitization 
since treatment of hepatocytes with the calcium ionophore A23187 was unable to elicit a
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reduction of either the adenylate cyclase activation or intracellular cAMP accumulation 
stimulated by glucagon (Savage et al, 1995).
It has become appaient that glucagon is able to stimulate the production of multiple 
second messengers, potentially leading to the activation of PKC. For instance, like other 
hormones which bind to receptors in the secretin receptor sub-family, such as parathyroid 
hormone (PTH) (A bou-Sam raa/., 1992) and calcitonin (Chabre etal,  1992), 
glucagon has been shown to cause not only an increase in cAMP production but also a 
significant increase in the level of intracellular calcium (Charest et al, 1983; Mauger et 
al, 1985; Sistare etal,  1985; Blackmore and Exton, 1986; Mine etal,  1988). In 
addition, glucagon has been shown to stimulate the hydrolysis of the membrane lipid 
phosphatidylcholine (PtdCho) by phospholipases C and D (Pittner and Fain, 1991). It 
has been shown that the increase in intracellular calcium concentration, is not, in itself, 
necessary for the desensitization as this was blocked neither by treatment of cells with 
EGTA, which chelates calcium, nor by the addition of La^+, which blocks the entry of 
calcium across the hepatocyte plasma membrane (Barritt and Hughes, 1991).
The ability of glucagon to lead to the generation of DAG (Bocckino et al, 1985; 
Pittner and Fain, 1991), together with the evidence, described above, that treatment of 
hepatocytes with DAG analogues or hormones which increase cellular DAG levels can 
attenuate the ability of glucagon to stimulate adenylate cyclase activity, suggests that the 
mechanism of glucagon and vasopressin-induced glucagon desensitization in hepatocytes 
may involve protein kinase C. In this regard it is interesting that the dose-dependence 
observed for the glucagon-induced desensitization of glucagon-stimulated adenylate 
cyclase activity in hepatocyte membranes (Ka of 0.45 nM) (Heyworth and Houslay,
1983; Murphy et al, 1987) is similai’ to that observed for the glucagon-induced 
stimulation of inositol phospholipid hydrolysis (Ka of 0.25 nM) (Wakelam et al, 1986). 
Furthermore, glucagon-stimulated PKC activation has been demonstrated in rat 
hepatocytes (Pittner and Fain, 1991; Tang and Houslay, 1992), and compounds known 
to inhibit PKC such as chelerythrine, calphostin C and staurosporine were found (albeit 
to differential extents) to block the vasopressin and glucagon-induced desensitization
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(Savage et al, 1995). These observations lend additional support to the conclusion that a 
DAG-activated kinase such as protein kinase C (PKC) is likely to mediate the 
desensitization of glucagon-stimulated cAMP accumulation in hepatocytes.
4.1.4, Aims and Objectives
The work described here was undertaken with the aim of gaining further insight 
into the natuie of the protein kinase species which confers phorbol ester-mediated 
inhibitory effects on glucagon-stimulated adenylate cyclase activity. The initial objective 
therefore was to obtain a model system for glucagon signalling by transfecting COS-7 
cells so as to effect the transient overexpression of glucagon receptors. In these cells, 
the dose and time-dependence of the glucagon-stimulated cAMP accumulation was then 
characterised and the activation of phospholipases investigated. Attempts were made to 
obtain a membrane assay for glucagon-stimulated adenylate cyclase activity. Thereafter, 
the aim was to re-create in transfected COS cells the PMA-mediated inhibition of 
glucagon-stimulated cAMP accumulation previously reported in hepatocytes. COS cells 
were thus co-transfected with the glucagon receptor and individual PKC isoforms that 
were shown to be present in hepatocytes and that therefore could be responsible for the 
PMA-mediated inhibition in these cells. Expression of these ti ansfected PKC isoforms 
was confirmed and assays undertaken to determine whether their expression could confer 
PMA-induced inhibition upon the glucagon-stimulated accumulation of cAMP.
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4.2. Results
4.2A. The transient transfection o f glucagon receptor cDNA
The cells chosen for transient expression of the glucagon receptor were COS-7 
cells. Due to their constitutive expression of the SV-40 large T antigen, they permit both 
the replication to a very high copy number and the expression of plasmids which contain 
an SV-40 origin and promoter region (Gluzman, 1981). These cells were transiently 
transfected with the mammalian expression vector pCDM8 containing the cDNA 
encoding the rat hepatic glucagon receptor (fig. 4.1.), as described in the Materials and 
Methods chapter.
4.2.1.1. The cAMP phosphodiesterase activity in GR-transfected COS 
cells and the effect of IBMX
In the experiments which follow, cAMP production by adenylate cyclase was 
gauged by the measurement of intracellular cAMP using the method described in the 
Materials and Methods chapter. The level of intiacellular cAMP, however, is not 
governed merely by the rate of cAMP production by adenylate cyclase, but also by the 
rate at which the cyclic nucleotide is converted to the mono-phosphate by cAMP 
phosphodiesterase iso-enzymes. Thus, in order to obtain an indication of the activity of 
adenylate cyclase, isobutylmethylxanthine (IBMX), a non-selective inhibitor of PDE 
isoforms (Beavo and Reifsnyder, 1990; Hoey and Houslay, 1990), was used to block 
cAMP degradation by these cAMP phosphodiesterase enzymes. In order to confirm that 
in glucagon-transfected cells IBMX is indeed an effective general PDE inhibitor, GR- 
ti’ansfected cells were homogenised and the extracts assayed for cAMP PDE activity in 
the presence and absence of IBMX at a concentration of 1 mM. The assay was 
performed as described in the Materials and Methods chapter with control incubations 
performed in the presence of buffer alone or buffer containing DMSO at a concentration 
equal to that present in the IBMX-treated samples. It was observed that in these 
tiansfected cells, this concentration of IBMX inhibited the detectable cAMP PDE activity
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by greater than 96% (n=3). Notably, DMSO alone did not affect the total PDE activity. 
Unless otherwise indicated, IBMX was included, thereafter, at a final concentration of 
1 mM, in all stimulations of COS cells where cAMP accumulation was measured.
4.2.1.2. Dose-response experiments in GR-transfected COS cells
To determine whether transfection of these cells by this method would successfully 
confer expression of functional glucagon receptors leading to a dose-dependent 
accumulation of intracellular cAMP in response to glucagon, dose-response experiments 
were carried out on untransfected and transfected COS cells (fig. 4.2.). In the 
untransfected cells a relatively small accumulation of intiacellular cAMP was observed, 
and this was only apparent at the highest concentrations of glucagon tested. It was 
observed that in the GR-transfected COS cells, at levels of the hormone of up to 
100 pM, there was no detectable change in the intracellular cAMP level. At higher . 
concentrations, however, the level of intracellular cAMP was seen to rise dramatically to 
a maximum level, observed at a concentration of 100 nM glucagon, that was 
approximately 10-fold greater than basal. The glucagon-stimulated increase in 
intracellular cAMP level occurred in a dose-dependent fashion with an EC50 value of 1.8 
± 0.4 nM (mean ± SD for 3 separate transfection experiments). The level of intracellular 
cAMP began to decline (by approximately 20%) at the higher concentration of 1 pm 
glucagon, possibly indicative of non-selective or even toxic effects of the hormone at this 
concentration.
In experiments performed thereafter on GR-transfected cells the concentration of 
glucagon utilised was that of the sub-maximal 10 nM.
4.2.1.3. Timecourse of glucagon-stimulated cAMP accumulation in GR- 
transfected COS cells
In order to ascertain the rate at which cAMP accumulated in response to glucagon in 
the transfected cells, GR-transfected COS cells were stimulated for durations ranging 
from 0 to 30 minutes in the presence and absence of 10 nM glucagon. Furthermore, to 
evaluate the extent to which PDE activity governs the level of cAMP in these cells, the
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experiments were, in addition, performed in the presence and absence of 1 mM IBMX. 
The results shown in fig. 4.3. show that, in the presence of IBMX, the maximal cAMP 
level was reached after 15 min of stimulation with glucagon, while in the absence of the 
hormone veiy little accumulation of intracellular cAMP was observed, thus indicating a 
low level of basal adenylate cyclase activity. In the absence of IBMX, the glucagon- 
stimulated accumulation of intracellular cAMP was only 14% of that observed in the 
presence of the PDE inhibitor, suggesting that the cAMP phosphodiesterase activity in 
these cells is far greater than that of adenylate cyclase.
4.2,1.4. Glucagon-stimulated PtdCho and PIP2 hydrolysis
In order to ascertain whether, in GR-transfected COS cells, glucagon treatment 
leads to activation of phospholipases C or D, as has been shown previously in 
hepatocytes (Wakelam gf aZ., 1986; Pittner and Fain, 1991; Bygrave and Benedetti, 1993; 
Bygrave et al, 1993), transfected COS cells were stimulated with glucagon and assayed 
for the activity of PC-PLC and PC-PLD, or for that of PI-PLC.
4.2.1.41. Determination of PtdCho hydrolysis
hi order to measure hydrolysis of PtdCho, cells were incubated with [^Hj-palmitic 
acid, the majority of which is incorporated into PtdCho (Cook et al, 1991). 
Determination of PtdCho-PLD and PtdCho-PLC activities was by measurement of the 
formation of [^Hl-PtdBut and [^Hj-PtdOH, respectively, in the presence of 0.3% (v/v) 
butan-l-ol. As butanol is a better nucleophiUc acceptor than water, hydrolysis of PtdCho 
by PLD results in the fomiation of phosphatidylbutanol (PtdBut) instead of PtdOH. 
Unlike the latter species, PtdBut cannot be further hydrolysed to diacylglycerol by 
phosphatidate phosphohydrolase (Pettitt et al, 1994). Diacylglycerol formed by PLC- 
catalysed hydrolysis of PtdCho, is converted into PtdOH by the action of diacylglyerol 
kinase.
Incubation of untransfected COS-7 cells with glucagon for 10 min at concentrations 
ranging from 0 to 1000 nM was observed to have no significant effect on the production 
of [^H]-PtdOH or that of [^HJ-PtdBut (figs. 4.4. A and B). In GR-transfected COS
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cells, however, incubation with 1 and 10 nM glucagon led to a statistically significant 
rise (by 25%) in the level of pH]-PtdOH (fig. 4.4. A). Again, however, no statistically 
significant change in the level of [^H]-PtdBut was observed (fig. 4.4. B). In a 
timecourse experiment (fig 4.5. A and B), in these cells, glucagon at a concentration of 
10 nM caused a steady rise in the level of [^H]-PtdOH which was significant (p=0.001) 
at 20 min, while the level of [^H]-PtdBut was unchanged.
4.2.1.4.2. Determination of PIP2 hydrolysis
Intracellular IP3 production was measured as described in the Materials and 
Methods chapter. The level of IP3 production in mock or transfected COS cells did not 
change significantly upon stimulation with 10 nM glucagon for 10 seconds (fig 4.6.).
4.21.5. Determination of adenylate cyclase activity in plasma 
membranes
hi addition to the determination of cAMP accumulation as a measure of glucagon- 
stimulated adenylate cyclase activity, it was considered desirable to determine glucagon- 
stimulated adenylate cyclase activity in isolated membranes. Thus glucagon receptor- 
transfected COS cells were homogenised and membranes prepared as described in the 
Materials and Methods section 2.4.11. The membranes were then incubated with GTP at 
the concentration, 100 pM, used previously to permit glucagon-stimulated adenylate 
cyclase activation (Heyworth and Houslay, 1983), in the presence or absence of 
glucagon, under the conditions described in the Materials and Methods section 2.4.13. 
The methylxanthine, theophylline, was included in the reactions to block membrane- 
associated PDE activity (Butcher and Sutherland, 1962). The level of cAMP production, 
was then determined by the cAMP binding assay as described in the Materials and 
Methods section 2.4.14.
It was found that membranes from both control and transfected COS cells displayed 
an adenylate cyclase activity which was not significantly increased upon the addition of 
glucagon (table 4.1.). However, in both control and transfected COS cells, adenylate 
cyclase activity was significantly stimulated by the addition of GTP alone (table 4.1.).
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This suggests that during cell disruption some modification of the adenylate cyclase 
signalling system occurs which can allow GTP-bound Gg to activate adenylate cyclase 
maximally.
It was also apparent that in the absence of hormone or GTP, the level of basal 
adenylate cyclase activity is greater in COS cells which have been transfected with the 
glucagon receptor than in control cells (table 4.1.). This may be a reflection of activation 
of the G protein by unoccupied receptors, a phenomenon which has been obseiwed for 
other transfected G protein-coupled receptors (Adie and Milligan, 1994; Mullaney et al, 
1996; Smit et al, 1996).
4.2.I.5.I. Membrane adenylate cyclase activity in different 
homogenisation buffers in glucagon receptor-transfected COS-7 and 
HEK-293 cells
It is known that exposure of cells to environmental stress such as ultraviolet 
radiation or osmotic or heat shock can lead to activation of a cascade of protein kinases 
culminating in the stimulation of stress-activated protein kinase (SAPK) (Davis, 1994; 
Sanchez et al, 1994; Yan etal,  1994). In addition, osmotic shock strongly activates the 
kinase cascade which leads to activation of the mammalian p38 kinase, which is similai* to 
the yeast osmo-sensing mitogen-activated protein kinase (MAPK), high-osmolarity 
glycerol response 1 (HOGl) (Han etal,  1994; Cano and Mahadevan, 1995). Thus it 
was considered possible that the oxidative stress induced by the loss of ATP during 
homogenisation might lead to the activation of one or more of these kinase cascades, the 
action of which could lead to the observed maximal stimulatory effect of GTP. To 
explore this possibility, membranes were prepaied from glucagon receptor-transfected 
COS cells by homogenisation in either 1 mM KHCO3 or the buffer used for the 
adenylate cyclase assay. The latter contains an ATP regenerating system comprising 
creatine phosphate and creatine kinase. Additionally, in view of the possibility that 
maximal stimulation of membrane adenylate cyclase by GTP might be an effect unique to 
COS cells, another immortalised cell type, HEK-293 cells was chosen. These cells.
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which are derived from human embryonal kidney cells, were also transfected with the
. ; tglucagon receptor and homogenised in the same way. Although these cells, unlike COS 
cells (Gluzman, 1981), do not constitutively express SV40 large T, transfection of DNA 
encoding the rat glucagon receptor was found to confer glucagon-induced stimulation of 
intracellular cAMP accumulation (figuie 4.7.). On measuring adenylate cyclase activity 
in membranes isolated from both of these cell types, however, it was again found that
activity was gauged exclusively by measuiing intracellular cAMP accumulation under
glucagon did not cause any additional increase in cAMP production over that elicited by 
GTP alone (table 4.2.). This result was not changed by homogenising the cells in the 
presence of an ATP regenerating system, although this procedure was noted to cause a 
general increase in the cAMP levels ascertained under each of the stimulation conditions 
(table 4.2.).
In view of the inability to detennine receptor-stimulated adenylate cyclase activity in 
isolated membranes, in subsequent experiments glucagon-stimulated adenylate cyclase
conditions where degradation of cAMP was blocked using the non-selective PDE 
inhibitor IBMX (Beavo and Reifsnyder, 1990; Hoey and Houslay, 1990). In 
homogenates of COS cells such a concentration of IBMX (1 mM) as used in these 
experiments was demonstrated to inhibit greater than 96% of the detectable PDE activity 
(see section 4.2.1.1.).
4.2.I.6. The effect of PMA on glucagon-stimulated cAMP accumulation 
in glucagon receptor-transfected COS cells
To determine whether treatment with the phorbol ester, 12-O-tetiadecanoylphorbol 
13-acetate (TPA, PMA) would lead to an inhibition of glucagon-stimulated cAMP 
accumulation in COS cells tiansfected with the glucagon receptor, such cells were 
stimulated with 10 nM glucagon for 10 minutes in the presence or absence of PMA at a 
concentration of 1 pM, after a pre-incubation period of 15 min with PMA in addition to
I'
IBMX. Control incubations were performed with DMSO at a final concentration equal to 
that present in the wells containing PMA.
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It was obseiwed that co-incubation with PMA failed to cause any observable 
reduction in the glucagon-stimulated cAMP accumulation (<2%, n= 6  experiments) in 
GR-transfected COS cells (fig. 4.3.). This finding contrasted markedly with the 
previously reported finding that in hepatocytes, the phorbol ester caused a pronounced 
inhibition of glucagon-stimulated cyclic AMP accumulation (Heyworth et al, 1984).
4.2.1.6.1. The effect of PMA on glucagon-stimulated cAMP 
accumulation in glucagon receptor-transfected 293 cells
It was considered possible that the PMA-mediated inhibition of this system, 
previously observed in hepatocytes, might require a particular environment, or set of 
cellular signalling components, which may be absent in COS cells. To address this 
issue, a different transfectable cell type was chosen in which to perform similar 
experiments. Thus HEK 293 cells were cultured and transfected with the GR-encoding 
plasmid. The degree of glucagon-stimulated cAMP accumulation in these cells was 
found to be 11.6 fold. Upon treatment of these cells with PMA, however, again no 
inhibition of glucagon-stimulated cAMP accumulation was observed (Fig. 4.7.).
4.2.1.6.2. Phosphatase inhibition by okadaic acid
The existence of multiple cellular phosphatases has been described (Hunter, 1995). 
In addition, a G protein coupled receptor phosphatase has been reported and has been 
identified as a member of the protein phosphatase type 2A (PP-2A) class (Pitcher et al, 
1995a). To determine whether the inability to observe PMA-mediated inhibition of the 
glucagon-stimulated cAMP accumulation in GR-tiansfected COS cells might be a 
consequence of potent phosphatase activity, glucagon-stimulated cAMP accumulation in 
GR-transfected COS cells was measured in the presence of PMA with the additional 
presence of okadaic acid. This substance is known to inhibit the phosphatases of both 
the PP-1 and the PP-2A classes (Hunter, 1995) and itself has been shown to mimic the 
PMA-mediated inhibition of glucagon-stimulated adenylate cyclase activity in hepatocytes 
(Savage et al, 1995). Despite the additional presence of this inhibitor, however, no
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PMA-induced attenuation of the glucagon-induced c AMP response was observed (Fig. 
4.8.).
4.2.I.6.3. Varying the quantity of DNA transfected
Transient tiansfection of COS cells with a plasmid containing an SV40 promoter 
and origin of replication leads to a high level of expression of the protein encoded by the 
cDNA inserted into the vector 3' to the promoter. It is conceivable therefore that, if 
PMA-mediated inhibition of glucagon-stimulated cAMP accumulation is dependent upon 
phosphorylation of the glucagon receptor, that the over-expressed receptor may be so 
abundant that even a small proportion of unphosphorylated ligand-activated receptors 
might be sufficient to couple to and activate Gs maximally. This could therefore result in 
an inability to observe PMA-induced reduction of glucagon-stimulated cAMP 
accumulation in transiently transfected COS cells.
To address this possibility, dishes of COS cells were transfected with different 
quantities of the GR-encoding plasmid and subsequently stimulated with glucagon in the 
presence of PMA and okadaic acid. Such a strategy, that of transiently transfecting a 
range of quantities of plasmid DNA to achieve a range of expression levels, has been 
used successfully in other laboratories, for example that of M. Karin (Claiet et al, 1996).
It was observed here that transfecting with only 1 \ig DNA per dish (rather than the 
previously used 5 |ig) did indeed result in a reduction (by 44%) of the glucagon-induced 
cAMP response, suggesting that the expression of the receptor was related to the quantity 
of DNA utilised to transfect the cells. In the presence of PMA, or PMA in combination 
with okadaic acid, however, no inltibition of the glucagon-stimulated cAMP accumulation 
was observed with any of the vai’ious transfected cDNA quantities (Fig. 4.8.).
4.2.2. Western blotting fo r  PKC isoforms in COS cells
It was regarded as likely that the failure to observe a PMA-induced inhibition of 
glucagon-stimulated cAMP accumulation in GR-transfected COS cells was due to 
inadequate expression in these cells of a signalling component required for this effect and
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which is expressed in hepatocytes. Several lines of evidence suggest that in the 
mechanism of the PMA-mediated inhibition of glucagon-stimulated cAMP accumulation 
in hepatocytes, one or more PKC isoforms is a key component (Savage et al, 1995). 
Thus it was of interest to determine whether any of the PKC isoforms expressed in 
hepatocytes aie absent or poorly expressed in COS cells. It has been demonstrated that in 
rat hepatocytes the isoforms that can be detected by immunoblotting aie PKC-a, (311 and 
E and Ç, but not PKC-j3l, y, Ô or rj (Tang et al, 1993). Using antisera specific for PKC- 
a ,  pil and e and therefore, Western blots were perfoimed on COS cell and rat 
hepatocyte extracts (Fig. 4.9.), as described in the Materials and Methods chapter. The 
immunoblots indicated that although PKC-a, pil and £ and Ç were all detectable in native 
COS cells, the levels of PKC-pII appeared to be lower in COS cells than in hepatocytes.
4.2.3, Co-transfections o f COS cells with GR and PKC 
iso form  cDNAs
Given the high expression level of the transfected GR, it was thought possible that 
inadequate PKC isoform expression in COS cells may be the cause of the inability to 
observe PMA-mediated inhibition in COS cells. Thus it was decided to co-transfect COS 
cells with the GR-encoding cDNA and with plasmids encoding each of the thiee PMA- 
responsive PKC isoforms present in hepatocytes (PKC-a, pil and e). As the activity of 
atypical PKC-Ç is known to be phorbol ester-independent (Ono et al, 1989) this isoform 
was not co-transfected.
4.2.31. Co-transfections of COS cells with GR and PKC-a cDNAs
Exponentially growing COS-7 cells, at between 40 and 60% confluence, were 
transfected with expression vectors encoding the rat hepatic glucagon receptor (in 
pCDM8) and PKC-a (in pMT2). The cells were incubated and treated as for the single 
transfectants.
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4.2.3.1.1. Confirmation of expression of PKC-a cDNA
In order to verify that this isoform was expressed in the co-transfected cells, 
Western blotting was perfoimed using a primary antiserum specific for PKC-a. Thus, 
confluent flasks of native, untransfected and GR/PKC-a co-transfected COS cells were 
each harvested directly into Laemmh sample buffer (Laemmli, 1970) and immunoblotting 
undertaken as described in the Materials and Methods chapter (see section 2.4.3). In the 
lane loaded with the co-transfected sample, two high intensity bands were visible 
indicating immunoreactive species migrating with molecular* weights of 84 and 88 kD 
(Fig. 4.11.A). In the native COS sample, however, although immunoreactive species 
were visible with identical molecular weights to those observed in the transfected cells, 
only relatively vei*y weak signals were detected. These results suggested that transfection 
of COS cells with the PKC-a cDNA led to the expression of the PKC isofoi*m, while the 
isoform was much less strongly expressed in native COS cells. The appear ance of a 
doublet for PKC-a is consistent with immunoblotting results previously reported for this 
isoform, and has been suggested to be related to the existence of phosphorylated and 
non-phosphorylated species of the kinase in COS cells, with differing mobilities (Pears et 
al, 1992).
4.2.3.1.2. Glucagon-stimulated cAMP responses in GR/PKC-a co­
transfected COS cells
To investigate the effects of PKC-a co-transfection on glucagon-stimulated cAMP 
accumulation in GR-transfected COS cells, tr*ansfections were performed with no cDNA 
(mock), PKC-a cDNA alone, GR cDNA alone or PKC-a and GR cDNA together*. It 
was obser*ved that glucagon, as expected, did not lead to an elevation of intr acellular* 
cAMP accumulation in COS cells transfected with no cDNA or PKC-a cDNA alone. In 
the cells transfected with the GR-encoding plasmid alone, the cAMP accumulation after 
10 minutes, in the presence of glucagon, was 9.7 fold greater than in its absence. The 
same incubation, however, in COS cells in which the expression vectors encoding both 
the glucagon receptor and PKC-a were co-transfected, gave rise to a 6 .1 fold stimulation
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(fig. 4.10.). This reduction in glucagon-stimulated cAMP accumulation associated with 
the transfection of an additional cDNA, may reflect the increased demands placed upon 
the finite transcriptional and translational capacity of these cells. Thus, it is likely that the 
expression of the cDNA encoding the glucagon receptor is reduced upon the transfection 
of an additional cDNA.
It was observed that, as before, co-incubation with the phorbol ester, PMA, did not 
lead to a reduction in glucagon-stimulated cAMP accumulation in GR-transfected COS 
cells. It was also found, however, that even in the additional presence of PKC-a, as 
confirmed by immunoblotting, PMA treatment again did not exert any inhibitory effect on 
the cellular cAMP response to glucagon. In fact, upon PMA treatment of the GR/PKC-a 
co-transfected cells, a small increase in the glucagon-stimulated cAMP accumulation was 
observed, although this was not statistically significant.
4.2.3 2. Co-transfections of COS cells with GR and PKC-pII and PKC-e 
cDNAs
Co-transfections of COS cells were carried out with pairs of cDNAs encoding GR 
and PKC piI or GR and PKC-e. In each case immunoblotting confiimed that the 
designated PKC isoform was over-expressed in the cells (Fig. 4.11.B and 4.1 l.C), and 
glucagon incubations in the presence and absence of PMA were performed. In these 
experiments the effect of glucagon stimulation was measured at both 5 and 10 minutes.
At neither of the time points, however, was a statistically significant inhibitory effect on 
glucagon-stimulated cAMP accumulation observed in the GR/PKC-pII or in the 
GR/PKC-e co-transfected cells (table 4.3.).
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4.3. Discussion
4.3.1. Glucagon-stimulated cAMP accumulation in transfected COS cells
Isobutylmethylxanthine (IBMX) elicited a profound inhibition (>96%) of the total 
phosphodiesterase activity in homogenates of glucagon receptor-transfected COS-7 cells. 
That complete inhibition was not observed may reflect the fact that IBMX is a reversible, 
competitive inhibitor of PDE action (Beavo and Reifsnyder, 1990; Hoey and Houslay, 
1990) and perhaps the presence of the PDE type VII isoform, which has been shown to 
be IBMX-insensitive (Lavan etal,  1989).
The initial objective was to create a model system in COS cells for glucagon- 
stimulated cAMP accumulation. In native COS-7 cells, challenge with glucagon in the 
presence of the cAMP phosphodiesterase inhibitor, IBMX, caused a small, dose- 
dependent increase in the intiacellulai' accumulation of cAMP. A marked response was, 
however, elicited by the hormone in COS cells which had been transfected with the 
glucagon receptor cDNA, confirming that functional expression of the transfected 
receptor had been conferred upon these cells. This had been predicted as the glucagon 
receptor cDNA is contained within the pCDM8 plasmid which contains an SV40 origin of 
replication and would therefore be expected to replicate to a high copy number in COS 
cells (Sambrook et al, 1989). The relatively small response to glucagon that was 
observed in native COS-7 cells suggests that although COS cells are kidney-derived 
(Gluzman, 1981) the level of glucagon receptor expression in these cells is low.
The observed EC50 value of 1.8 ± 0.4 nM for the glucagon response in the 
glucagon receptor-transfected COS cells is comparable to the values reported for the 
native response seen in intact hepatocytes in the presence of PDE inhibitors: 2 nM 
(Christoffersen and Berg, 1974), 0.5-3.0 nM (Sonne et al, 1978) and 1.2 nM 
(Heywoith et al,  1983). Jelinek et al. (Jelinek et al, 1993) in their studies using the 
cloned rat glucagon receptor observed a value of 0.7 nM. In contrast, the level of 
glucagon detected in the serum of fasting patients has been reported to be only 30 ± 4 .3
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pM (Baron et al, 1987). However, since glucagon is secreted by the pancreas and 
caiTied in the blood in the hepatic portal vein to the liver where it undergoes degradation 
(Jaspan et al, 1981), only a fraction of the glucagon secreted by the pancreas can actually 
be measured in seiiun samples obtained from the peripheral ckculation. Hepatocytes, 
therefore, aie likely to be exposed to much higher concentrations of glucagon than were 
measured peripherally by Baron et al.
The timecourse for glucagon-stimulated cAMP accumulation in glucagon receptor- 
transfected COS cells showed that the response was only apparent if the non-selective 
PDE inhibitor, IBMX (Beavo and Reifsnyder, 1990; Hoey and Houslay, 1990), was 
added to assays. This is likely to reflect the potent activities of endogenous cAMP 
phosphodiesterases which have been demonstrated in these cells (Shakur et al, 1993).
As IBMX is a reversible, competitive inhibitor of PDE action then the plateau in 
accumulation reached after about 15 min presumably reflects a steady state where the 
glucagon-stimulated production of cAMP matches the degradation by the residual PDE 
activity.
4.3.2. Investigation of glucagon-induced lipid signalling
The inability to detect a significant stimulation of IP3 production in mock or 
transfected COS cells stimulated with 10 nM glucagon is a finding that is consistent with 
the current literature regarding the effects of glucagon. Thus, while there have been 
reports of glucagon-stimulated inositol phospholipid hydiolysis, the magnitude of the 
reported stimulation has varied between only 18 and 25% (Wakelam et al, 1986; Whipps 
et al, 1987; Unson et al, 1989). Furthermore, in rat hepatocytes, Pittner and Fain were 
unable to detect any glucagon-induced rise in inositol phosphate production (Pittner and 
Fain, 1991). While it is certainly acknowledged that glucagon causes a rapid transient 
increase in the level of intracellular* calcium (Charest et al, 1983; Mauger et al, 1985; 
Sistare et al, 1985; Blackmore and Exton, 1986; Mine et al, 1988), it is likely, in view 
of the relatively small glucagon-induced release of inositol phosphates that this is
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mediated by an influx of the ion from the extracellular medium rather than by a release 
from intracellular stores.
The finding that glucagon stimulation of GR-transfected COS cells led to an 
increase in the level of [^H]-PtdOH, in the presence of 0.3% (v/v) butan-l-ol, suggests 
that glucagon in these cells stimulates the activity of PtdCho-PLC. However, no 
significant stimulation of the production of pH]-PtdBut was observed, indicating that 
PtdCho-PLD activity was not increased by this hormone.
Glucagon treatment of rat hepatocytes results in PKC activation, presumably by 
elevating DAG levels (Pittner and Fain, 1991). PtdCho-PLD coupled to phosphatidate 
phosphohydrolase activity was assumed by these authors to provide the DAG signal 
since the glucagon-stimulated formation of choline exceeded that of phosphocholine. 
However, this interpretation is compromised since choline and phosphocholine are 
readily interconverted ie. choline could be produced by the combination of PtdCho-PLC 
and phosphocholine phosphatase activity.
It appears from the experiments in transfected COS cells that PtdCho-PLC rather 
than PtdCho-PLD activity is predominant. Thus, production of DAG is a likely 
consequence in these cells with the implication that glucagon stimulation of COS cells 
will lead to the activation of PKC and other DAG-activated kinases.
4.3,3. Measurement of adenylate cyclase activity in plasma membranes of 
transfected cells
The inability to determine glucagon-stimulated adenylate cyclase activity in isolated 
membranes together with the maximal stimulation of adenylate cyclase activity that was 
elicited by the addition of GTP alone, was resolved neither by transfection of an 
alternative cell line, HEK293 cells, nor by homogenisation in the presence of an ATP 
regenerating system. This suggests that during cell disruption some modification of the 
adenylate cyclase signalling system occuis which can allow GTP-bound Gg to activate 
adenylate cyclase maximally. This might be a consequence of the high level of 
expression of transfected receptors, leading to the adoption of an active conformation by
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a significant number of empty receptors, although representing only a small proportion of 
the total number of transfected receptors. Perhaps, due to cell disruption, an alteration in 
the ionic composition of the membrane environment occurs, which effects an increased 
stability of any receptor-Gg interactions. A proportion of empty receptors would then be 
able to couple to Gg, and the addition of GTP, even in the absence of glucagon, might be 
sufficient to permit maximal adenylate cyclase activation by these G proteins. In support 
of this hypothesis, it was observed that in the absence of hormone or GTP, the level of 
basal adenylate cyclase activity is greater in COS cells which have been transfected with 
the glucagon receptor than in control cells. Such an activation of membrane adenylate 
cyclase by unoccupied transfected receptors has been demonstrated previously in 
NG108-15 cells expressing either the human p2 adrenoceptor (Adie and Milligan, 1994) 
or the 0-opioid receptor (Mullaney et al, 1996) and in Chinese hamster ovary cells 
expressing histamine H2 receptors (Smit et al, 1996). In addition, the occurrence of 
altered signalling properties during membrane isolation has been obseiwed in other 
systems (Anderson and Jaworski, 1979).
The determination of glucagon-stimulated adenylate cyclase activity was undertaken 
in subsequent experiments by the measurement of intracellular cAMP accumulation under 
conditions where degradation of cAMP was blocked using the non-selective PDE 
inhibitor IBMX (Beavo and Reifsnyder, 1990; Hoey and Houslay, 1990).
4.3.4. The effect of pre-incubation of transfected COS cells with PMA
Several lines of evidence (discussed in section 4.1.) have implicated a DAG- 
activated kinase in the desensitization of the glucagon receptor elicited both by glucagon 
itself and by other hormones able to elevate cellular DAG levels. In order to gain an 
insight into the mechanism involved in this desensitisation the intention was to study one 
component of this mechanism, the PMA-stimulated inhibition of glucagon-stimulated 
cAMP accumulation. However, in neither COS nor HEK293 cells, transfected with the 
rat hepatic glucagon receptor, was any PMA-stimulated inhibition of glucagon-stimulated 
cAMP accumulation observed. This contrasted with the published observations that in
155
hepatocytes, treatment with the phorbol ester PMA causes an inhibition of glucagon- 
stimulated cyclic AMP accumulation (Heyworth etal, 1984). Furthermore, upon 
performing a glucagon time-course experiment with GR-transfected COS cells, the 
transience of the cAMP response, previously noted in hepatocytes (Christoffersen and 
Berg, 1974; Heyworth et al, 1983; Murphy et al, 1987), was not observed. Rather a 
continuous accumulation of cAMP ensued, over a compai'able time-course to that 
investigated in hepatocytes.
The inability to observe any PMA-elicited inhibition of glucagon-stimulated cAMP 
accumulation in these transfected COS cells seemed unlikely to be due to any potent 
protein phosphatase activity as performing experiments in the presence of the protein 
phosphatase PP-1/PP-2A inhibitor, okadaic acid (Hunter, 1995), which itself has been 
shown to mimic the PMA-mediated inhibition of glucagon-stimulated adenylate cyclase 
activity in hepatocytes (Savage et al, 1995), failed to allow PMA to exert an inhibitoiy 
effect on glucagon-stimulated cAMP accumulation in transfected COS cells (<2% 
inhibition).
It was considered that owing to the nature of transient transfection, the receptor 
might be over-expressed to such a degree that even full activation of the cellular' kinase 
responsible in hepatocytes for the PMA-elicited inhibition would be incapable of 
phosphorylating a sufficient proportion of the receptors to prevent complete activation of 
the Gs population. In support of this hypothesis, it is evident from earlier published data 
on the rat hepatic glucagon receptor that, in fact, only a small proportion of the receptors 
need be occupied for activation of adenylate cyclase to occur (England et al, 1983). 
Similarly, it has been shown that in hepatocytes, over 75% of glucagon receptors must be 
lost for any reduction in the glucagon-mediated stimulation of adenylate cyclase to be 
manifest (Houslay et al, 1980). For this reason, with the objective of varying the degree 
to which the receptor was over-expressed, the effect of varying the quantity of transfected 
cDNA was studied. Transfection of varying quantities of glucagon receptor cDNA, was, 
indeed, found to lead to a marked variation in the glucagon-stimulated cAMP 
accumulation in these cells, implying that the maximum copy number reached may
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depend upon the number of copies initially ti'ansfected. In fact, transient transfection 
using a range of plasmid DNA quantities has been used successfully by others to achieve 
varying levels of expression (Claret et al, 1996). Reducing the quantity of cDNA 
transfected, in the present study, did not, however, lead to an ability of PMA to inhibit 
the response to glucagon.
It was subsequently considered that COS cells might lack some important cellular 
signalling component that is required for PMA-induced inhibition of glucagon-stimulated 
cAMP accumulation and which is not only present in hepatocytes but also capable of 
being activated by DAG or phorbol ester. The most likely candidates for such a 
component were considered to be the various isoforms of protein kinase C (PKC). 
Protein kinase C activity is supplied by a large family of isoforms (Hug and Saire,
1993). These fall into a number of distinct classes which are: conventional (cPKCs), 
PKC-a, pi, pll and % novel (nPKCs), PKC-Ô, e, r|, 0; and atypical (aPKCs), PKC-Ç, 
t/À, \l (Johannes et al, 1994). The precise reasons for the existence of such a complex 
gene family have yet to be fully elucidated. However, there is now evidence to suggest 
that particular PKC isoforms can mediate specific biological effects and, that expression 
patterns of isoforms are cell specific (Dekker and Parker, 1994; Spence et al, 1995).
It is possible that the inability to observe PMA-mediated inhibition of glucagon- 
stimulated cAMP accumulation in COS cells might have been due to inadequate PKC 
expression. Hepatocytes have been shown to express PKC isoforms PKC-a, pll and e 
and Ç, but not PKC-pI, y, ô or -q (Tang et al, 1993). Immunoblotting indicated that 
although PKC-a, pll and e and Ç were all detectable in native COS cells, the levels of 
PKC piI appeared to be lower in COS cells than in hepatocytes. In order to increase 
levels of PKC isoforms it was decided to co-transfect COS cells with the glucagon 
receptor-encoding cDNA and with plasmids encoding each of the three PMA-responsive 
PKC isoforms present in hepatocytes (PKC-a, pll and e). As the activity of atypical 
PKC-Ç is known not to be stimulated by phorbol ester (Ono et al, 1989) transfection of 
this isoform was not attempted. Immunoblotting analyses showed that transfection of 
COS cells with these various PKC cDNAs led to the over-expression of the appropriate
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isoform. However, in no instance was PMA-induced inhibition of glucagon-stimulated 
cyclic AMP accumulation reconstituted by co-transfection with the plasmids encoding 
these PKC isoforms. In conclusion, the co-expression in the glucagon receptor- 
transfected COS cells of any individual PKC isofoim present in hepatocytes, was not, in 
itself, sufficient to confer PMA-induced inhibition of the glucagon-stimulated cAMP 
accumulation.
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Untransfected GR-transfected
control PMA control PMA
control 94 + 51 245 ± 47 378 ± 42 569 ± 15
glucagon 97 ± 30 "s 285 ± 55 ns 484 ± 60 ns 759 ± 104 ns
GTP 333 ± 38* 594 + 111* 683 ± 26 ** 102 0  ± 6 **
glucagon+GTP 389 ±9** 591 ± 8 8 * 700 ± 60 ** 1063 ± 24 **
Table 4.1, Glucagon and GTP-stimulated adenylate cyclase activities in 
membranes prepared from control and PMA-treated untransfected and GR- 
transfected COS cells.
Confluent untransfected or GR-transfected COS cells were incubated for 15 min 
with either control (0.1% DMSG) medium or 1 pM PMA at 37 “C. Membranes were then 
prepared as described in the Materials and Methods chapter, and incubated at 30 °C for 10 
min with 10 nM glucagon, 100 pM GTP, or both together, prior to cAMP determination. 
The values shown, expressed in pmol/mg, represent means ± SE of three experiments.
* Significant at P<0.05, ** Significant at P<0.01, not significant (Student's t test, 
relative to control, unstimulated with glucagon or GTP).
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Transfected COS-7 cells Transfected HEK293 cells
ImM ATP regen. ImM ATP regen.
KHCO3 system KHCO3 system
control 280 ± 19 1080 ± 45 129 ±9 642 ± 33
GTP 927 ± 39 1720 ± 63 920 + 110 1300 ± 35
glucagon+GTP 901 ± 85 1720 ± 98 958 ± 24 1370 + 47
Table 4.2. Glucagon and GTP-stimulated adenylate cyclase activities in 
membranes prepared from GR-transfected COS and HEK-293 cells.
GR-transfected COS cells and HEK-293 cells were homogenised in the presence of 
either 1 mM KHCO3 or an ATP regenerating system containing creatine kinase and 
creatine phosphate. Subsequently, membranes were prepared as described in the 
Materials and Methods chapter and incubated at 30 "C for 10 min with 10 nM glucagon, 
100 pM GTP, or both together, prior to cAMP determination. The values shown, 
expressed in pmol/mg, represent means ± SE of three experiments.
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Transfection Glucagon-stimulated cAMP production in
presence of PMA(% of control ie. glucagon alone)
5 min 10 min
GR 124±7 1 0 1 + 6
GR+PKC a ND 113+6
GR+PKC (511 104±8 94.5±1.1
GR+PKC e 98.0+3.2 87.1+11.5
Table 4.3. The effect of PMA on the glucagon-stimulated cAMP response 
in COS cells co transfected with cDNA encoding the GR and PKC-a, 
PKC-pII or PKC-e
Transfected COS cells, grown to confluence in 6-well plates as described in the 
Materials and methods chapter, were pre-incubated for 15 min at 37 “C with semm-free 
DMEM containing 1 mM IBMX, and either 0.1% DMSG (control) or 1 pM PMA. 
Glucagon was then added to a final concentration of 10 nM and the incubation was 
continued for another 5 or 10 minutes. 2% PC A was then added, the cells were haiwested 
and their cAMP content determined. The results shown represent means of triplicate 
determinations of cAMP ±SE. The glucagon stimulated cAMP production in the presence 
of PMA is expressed as a percentage of the control (no PMA) value. ND, not determined.
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Glucagon Receptor 
cDNA (2.0Kb)
Not I
Hind
PCMV
pCDMS-GR
6.40 Kb (total)
sup F tRNA
SV40 ori
Figure 4.1. The pCDMS-GR construct
This plasmid was constmcted by the insertion of the entire intron-free rat hepatic 
glucagon receptor coding sequence (Genbank accession no. L04796) into the HinD 
ni/Not I digested mammalian expression vector pCDM8 (Svoboda et al, 1993b). High 
level expression is driven by the CMV promoter and replication to high copy number is 
conferred by the SV40 origin of replication. Bacterial selection is made possible by the 
expression of the sup F tRNA gene. The product of this gene suppresses the amber 
mutations in the ampicillin and tetracycline resistance genes on the P3 episome, which is 
contained within bacteria such as the MC1061/P3 strain of E. coli. This leads to the 
translation of these antibiotic resistance genes and, consequently, permits the selection of 
the transformed bacteria.
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Figure 4.2. Dose response curve for glucagon-stimulated cAMP 
production in untransfected and GR-transfected COS cells.
This figure shows dose response cui'ves for the glucagon-stimulated cAMP 
production in intact COS cells, either control (open diamonds) or transfected with 
pCDM8-GR DNA (filled squares). Cells were stimulated for 6  minutes with the 
indicated concentrations of glucagon, in the presence of the cAMP phosphodiesterase 
inhibitor, IBMX. Incubations were terminated by the addition of 2% PCA and cAMP 
production was determined by the cAMP binding assay. Means (±SE) of three 
experiments are shown.
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Figure 4.3. Timecourses for glucagon-stimulated cAMP production in 
GR-transfected COS cells.
This figm-e shows time courses for glucagon-stimulated cAMP accumulation in 
GR-transfected CCS cells in the presence and absence of IBMX. GR-transfected COS 
cells were stimulated with 10 nM glucagon (filled symbols) or control medium (open 
symbols), in the presence (squares) or absence (circles) of the phosphodiesterase 
inhibitor, IBMX, at a concentration of 1 mM. The response to glucagon, in the presence 
of IBMX and 1 jxM PMA, is also indicated (filled diamonds). Incubations were 
terminated after the times indicated by the addition of 2% PCA. The values shown 
represent means (± SE) from three experiments.
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Figure 4.4. PtdOH and PtdBut production in mock and glucagon 
receptor-transfected COS cells upon stimulation with varying 
concentrations of glucagon.
COS-7 cells were either mock-transfected or transfected with the GR-encoding 
plasmid, and subsequently grown in 24-well plates. When 80% confluent, the culture 
medium was replaced with DMEM containing 1% (v/v) foetal calf serum (PCS) and 
2 jxCi [^H]-palmitic acid/ml. After an incubation period of 24 hours the cells were then 
washed in 0.25 ml serum-free DMEM at 37 “C for 30 minutes prior to incubation for a 
further 5 min in 0.25 ml of serum-free DMEM containing 0.3% (v/v) butan-l-ol. 
Incubations were commenced by the addition of 28 jxl glucagon in DMEM/0.3% (v/v) 
butan-l-ol giving the desired final concentration and were continued at 37 °C for a 
further 10 minutes. Incubations were temiinated by aspiration of the medium and the 
addition of 0 .2  ml of ice-cold methanol to each well.
Samples were harvested on ice and transferred to glass vials. Each well was then 
rinsed with a further 0.2 ml methanol which was combined with the first. Lipids were 
extracted for at least 15 min at room temperature with 0.4 ml of chloroform. The 
solvent mixture was evaporated in vacuo and the lipids re-dissolved in 100 pi of 
chloroform/methanol (19:1, v/v) by vortex-mixing. Subsequently, 10 pi of the sample 
was transferred to a scintillation vial for counting in order to measure total hpid labelling 
and allow normalisation of sample size. The remainder of the sample was applied to a 
Whatman LK5D 150 Â TLC plate which was developed in the organic phase of 2,2,4- 
trimethylpentane/ethyl acetate/acetic acid/water (5:11:2:10, by vol.) using an unlined 
chr omatography tank, until the solvent reached 1 cm from the top of the plate.
-PtdOH (A) and [^Hj-PtdBut (B), identified, upon iodine-staining, by their co­
migration with authentic PtdOH and PtdBut standards, were excised from the plates and 
their radioactivity determined by scintillation counting. The counts from individual wells 
were corrected for sample size and the means calculated from triplicate determinations. 
The results were then normalised to the control value (in the absence of glucagon) for 
each cell type, and the means of the normalised values from two similar experiments were 
then calculated. Statistical significance was determined by Student’s t test.
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Figure 4.5. Timecourse of PtdOH and PtdBut production in glucagon 
receptor-transfected COS cells in response to glucagon.
COS-7 cells were transfected with the GR-encoding plasmid, and subsequently 
grown in 24-well plates. When 80% confluent, the culture medium was replaced with 
DMEM containing 1% (v/v) foetal calf serum (PCS) and 2 pCi -palmitic acid/ml. 
After an incubation period of 24 hours the cells were then washed in 0.25 ml serum-free 
DMEM at 37 “C for 30 minutes prior to incubation for a further 5 min in 0.25 ml of 
serum-free DMEM containing 0.3% (v/v) butan-l-ol. Incubations were commenced by 
the addition of 28 pi glucagon in DMEM/0.3% (v/v) butan-l-ol giving the desired final 
concentration and were continued at 37 “C for the times indicated. Incubations were 
terminated by aspiration of the medium and the addition of 0 .2  ml of ice-cold methanol to 
each well.
Samples were haiwested on ice and transferred to glass vials. Each well was then 
rinsed with a further 0.2 ml methanol which was combined with the first. Lipids were 
extracted for at least 15 min at room temperature with 0.4 ml of chloroform. The 
solvent mixture was evaporated in vacuo and the lipids re-dissolved in 100 pi of 
chloroform/methanol (19:1, v/v) by vortex-mixing. Subsequently, 10 pi of the sample 
was transferred to a scintillation vial for counting in order to measure total lipid labelling 
and allow normalisation of sample size. The remainder of the sample was applied to a 
Whatman LK5D 150 Â TLC plate which was developed in the organic phase of 2,2,4- 
trimethylpentane/ethyl acetate/acetic acid/water (5:11:2:10, by vol.) using an unlined 
chromatography tank, until the solvent reached 1 cm from the top of the plate.
[^Hl-PtdOH (A) and [^Hl-PtdBut (B), identified, upon iodine-staining, by their co­
migration with authentic PtdOH and PtdBut standards, were excised from the plates and 
their radioactivity determined by scintillation counting. The counts from individual wells 
were corrected for sample size and the means calculated from tiiphcate determinations. 
Statistical significance was deteimined by Student’s t test.
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Figure 4.6. Dose response of Ins(l,4 ,5 )p3 production upon glucagon
stimulation of mock and GR-transfected COS cells
Mock and GR-transfected COS cells, grown for 48 hours in DMEM containing
10% (v/v) PCS were incubated in 0.5 ml DMEM containing 1% (v/v) PCS for a further 
24 hours. The cells were then washed in 0.25 ml semm-free DMEM at 37 °C for 30 
minutes. Stimulations were performed by the addition of 11 pi glucagon diluted 
appropriately in DMEM to give the desired final concentrations. Reactions were 
terminated after 10 seconds by the addition of 25 pi ice-cold 10% (v/v) perchloric acid. 
Samples were harvested on ice and neutralised in the presence of a trace of Universal 
Indicator by the addition of approximately 25-30 pi 1.5 M KOH/60 mM HEPES. A 
sample of 110 pi was taken for Ins(l,4 ,5)p3 mass measurement. Ins(l,4 ,5 )P3 mass 
was quantified using a stereospecific radioligand binding assay (Palmer and Wakelam, 
1990), as described in the Materials and Methods chapter. The values indicated represent 
the means ± SE calculated from triplicate determinations.
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Figure 4,7. Glucagon-stimulated cAMP production in control and PMA- 
treated untransfected and GR-transfected HEK-293 cells.
Confluent untransfected or GR-transfected HEK-293 cells were pre-incubated for 
15 min with either control (0.1% DMSO) medium or 1 pM PMA at 37 °C, prior to 
stimulation for 10 minutes with 10 nM glucagon, in the presence of the cAMP 
phosphodiesterase inhibitor, IBMX. Incubations were terminated by the addition of 2% 
PCA and cAMP production was determined by the cAMP binding assay. Means (+SE) of 
three experiments are shown. The level of cAMP produced in response to glucagon in 
the presence of PMA was not significantly different from that obtained in the presence of
glucagon alone (Student's t test).
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Figure 4.8. The effect of okadaic acid, PMA and varying the quantity of 
transfected GR DNA on the glucagon-stimulated cAMP response in COS 
cells
Intact COS-7 cells, transfected with 1, 5 or 16 pg of pCDM8-GR DNA were pre- 
incubated for 15 minutes with control medium, or medium containing 1 pM PMA + 100 
nM okadaic acid, and subsequently stimulated for 10 minutes with 10 nM glucagon. 1 
mM IBMX was present during the pre-incubations and the glucagon stimulations. The 
reactions were terminated by the addition of 2% PCA and cAMP production was 
measured by the cAMP binding assay. Means (± SE) of triplicate determinations are 
shown.
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Figure 4.9. Immunoblots for PKC a , PKC pll, PKC e and PKC Ç 
isoforms in untransfected COS-7 and hepatocyte extracts
Homogenates of untransfected COS-7 cells or rat hepatocytes, prepared in the 
presence of protease inhibitors, were boiled for 3 min following the addition of Laemmli 
buffer. 50pl of each sample, containing 100 (xg protein, was subsequently loaded onto an 
8 % SDS poly-acrylamide gel. Blotting was carried out as described in the Materials and 
Methods chapter with primary antibody dilutions of 1 in 100.
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Figure 4.10. The effect of PMA on the glucagon-stimulated cAMP 
response in PKC alpha and glucagon receptor co transfected COS cells.
Unti’ansfected COS cells, or COS cells transfected with cDNA encoding PKC 
alpha, the glucagon receptor, or both plasmids together, were grown to confluence in 6 - 
well plates as described in the Materials and Methods chapter. The cells were then pre- 
incubated for 15 min at 37°C with serum-free DMEM containing 1 mM IBMX, and either 
0.1% DMSO (control) or 1 |iM PMA. Glucagon was then added to a final concentration 
of 10 nM and the incubation was continued for another 10 minutes. 2% PCA was 
subsequently added, the cells were harvested and theh cAMP content determined. The 
results shown represent means ± SE of three assays.
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Figure 4.11. Confirmation of expression of transfected cDNA encoding 
PKC a, PKC pll and PKC e by Western blotting.
Transfected or control COS cells were grown to confluence, washed 4 times with 
PBS, scraped into 0.5 ml Laemmli buffer per 75 citf flask, and immediately boiled for 5 
minutes. Subsequently, 30 \i\ of each sample was loaded onto an 8% SDS poly­
acrylamide gel. Blotting was carried out as described in the Materials and methods 
chapter with primary antibody dilutions of 1 in 500 for PKC a (A) and PKC s (C), and 1 
in 2000 for PKC pll (B).
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CHAPTER 5
Co-expression of the GR with GRK2, GRK3 
and PKD in COS-7 cells, and the effects of 
PMA on the individual steps leading from 
glucagon binding to cAMP accumulation
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5.1. Introduction
Following the experiments described in chapter 4 in which it was attempted to 
reconstitute, with co-transfected PKC isoforms, the PMA-induced attenuation of 
glucagon-stimulated cAMP accumulation in glucagon receptor-transfected COS cells, it 
was considered useful to investigate the possible alternative kinases which are known to 
play a role in the desensitization of G protein coupled receptor-mediated responses to 
extracellular signals. The kinases which are known to mediate such actions generally fall 
into one of two categories (Lohse, 1993), namely the receptor-specific kinases and the 
non-receptor-specific cellular kinases.
The receptor specific kinases constitute a family, known as the G protein coupled 
receptor kinases (GRKs), the identification of which was a consequence of the analysis 
of the regulation of adrenoceptors. There aie now six cloned mammalian members of 
this family, known as GRKl-6  (see chapter 1), whose only known function is to 
specifically phosphorylate the agonist-occupied form of these receptors, thus mediating 
receptor-specific desensitization (Hausdorff et al, 1990). The phosphorylation leads to 
the binding of the inhibitor proteins named arrestins, and the subsequent uncoupling of 
the receptor from the G protein (Lohse et al, 1992).
GPCRs may also be phosphorylated and uncoupled by the action of the effector 
kinases of receptor systems, such as protein kinases A and C, for which such receptors 
are only one of a great number of potential cellular substrates. PKA has been 
demonstrated to mediate the desensitization of a number of GPCRs including not only the 
P2-adrenergic receptor (Benovic et al, 1985), but also the PGEi receptor (Clai'k et al, 
1988) and the peripheral DAi-dopamine receptor (Bates et al, 1991). Similarly, many 
receptors which lead to the activation of PKC can undergo desensitization mediated by 
this kinase, in addition to receptor-specific desensitization. Such receptors include the 
Hi-histamine receptor (Leurs et al, 1991; Smit et al, 1992), the thrombin receptor 
(Brass, 1992) the 5HT2 -serotonin receptor (Kagaya et al, 1990), the parathyroid 
hormone receptor (Dunlay and Hruska, 1990), the angiotensin II receptor (Sakuta et al.
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1991; Oppermann et al, 1996) and the glucagon-like peptide-1 (GLP-1) receptor 
(Widmann et al, 1996).
The glucagon receptor might, as a member of the GPCR superfamily, be expected 
to be a substrate for one or more of the receptor-specific kinases or effector kinases. 
Certainly, there is now an abundance of published data supporting desensitization of the 
glucagon receptor system by not only glucagon, but also by other hormones and 
synthetic diacylglycerols (see section 4.1.3.). Moreover, exposure of hepatocytes to 
glucagon is known to lead not only to the elevation of cAMP, but also, to that of 
intracellular Ca^+, IP3 , and DAG (see section 4.1.3.) which could potentially serve to 
activate various kinases that might mediate desensitization of the receptor. It is unlikely 
that calcium itself is important in such a role, given the lack of an observable 
desensitization of glucagon-stimulated adenylate cyclase activity that occurred when 
hepatocytes were treated with the Ca^+ ionophore, A23187 (Savage et al, 1995). 
Similaiiy the increase in cAMP levels does not appear to lead to any PKA-mediated 
desensitization in view of the inability of membrane-permeant cAMP analogues such as 
dibutyryl cAMP to induce desensitization in hepatocytes (Heyworth and Houslay, 1983).
In view of the published evidence described in section 4.1.3., it is, however, likely 
that a DAG/PMA-activated kinase mediates the desensitization in hepatocytes. From the 
data presented in the preceding chapter, this would appear not to be an isofoim of protein 
kinase C since it was found that co-ti ansfection of the PKC isoforms present in 
hepatocytes was insufficient to confer PMA-mediated inhibition of glucagon-stimulated 
cAMP accumulation in glucagon receptor-transfected COS cells (see section 4.2.3.). 
Kinases other than PKC isoforms have, however, recently been shown to be activated by 
PMA. These include the p-adrenergic receptor kinase-1 (pARK-1), which can effect the 
attenuation of functioning of Gg coupled p-adrenoceptors in a markedly PMA-enhanced 
fashion (Chuang et al, 1995), and the recently discovered protein kinase D (PKD) 
(Valverde etal, 1994; Van Lint etal, 1995),
The mechanism of activation of pARK-1 (which corresponds to GRK2 in the 
GRK-terminology) certainly involves agonist stimulation of the receptor, presumably
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leading to a conformational change in the receptor that is necessary for the subsequent 
translocation of the kinase to the membrane (Strasser et al, 1986; Mayor et al, 1987; 
Garcia-Higuera and Mayor, 1992) and its interaction with the receptor. In addition, its 
ti anslocation to the membrane may be enhanced by the ability of the pleckstrin homology 
(PH) domain that is contained within the C-tenrdnal, membrane targeting, region of 
pARK-1 and 2 (Musacchio et al, 1993), to interact both with released G protein py- 
subunits (Touhara et al, 1994) and with membrane lipids such as phosphatidylinositol- 
3,4-bisphosphate (PIP2) (Harlan et al, 1994; Pitcher et al, 1995b). It now appears 
however, that the regulation of the pARKs is more complex as it has been reported that 
PKC mediates the phosphorylation and activation of pARK-1 both in vitro and in vivo 
(Chuang et al, 1995). This action by PKC is believed to involve phosphorylation of the 
C-terminal region of PARK, leading to increased membrane attachment by this domain 
and the consequent translocation of the kinase to the plasma membrane (Lohse et al, 
1996).
A novel protein kinase, called protein kinase D (PKD), which shares structural 
identity with PKC isoforms, has recently been identified (Valverde et al, 1994). Like 
PKCs of the conventional and novel classes, it exhibits N-terminal, cysteine-rich, zinc- 
finger-like domains (Nishizuka, 1988). It is not surprising therefore that a bacterially 
expressed fusion protein containing the regulatory domain of PKD has been found to 
bind phorbol ester, thus indicating that PKD can serve as a novel phorbol ester receptor 
(Valverde et al, 1994). Furthermore, it has been shown that transient expression of the 
kinase in COS cells confers phorbol ester binding on these cells and that the activity of 
PKD, immunoprecipitated from the transfected COS cells, can be markedly stimulated by 
phorbol ester in the presence of phosphatidylserine (PS) (Van Lint et al, 1995). 
Moreover, an important finding is that PKD appears to possess a distinct substrate 
specificity which distinguishes it from members of the PKC family (Van Lint et al, 
1995).
It has been demonstrated very recently that the GRK phosphorylation sites in 
several receptors, including the p2-adrenergic receptor and rhodopsin, all possess a pair
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of acidic residues located on the amino-terminal side of the phosphorylation site 
(Fredericks et al, 1996). This supports the conclusions reached originally from peptide 
studies that an acidic environment of a potential target residue is important for GRK2 
activity (Onorato et al, 1991). In this respect it is interesting that in the sequence of the 
rat glucagon receptor C-terminal tail, there is a pair of glutamate residues (Glu 427 and 
428) on the amino-terminal side of a pair of serines (Ser 432 and 433). There are, in 
addition, residues in this region of the glucagon receptor which conform to the putative 
PKD phosphorylation site consensus sequence as defined by studies of peptide 
phosphorylation (Van Lint et al, 1995). This will be discussed later in greater detail.
One of the studies described in this chapter involves an assay of the coupling of Gg 
to adenylate cyclase. This was achieved by determining the level of intracellular cAMP 
accumulation generated in response to cholera toxin treatment of glucagon receptor- 
transfected COS cells. Cholera toxin elicits activation of adenylate cyclase after a 
characteristic lag phase (Houslay and Elliott, 1979). During the latter it is considered 
(Houslay and Elliott, 1981; Orlandi et al, 1993) to enter the cell by endocytosis and is 
subsequently processed, delivering its activated a sub-unit at the cytosol surface of the 
plasma membrane. This species then elicits the NAD+ -dependent ADP-ribosylation of oc- 
Gg (Gilman, 1987; Birnbaumer et al, 1990a). This action, by inactivating the GTPase of 
the sub-unit, leads to chr onic activation of the entire Gg pool and the consequent 
constitutive activation of adenylate cyclase (Houslay and Elliott, 1979; Houslay and 
Elliott, 1981; Seamon etal, 1981; Gilman, 1987; Birnbaumer etal,  1990a). In 
addition, to gauge the effect of PMA on the activity of adenylate cyclase itself, cAMP 
accumulation was determined following stimulation by the diterpene, forskolin, which is 
known to activate the catalytic unit of adenylate cyclase directly (Gilman, 1987).
Aims and objectives
It was shown in the previous chapter that PMA-induced inhibition of the glucagon- 
stimulated cAMP accumulation was not conferred upon glucagon receptor-transfected 
COS cells by the co-transfection of the cDNAs encoding individual PKC isoforms that
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were shown to be expressed in hepatocytes. Having identified other kinases that can be 
activated by phorbol ester, the subsequent objective was, therefore, to determine whether 
they are expressed in hepatocytes and, if so, to co-transfect cDNAs encoding them into 
COS cells. Subsequently, the expression of the transfected cDNAs was confirmed and 
assays performed in order to determine whether PMA-induced inhibition of the glucagon 
response had been conferred. Upon discovering that such an effect was, indeed, 
conferred by the co-transfection of one PMA-stimulated kinase, the objective was then to 
confirm that this was not due to an effect of co-transfection of this kinase upon total 
cellular phosphodiesterase activity, or upon the ability of IB MX to block this activity. An 
analysis was also undertaken to ascertain more precisely where the kinase acts in the 
glucagon receptor signalling system. This involved investigating its effect upon glucagon 
binding, receptor-G protein coupling, Gg-cyclase coupling and the catalytic unit of 
adenylate cyclase itself.
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5.2. Results
5.2. i. Detection o f PMA-sensitive kinases other than PKCs in 
hepatocytes
At the time of writing, the studies published have identified, other than PKC 
isoenzymes, only GRK2 and PKD as PMA-sensitive kinases. However, as GRK3 
possesses, like GRK2, a PH domain in its membrane-targeting region (Musacchio et al, 
1993), and since it is this PH domain that is believed to confer PMA-enhanced activation 
upon GRK2 (Chuang et al, 1995), it was reasoned that although it remains to be tested, 
the activity of GRK3, like that of GKR2, is likely to be responsive to PMA. Therefore, 
the expression of GRK2, GRK3 and PKD was examined in hepatocytes and COS cells.
5.2.1.1. Western blotting
A polyclonal antiserum (PA-1) raised against a 15-residue peptide contained within 
the C-terminal region of PKD (Valverde et al, 1994) was used to perform an 
immunoblot on hepatocytes and COS cell extracts. While no signal was detectable in the 
COS cell extract using this antiserum, a weak signal was detected in the hepatocyte 
cytosol extract (results not shown). Unfortunately, no GRK-specific antisera were 
available. It was therefore decided to undertake RT-PCR analyses in order to ascertain 
whether PKD, GRK2 or GRK3 are expressed in rat hepatocytes and COS cells.
5.2.1.2. Design of oligonucleotide PCR primers
Using the nucleotide sequence deposited in Genbank for murine PKD (Valverde et 
al, 1994) (accession number: Z34524), oligonucleotide PCR primers were designed as 
indicated below, to permit the amplification of a specific 565 bp product corresponding to 
nucleotides 2123-2687 of the open reading frame.
5’ sense oligonucleotide ET-PKD-sl; TCGTTCACTGTGACCTCAAGC 
3' antisense oligonucleotide ET-PKD-asl; CTAGCACTCAGACTGATCAGG.
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Similarly, as no antisera were available specific for GRK2 or GRK3, PCR primers 
were designed which would specifically recognise each of these kinases. The objective 
was to prepare oligonucleotides which would be specific for an individual GRK yet 
recognise the designated kinase sequence in a species-independent fashion, detecting both 
rat and COS (primate) homologues in addition to the plasmid cDNA-encoded tianscripts 
(bovine). To accomplish this, nucleotide sequences of rat, human, and bovine GRKs 
were obtained from Genbank, aligned using the GeneJockey II software package running 
on a Macintosh LC475 computer, and examined for regions of 100% identity. Where a 
suitable region of identity between species could not be found, a sequence with the 
maximum possible homology was chosen instead, and the respective oligonucleotide 
designed so as to recognise alternative forms of the sequence ie. with degeneracy in the 
appropriate nucleotide positions. By performing additional sequence alignments of 
differing GRKs, and by using the "modal search" facility of the GeneJockey II software 
package to screen a library of GRK sequences, the chosen primer sequences were also 
checked for inter-GRK specificity.
The sequences of the primers designed as above specific for GRK2 ((3ARK) were: 
5’ sense oligonucleotide ET-GRK2-sl; 5'-AAGCTGGAGAC(A/G)GAGGAGG 
3' antisense oligonucleotide ET-GRK2-asl; 5'- 
TCGTCCAG(C/A)AGGATGTTGG. This allowed for the amplification of a specific 
701 bp product corresponding to nucleotides 280-980 of the open reading frame of 
bovine GRK2 (Benovic etal, 1989)(Genbank accession no. M34019).
SiiTiilarly, for GRK3 ((3ARK2) the primer pair designed was:
5' sense oligonucleotide ET-GRK3-sl; 5'-TTCAGAGGCATCGACTGG 
3' antisense oligonucleotide ET-GRK3-asl; 5 -CATGAATGTCTCCGTCAGC 
This allowed for the amplification of a specific 600 bp product corresponding to 
nucleotides 1357-1956 of the open reading frame of bovine GRK3 (Benovic et al, 1991) 
(accession no. M73216).
In order to check the viability of the RNA and first strand cDNA prepaiutions, RT- 
PCR was performed using primers specific for the ubiquitously expressed p-actin gene.
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For this purpose the sense and antisense oligonucleotide primers designed were 
CATCGTCACCAACTGGGACGAC and CGTGGCCATCTCTTGCTCGAAG, 
respectively, allowing for the amplification of a specific 466 bp product corresponding to 
nucleotides 222-687 of the open reading frame of human (3-actin (Ponte et al, 1984) 
(accession no. M l0278).
5.2.I.3. RT-PCR analysis of GRK2, GRK3, PKD and (3-actin expression 
in hepatocytes and native COS cells
The GRK2, GRK3, PKD and (3-actin primers, so designed, were used to perform 
RT-PCR on RNA prepared from rat hepatocytes and untransfected COS cells. Thus 
RNA was extracted as described in section 2.2.12. and 5 jXg was used for first-strand 
cDNA synthesis as described in section 2.2.14. Thereafter, PCR was performed with 
the reaction conditions described in table 5.1.
These RT-PCR analyses showed that GRK2 was present in hepatocytes but not in 
COS cells (figure 5.1.A) and that GRK3 was not present in either cell type (figure
5.1.B). PKD transcripts were detected by RT-PCR in hepatocyte but not in COS cells 
(figure 5.1.C). A strong signal of the predicted size, 466 bp, was, however, detected by 
PCR from the first-strand cDNA prepared from both hepatocytes and COS cells using the 
(3-actin primers (figure 5.1.D), thus providing confirmation that the RNA extraction and 
first strand cDNA synthesis had been correctly performed, and that nothing contained 
within the COS cell cDNA preparation was inhibiting the PCR reactions.
5.2.2. Co-transfection o f COS-7 cells with plasmids encoding 
both the glucagon receptor and GRK2
On the basis of the rationale outlined in section 5.1.1., it was considered 
worthwhile to investigate the effect of co-expressing GRK2 with the GR in COS cells. 
Thus an expression plasmid, pBCgARKl, constructed by the insertion of a 3083 bp 
HinD in fragment containing the cDNA encoding bovine GRK2 into the multiple cloning 
site of pBC12BI (Benovic et al, 1989), was co-transfected with that encoding the
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glucagon receptor into COS-7 cells. Verification of transfection and transcription of the 
GRK2 cDNA was performed using the GRK2-specific primers in an RT-PCR reaction 
(figure 5.2.).
Co-transfection with this cDNA did not however confer upon these cells an ability 
of PMA to inhibit the glucagon-stimulated cAMP accumulation (figure 5.3.). In the 
presence of PMA the response to glucagon was 106 ± 5 % (at 5 min) and 108 ± 8 % (at 
10 min) of that observed in the absence of the phorbol ester (mean ± SD, n=3). The 
changes were not statistically significant.
5.2.3. Co-transfection o f COS-7 cells with plasmids encoding 
both the glucagon receptor and GRKS
To investigate whether GRK3 or a similar kinase might mediate an inhibitory effect 
of PMA, the construct pBCPARK2, made by blunt-end ligation of a 2725 bp EcoRl 
fragment containing the pARK2 coding sequence into the blunted HinD m  site of 
pBC12BI (Benovic et al, 1991), was co-transfected with the vector encoding the 
glucagon receptor into COS-7 cells. Again, owing to the lack of an appropriate 
antiserum, RT-PCR was used to verify that the GRK was indeed expressed, at least at 
the level of transcription (figure 5.2.). The GRK3-specific 600 bp product was of 
relatively low intensity. A similar' low efficiency PCR amplification was however also 
observed when the GRK3-specific primer pair was used to amplify from the GRK3 
expression plasmid itself (results not shown), suggesting that the primer pair sequences 
or the PCR conditions were sub-optimal.
Importantly, co-transfecting the GRK3 cDNA failed to confer any significant PMA- 
induced inhibition of glucagon-stimulated cAMP accumulation (figure 5.4.).
5.2.4, Co-transfection o f COS-7 cells with plasmids encoding 
both the glucagon receptor and PKD
The pcDNA3-PKD construct, formed by the insertion of a 3304 bp cDNA fragment 
containing the entire coding sequence of murine PKD into the mammalian expression
1 8 2
vector pcDNA3 (Van Lint et al, 1995), was co-transfected with the cDNA encoding the 
rat hepatic glucagon receptor into COS-7 cells. A Western blot performed with the PKD- 
specific polyclonal antiserum described in section 5.2. strongly detected a protein of the 
appropriate molecular weight in PKD-transfected COS cells but not in the contr ol COS 
cells, showing that the transfection led to the successful expression of PKD (figure 5.5.).
In such co-transfected cells, the level of glucagon-stimulated cAMP accumulation 
was found to be 10-20% (n=3) lower than that observed in cells which had been 
transfected with the glucagon receptor alone. However, when such co-transfected cells 
were challenged with PMA, then a profound further inhibition of glucagon-stimulated 
cAMP production was observed (table 5.2., fig. 5.6.). This effect appeared to be 
directed at the level of synthesis of cAMP as studies of homogenate cAMP PDE activity 
showed no change in total PDE activity (<5% change; n=3) and IBMX was able to inhibit 
a similar fraction of the total activity, namely >94% (n=3).
Co-transfection of COS cells with cDNAs encoding both a kinase-inactive form of 
PKD, PKDK618M (Zugaza et al, 1996), and the glucagon receptor gave rise to no 
observable PMA-induced inhibition of the glucagon-stimulated cAMP accumulation (table 
5.2).
5.2.5. Co-transfection o f COS-7 cells with plasmids encoding 
PKD and either the P2 AR or the P3 A R
To investigate whether PMA-induced activation of transfected PKD could confer an 
inhibition of hormone-stimulated cAMP accumulation in COS cells transfected with 
GPCRs other than the glucagon receptor, cDNA encoding either the P2-adrenoceptor 
(P2AR) or the Pg-adrenoceptor (pgAR) was tiansfected with that encoding PKD. 
Following stimulation for 10 min with isoprenaline, at a concentration of 1 |iiM or 100 
|iM, respectively, intracellular cAMP accumulation was determined as described in 
section 2.4.14. These incubations were carried out both in the presence and absence of 1 
jxM PMA. It was observed that in COS cells co-transfected with PKD and either the 
P2AR or p3AR, the isoprenaline-stimulated cAMP accumulation was reduced, in the
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presence of PMA, by 31±7% and 18±4%, respectively. However, these inhibitions 
were found not to be statistically significant, as determined by Student's t tests.
Similarly, no statistically significant inhibition was effected by PMA in COS cells which 
had been transfected with either the P2AR or the P3AR alone (<14% reduction from 
control values).
5,2,6, Investigation o f the effects o f  PMA on the individual 
steps leading from  glucagon binding to cAMP accumulation
5.2.6.1 The effect of PMA on glucagon binding
In order to determine whether, in COS cells co-transfected with the glucagon 
receptor and PKD, PMA might have an effect on the binding of glucagon to the 
transfected glucagon receptor, the binding of [i^^IJ-labelled glucagon to COS cell 
membranes was determined. This was assessed as described in the Materials and 
Methods chapter (see section 2.4.7.).
Levels of specific binding of [l^^I]-glucagon to COS cell membranes were <1 
fmol/mg in non-transfected COS cells and 105 ± 17 fmol/mg in glucagon receptor 
transfected cells (mean ± SE; n-3 separate determinations). In cells which had been co­
transfected with PKD, specific glucagon binding was 114 ± 8 fmol/mg. Challenge of 
cells with PMA did not affect this with specific binding of 131 ± 10 fmol/mg seen for GR 
and PKD co-transfected cells (means ± SE; n=3 separate experiments). These results 
demonstiate that PMA treatment of neither the GR-transfected nor the GR/PKD co~ 
tiansfected COS-7 cells results in a reduction of specific glucagon binding. This 
suggests that PMA treatment did not elicit its inhibitory effect in the co-transfected cells 
by simply attenuating the specific binding of glucagon to its receptor.
S.2.6.2. The effect of PMA on Gs-cyclase coupling and on adenylate 
cyclase function
In order to evaluate the possibility that PMA exerts effects on individual coupling 
steps of the pathway that may not be detected by measuring solely the glucagon-
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stimulated cAMP accumulation, the effect of PMA on the cAMP response of COS cells to 
agents which activate Gg or adenylate cyclase directly, was determined. Gg-adenylate 
cyclase coupling was assessed by the use of cholera toxin, which elicits activation of 
adenylate cyclase by activating Gg, as described in section 5.1. To investigate whether 
PMA might effect an alteration in the functioning of adenylate cyclase, the effect of PMA 
was determined on intracellular cAMP accumulation in unstimulated COS cells and in 
COS cells treated with the diteipene, forskolin, which is known to directly activate the 
adenylate cyclase catalytic unit (Gilman, 1987). It was found that transfection of COS 
cells with PKD did not cause PMA to inhibit the accumulation of cAMP that was elicited 
by either cholera toxin or forskolin (table 5.3.).
5.2.6 3. The effect of PMA on the GTP-induced reduction in receptor 
affinity for glucagon
It has been shown (Rodbell et al,l91lc\  Limbird et al, 1980; Rodbell, 1980) that 
the binding of GTP by Gg leads the associated receptor to adopt a low affinity state.
Thus addition of GTP to binding assays will cause a reduced specific binding of receptor 
ligand. This has been shown for the glucagon receptor (Rodbell etal, 1971c; Rodbell et 
al, 1974; Rojas and Birnbaumer, 1985). As such it can be used as an index of receptor- 
Gg coupling.
Intriguingly, however, it was found that the ability of GTP to induce glucagon 
dissociation from membranes isolated from GR/PKD co-transfected COS cells was not 
reduced by PMA treatment (table 5.4.). This implies that PMA does not inhibit 
glucagon-stimulated cAMP accumulation by simply attenuating receptor-Gg coupling. 
Indeed it was also found that PMA does not affect GR-Gg coupling in native hepatocytes, 
demonstrating the similarity of these systems (table 5.4.).
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t5.2.7. RT-PCR analysis o f  PKD expression in CHO cells
A  study on the phosphorylation of the human glucagon receptor stably expressed 
in Chinese hamster ovary (CHO) cells has been published very recently (Heurich et al.
1996). The authors report that phosphoiylation of the receptor was observed in response 
to glucagon, but, interestingly, not in response to phorbol ester. To investigate whether 
PKD is expressed in CHO cells, RT-PCR using the PKD-specific primers described in 
section 5.2.1.2. was performed on RNA extracted from these cells and from hepatocytes 
(figure 5.7.). While a band of slTong intensity, migi'ating with a mobility corresponding 
to that predicted for the PKD-specific product, was detected in the PCR reaction using 
hepatocyte-derived cDNA, only a very weak signal resulted from the PCR in which the 
template consisted of cDNA derived from CHO cell RNA (figui'c 5.7,).
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5.3. Discussion
The RT-PCR analyses conducted in this study showed that GRK2 was present in 
hepatocytes but not in COS cells and that GRK3 was not present in either cell type. The 
detection of the expression of GRK2, but not that of GRK3, in hepatocytes is interesting 
as Northern blotting has been reported to detect neither GRK2 (Benovic et al, 1989) nor 
GRK3 (Benovic et al, 1991) in bovine liver. It was also noted by these authors that the 
level of abundance of GRK3 mRNA was only about 10-20% of that of GRK2 in the 
tissues in which both transcripts were detectable by this technique (Benovic etal, 1991). 
The detection of GRK2 in hepatocytes in the present study, therefore, may reflect both 
the greater sensitivity of RT-PCR and the use of isolated hepatocytes rather than liver 
tissue which contains a heterogeneous population of cells.
That expression of the novel protein kinase, PKD, was detected in hepatocytes (see 
section 5.2.1.) only by the use of the sensitive technique of RT-PCR, and not by 
Western blotting, suggests that the expression level of this kinase in hepatocytes is low. 
This conclusion is consistent with the findings of Valverde et al. (1994) who reported the 
detection by Northern blotting of PKD expression in liver, but at a much lower level than 
that detected in brain, lung, testis, heart muscle and kidney (Valverde et al, 1994). In 
human liver samples, however, Northern blotting detected levels of mRNA of PKC-p, 
the homologue of PKD, at levels which were similai* to those obtained with several other 
tissues (Johannes et al, 1994). These authors also reported that expression of this PKD 
homologue in control COS cells was not detected by Northern blotting or by 
immunoprécipitation followed by Western blotting (Johannes et al, 1994), These 
results, therefore concur with the inability in the present study to detect PKD transcripts 
by RT-PCR in COS cell RNA.
Co-transfection of the glucagon receptor cDNA with cDNAs encoding each of the 
two G protein-coupled receptor kinases, GRK2 and GRK3, did not confer any PMA- 
induced inhibitory action on glucagon-stimulated cAMP accumulation in COS cells. This 
was unlikely to have been simply due to a failure of transfection as the appropriate
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transcripts for these kinases were detected in transfected COS cells by RT-PCR, although 
the GRK2 signal was somewhat more intense than that of GRK3. It is conceivable, 
however, that another untested GRK mediates the inhibitory effect of PMA on glucagon- 
stimulated cAMP accumulation in hepatocytes. In this respect, it is interesting to note that 
GRK6 , which has a similar tissue distribution to that of GRK2, appears to have a distinct 
substrate specificity from that of GRKl, GRK2 and GRK5 (Benovic and Gomez, 1993; 
Loudon and Benovic, 1994). There is, however, no evidence yet that the activity of 
GRK6  is increased by phorbol esters.
Co-transfection of COS cells with cDNAs encoding both the glucagon receptor and 
PKD was shown by immunoblotting analyses to have led successfully to the expression 
of PKD. In such co-transfected cells, the reduction in the level of glucagon-stimulated 
cAMP accumulation by 10-20% from that observed in cells which had been tiansfected 
with the glucagon receptor alone, was not specific to PKD co-transfection, as a similar 
reduction in glucagon-stimulated cAMP accumulation was obseiwed following co­
transfection with a control expression plasmid encoding chloramphenicol acetyl 
transferase. Such an effect, reflecting the increased demands placed upon the cell's finite 
transcriptional and translational capacity by the introduction of additional cDNA into these 
cells, is consistent with successful co-tiansfection.
When such GR and PKD cDNA co-transfected cells were challenged with PMA, a 
profound inhibition of glucagon-stimulated cAMP production was observed. This result 
contrasted markedly with the previous experiments performed on COS cells transfected 
either with the GR alone or with the GR together with PKC isoforms or GRK family 
members. Moreover, the effect appeared to be directed at the level of synthesis of cAMP 
rather than at its degradation as studies of homogenate cAMP PDE activity showed that 
total PDE activity was unchanged and that IBMX was able to inhibit a similar fraction of 
the total activity.
COS cells which were transfected with cDNA encoding a kinase-inactive mutant 
form of PKD, PKDK618M (Zugaza et al, 1996), together with a plasmid encoding the 
GR, failed to exhibit an observable PMA-induced inhibition of glucagon-stimulated
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cAMP accumulation (table 5.2). Tliis suggests that the profound inhibitoiy effect of 
PMA observed in COS cells co-transfected with cDNAs encoding the GR and wild-type 
PKD is dependent upon the catalytic activity of the kinase.
In order to elucidate the precise mechanism of PMA-induced PKD-mediated 
inhibition of glucagon-stimulated intracellular cAMP accumulation, a variety of 
experimental approaches were employed. Measurement of levels of specific binding of 
[125i]-giucagon to COS cell membranes indicated that in neither GR-transfected COS 
cells nor cells co-transfected with PKD did PMA treatment elicit its inhibitory effect by 
attenuating the specific binding of glucagon to its receptor. Such a situation is consistent 
with that seen for the glucagon receptor in hepatocytes (Houslay, 1994). Cholera toxin- 
stimulated cAMP accumulation was not inhibited in PKD-transfected COS cells by PMA 
treatment, indicating that phorbol ester-activated PKD does not prevent activated G^a 
itself from stimulating adenylate cyclase. Such a conclusion is supported by the 
observation from studies on hepatocyte membranes that PMA treatment does not attenuate 
the NaAlF-stimulated adenylate cyclase response (Houslay, 1994). Furthermore, in 
PKD-transfected COS cells, forskolin-stimulated cAMP accumulation was not attenuated 
upon phorbol ester treatment, suggesting that PKD does not affect the functioning of the 
catalytic unit of adenylate cyclase. Intriguingly, while it might have been predicted from 
these observations that PMA-induced activation of PKD would interfere with the 
coupling between the glucagon receptor and Gg, the experiments which tested the ability 
of GTP to reduce the specific binding of glucagon by the receptor, did not support such a 
conclusion. In fact it would appear that the activation of PKD, rather than simply 
attenuating receptor-Gg coupling, may reduce glucagon-stimulated cAMP accumulation 
by an action which reduces the ability of the receptor-Gg complex to activate the catalytic 
unit of adenylate cyclase. Nevertheless, the modification appears to permit the activation 
of adenylate cyclase by Gg activated by either cholera toxin or NaAlF. Such an effect 
could, conceivably, be mediated by phosphorylation of the receptor, Gga or adenylate 
cyclase by PKD. The identity of the precise tar get of PKD remains to be elucidated. 
Certainly, from these studies, the receptor itself would appear to be a possible target.
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Van Lint et al. demonstrated, by peptide phosphorylation studies, that an aiginine at 
position -3 relative to that of serine is an important requirement for phosphorylation by 
PKD (Van Lint et al, 1995). Such a motif, RxxS, is indeed found in the eytosolic, C- 
temiinal tail of the glucagon receptor (R^^^MAS^^^), Moreover, the PKD target is 
unlikely to be Gg, as the G protein can be immunoprecipitated from desensitised 
hepatocytes in a non-phosphoiylated form (Pyne et al, 1989; Tang and Houslay, 1992).
In the current studies no statistically significant PMA-induced reduction in the 
isoprenaline-stimulated cAMP accumulation was detectable in COS cells transfected with 
PKD and either the P2AR or the P3AR (table 5.2). This is consistent with the possibility 
that, in the co-transfected COS cells in which the inhibitory effect is observed, the target 
of PKD is the glucagon receptor itself. Interestingly, the RxxS motif, which is believed 
to constitute a requirement for phosphorylation by PKD (Van Lint et al, 1995), is absent 
from the primary sequence of the P3 AR, but is found in the C-terminal tail of the GR 
(r429maS"^32) and in both the third intracellular loop (R^^^RSS^^^) and C-terminal tail 
(R343RSS346) of the P2AR. The apparent inability of PMA to effect a statistically 
significant inhibition of isoprenaline-stimulated cAMP accumulation in COS cells 
transfected with PKD and the P2AR thus suggests that the presence of the RxxS motif in 
a prospective substrate may be necessary but insufficient to permit its PKD-mediated 
phosphorylation.
Very recently, Heurich et al, studying the phosphorylation of the human glucagon 
receptor expressed stably in CHO cells, detected phosphorylation of the receptor in 
response to treatment of the cells with glucagon but not phorbol ester (Heurich et al, 
1996). The finding here that the especially sensitive technique of RT-PCR yielded only a 
very weak PKD signal in CHO RNA (figure 5.7.) suggests, however, that the reported 
absence of PMA-induced glucagon receptor phosphorylation in CHO cells may be a 
consequence of a very low PKD expression level. Alternatively, it is possible that even if 
PKD is expressed at a sufficiently high level, the PKC isoforms required for PKD 
activation may not be. Sequence variation between the rat and human homologues of the 
glucagon receptor does not, in itself, appear to be sufficient to explain the lack of PMA-
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induced glucagon receptor phosphorylation observed by Heurich et al. since the human 
receptor contains two distinct serine residues, at positions 431 and 437, respectively, 
which conform to the RxxS consensus.
Finally, it may be that the substrate of PKD is adenylate cyclase rather than the 
receptor itself. As there are at least nine isoforms of adenylate cyclase with differing 
tissue distribution and mechanisms of regulation, it is quite conceivable that an adenylate 
cyclase isoform is modified by PKD in COS cells but is not expressed in CHO cells. In 
fact, as can be seen from table 5.5, primaiy sequence inspection reveals that each of the 
nine isoforms of adenylate cyclase possesses at least one intracellularly-located RxxS 
motif which might serve as a target for phosphorylation by PKD. It is possible, 
however, that the presence of RxxS in a potential substrate is necessary but not sufficient 
to permit efficient phosphorylation by PKD, although the specific additional sequence 
requirements remain to be determined.
5.3.1. The possible role of PKD in hepatocytes
It is possible that, by virtue of its property of DAG-induced activation, PKD may 
play an important role in hepatocytes, acting to desensitize the glucagon receptor in 
response to hormonal activation of receptors which lead to the production of DAG. Thus 
it may mediate part or all of the observed desensitization of the glucagon-induced cAMP 
accumulation that follows treatment of hepatocytes with vasopressin, angiotensin II and 
glucagon itself. In this respect, it is interesting to note that Savage et al. (Savage et al, 
1995) demonstrated that the vasopressin-induced desensitization was completely 
abolished by the relatively selective PKC inhibitor chelerythrine (Herbert et al, 1990) at a 
concentration of 1 pM whereas that induced by glucagon was only half blocked, even at a 
concentration of 5 pM (Savage et al, 1995). Similar differential effects were obseiwed 
when other PKC inhibitors were used. This might reflect the possible involvement of 
different PKC isofoims in the two desensitization processes, conceivably activated by 
different DAG species.
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An alternative explanation, however, would be that the desensitization induced by 
glucagon itself is not mediated by PKC, but by a distinct kinase, such as PKD or even a 
receptor-specific kinase. In fact, PKD might also mediate the vasopressin-induced 
desensitization. In this scenario, the sensitivity of this process to PKC inhibitors eould 
be accounted for by the finding that activation of PKD can be mediated not only by direct 
activation by phorbol ester or DAG, but also through a PKC-mediated pathway (Zugaza 
et al, 1996).
Glucagon-induced glucagon desensitization is an example of a common feature of 
hormone responsive signalling, in which desensitization allows cells to attenuate their 
response to the continuing presence of an agonist or to reduce the effect of a subsequent 
agonist challenge. Desensitization of the glucagon response as a consequence of lipid 
signalling stimulated by other hormones, however, may also play an important 
physiological role. Vasopressin, for example, is already known to potentiate insulin 
secretion (Widmann et al, 1996). Its ability to induce the desensitization of glucagon- 
stimulated cAMP accumulation in hepatocytes (Savage et al, 1995) may therefore seiwe 
as an additional glucose-lowering mechanism by this hormone.
PKD activation in response to glucagon exposure, eould, in theory, occur through a 
number of different mechanisms. For example, activation of PKD may be elicited by 
DAG generated following activation of either PC-PLC or PI-PLC (see section
1.4.1.4.1.). Alternatively DAG, produced in this fashion, may activate PKC isoforms 
which eould then, subsequently, activate PKD (Zugaza et al, 1996). A further 
possibility which has not been tested, is that G protein py sub-units, released from the a  
sub-unit following activation of G  ^by the ligand-occupied receptor, might then effect the 
translocation of PKD to the plasma membrane thiough an interaction with the pleckstrin 
homology domain of the kinase. In support of the latter hypothesis is the observation 
that G protein Py sub-units cause the membrane translocation of GRK2 by a mechanism 
that is believed to involve an interaction of Py with the C-terminal region of the kinase’s 
PH domain (Pitcher etal, 1995b).
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GRK2 G RK 3 PKD p-actin
Dénaturation 95“ 1 min 95“ 1 min 95“ 1 min 95“ 1 min
Annealing 54.7“ 2 min 52.6“ 2 min 52.5“ 2 min 52.5“ 2 min
Extension 72“ 3 min 72“ 3 min 72“ 3 min 72“ 3 min
No. of cycles 35 cycles 35 cycles 35 cycles 35 cycles
Predicted product 701 bp 600 bp 565 bp 466 bp
Table 5.1. PCR conditions for amplification of GRK2, GRK3, PKD and 
P-actin
The annealing temperatures were chosen so as to be approximately 5 degrees below 
the tme melting temperatures of the primers, which was determined by the software 
package Gene Jockey H.
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Transfection Glucagon-stimulated cAMP production in presence of 
PMA (expressed as % of control response, observed 
without PMA, in each transfection)
GR 101 ± 6  ns (noPMA=100)
GR+GRK2 108 ± 8  ns
GR+GRK3 115 ±2 ns
GR+PKD 49 ±1 **
GR+PKDK618M 99 ±4 ns
paAR+PKD 69 ± 7  ns
PsAR+PKD 82 ± 4  ns
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Table 5.2. The effect of PMA on the hormone-stimulated cAMP response 
in COS cells co-transfected with cDNA encoding either the GR or a pAR  
in addition to GRK2, GRK3 or PKD
Transfected COS cells, grown to confluence in 6-well plates as described in the 
Materials and Methods chapter, were pre-incubated for 15 min at 37 °C with serum-free 
DMEM containing 1 mM IBMX, and either 0.1% DMSG (control) or 1 jxM PMA.
Where the GR was transfected, glucagon was then added to a final concentration of 10 
nM and the incubation was continued for another 10 minutes. Where the P2AR or pgAR 
was transfected, however, isoprenaline was added instead of glucagon to a final 
concentration of 1 jxM or 100 pM, respectively. 2% PC A was subsequently added, the 
cells were harvested and their cAMP content deteimined. The results shown represent 
means ± SE of three experiments. The glucagon or isoprenaline-stimulated cAMP 
production in the presence of PMA is expressed as a percentage of the control (without 
PMA). The absolute value, in the absence of PMA, for the cAMP accumulation in the 
control, GR-transfected, cells following glucagon stimulation for 10 minutes was 921 ± 
24 (mean + SE) pmol cAMP per million cells. ** Significant at P<0.01, not significant 
(Student's t test).
■ i
Control
(fold change over basal)
PMA-treated
(fold change over basal)
control COS
basal (1) (1)
48 ± 6  
15 ± 3
53 ±5 
17 ±1
cholera toxin 
forskolin
PKD-transfected 
COS
basal
cholera toxin 
forskolin
48 ± 5  
14±3
56 + 4 
14 ± 3
Table 5.3. The effect of PMA treatment on the forskolin and cholera 
toxin-induced cAMP response in control and PKD-transfected COS cells
Control or PKD-transfected COS cells, grown to confluence in 6 -well plates as 
described in the Materials and Methods chapter, were pre-incubated for 15 min at 37 “C 
with serum-free DMEM containing 1 mM IBMX, and either 0,1% DMSG (control) or 1 
|iM PMA. Cholera toxin or forskolin, where indicated, were then added to final 
concentrations of 1 fxg/ml and 10 pM, and the incubations were continued for 1 hour or 
20 min, respectively. 2% PCA was then added, the cells were harvested, and their 
cAMP content determined. The intracellular cAMP levels under basal conditions for 
PKD-transfected cells were 70 ± 12 pmol/10^ cells with control medium and 69 ±18 
pmol/10  ^cells in the presence of PMA. For untransfected cells the cAMP levels were 85 
±16 pmol/lO^ cells and 81 ±12 pmol/10  ^cells, respectively. The results shown in the
table represent means ± SD of three experiments, expressed as fold stimulation over basal 
values.
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Control PMA ■treated
GTP (pM): 0 10 0 10
GR7PKD COS 114±8 26 ±12 131 ±10 17 ±12
hepatocytes 41 ± 6 6 ± 2 45 ±12 5 ± 2
Table 5.4. The effect of PMA treatment on the GTP-mediated inhibition 
of specific glucagon binding (fmol/mg) to membranes isolated from 
GR/PKD co-transfected COS cells and from hepatocytes.
Hepatocytes, or COS cells co-transfected with cDNA encoding the GR and PKD, 
were treated for 15 min with 1 pM PMA or control (0.1% DMSG) at 37 °C. Hepatocytes 
were then pelleted by centrifugation for 2 min at lOOOg at 4°C. Homogenisation, 
membrane preparation and [l^^I]-glucagon binding were then performed as described in 
the Materials and Methods chapter. 10 pg hepatocyte or COS cell membrane proteins 
were added per binding. Results, expressed in fmol/mg, representing specific binding 
following the subtraction of non-specific binding, are given as means ± SE of three
experiments.
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AC Species Acc. No. Sequence Position Intracellular ?
I bovine M25579 RTAS 542 yesRNRS 549 yesRVSS 748 yesRMDS 1011 yesRRGS 1032 yes
II rat M80550 RVFS 106 noRLAS 300 yesRTKS 540 yesRMDS 1029 yesRSLS 1081 yes
III rat M55075 RMES 1073 yes
IV rat M80633 RLFS 3 yesRPLS 90 noRPES 163 noRLAS 284 yesRSCS 940 yesRMES 1005 yesRTGS 1057 yes
V rat M96159 RSAS 80 yesRLHS 175 noRTNS 420 yesRLRS 488 yesRMDS 965 yes
VI rat LOI115 RSGS 7 yesRYMS 55 yesRQDS 216 noRSPS 245 noRANS 585 yesRAFS 600 yesRVHS 751 noRMDS 1128 yes
VII murine U12919 RLTS 26 yesRLAS 292 yesRSAS 534 yesRMES 1040 yes
VIII rat L26986 RKAS 63 yesRSGS 109 yesRRKS 175 yesRRNS 608 yesRLNS 849 yesRMDS 1117 yes
IX murine Z50190 RASS 85 yesRVDS 201 noRSRS 305 yesRESS 598 yesRPAS 973 noRVLS 1214 yes
Table 5.5. RxxS consensus searches in primary sequences of adenylate 
cyclase isoforms
The primary sequence of each adenylate cyclase isoform was obtained, in Genbank 
format, from the server of the National Centre for Biotechnology Information, using the 
accession number shown. After converting each file to a format which could be 
recognised by the Apple Macintosh GeneJockey U software package, the occurrences in 
the sequence of the amino acid motif RxxS were identified using the Consensus Search 
facility of the program. The presence of the RxxS sequence in a potential substrate 
protein appears to be a pre-requisite for its phosphorylation by PKD (Van Lint et al, 
1995).
The sequences of all occurrences of RxxS in each isoform are shown, together with 
their locations in the protein sequence. Whether or not these residues are located 
intracellularly was predicted by ascertaining their position with respect to the predicted 
transmembrane regions of the isoform concerned.
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Figure 5.1. RT-PCR detection of GRK2, GRK3, PKD and p-actin in
hepatocyte and untransfected COS cell RNA
RNA was prepared from washed hepatocytes or COS cells using Tri Reagent™ as 
described in the Materials and Methods chapter. First stiand cDNA synthesis was caiiied 
out using identical quantities of RNA, and was checked by PGR using oligonucleotide
primers specific for p-actin. The GRK 2 (panel A), GRK 3 (panel B), PKD (panel C) 
and p-actin (panel D) primers were designed to amplify 701 bp, 600 bp, 565 bp and 466 
bp DNA sequences, respectively. PCR reactions were carried out as described in the 
Materials and Methods chapter using a template consisting of the cDNA derived from 
COS cells (lanes C), hepatocytes (lanes H) or plasmid control DNA containing the 
appropriate cDNA (lanes P). Promega (j)xl74/Haein DNA maikers were mn in lanes 
(M) alongside the PCR products on a 2% agarose gel.
:
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Figure 5.2. RT-PCR detection of GRK2, GRK3 and P-actin in
transfected and untransfected COS cell RNA
RNA was prepared from washed transfected or native COS cells using Tri 
Reagent™ as described in the Materials and Methods chapter. First strand cDNA 
synthesis was carried out using identical quantities of RNA, and was checked by PCR 
using oligonucleotide primers specific for p-actin. The GRK 2 (lanes 1 and 2), GRK 3 
(lanes 3 and 4) and p-actin (lanes 6,7 and 8) primers were designed to amplify 701 bp, 
600 bp and 466 bp DNA sequences, respectively. PCR reactions were carried out as 
described in the Materials and Methods chapter using a template consisting of the cDNA 
derived from GRK2-transfected COS cells (lanes 1 and 6), GRK3-transfected COS cells 
(lanes 3 and 7) or untransfected control COS cells (lanes 2,4, and 8). Promega 
(|)xl74/HaeIII DNA markers were mn in lane 5 alongside the PCR products on a 2% 
agarose gel.
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Figure 5.3. The effect of PMA on the glucagon-stimulated cAMP
response in GRK2 and glucagon receptor co-transfected COS cells.
COS cells co-transfected with cDNA encoding both the glucagon receptor and 
GRK2 were grown to confluence in 6-well plates as described in the Materials and 
Methods chapter. The cells were then pre-incubated for 15 min at 37"C with serum-free 
DMEM containing 1 mM IBMX, and either 0.1% DMSG (control) or 1 pM PMA. 
Glucagon was then added to a final concentration of 10 nM and the incubation was 
continued for another 10 minutes. 2% PCA was subsequently added, the cells were 
harvested and their cAMP content determined. The results shown represent means ± SD 
of three incubations.
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Figure 5.4. The effect of PMA on the glucagon-stimulated cAMP
response in GRK3 and glucagon receptor co-transfected COS cells,
COS cells co-transfected with cDNAs encoding both the glucagon receptor and 
GRK3 were grown to confluence in 6-well plates as described in the Materials and 
Methods chapter. The cells were then pre-incubated for 15 min at 37“C with semm-free 
DMEM containing 1 mM IBMX, and either 0.1% DMSO (control) or 1 pM PMA. 
Glucagon was then added to a final concentration of 10 nM and the incubation was 
continued for another 10 minutes. 2% PCA was subsequently added, the cells were 
harvested and their cAMP content determined. The results shown represent means + SD 
of three incubations.
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Figure 5.5. Immunoblot confirming the expression of transfected cDNA 
encoding PKD in transfected COS cells.
Transfected or control COS cells were washed 4 times with PBS, scraped into 0.5 
ml Laemmli buffer per confluent 75 cm  ^flask, and immediately boiled for 3 min. 30 pi 
of each sample was subsequently loaded onto an 8% SDS poly-aci*ylamide gel. Blotting 
was carried out as described in the Materials and Methods chapter with a primaiy 
antibody dilution of 1 in 500.
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Figure 5.6. Timecourses for glucagon-stimulated cAMP production in 
the presence and absence of PMA in COS cells transfected with cDNAs 
encoding both the GR and PKD.
Following a pre-incubation for 15 minutes in the presence (filled symbols) or 
absence (open symbols) of the phorbol ester, PMA, at a concentration of 1 pM, glucagon 
was added to a final concentration of 10 nM. Incubations were terminated after the times 
indicated by the addition of 2% PCA. IBMX was present throughout at a concentration 
of 1 mM. The values shown are expressed as fold stimulation over basal values and 
represent means (± SD) from three incubations.
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Figure 5,7. RT-PCR detection of PKD and p-actin transcripts in 
hepatocyte and CHO cell RNA
RNA was prepared from washed hepatocytes or CHO cells using Tri Reagent™ as 
described in the Materials and Methods chapter. First strand cDNA synthesis was carried 
out using identical quantities of RNA, and was checked by PCR using oligonucleotide 
primers specific for p-actin. The PKD (lanes 1 and 2) and p-actin (lanes 4 and 5) primers 
were designed to amplify 565 bp and 466 bp DNA sequences, respectively. PCR 
reactions were carried out as described in the Materials and Methods chapter using a 
template consisting of the cDNA derived from hepatocytes (lanes 1 and 4) or from CHO 
cells (lanes 2 and 5). Promega (j)xl74/Haein DNA markers were resolved in lane 3 
alongside the PCR products on a 2% agarose gel.
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CHAPTER 6
Relationship between the induction of 
diabetes and the expression levels of PMA 
activated kinases in rats
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6.1. Introduction
6.1.1. The use of streptozotocin to induce diabetes
The diabetic state can be induced in animals by the injection of streptozotocin 
(Gawler et al, 1987). Streptozotocin is a toxin which causes necrosis of the pancreatic 
P cells with consequent loss of insulin secretion, resulting in hypoinsulinaemia, 
hyperglycaemia and insulin resistance in liver and adipose tissue (Houslay, 1990). This 
diabetic state, therefore, resembles that of human type I, insulin-dependent diabetes 
mellitus (IDDM). Insulin resistance is a recognised feature of this condition, although it 
is more typically associated with type II, non-insulin-dependent diabetes mellitus 
(NIDDM), obesity and hypertension (Donnelly and Connell, 1992).
The regulation of adenylate cyclase is believed to be defective in a number of animal 
models of diabetes and obesity, and in humans. Such reported defects include reduced 
levels of expression of Gi-2 in the liver of streptozotocin or alloxan-treated rats, and the 
loss of the "tonic" inhibitory input that is normally supplied by this G protein (Gawler et 
al, 1987; Murphy et al, 1989). These defects have also been found in the adipocytes of 
genetically diabetic (db/db) mice (Begin-Heick, 1992), obese (fa/fa) Zucker rats 
(Strassheim et al, 1991) and in human platelets (Livingstone et al, 1991). The reduced 
expression is likely to result from a decrease in the levels of the mRNA which encodes 
such G proteins, in particular a-Gi-2 and a-Gi-3, whose mRNA has been shown to be 
less abundant in hepatocytes derived from streptozotocin-treated than from conUol rats 
(Bushfield et al, 1990a; Griffiths et al, 1990). In addition, loss of functional Gi and 
impaired Gs function has been observed in liver plasma membranes of obese (fa/fa) but 
not lean (Fa/Fa) Zucker rats (Houslay et al, 1989).
Thus, in the diabetic state it is conceivable that, due to G protein abnoimalities, the 
ability of glucagon to stimulate the activity of adenylate cyclase may be altered, perhaps 
contributing to the hyperglycaemia associated with the condition. In fact, it has been 
observed that the degree of glucagon-induced stimulation of adenylate cyclase activity is
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increased following the induction of diabetes by streptozotocin (Gawler et al, 1987). 
Moreover, the regulation of glucagon-induced adenylate cyclase stimulation is of 
particular importance given that in diabetes, the level of circulating glucagon is known to 
be elevated (Baron et al, 1987), and the hepatic cAMP content is increased (Pilkis et al, 
1974).
6.1.2. Changes in expression and activity of PKC isoforms in diabetes
In diabetes, a number of important changes have been demonstrated in the activity, 
detectable levels and intracellular distribution of PKC isoforms. Induction of 
streptozotocin diabetes in rats is associated with the phosphorylation of Gi-2, with the 
consequent inactivation of this G protein subunit (Bushfield et al, 1990a). It is believed 
that this covalent modification, which has been shown to occur at the protein kinase C 
phosphorylation site (Morris et al, 1996), rather than the reduced expression level of the 
G protein, is the principal change underlying the observed aberrant Gi functioning in 
these animals (Houslay, 1994). Interestingly, insulin tieatment inhibits this 
phosphoiylation (Morris et al, 1995b), perhaps through an inhibition of PKC, 
stimulation of a phosphatase or by effecting normoglycaemia and thus reducing the 
production of DAG. Such a generation of DAG in response to hyperglycaemia may 
occur by de novo synthesis (Hoffman et al, 1991; Wolf et al, 1991; Inoguchi et al, 
1992), or, alternatively, may result from the increased circulating level, in the diabetic 
state, of the hormone vasopressin (Houslay, 1990), which is known to cause the 
generation of DAG by stimulating phospholipase C (Bocckino etal, 1985).
In addition to changes in the activity of PKC isoforms in diabetes, alterations in the 
intracellular localisation and levels of these enzymes have been demonstrated. Thus, in 
the membrane fraction of aorta and heart of streptozotocin diabetic rats, the level of PKC- 
pll was found to be elevated whereas that of PKC-a was unchanged (Inoguchi et al,
1992). The authors of this study, however, were unable to determine whether this was 
due to membrane translocation alone or PKC synthesis and translocation, since no 
significant change in the level of cytosolic PKC-piI was detected (Inoguchi et al, 1992).
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In a separate study, investigating PKC isoform levels in hepatocytes from such animals, 
the induction of streptozotocin diabetes was found to be associated with marked increases 
in the levels of both cytosolic and membrane PKC-a and PKC-pII (Tang et al, 1993). 
Thus the total cellular level of these isofoims is increased, reflecting either an increased 
rate of synthesis or a reduced rate of degradation. The former could be mediated by a 
DAG-stimulated PKC activity leading to activation of the MAPK pathway (Kolch et al,
1993), and the subsequent stimulation of the transcription of these PKC isoforms 
through the phosphorylation of the transcription factor complex, AP-1 (Meek and Street,
1992).
It remains to be ascertained, however, whether such changes in PKC levels occur 
in the principal peripheral target tissues for insulin-stimulated glucose uptake, namely 
adipose tissue and skeletal muscle.
6.1.3. The use of semi-quantitative RT-PCR to determine levels
The technique of RT-PCR was used to determine whether specific transcripts were 
present in a variety of tissues, and also to examine whether expression varied with the 
induction of the diabetic state. In such experiments, the viability of the first strand cDNA 
preparations was verified by conducting PCR with control primers. In addition, a dose 
response experiment was undertaken, to check that increasing quantities of RNA did 
indeed lead to the generation of signals of greater intensities. The use of PCR to 
determine whether a specific DNA sequence is present or absent is a well-established 
practice, for example, in the diagnosis of viral infections. Several groups have, 
however, used RT-PCR to evaluate in a semi-quantitative (Johannes et al, 1994), and 
even a quantitative (Firsov et al, 1995), manner the abundance of a paiticular transcript. 
RT-PCR has also been used recently in our laboratory to determine the effect of PMA 
treatment on PDE-1 transcript levels in Chinese hamster ovary cells (Spence et al, 1995).
6.1.4. Aims and objectives
The aim of the work presented in this chapter was to investigate changes in PKC 
isofoim levels between normal and diabetic rats. An additional objective was to examine
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the expression of PKD in various rat tissues and to ascertain whether streptozotocin- 
induced diabetes is associated with changes in the level of expression of PKD, GRK2 or 
GRK3.
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6.2. Results
6,2A, Determination o f changes in PKC isoform levels in
diabetes
A  series of polyclonal antisera were raised previously, against peptides 
corresponding to unique regions within the amino acid sequences of PKC-a, pi, pil, y, 
Ô, e, and Ç (Tang et al, 1993). The isoform-specificity of the antisera thus obtained was 
verified previously (Tang et al, 1993). Using these antisera, immunoblotting was 
performed to investigate the expression of these isofoims in hepatocytes and adipocytes 
of both streptozotocin diabetic and control rats.
6.2.1.1. Immunoblotting of hepatocytes
Hepatocytes were isolated from two streptozotocin diabetic and two control rats as 
described in section 2.4.9. with the kind assistance of Dr Li Zeng. Following 
homogenisation in buffer (20 mM Tris pH 7.5, 10 mM EGTA, 2 mM EDTA, 0.5% 
Triton XlOO and 50 mM p-mercaptoethanol) containing protease inhibitors as described 
in section 2.4.11, equal quantities of protein were boiled in Laemmli buffer and applied 
to each lane on an 8% SDS poly-acrylamide gel. Electrophoresis and immunoblotting 
were subsequently performed as described in sections 2.4.1. and 2.4.3. While no 
differences were apparent between control and diabetic rats in the electi'ophoretic 
mobilities of the immunoreactive species, certain differences were observed in the relative 
intensities of the respective signal (figure 6.1.). Blots probed with the antisera specific 
for PKC-a, pil, y and e all exhibited an immunoreactive species of approximately 87 kD. 
Interestingly, no signal was detected with the antisera specific for PKC-|3I, while that 
raised against the peptide corresponding to a sequence present in PKC-Ç gave rise to 
several immunoreactive species. Of these, the species with the highest mobility 
(corresponding to a molecular weight of approximately 77 kD) is likely to represent this 
isoform as purified PKC-Ç has been reported to migrate on SDS polyacrylamide gels 
with a MWt of 78 kD (Nakanishi and Exton, 1992). The blot probed with the PKC-Ô-
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specific antisemm revealed a prominent immunoreactive species of approximately 160 
kD, possibly representing a homo-dimer, and, additionally two species of much lower 
intensity of approximately 83 kD. A densitometer was used to compare the signal 
intensities observed in blots of hepatocytes isolated from streptozotocin diabetic rats with 
those of control rats. It was found that the signal obtained from blots probed with 
antisera speeifie for PKC-a, pn, e and Ç were more intense (2.0, 1.5, 1.4 and 1.6 x fold 
increases, respectively) in hepatocytes isolated from the diabetic rats than in those 
prepared from the control animals (fig. 6.1. ).
6 2.1.2. Immunoblotting of adipocytes
As no data had been published pertaining to the expression levels of PKCs in 
adipocytes, one of the principal peripheral targets for insulin action, it was decided to 
isolate such cells from two sources, namely epididymal and peri-nephric fat. These 
tissues were excised from the abdomen of a normal male rat and the adipocytes isolated 
by the use of collagenase as described in section 2.4.10. Subsequently, the adipocytes 
were washed five times in fresh buffer containing protease inhibitors. Upon 
immunoblotting the adipocyte proteins, it was found, however, that no immunoreactive 
species of the predicted molecular weight was detectable. Instead, a species of very high 
intensity was detected in both adipocyte preparations, which co-migrated with albumin 
contained within the molecular weight markers. Such a signal is likely to represent the 
albumin which is included in the buffer used in order to stabilise the cells during the 
collagenase incubation. It is probable, therefore, that the albumin remained bound to the 
adipocytes, despite repeated washing of the cells. Interestingly, it has been found 
recently that the albumin can be replaced by 200 nM adenosine, which maintains 
stabilisation of the adipocytes while permitting collagenase digestion (I. Fleming, 
personal communication, 1996).
In view of the difficulty described above (and experienced also by others in our 
depaitment) in utilising polyclonal antisera in immunoblots of adipocytes, it was decided 
to homogenise and fractionate epididymal fat tissue, per se, instead of performing a
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collagenase incubation. Thus the epididymal fat pads were excised from two control and 
two streptozotocin diabetic rats, homogenised, and subjected to a low speed spin to 
permit removal of fat and cell debris. This yielded a crude homogenate which was then 
fractionated by ultracentrifugation to sediment the plasma membrane fraction, leaving a 
supernatant containing the cytosol.
Immunoblots were subsequently peifoimed (with equivalent quantities of protein) 
on the crudely extracted homogenates, and the cytosol and membrane fractions (figure
6.2.), using two antisera, specific for PKC-pII and PKC-8, which had been found 
consistently to yield good immunoblots of hepatocyte proteins. In this instance, it was 
found that the PKC-pII antiserum strongly detected an immunoreactive species in all of 
the samples, particularly in the homogenates and in the cytosol fractions. Notably, no 
difference was observed between the intensity of the signal that was elicited from the 
control and that from the diabetic samples. With the PKC-e antisemm, however, an 
immunoreactive species was identified in the cmde homogenate and the cytosol but not in 
the membrane fraction. Interestingly, an increased intensity of this species was noted in 
the samples of homogenate prepaied from diabetic rats, but not in the cytosol fraction. It 
is possible that the proteins in both of the membrane fractions had undergone degradation 
during preparation, and the lack of increase in intensity in the cytosolic signal may reflect 
translocation of PKC to the membrane.
A similar method was used to prepare emde homogenates from human adipose 
tissue. Despite immunoblotting with PKC-a, PKC-pII, PKC-e and PKC-Ç, however, 
no immunoreactive species was detected. This may reflect degradation of the PKCs or 
extremely low expression levels in this tissue. Alternatively, it may be a result of 
sequence variations, between the human and rat PKC homologues, in the sequence 
corresponding to that of the peptide used to raise the antisera.
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6,2,2, PKD expression studies
6.2.2.I. Optimisation of PKD-specific PCR
The initial PCR reactions performed with the primers designed so as to amplify the 
cDNA between nucleotides 2123 and 2687 of the PKD open reading frame, as described 
in section 5.2.1.2, yielded signals of low intensity. In order to improve the PKD- 
specific PCR signal and to peimit the maximum subsequent amplification of PKD- 
specific products by RT-PCR, a number of preliminary experiments were caiTied out. In 
these experiments, the PKD-encoding expression plasmid was used as a template.
To prevent extension from any primer dimer pairs that might have been formed, a 
"hot-stait" technique was used, in which the Taq polymerase was added to the reaction 
mixture only once the dénaturation temperature had been reached. This technique, 
however, was not found to improve the signal (figure 6.3.).
Additionally, in order to test the possibility that the primer solutions may be 
defective, perhaps containing residual salts or ethanol, both oligonucleotides were re­
purified from the original stocks. Furthermore, a fresh dilution of the dNTPs was 
prepared. PCR reactions were subsequently perfoimed using the newly purified primers 
at the previously used concentration of 75 pmol per 50 jal reaction volume and also at a 
10-fold higher concentration. The freshly prepared dNTPs were used in a separate 
reaction, and, for comparison, the original constituents were used in a further PCR. It 
was observed that the use of newly purified primers, even at the higher concentration, did 
not lead to an improvement in the PCR yield. Similarly, an increased template dilution, 
undertaken prior to PCR, did not peimit efficient amplification. Surprisingly, however, 
the utilisation of a freshly prepared dilution of dNTPs, did lead to a signal of a 
considerably greater intensity (figure 6.4.), implying that the dNTPs in the previous 
mixture had undergone degradation. Fresh dNTPs were used in all subsequent PCR 
reactions.
As slight variations in the MgClg concentrations have been shown previously to 
compromise the efficiency of the PCR (Saiki, 1989) a further experiment was undertaken
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to optimise the PKD-specific PCR with respect to this salt. Using a range of MgCl2 
concentrations, however, it was found that the original concentration used, that of 75 
nmols in 50 fll (i.e. 1.5 mM) yielded the optimal result (figure 6.5.).
6.2.2.2. PKD tissue distribution
In order to examine the tissue distribution of PKD, RT-PCR was performed on 
RNA (extracted as described in section 2.2.12.) using oligonucleotide primers designed 
as described in section 5.2.1.2. to amplify a 565 bp specific PCR product from the C- 
terminal region of the PKD cDNA sequence. Thus RNA was extracted from heart, 
striated muscle, lung, and fat tissues freshly excised from male Sprague-Dawley rats, and 
an equal quantity, 5 }xg, was used in each case for the immediate synthesis of first strand 
cDNA, as described in section 2.2.14. In addition, a sample of human fat tissue was 
excised from a healthy female patient, snap-frozen in liquid nitrogen, and, following 
thawing, subsequently subjected to the same processes of first strand cDNA synthesis 
and PCR as described above. A sample of excised rat striated muscle was also snap- 
frozen in order to allow the subsequent comparison of fresh isolation of RNA with 
extraction from tissues after freeze-thawing.
No PKD-specific DNA product of the predicted size (565 bp) was detected in the 
RT-PCR reactions undertaken with RNA isolated from snap-frozen rat striated muscle or 
human fat. Such species were, however, detected in the reactions performed with RNA 
isolated fresh from rat epididymal fat, heart, and lung (figure 6.6.). Only a weak signal 
of the predicted size was visualised in RT-PCR from freshly-isolated rat stiiated muscle 
RNA, and interestingly this reaction also gave rise to an additional band of lower mobility 
(corresponding to a size of approximately 700 bp) which was also detected in the 
reactions performed with RNA from heart and fat. While such signals may represent 
non-specific amplification, it is possible that they result from the presence of an 
alternative splice form of the PKD transcript.
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6,2,3, Detection o f expression o f PMA-activated kinases and 
the glucagon receptor in control and diabetic animals
In view of the potential role for PKD in mediating glucose homeostasis implied by 
the above studies, additional experiments were undertaken to compare the levels of 
expression of PKD between diabetic rats and control rats. As no immunoreactive species 
could be detected in rat hepatoeyte homogenates by Western blotting with an antiserum 
raised against a peptide derived from PKD (figure 6.7.), the more sensitive technique of 
RT-PCR was employed for this purpose. The primers utilised were those specific for the 
C-terminal region of the PKD coding sequence, allowing the amplification of a 565 bp 
specific product (corresponding to the PKD open reading frame between nucleotides 
2123 and 2687).
6.2.3.I. Transcript detection in hepatocytes
From normal or diabetic rats, RNA was exti'acted from freshly isolated hepatocytes, 
as described in the Materials and Methods chapter. Confirmation of the diabetic state was 
achieved by the observation of signs of diabetes such as thirst and polyuria, and by 
testing for glycosuria. In addition, following euthanasia, the presence of hyperglycaemia 
was eonfirmed.
Equal quantities of the extracted RNA were reverse-transcribed from the poly- 
adenylated RNA species using a First-Strand cDNA Synthesis Kit as described in the 
Materials and Methods chapter, and equal volumes subsequently used as a substrate for 
PCR with the conditions that were optimised as described in section 6.2.2.1.
It was found that while a signal of the predicted mobility could be amplified from 
RNA extracted from control rat hepatocytes, no such product was detectable following 
PCR performed on RNA extracted from diabetic rat hepatocytes (figure 6.8.).
RT-PCR was also performed, in a similar manner, on these first-strand cDNA 
preparations in order to examine the expression in such animals of the G protein-coupled 
receptor kinases, GRK2 and GRK3. The primers used were those designed as described 
in section 5.2.1.2, so as to amplify specific products of 701 and 600 bp, corresponding
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to nucleotides 280-980 and 1357-1956 of the bovine GRK2 and GRK3 open reading 
frames, respectively. While GRK2 transcripts were detected with signals of equal 
intensity in both control and diabetic hepatocytes, no GRK3-specific signal was detected 
utilising either source of RNA (figure 6.9.).
In addition, RT-PCR was undertaken to ascertain whether the level of glucagon 
receptor mRNA itself is altered in the diabetic state. Thus PCR was performed using 
primers designed as described in section 3.2.1. so as to amplify a specific 941 bp product 
(encompassing nucleotides 1 to 932 of the GR-encoding open reading frame in addition 
to a 9 bp extension). A glucagon receptor-specific product was detected, however, in 
the RNA prepared from both sources (figure 6.10.) with no apparent difference in 
intensity. This finding is consistent with a previously reported study of the relative levels 
of mRNA in diabetic (db/db) and control (db/+) mice, in which no difference was 
detected (Yoo-Warren etal, 1994).
6.2.3.2. PKD-specific transcript detection in epididymal fat
In order to explore further the apparent loss of PKD transcripts accompanying the 
induction of diabetes, PKD transcripts were analysed in adipose tissue. This tissue was 
chosen on account of its known important role in extra-hepatic glucose homeostasis, and 
as it had been found, as discussed above, to express PKD.
Epididymal fat was excised from three healthy rats and a total of 13 rats in which 
diabetes had been induced by the injection of streptozotocin. Five of these diabetic 
animals were then treated for 7 days with insulin (10-12 units administered twice daily by 
sub-cutaneous injection) in order to eliminate the hyperglycaemia, which was confirmed 
by checking for the absence of the signs described above. RT-PCR was carried out on 
cDNA prepaied as described above on RNA freshly extracted from adipose tissue 
immediately after the euthanasia of these animals. The PCR primers utilised to amplify 
PKD-specific cDNA were those described above in section 5.2.1.2. so as to amplify a 
565 bp specific PCR product from the C-terminal region of the PKD cDNA sequence. In 
addition, in order to verify the condition of the first-strand cDNA preparation, and thus
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the quality of the RNA prepai'ation and cDNA synthesis reaction, additional RT-PCR 
reactions were undertaken utilising p-actin-specific primers in combination with the 
cDNA preparations obtained from the adipose tissue excised from these animals. The 
primers used were those designed as described in section 5.2.1.2, allowing for the 
amplification of a specific 466 bp product corresponding to nucleotides 222-687 of the 
open reading frame of human p-actin.
In order to verify that the intensity of the resulting PKD-specifrc RT-PCR product 
would reflect, to an appreciable extent, the level of PKD-specific mRNA available for 
first strand cDNA synthesis, a range of quantities of RNA were used in a series of 
parallel cDNA reactions. From each, an equal volume was subsequently added to a PCR 
reaction mixture, containing PKD-specific primers. The products from this series of 
PCR reactions were compared following electrophoresis in an agarose gel (figure 6.11.). 
While no signal was detected when a quantity of less than 37 ng RNA was utilised for the 
first strand cDNA reaction, with the use of higher quantities, up to 9.4 \xg the signal was 
observed to increase in intensity. This, therefore, provided support for the supposition 
that the magnitude of the PCR amplification would increase with greater quantities of 
template RNA. The quantity of RNA routinely used in the first-strand cDNA syntheses 
was 5 jig, which thus lies within this range.
It was found that while strong signals resulted in all cases from P-actin-specific RT- 
PCR on the cDNAs thus isolated from the healthy controls, the insulin-treated diabetic 
animals, and the untieated diabetic animals, the intensity of the resulting PKD-specific 
signal varied greatly between these groups, despite the use of identical RT-PCR 
conditions. PKD was detected in the cDNAs prepared from all 3 untreated healthy 
animals, but of the eight cDNA samples prepaied from untreated diabetic rats, three failed 
to yield a detectable product and the other five gave rise to an amplification product of 
only a very weak intensity (fig. 6.12. and table 6.1.). Furthermore, the treatment of 
diabetic animals with sufficient insulin to reverse those elinical features of the condition 
that were described above, led to an apparent restoration of the PKD transcript level, as 
cDNAs prepared from 4 out of the 5 animals thus treated exhibited a detectable PKD-
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specific RT-PCR signal which was of a similar intensity to that observed following the 
RT-PCR from healthy animals’ RNA (fig. 6.12. table 6.1.).
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6.3. Discussion
6.3.1. Immunoblotting fo r  PKC isoforms
The inability to detect an immunoreactive species when immunoblotting hepatocyte 
proteins with the PKC-pI-specific antisemm is a finding that is consistent with the 
recognised limited tissue distribution of this isoform (Wetsel et al, 1992). It has been 
reported to be expressed principally in brain and spleen and to be undetectable in liver 
tissue (Wetsel et al, 1992). Similarly, the veiy weak signal elicited by the use of the 
PKC-y-specific antiserum is consistent with the observations of others that this PKC 
isoform is expressed only in cells of the nervous system (Wetsel et al, 1992; Hug and 
Sarre, 1993).
Immunoblotting with PKC isoform-specific antibodies suggested differences in the 
level of abundance of individual isoforms between hepatocytes isolated from 
streptozotocin diabetic and those obtained from normal rats. Specifically, PKC-a, piI, e 
and Ç appeared to be present at higher levels (2.0, 1.5, 1.4 and 1.6 x fold increases, 
respectively) in hepatocytes isolated from the diabetic than in those prepared from normal 
rats. Increased levels of PKC-a, PKC piI and PKC-e have been reported previously in 
hepatocytes (Tang et al, 1993) and an elevated level of PKC-pII has been obseiwed in 
macrovascular tissues (aorta and heart) (Inoguchi et al, 1992) of sti'eptozotocin diabetic 
rats. Such changes were shown to be reversible upon insulin treatment (Tang et al, 
1993; Inoguchi et al, 1994).
The results of the present study, indicating that changes may occur in the levels of 
members of all three classes of PKC isoforms in diabetes, constituted, however, a novel 
finding at the time when this work was undertaken. More recently, all four PKC 
isoforms mentioned above, PKC-a, pII, e and Ç, have been shown to be expressed in 
the livers of Zucker diabetic rats at higher levels than in the contiol animals (Considine et 
al, 1995). Furthermore, three of the four isoforms, PKC-a, 8 and were shown by 
immunoblotting of human liver samples, to be expressed in patients with NIDDM at
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levels which aie approximately two-fold higher than in control patients (Considine et al., 
al, 1995).
It is believed that changes in PKC expression levels such as those observed in the 
present study, may be one of the factors which underlie insulin resistance, a phenomenon 
associated with human diabetes of type I (IDDM) and especially with that of type II 
(NIDDM). Several lines of evidence support this contention. Firstly, it has been shown 
that the insulin receptor's tyrosine kinase activity is cmcial to the mediation of many of 
insulin’s effects (Kilgour, 1993). It has also been demonstrated that TPA-induced 
activation of PKC causes not only the phosphorylation of solubilised insulin receptors 
but also a reduction of the insulin receptor tyrosine kinase activity (Bollag et al, 1986). 
This was subsequently confirmed in Fao hepatoma cells, in freshly isolated hepatocytes 
(Takayama et al, 1988; Caro et al, 1992) and, more recently, in CHO cells transfected 
with the human insulin receptor and cDNAs encoding specific PKC isoenzymes (Chin et 
al, 1993). The role of PKC in this process has been further supported by the ability of 
staurosporine to block the TPA-induced insulin receptor phosphorylation (Duronio and 
Jacobs, 1990), and by the observed potentiation of insulin receptor auto-phosphorylation 
which follows the PMA-induced down-regulation of PKC (Pillay et al, 1990). 
Phosphorylation of the insulin receptor by PKC occurs on the (I subunit at Thr-1336 
(Lewis etal, 1990), Thr-1348 and Ser-1305/1306 (Chin et al, 1993).
In addition to the implication from the above experimental systems that PKC can 
phosphorylate the insulin receptor and thus inhibit its tyrosine kinase activity, several 
studies have shown that in patients with NIDDM, the activity of the insulin receptor 
tyrosine kinase is indeed reduced. This has been demonstrated for liver (Caio et al,
1986), muscle (Amer etal, 1987; Caro etal, 1987; Obermaier-Kusser etal, 1989) and 
fat (Freidenberg etal, 1987; Sinha etal, 1987).
It remains to be determined, however, whether PKC isoenzymes are involved in 
this process in vivo, and, if so, then which specific isoforms aie important. The 
immunoblotting studies discussed above (Tang et al, 1993; Considine et al, 1995), and 
the results of the present study, certainly indicate an association of altered PKC
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expression with diabetes in rat models of diabetes, and in man. Such changes, however, 
are possibly secondary consequences of hyperglycaemia, and may occur independently 
of changes in insulin receptor functioning. Nevertheless, PKC isoforms have been 
shown to phosphorylate and regulate not only the insulin receptor, but also the type 1A 
angiotensin II receptor (Oppermann et al, 1996) and the glucagon-like peptide-1 (GLP- 
1) receptor (Widmann et a l , 1996). Thus it is likely that aberrant expression of specific 
PKC isoforms does cause alterations in cellular signalling pathways, leading to hormone 
resistant states,
6.3.2, PKD expression studies
The detection of PKD-specific transcripts in rat lung and heart, and, albeit weakly, 
in muscle tissue is consistent with previous observations from Northern blotting of RNA 
extracted from mouse tissues (Valverde et al, 1994). As PKD expression in adipose 
tissue was not examined by Valverde et al., the detection of a PKD-specific signal 
resulting from RT-PCR performed on RNA isolated from fat, is a novel finding.
Freeze-thawing of tissue prior to RNA extraction was found to lead to an inability 
to detect any RT-PCR product. Thus, while 5 |Lig of RNA was obtained for first strand 
cDNA synthesis, it is likely that, owing to degradation of RNA occurring during freeze- 
thawing, only small cDNA fragments were available after cDNA synthesis for the 
subsequent PCR amplification.
The additional product observed following RT-PCR reactions performed on RNA 
isolated from freshly excised rat striated muscle, heart and adipose tissue, indicated that 
alternatively-spliced PKD transcripts might exist. This possibility could be further 
investigated using Northern and Western blotting of RNA and protein extracts, 
respectively. Such alternative transcripts have not, however, been reported previously in 
the studies on PKD and PKC-|Lt expression (Johannes et al, 1994; Valverde et al, 1994; 
Van Lint et al, 1995) and it is more likely that the 700 bp band resulted from non­
specific aimealing of one or both of the oligonucleotide primers.
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The greatly reduced PKD-specific PCR signal obtained from cDNA prepared from 
hepatocytes and adipose tissue from diabetic rats is likely to indicate a reduction in the 
level of PKD transcript associated with the induction of this condition in these animals. 
The efficient amplification of P-actin-specific PCR products from the cDNAs prepared 
from these animals indicates that the failure of amplification of PKD products is not 
merely a consequence of poor quality cDNA synthesis or RNA isolation. Nor, in view 
of the results obtained with this P-actin control, is it likely to be due to the presence in the 
diabetic animal cDNA preparations of a substance which non-specifically inhibits the 
PCR reaction. The increase in intensity of the PKD-specific signal which was observed 
to result from increasing the quantity of RNA available for the first strand cDNA 
synthesis reaction lends further support to these conclusions and, additionally, 
demonstrates the absence, in the cDNA prepared from diabetic rats, of any inhibitor of 
PKD amplification by PCR. It would appear that the tieatment with insulin is associated, 
in a number of animals, with the restoration of PKD transcript levels to that which 
supports the amplification by RT-PCR of a detectable signal.
The insulin treatment serves to reduce the elevated blood sugar levels in these 
animals, with the observable consequence that polyuria is prevented and thirst is 
diminished. While the mechanism of the diabetes-induced apparent PKD transcript 
reduction is not clear, it may be postulated that it is a consequence of the hyperglycaemia 
which is present in the diabetic rats but not in those that have been treated with insulin.
In fact, such a glucose-mediated regulation of the levels of a specific tianscript has been 
reported, for instance, for the glucagon receptor mRNA, for which a small but significant 
increase in levels was detected following the incubation of rat hepatocytes in 
hyperglycaemic medium overnight (Abrahamsen et al, 1995). Of great interest, in view 
of the changes in PKD mRNA levels implied by the present study, is the demonstration 
that immunoreactive PKC-p levels are reduced by a factor of 10 following overnight 
treatment of A-10 vasculai* smooth muscle cells with 25 mM glucose (Cooper et al,
1993). It is thus possible that a similar hyperglycaemia-mediated reduction of PKD level 
occurs in the adipocytes of diabetic rats.
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It is possible that the de novo DAG synthesis and PKC activation that has been 
shown in a number of cell types, including rat adipocytes, to be a consequence of 
hyperglycaemia (Hoffman et al, 1991; Wolf et al, 1991; Inoguchi et al, 1992; Berti et
: %al, 1994; Williams, 1995) could, by activating Raf (Kolch et al, 1993; Marquai'dt et al,
1994) lead to the subsequent covalent modification of DNA-binding proteins (Meek and 
Street, 1992), and thus modify the tianscriptional activity of individual genes, including 
perhaps, that of PKD. The precise nature of the upstream DNA regulatory elements of 
the PKD gene remains to be elucidated, but the role of such a PKC-mediated mechanism 
in the apparent reduction in the level of PKD transcripts in fat cells of diabetic animals is 
supported by the finding that PKC is indeed activated in rat adipocytes subjected to
prolonged hyperglycaemia (Hoffman et al, 1991; Muller etal, 1991). An alternative 
mechanism for the reduction in PKD transcript level is that a reduction in mRNA stability 
may be a consequence in these ceUs of the diabetic state. A less likely, but nevertheless 
conceivable fuither alternative, would be a reduction in polyadenylation of the PKD 
transcripts, resulting in failure of the oligo-dT primed cDNA synthesis.
While the effects discussed above are based on the assumption that the observations
,are a result of the effects of hyperglycaemia, it is, of course, feasible that insulin itself 
may play a pivotal role in the maintenance of PKD tianscription. In this scenario, the 
diminution in insulin production resulting from streptozotocin treatment (Gawler et al,
1987), would lead to an abrogation of insulin-stimulated transcription (O’Brien and 
Granner, 1991) of genes, perhaps including that of PKD.
6.3.3. Implications o f results fo r  the pathogenesis o f diabetes I6.3.3.I. Postulated physiological role of PKD in glycaemic homeostasis
It is well established from studies in a variety of cell types, including rat adipocytes 
(Hoffman et al, 1991), vascular smooth muscle cells (Cooper et al, 1993; Williams,
1995) and endothelial cells (Wolf et aA,1991; Inoguchi et al, 1992) that hyperglycaemia 
leads to an elevation of cellular diacylglycerol levels, possibly thiough the de novo
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synthesis of this second messenger (Inoguchi et al., 1992). Thus, as PKD is a DAG- 
activated kinase (Valverde et al, 1994; Rozengurt et al, 1995; Van Lint et al, 1995), 
and as the results discussed in the previous chapter have shown that its action attenuates 
the response of adenylate cyclase to glucagon, it follows that, under normal 
circumstances, PKD may mediate an auto-regulatory process involved in glucose 
homeostasis. Thus, activation of PKD might occur physiologically in response to 
hyperglycaemia and lead to an attenuation of glucagon-stimulated gluconeogenesis and 
glycogenolysis. Such a negative feedback mechanism may operate in conceit with, or 
independently of, the mechanism of glucagon-induced homologous desensitisation of the 
glucagon stimulation of adenylate cyclase.
6.3.3.2. Implications of diminished expression of PKD
If PKD does indeed play such a role in glycaemic control, then the finding that the 
expression of PKD appears to be diminished in the diabetic state may have important 
implications for the understanding of the pathogenesis of the hyperglycaemia that is 
associated with untreated diabetes mellitus. It might be envisaged that the impairment of 
such a PKD-mediated regulation of excessive action of glucagon, a hormone which is 
counter-regulatory to insulin, would have the consequence of further elevating blood 
glucose levels in diabetic patients. This would potentially lead to an exacerbation of the 
condition, and thus contribute to an increased tendency to hyperglycaemic episodes.
Inappropriate elevation of basal hepatic glucose output (bHGO) is a well 
documented finding in patients with NIDDM (Baron et al, 1987). This phenomenon is 
believed to play a significant role in the pathogenesis of the disease, as there is a strong 
correlation between the degree of bHGO and the level of fasting hyperglycaemia, and, in 
particular, between improvements in glycaemic conti’ol and reduction in bHGO 
subsequent to therapeutic intervention (Best et al, 1982). Moreover, it is clear that in 
untreated NIDDM hyperglycaemia results not only from insulin resistance but also from a 
paradoxical hyperglucagonaemia. In fact, in diabetic subjects, the contribution to HGO
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attributable to the hyperglucagonaemia was deteimined to be as high as 58% (Baron et 
al, 1987).
6.3.3.3. Homologous glucagon desensitization in diabetic rats
Previous workers in our laboratory, who studied the ability of glucagon pre­
exposure to induce desensitization of the subsequent stimulation of adenylate cyclase by 
glucagon in hepatocytes isolated from diabetic or from control rats, found that 
desensitization was a feature of both populations of cells (Murphy et al, 1989). The 
degree of desensitisation observed in the control hepatocytes was however, 53% greater 
than in the cells isolated from diabetic animals (Murphy et al, 1989). These results 
would, therefore, be consistent with a role for PKD in the desensitization process, and 
with the reduced expression of tliis kinase in the diabetic state. That the glucagon- 
induced desensitisation observed in the diabetic rat hepatocytes was not completely 
abolished is consistent with the observation that PKD is often detectable by RT-PCR in 
the tissue excised from the diabetic animals, albeit at a much reduced intensity (table
6 . 1.).
It is also conceivable that PKD is not the only kinase involved in this regulatory 
process. It is possible, in this respect, that a kinase of the GRK class may also be 
involved, in a manner which might be similar to that demonstrated for the (32- 
adrenoceptor. This receptor is believed to be phosphorylated by an effector kinase, such 
as PKA, at low agonist concentrations, while at higher concentrations of agonist, 
phosphoiylation by the (3-adrenergic receptor kinase takes place (Clark et al, 1988; 
Hausdorff et al, 1989; Lohse et al, 1990).
Finally, it is interesting to speculate on the mechanism of the increase, by 
approximately 70%, in the magnitude of the response of adenylate cyclase to glucagon, 
that is observed in hepatocytes isolated from streptozotocin-diabetic rats relative to the 
results obtained from the hepatocytes of healthy rats (Gawler et al, 1987). While such 
an increase could certainly be solely attributable to the loss of functional Gi described 
above, it is also conceivable that it reflects a loss of a regulatoiy tonic inhibition by PKD.
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Rat PKD (3-Actin
Control
1 +++ 4-4-+2 +++ +++3 +++ +++
STZ-treated
1 ——— +++2 +++3 --- +++4 --- +++5 — h +++6 -—h +++7 —+ +++8 ---h +++
STZ+Insulin -treated
1 +++ +++2 +++ +++3 +++ +++4 — +++5 4—1—H +++
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Table 6.1. RT-PCR of PKD-specific cDNA from rat epididymal fat
Adult male Sprague-Dawley rats were injected, by the intraperitoneal route, with 80 
mg/Kg streptozotocin dissolved in 0.3 ml O.IM sodium citrate, pH 4.5. After 4 days, 
the urine glucose level was tested using Diabur-Test 5000 (Boehringer Mannheim) test 
strips, to confiim the induction of diabetes mellitus. The glucose concentration was 
typically at least 280 mM. At the time of dissection of killed diabetic rats, the level of 
blood glucose was also checked using Dextrostix and found, typically, to be greater than 
450 mg/ml. Animals which were treated with insulin, received 10 units of a long-acting 
insulin preparation (Humulin Lente), every 12 hours, for 7 days. Urine was checked as 
above to confirm the absence of glucose.
First strand cDNA synthesis and PCR were cairied out as described in the Materials 
and Methods chapter using the PKD-specific oligonucleotide primers:
5' sense oligonucleotide ET-PKD-sl; TCGTTCACTGTGACCTCAAGC 
3' antisense oligonucleotide ET-PKD-asl; CTAGCACTCAGACTGATCAGG. 
This allowed for the amplification of a specific 565 bp product (see figure 6.12) 
corresponding to nucleotides 2123-2687 of the open reading frame of murine PKD 
(accession no. Z34524). The relative intensity of the specific RT-PCR product was 
gauged under ultraviolet light, following staining with ethidium bromide, and is 
represented thus: +++ strong; ++- weak; —+ very weak; — not detected. Excluded from 
the above table are two animals: one which was injected with streptozotocin but failed to 
become diabetic, and one whose RNA failed to yield a viable cDNA preparation.
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Figure 6.1. Immunoblots for PKC alpha, beta II, epsilon and zeta In
extracts of hepatocytes prepared from control and streptozotocin diabetic
rats
An 8% polyacrylamide SDS gel was loaded with equal quantities of protein 
extracted from whole hepatocytes prepared from two contiol (lanes 1 and 2) and two 
streptozotocin diabetic rats (lanes 3 and 4). In each case an aliquot containing 100 pg of 
protein was boiled in Laemmli sample buffer prior to loading. Following 
electrophoresis, the proteins were transferred to nitrocellulose and blocking was 
performed by incubation in 5% (w/v) dried milk protein. The nitrocellulose blots were 
then incubated for 2 hours at room temperature with antisera specific for PKC alpha (A), 
PKC beta II (B), PKC gamma (Ù ), PKC epsilon (cj, PKC zeta (E) diluted 1 in 100. 
Following the removal of unhybridised antibodies by successive washing, the blots were 
incubated in HRP-conjugated anti-rabbit IgG, and detection performed by enhanced 
chemiluminescence.
227
1 2 3 4 5 6 7 8
kDa
206
— 105
— 70.8
— 43.6
B 1 2 3 4  5 6 7  8
kDa
206
— 105
—  70.8
Figure 6.2. Immunoblots for PKC beta II and epsilon in extracts of 
epididymal fat prepared from control and streptozotocin diabetic rats
An 8% polyacrylamide SDS gel was loaded with equal quantities of protein from 
cmde homogenate (lanes 1-4), cytosol (lanes 5 and 6) or membranes (lanes 7 and 8), 
which were prepared from control rats (lanes 1,3,5 and 7) or diabetic rats (lanes 2,4, 6 
and 8). In each case an aliquot containing 200 pg of protein was boiled in Laemmli 
sample buffer prior to loading. Following electrophoresis, the proteins were transferred 
to nitrocellulose and blocking was performed by incubation in 5% (w/v) dried milk 
protein. The nitrocellulose blots were then incubated for 2 hours at room temperature 
with antisera specific for PKC beta II (A) or PKC epsilon (B), diluted 1 in 100. 
Following the removal of unhybridised antibodies by successive washing, the blots were 
incubated in HRP-conjugated anti-rabbit IgG, and detection performed by enhanced 
chemiluminescence.
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Figure 6.3. Amplification by PCR of the cDNA encoding protein kinase
D
Ethidium bromide stained 2% agarose gel electrophoresis of the PCR amplification 
product from the PKD-encoding plasmid with the PKD-specific primers with Taq 
polymerase added either prior to PCR (lane 3) or following the initial dénaturation ie. 
“hot start” (lane 2). Lane 1 contained (])X174 / Hae III DNA markers. The sizes aie 
indicated in bp. The arrow indicates the predicted amplification product which was 
detected only weakly, under either condition.
I
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■Figure 6.4. Amplification by PCR of the cDNA encoding protein kinase
D
Ethidium bromide stained 2% agarose gel electrophoresis of the PCR amplification 
product from the FKD-encoding plasmid in the presence of the original preparation of 
PKD-specific primers (lane 1) or a fresh preparation of primers (lanes 2^ 4-61 The primer 
concentrations were 75 pmol per 50 pi in each reaction, but were 4-fold higher in the 
PCR reaction loaded in lane 5. The quantity of PKD plasmid template was 100-fold less 
in the PCR reaction loaded in lane 6. The concentration of dNTPs was 20 pM in each 
reaction and a freshly prepared stock was utilised for the reaction loaded in lane 4. Lane 
3 contained (])X174 / Hae III DNA markers. The sizes are indicated in bp. The arrow 
indicates the predicted amplification product which was detected with greatest intensity 
when freshly prepared dNTPs were added.
:
230

1 2 3 4  5 6 7 8
Figure 6.5. Effect of varying the MgCl2 concentration upon PKD- 
specific RT-PCR
Ethidium bromide stained 2% agarose gel electrophoresis of the PCR amplification 
products from the first-strand cDNA synthesised from rat hepatocyte RNA, in the 
presence of varying MgCl2 concentrations: 87.5 nmol/50 |il (lane 1), 62.5 nmol/50 pi 
(lane 2), 50 nmol/50 pi (lane 3) and 75 nmol/50 pi (lane 6). The primer concentrations 
were 75 pmol per 50 pi in each reaction. In order to provide a positive control, PKD 
plasmid template was included in the PCR reaction loaded in lane 8. The concentration of 
dNTPs was 20 pM in each reaction. Lane 4 contained ({)X174 / Hae HI DNA markers. 
The sizes are indicated in bp. The arrow indicates the predicted PKD-specific 
amplification product, which was detected using first-strand cDNA as template with 
greatest intensity when the MgCla concentration employed was 75 nmol/50 pi.
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Figure 6.6. Amplification by PCR of the cDNA encoding protein kinase
D from RNA isolated from various tissues
Ethidium bromide stained 2% agar ose gel electrophoresis of the PKD-specific PCR 
amplification product from first strand cDNA prepared from equal quantities of RNA 
extracted from freeze-thawed human fat (lane 1) and rat striated muscle (lane 2), and from 
freshly excised rat epididymal fat (lane 3), rat heart (lane 4), rat lung (lane 6) and rat 
striated muscle (lane 7). In addition, to provide a PCR control, amplification was also 
performed in parallel from the PKD-encoding plasmid (lane 8). The primer 
concentrations were 75 pmol per 50 pi in each reaction. Lane 5 was loaded with 1 
kilobase DNA markers. The arrow indieates the predicted PKD-specific PCR 
amplification product.
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Figure 6.7. Immunoblots for PKD in homogenates of rat hépatocytes and
control and transfected COS cells
All 8% polyacrylamide SDS gel was loaded with 50 pg of protein from PKD 
cDNA-transfected COS cells (lanes 1), 100 pg protein extracted from control COS cells 
(lane 2), 100 jxg (lane 4) and 400 p,g (lane 5) of protein extracted from whole 
hepatocytes, and protein standards in lane 3. In each case the protein extract was boiled 
in Laemmli sample buffer prior to loading. Following electi'ophoresis, the proteins were 
transferred to nitrocellulose and blocking was performed by incubation in 5% (w/v) dried 
milk protein. The nitrocellulose blots were then incubated for 2 hours at room 
temperature with antisera specific for PKD, diluted 1 in 200. Following the removal of 
unhybridised antibodies by successive washing, the blots were incubated in HRP- 
conjugated anti-rabbit IgG, and detection performed by enhanced chemiluminescence.
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Figure 6.8. Amplification by RT-PCR of the cDNA encoding protein
kinase D from RNA isolated from control and diabetic rat hepatocytes
Ethidium bromide stained 2% agarose gel electrophoresis of the PKD-specific PCR 
amplification product from first strand cDNA prepaied from equal quantities of RNA 
extracted from hepatocytes isolated from a healthy animal (lane 2) and one which had 
been treated with streptozotocin to induce a diabetic state (lane 3). The primer 
concentrations were 75 pmol per 50 jxl in each reaction. Lane 1 contained (j)X174 /
Hae in DNA markers. The arrow indicates the predicted PKD-specific PCR 
amplification product.
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Figure 6.9. Amplification by RT-PCR of the cDNAs encoding GRK2 and
GRK3 from RNA isolated from control and diabetic rat hepatocytes
Ethidium bromide stained 2% agarose gel electi'ophoresis of the PCR amplification 
products following PCR reactions using first strand cDNA preparations as template. The 
latter were synthesised from equal quantities of RNA extracted from hepatocytes isolated 
from a healthy animal (lanes 1 and 3) or from one which had been treated with 
streptozotocin to induce a diabetic state (lanes 2 and 4). GRK2-specific primers (lanes 1 
and 2) or GRKS-specific primers (lanes 3 and 4) were present at concentrations of 75 
pmol per 50 pi in each reaction. Lane 5 was loaded with (j)X174 / Hae III DNA 
markers.
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Figure 6.10. Amplification by RT-PCR of glucagon receptor cDNA from
RNA isolated from control and diabetic rat hepatocytes
Ethidium bromide stained 2% agarose gel electrophoresis of the PCR amplification 
products following PCR reactions, using as template, preparations of first strand cDNA 
synthesised from equal quantities of RNA extracted from hepatocytes which had been 
isolated either from a healthy animal (lane 2) or one which had been treated with 
streptozotocin to induce a diabetic state (lane 3). Glucagon receptor-specific primers 
were present (lanes 2 and 3) at concentrations of 75 pmol per 50 pi in each reaction. 
Lane 1 contained (|)X174 / Hae III DNA mai’kers.
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Figure 6.11. RT-PCR of the cDNA encoding protein kinase D from a 
range of quantities of RNA isolated from rat epididymal fat
.Ethidium bromide stained 2% agarose gel electrophoresis of the PKD-specific PCR 
amplification product from first strand cDNA mixtures prepaied from a range of 
quantities of RNA extracted from epididymal fat excised from a healthy animal. The 
quantities of RNA used as a template for each first-strand cDNA synthesis reaction 
ranged from 2.3 ng (lane 2) to 9.4 jxg (lane 8) increasing in successive 4-fold steps as 
indicated. In addition, as a PCR control, amplification was also performed in parallel 
from the PKD-encoding plasmid (lane 1). The primer concentrations were 75 pmol per 
50 pi in each reaction. The arrow indicates the predicted PKD-specific PCR 
amplification product, which was detected in lanes 6-8, and, in higher exposures (not 
shown), also in lanes 4 and 5.
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Figure 6.12. Amplification by RT-PCR of the cDNAs encoding protein
kinase D and p-actin from RNA isolated from control, diabetic and
insulin-treated diabetic rat epididymal fat
A and B. Ethidium bromide stained 2% agarose gel electi'ophoresis of the products 
resulting from PCR with PKD-specific primers (A) from first strand cDNA prepaiations 
synthesised from equal quantities of RNA extracted from rat epididymal fat. The tissue 
was excised fiom three healthy animals (lanes 1-3) and three which had been treated with 
streptozotocin to induce a diabetic state (lanes 5-7). In addition, to confirm the viability 
of the cDNA preparations, amplifications were also performed in parallel, using primers 
specific for p-actin, from the same first-strand cDNA preparations (B). The primer 
concentrations were 75 pmol per 50 jxl in each reaction. Lane 4 contained (|)X174 /
Hae III DNA markers.
C. Ethidium bromide stained 2% agarose gel electrophoresis of the products 
obtained by PCR with PKD-specific primers (lanes 1,2 and 4) from template DNA 
consisting of the PKD expression construct (lane 4) or of first strand cDNA prepared 
from equal quantities of RNA extracted from rat epididymal fat (lanes 1 and 2). The 
tissue was excised from two animals which had been treated with stieptozotocin to induce 
a diabetic state and, subsequently, treated with 10 units of a long-acting insulin 
preparation (Humulin Lente), every 12 hours, for 7 days. Urine was checked in order to 
confirm the absence of glucose. To confirm the viability of the cDNA preparations, 
amplifications were also perfoimed in paiallel, using primers specific for p-actin, from 
the same two first-strand cDNA preparations (lanes 5 and 6). The primer concentrations 
were 75 pmol per 50 p,l in each reaction. Lane 3 contained (|)X174 / Hae III DNA 
markers.
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CHAPTER 7
Conclusions
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7,1. Analysis and manipulation o f the glucagon receptor 
cDNA
At the outset of this study I was provided with a cDNA clone containing the coding 
sequence encoding part of the rat hepatic glucagon receptor. An initial BamH I /
HinD III analysis, however, suggested to me that this clone might contain a 300 bp 
intron, and, unfortunately, the results of a number of subsequent restriction digests on 
this clone confirmed my suspicion. The incoiporation of this intronic DNA into the 
completed constiuct would have compromised the expression of the receptor (Svoboda et 
al, 1993a). It is unusual, but certainly not without precedent, for a clone isolated from a 
cDNA library to contain intronic sequences, implying that despite the formation of the 
library from poly-adenylated mRNA, a number of these mRNA molecules had not been 
fully spliced prior to poly adénylation. This phenomenon has been described previously 
(Lewin, 1985; Svoboda et al, 1993a), and is unlikely to be due to anomalous splicing 
signals, as the donor and acceptor splice sites of each of the four inti'ons present in the 
GR genomic sequence do conform to the consensus dinucleotide sequences GT and AG, 
respectively (Ohshima and Gotoh, 1987). Fortunately a plasmid construct was 
subsequently obtained, obviating the necessity to use the intron-containing cDNA 
species.
While the incorporation of a coding sequence for a VSV epitope tag at the 5’ end of 
the glucagon receptor sequence was successfully achieved by PCR, difficulties were 
encountered in the subsequent ligation of the 832 bp product into the expression vector 
containing the remainder of the coding sequence of the GR. The possible reasons for this 
include a failure of efficient restriction digestion at one or both extremities of the PCR 
product. Such incomplete digestion might have resulted from the degradation of the ends 
of the amplified products by the exonuclease activity of the proof-reading polymerase 
during PCR. Another possible explanation for the difficulty encountered in ligating the 
PCR product into the expression vector was that despite the precautions taken, such as 
the use of two different restriction enzymes and the inclusion of a phosphatase step, the
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cut vector may have re-circularised without the inclusion of the insert. Furthermore, 
additional difficulties were created on account of the vector containing the GR-encoding 
sequence being pCDM8 , a plasmid which contains few unique restriction sites at the 5' 
and 3' ends of the inserted cDNA sequence and which necessitates the use of the 
MC1061/P3 strain of E. coli (Seed, 1987). These bacteria contain an endonuclease 
which makes plasmid purification and subsequent manipulations difficult, and their use 
relies upon an antibiotic selection system involving the suppression by a plasmid- 
encoded suppressor tRNA of premature stop-codons in the antibiotic resistance genes of 
the P3 episome. This process may, itself, yield false-positive colonies. Thus, in 
retrospect, in order to facilitate further studies, it might well have been beneficial to sub­
clone the coding region of the glucagon receptor from pCDM8 into a more easily 
manipulated mammalian expression vector, such as pc DNA3 or pSV-Sportl.
7.2. Transient transfection studies
A model system for the investigation of glucagon receptor function was created by 
tiansfecting COS-7 cells with the pCDM8 expression plasmid containing the glucagon 
receptor cDNA. In such ti'ansfected cells the GR was found to be functionally 
expressed, yielding a cAMP response to glucagon which greatly exceeded that observed 
in untransfected COS cells, with an observed EC50 value of 1.8 ± 0.4 nM. In fact, 
similar values have been reported for the native response seen in intact hepatocytes in the 
presence of PDE inhibitors: 2 nM (Christoffersen and Berg, 1974), 0.5-3.0 nM (Sonne 
et al, 1978) and 1.2 nM (Heyworth et al, 1983). That the response observed here was 
only apparent if the non-selective PDE inhibitor, IBMX (Beavo and Reifsnyder, 1990; 
Hoey and Houslay, 1990) was added to assays, is likely to reflect the potent activities of 
endogenous cAMP phosphodiesterases which have been demonstrated in these COS cells 
(Shakur et al, 1993). Moreover, as IBMX is a reversible, competitive inhibitor of PDE 
action then the plateau in accumulation reached after about 15 min of exposure to 
glucagon presumably reflects a steady state where the glucagon-stimulated production of 
cAMP matches the degradation by the residual PDE activity.
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Stimulation of mock or transfected COS cells with 10 nM glucagon failed to lead to 
a detectable significant stimulation of IP3 production. This is not surprising, given the 
cuiTent literature regarding the effects of glucagon. For example, in rat hepatocytes, 
Pittner and Fain were unable to detect any glucagon-induced rise in inositol phosphate 
production (Pittner and Fain, 1991) and, in those instances where glucagon-stimulated 
inositol phospholipid hydrolysis has been reported, the magnitude of the reported 
stimulation has varied between only 18 and 25% (Wakelam et al, 1986; Whipps et al, 
1987; Unson et al, 1989).
Glucagon-stimulated hydrolysis of phosphatidylcholine was, however, observed in 
the present study in the COS cells which had been transfected with GR-encoding cDNA, 
with a predominance of PtdCho-PLC rather than PtdCho-PLD activity. Thus, glucagon- 
induced production of DAG would be predicted to occur in these cells, with the 
implication that the stimulation of these COS cells by glucagon is likely to lead to the 
activation of PKC and other DAG-activated kinases.
From several lines of evidence it has been inferred that the reduction in the response 
of adenylyl cyclase to glucagon that can be elicited in hepatocytes by the prior exposure 
of the cells to this hormone, is mediated by a DAG-activated kinase. In order to gain an 
insight into the mechanism involved in this desensitisation the intention was to study the 
PMA-stimulated inhibition of glucagon-stimulated cAMP accumulation in transfected 
cells.
The unexpected finding, however, was that in neither COS nor HEK293 cells, 
transfected with the rat hepatic glucagon receptor, was any PMA-stimulated inhibition of 
glucagon-stimulated cAMP accumulation observed. This contiasted with the published 
observation that treatment of hepatocytes with the phorbol ester, PMA, caused an 
inhibition of glucagon-stimulated cyclic AMP accumulation (Heyworth et al, 1984). 
From subsequent experiments, discussed in chapter 4, the lack of detectable inhibition by 
PMA appeared to reflect neither any potent protein phosphatase activity nor the quantity 
of DNA with which the COS cells were transfected.
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It was subsequently considered that the PMA-induced inhibition of glucagon- 
stimulated cAMP accumulation might depend upon a specific cellular* signalling 
component that is absent in COS cells but which is present in hepatocytes and is capable 
of being activated by DAG or phorbol ester. It appeared that the various members of the 
protein kinase C (PKC) family were the most likely candidates for such a component, 
and that the inability to observe PMA-mediated inhibition of glucagon-stimulated cAMP 
accumulation in COS cells might have been due to the inadequate expression of a 
particular PKC isoform.
Immunoblotting studies had previously shown that hepatocytes express PKC-a, 
pil, e and Ç isoforms, but not PKC-pi, y, ô or rj (Tang et al, 1993). In the experiments 
discussed in chapter 4, PKC-a, pil, E and Ç were all detected in native COS cells, 
although the levels of PKC-pII appeared to be lower in COS cells than in hepatocytes.
In order to increase the expression levels of PKC isoforms it was decided to co-transfect 
COS cells with the glucagon receptor-encoding cDNA and with plasmids encoding each 
of the three PMA-responsive PKC isoforms known to be present in hepatocytes (PKC- 
a, pil and e). Over-expression of the appropriate PKC isoform, following the 
transfection of COS cells with the respective cDNA, was demonstrated, but in no 
instance did co-transfection with the plasmids encoding these PKC isoforms lead to the 
reconstitution of PMA-induced inhibition of glucagon-stimulated cyclic AMP 
accumulation. It was therefore concluded that the co-expression in the glucagon 
receptor-transfected COS cells of any individual PKC isoform present in hepatocytes, 
was not, in itself, sufficient to confer PMA-induced inhibition of the glue agon-stimulated 
cAMP accumulation.
In order to identify the PMA-activated kinase responsible for the glucagon-induced 
inhibition of the response of hepatocytes to glucagon, the cDNA encoding the glucagon 
receptor was then co-transfected into COS-7 cells with plasmids encoding each of three 
additional PMA-responsive kinases. These kinases, GRK2, GRK3 and PKD, were 
known to possess substrate specificities and stmctural chaiacteristics distinct from those 
of PKC isoforms. Although transcription of the cDNAs encoding GRK2 and GRK3
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was confirmed using RT-PCR, no PMA-induced inhibition of the glucagon-stimulated 
adenylate cyclase response could be detected. Intriguingly, however, co-expression of
7.5. Investigations into the mechanism o f the PKD-mediated 
inhibition
The mechanism by which glucagon-stimulated intracellular cAMP accumulation
protein kinase D (PKD) with the glucagon receptor led to a striking PMA-induced 
inhibition of glucagon-stimulated cAMP accumulation in these co-transfected COS cells.
*The inability of a transfected inactive mutant PKD enzyme to confer this inhibition 
suggests that the effect is indeed due to the catalytic activity of the kinase. Furthermore, 
from the determination of the cellular PDE activity, it was ascertained that the inhibition 
of cAMP accumulation was directed at the level of cAMP synthesis rather than at its 
degradation.
■S;.
might be inhibited by PMA-induced PKD activation was investigated by measuring the 
effect of PMA treatment on both the level of specific binding of [l^^I]-glucagon to COS 
cell membranes and the stimulation of cAMP accumulation elicited by cholera toxin or 
forskolin. From these experiments it appeared that the action of PKD may reduce i
glucagon-stimulated cAMP accumulation by an action which reduces the ability of the
receptor-Gg complex to activate the catalytic unit of adenylate cyclase.
Although PMA treatment maikedly attenuated the glucagon-stimulated cAMP 
accumulation in COS cells co-transfected with cDNAs encoding the GR and PKD, it did 
not elicit a statistically significant reduction in the isoprenaline-stimulated cAMP 
accumulation in COS cells co-transfected with cDNAs encoding PKD and either the p2- 
AR or the P3-AR. This is consistent with the possibility that, in the co-transfected COS 
cells in which the inhibitoiy effect is observed, the glucagon receptor, itself, is a target of 
PKD.
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7,4. Inferences regarding the possible roles o f  PKD in 
hepatocytes
The above findings have important implications for our understanding of glucagon 
action in hepatocytes. Firstly, in view of the activation of PKD by DAG, it is 
conceivable that this kinase plays an important role in hepatocytes. In these cells it may 
effect the desensitization of the glucagon receptor and possibly a number of other 
GPCRs, in response to the generation of DAG induced by glucagon and other honnones 
such as vasopressin. Secondly, desensitization of the glucagon response, specifically, 
may play an important additional role, responding not only to hormone-stimulated lipid 
signalling, but also to DAG generated de novo in response to hyperglycaemia.
The detection of a PKD-specific signal resulting from RT-PCR performed on RNA 
isolated from fat was, in itself, a novel finding. Intriguingly, the PKD-specific PCR 
signal obtained using hepatocytes and adipose tissue of streptozotocin diabetic rats was 
of much lower intensity than that obtained using samples from control rats. Moreover, 
this difference appeared to be eliminated upon the treatment of the diabetic rats with 
insulin, suggesting that a reduction in the level of PKD-specific mRNA may be a 
consequence of hyperglycaemia itself.
A number of potential mechanisms might be envisaged by which the streptozotocin- 
induced diabetic state could bring about the reduction in PKD mRNA. One possibility is 
that the de novo DAG synthesis and PKC activation that has been shown in a number of 
cell types, including rat adipocytes, to be a consequence of hyperglycaemia (Hoffman et 
al, 1991; Wolf et al, 1991; Inoguchi et al, 1992; Berti et al, 1994; Williams, 1995), 
could effect the activation of Raf kinase (Kolch et al, 1993; Maïquardt et al, 1994) and, 
consequently, MAPK, with the subsequent modulation by phosphorylation of 
transcription factor activity (Meek and Street, 1992). An alternative mechanism, 
however, might be envisaged, if the gene encoding PKD were to constitute one of those 
whose transcription is markedly stimulated by insulin itself. In such a situation, the 
diminution in insulin production resulting from streptozotocin treatment (Gawler et al, 
1987) could lead to an abrogation of insulin-stimulated transcription (O’Brien and
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Granner, 1991) of the kinase. The mechanisms by which PKD gene transcription is 
regulated, however, remain to be chai'acterised.
An inhibition, by 51%, of the glucagon-induced desensitization of the response to 
glucagon was observed in hepatocytes (Savage et al, 1995) in the presence of the PKC 
inhibitor, chelerythrine (Herbert et al, 1990). Interestingly, recent studies on the 
regulation of PKD expressed in Swiss 3T3 and Rat-1 cells have indicated that the 
activation of PKD in vivo may be dependent upon its phosphorylation by PKC isoforms 
(Zugaza et al, 1996). The chelerythiine-induced inhibition of the desensitization might 
therefore be a consequence of the inhibition by this compound of the PKC isoforms 
whose action is required for the activation of PKD. The alternative possibility, that 
chelerythrine can inhibit PKD directly, remains to be investigated, although other 
inhibitors that exhibit specificity towards PKC isoforms, such as calphostin C and Ro 
31-8220, appear to have no effect on the activity of PKD in vitro (Johannes et al, 1995; 
Zugaza et al, 1996).
7.5. Postulated physiological and pathological importance o f  
PKD
As PKD is a DAG-activated kinase (Valverde et al, 1994; Rozengurt et al, 1995; 
Van Lint et al, 1995), and as the results discussed above have indicated that its action 
can attenuate the response of adenylate cyclase to glucagon, I propose that PKD may 
mediate a homeostatic mechanism involved in glycaemic control. Thus, the activation of 
PKD upon de novo DAG synthesis might occur physiologically in response to 
hyperglycaemia and lead to an attenuation of glucagon-stimulated gluconeogenesis and 
glycogenolysis (fig. 7.1.). Conceivably, a glucagon-induced desensitisation of the 
response of adenylate cyclase to glucagon could operate either in concert with, or 
independently of, this postulated negative feedback mechanism.
If PKD does play such a role in glucose homeostasis, the diminished expression of 
the kinase, which appears to be associated with the diabetic state, may have important 
implications for our understanding of the pathogenesis of the hyperglycaemia that is
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associated with untreated diabetes mellitus. Thus, in untreated diabetic patients, the t
■impainnent of such a PKD-mediated regulation of the glucagon-induced glucose 
production, could have the consequence of further elevating blood glucose levels, i
potentially exacerbating the condition, and thus contributing to an increased tendency to 
hyperglycaemic episodes. Supporting such a hypothesis is the reported finding that an 
inappropriate elevation of the hepatic glucose output is indeed a significant pathogenic 
factor in patients with NIDDM (Baron et al, 1987).
The apparent reduction in the level of PKD mRNA and the inhibitory role of PKD 
proposed above are both consistent with previous observations regarding glucagon- 
stimulated cAMP accumulation in rat hepatocytes. Firstly, in the hepatocytes of rats 
which have been treated with streptozotocin, thus rendering them diabetic, the magnitude 
of the response of adenylate cyclase to glucagon has been shown to be approximately 
70% greater than that which is observed in hepatocytes isolated from the hepatocytes of 
healthy rats (Gawler et al, 1987). Such an increase could reflect a loss of a regulatory 
tonic inhibition by PKD, although alternative mechanisms have been described involving 
the loss of functional Gi (Gawler et al, 1987; Murphy et al, 1989; Bushfield et al,
1990a; Morris et al, 1996). Secondly, the ability of glucagon pre-exposure to induce 
desensitization of the subsequent stimulation of adenylate cyclase by this hormone in 
hepatocytes isolated horn control rats has been shown to be 53% greater than in 
hepatocytes from diabetic animals (Muiphy et al, 1989). Again these results would be 
consistent both with a role for PKD in the desensitization process and with the reduced 
expression of this kinase in the diabetic state.
7.6. Future studies
Many aspects of PKD expression and functional characteristics remain to be 
investigated. These include its precise mechanism of activation, substrate preference and 
role in cellular signalling and disease. For instance, it is conceivable that the activation of 
PKD is associated with a translocation in a manner analogous to the membrane 
translocation of GRK2. The latter occurs by a mechanism that is believed to involve an
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interaction of G protein py sub-units, released from the a  sub-unit following the 
activation of Gg by the ligand-occupied receptor, with the pleckstrin homology (PH) 
domain of the kinase (Pitcher et al, 1995b), Thus, although PKD is known to be 
activated by DAG, and is thus likely to be stimulated following the hormone-induced 
stimulation of either PC-PLC or PI-PLC, it is interesting to speculate that, given the 
possession by PKD of a PH domain, the mechanism of activation of the kinase may also 
involve its translocation to the plasma membrane by an interaction with G protein Py sub­
units. In fact, as a prelude to the testing of this hypothesis, I have sub-cloned the cDNAs 
which encode the GPi and Gy2 sub-units into expression vectors. This should permit 
the future determination of whether co-expression of these sub-units with PKD can lead 
to membrane translocation of the kinase in COS cells.
Particularly desirable would be an experiment designed to test the hypothesis 
proposed above that PKD mediates a hyperglycaemia-induced inhibition of glucagon- 
stimulated cAMP accumulation in hepatocytes. If viable hepatocytes could be sustained 
for a sufficient period, then it should be possible to test whether prolonged exposure of 
these cells to raised extracellular glucose (20-25 mM) would cause an attenuation of the 
subsequent response of adenylate cyclase to glucagon. Incubation with a PKD-specific 
antisense oligonucleotide could then be used to detennine whether the expression of this 
kinase is a pre-requisite for the inhibitoiy effect.
Finally, the mechanisms by which PKD effects an inhibition of glucagon- 
stimulated cAMP accumulation could be investigated by studying the phorbol-ester 
stimulated phosphorylation of the glucagon receptor, G proteins or adenylate cyclase 
isoforms in vitro or in transfected COS cells. In fact, as mentioned above, analysis of 
the glucagon receptor coding sequence has identified a potential phosphorylation site for 
PKD in the C-terminal tail. Thus, using the PCR-based strategy outlined in figure 7.2, 
the cDNA encoding the receptor could be subjected to site-directed mutagenesis to change 
the amino acid sequence in this region from RMASS to RMAAA, thus eliminating the 
two potential target residues, Ser 432 and Ser 433. The mutant cDNA constmct could
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then be employed in subsequent transfection or phosphorylation experiments to 
determine the effects of these amino acid substitutions.
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Figure 7.1. The proposed role of PKD in a homeostatic mechanism 
regulating hepatocyte gluconeogenesis
It is postulated that a raised exti'acellular glucose level may, via the induction of de 
novo synthesis of diacylglycerol (DAG), lead to the stimulation of PKD. This, in view 
of the data presented in the preceding chapters, is proposed to cause the inhibition of 
glucagon-stimulated cAMP accumulation, thus negatively regulating gluconeogenesis in 
these cells. Several studies have demonstrated hyperglycaemia-induced synthesis of 
DAG (Hoffman et al, 1991; Wolf et al, 1991; Inoguchi et al, 1992; Berti et al, 1994; 
Williams, 1995), which has been shown to activate PKD (Valverde et al, 1994; 
Rozengurt et al, 1995; Van Lint et al, 1995). The consequence of a loss of PKD 
expression in the diabetic state would therefore be a loss of this regulatory mechanism, 
with a resulting exacerbation of the diabetes-associated hyperglycaemia.
In tliis figure, the aiTows depicted in black represent steps which have previously 
been demonstrated to occur, while those indicated in grey represent steps in a 
hypothetical pathway, proposed on the basis of the evidence presented in the preceding 
chapters.
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Figure 7.2. Strategy for the site-directed mutagenesis of the coding 
sequence of the rat hepatic glucagon receptor.
This scheme is based on the technique of overlap extension PCR (Ho et al, 1989). 
Two pairs of PCR oligonucleotide primers (a+b and c+d) are designed in such a way as 
to result in complementaiity between oligonucleotides b and c. Thus, the PCR reactions 
generates two DNA products with overlapping ends. The novel DNA sequence 
containing the desired specific nucleotide substitutions is incorporated into the region of 
overlap. In a subsequent 'fusion' reaction, the overlapping ends aie permitted to anneal, 
allowing the 3' overlap of each strand to serve as a primer for extension, with the other 
member of the overlapping primer pair serving as template. The product of this fusion 
reaction may then be amplified by successive rounds of PCR, thus incorporating the 
mutant sequence into all of the resulting DNA copies. By this method, using the 
indicated oligonucleotide primers, the putative site for phosphoiylation by PKD may be 
mutated from RMASS to RMAAA thus eliminating the tai'get residues, Ser^32 
Ser^ 33.
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APPENDIX
Attempts to obtain a glucagon receptor-
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A./. Testing antisera raised against GR-based peptides
In order to raise GR-specific antisera, a previous worker in our laboratoiy had 
obtained synthetic peptides con esponding to the regions of the OR amino acid sequence 
indicated in table A.I. These peptides were conjugated, as haptens, to the canier 
molecule, keyhole limpet haemocyanin (KLH), prior to injection into New Zealand White 
rabbits. Pre-immune sera were obtained from these rabbits prior to peptide injection. 
Initially, the antisera from rabbits YE625 and YE627 raised against the C-terminal 
peptides 4 and 5, respectively, were tested in parallel with the respective pre-immune 
sera, in order to determine which immunoreactive species could be detected in liver 
membranes by the immune but not by the pre-immune antisera. The YE625 immune 
serum was found to detect immunoreactive species of 75 and 72 kDa which were, 
however, also detectable, albeit at very low intensity, by the respective pre-immune 
serum (figure A.I.). In addition, the YE625 immune serum detected a species of 
40 kDa which was not detected by the pre-immune serum. This, however, was 
considered to be of too high a mobility to represent the glucagon receptor, which, in early 
cross-linking studies, had been observed to migrate with an apparent molecular mass of 
approximately 63 kDa (Iyengar and Herberg, 1984).
The YB627 immune semm, in contrast, detected two immunoreactive species of 
apparent moleculai’ weights 88 kDa and 65 kDa which were not detectable by the 
respective pre-immune serum (figure A.2.). The 65 kDa species, whose signal was of 
much greater intensity, was considered to possibly represent the glucagon receptor.
In subsequent immunoblots, to test its specificity, this YE627 antiserum was again 
used to probe liver membrane proteins, after pre-incubation of the antiserum with either 
peptide 4 (non-specific) or the peptide against which this antisemm was raised, peptide 
5, as described by Tang et al. (Tang et al, 1993). In such immunoblots, however, it 
was found that the detection of the two immunoreactive species was impaired by both of
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these peptides, with the non-specific peptide 4 appai'ently having the greatest inhibitory 
effect (figure A.3.).
Subsequently, the YE627 pre-immune and immune antisera were used to probe 
extracts of untransfected or GR cDNA-transfected COS-7 cells. Thus crude lysate, 
membrane and cytosol fractions were prepared from these COS cells and 100 pg protein 
applied to individual wells of an 8% SDS poly-aciylamide gel. The immunoblot again 
revealed the presence of an immunoreactive species with an apparent molecular weight of 
65 kD, in the crude lysate and membrane fractions, that was detectable with the immune 
serum but at relatively lower intensity with the pre-immune serum. This species, 
however, was observed to be of the same intensity in both untransfected and GR cDNA- 
transfected COS cell extracts (figure A.4.).
Subsequently, a series of Western blots of GR-transfected and control COS cells 
undertaken with the other antisera raised against GR-peptides in rabbits YE619-628, with 
the exception of the antisera from rabbits YE623 and YE624 which showed negligible 
immunoreactivity by ELISA (performed by Dr. A. Campbell in our department). It was 
found that the antisera obtained from rabbits YE621, 622, 625, 628 (injected with 
peptides 2, 2,4 and 5, respectively) deteeted immunoreactive species of approximately 
60-65 kDa (figure A.5.). In none of these immunoblots, however, was the signal any 
less intense in the untransfected control COS cells than in the GR cDNA-ti’ansfected COS 
extract. This was unlikely to have been a result of failure of GR expression in the 
transfected cells, as such cells exhibited a mai'ked adenylate cyclase response to glucagon 
(see chapter 4). Moreover, following the electrophoretic separation, transfer to 
nitrocellulose and protein staining of the proteins extracted from both the transfected and 
control cells, an additional band was visible in the transfected COS cell extiact with an 
apparent molecular weight of 65 kDa (figure A.6 .). As this was the only protein species 
to be detected in transfected but not in control COS, it is likely that this reflected the 
expression of the glucagon receptor cDNA. Interestingly, a very intensely stained 
protein band was detected in the hepatoeyte extract, migrating with a similar MWt to that 
of the glucagon receptor. The abundance of this protein, which may represent albumin,
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in hepatocyte preparations may account for the species detected previously by the antisera 
raised against glucagon receptor peptides, which may therefore have detected this protein 
non-specifically.
A.2. Testing antisera raised against a GST-GR fusion protein
A  fusion protein was engineered by the in-frame fusion of the entire C-terminal tail 
of the glucagon receptor to the GST-encoding sequence of the pGEX-3X vector. The 
GST-GR fusion protein was subsequently expressed in E. coli, purified and injected into 
two rabbits. The antisera, Ig7 and Ig8 , thus obtained were immuno-purified by 
adsorption onto a GST column, in order to remove GST-reactive antibodies. This work 
was done by Dr. Pascal Julien in our laboratory.
The antisera obtained pre- and post-purification were then used to perfoim 
immunoblots of hepatocyte homogenate, and of homogenate, PI and P2 fractions of both 
transfected and control COS cells. In addition, purified extracts from E. coli expressing 
cDNA encoding either GST-GR or GST were included, serving as positive and negative 
controls, respectively. Both of the unpurified antisera yielded sti'ong signals 
corresponding to both the predicted 34 kDa GST-GR fusion protein and the 28 kDa 
GST protein, implying the presence in both antisera of GST-reactive antibodies (results 
not shown). Following purification, while both antisera yielded a strong signal 
corresponding to the predicted 34 kDa GST-GR fusion protein, no signal (Ig8) or one of 
only relatively low intensity (Ig7) was detected corresponding to the 28 kDa GST 
protein, thus confirming that the GST-reactive antibodies had been removed (figure 
A.7.). Interestingly, an immunoreactive species of 74 kDa was detected in both the GR- 
GST and the GST extracts by the purified Ig7 antisemm. This is likely to reflect a 
bacterial protein co-purified with the fusion protein by the glutathione beads, as a similai" 
species has been detected in our laboratory with a different fusion protein which was 
purified by the same method (Dr. I. Wilkinson, personal communication).
Unfortunately, despite the detection of the GR-GST fusion protein by both the Ig7 and
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Ig8 antisera following purification, no immunoreactive species were detected by either of 
the two antisera in the hepatocyte or COS cell extracts (figure A.7.).
A.3. Testing the ability o f fusion protein antisera to 
immunoprecipitate the GR
The antisera were also tested for their ability to immunoprecipitate the GR, as 
measured by a -glucagon binding assay, from a hepatocyte membrane fraction. It 
was found however that the binding activity immunoprecipitated by neither of the antisera 
was significantly greater than that obtained with the pre-immune sera (figure A.8 .).
A,4. Phosphatase treatment o f membrane proteins prior to 
im m unoblotting
The possibility was considered that phosphorylation of the C-terminal tail of the 
GR by a cellular kinase may have prevented recognition by the antisera Ig7 and Ig8 , 
which were raised against a fusion protein containing the sequence corresponding to this 
region. To address this hypothesis, 200 pg of membrane proteins prepared from either 
untransfected or GR cDNA-transfected COS cells were treated, where indicated, in a total 
volume of 100 pi with 20 units of alkaline phosphatase for 1 hour. This was done 
following a 15 min pre-incubation either at 70 °C to inactivate any kinases isolated with 
the membranes, or on ice (control). These samples were then immunoblotted as before 
with Ig7 and Ig8 antisera. Despite these tieatments, no immunoreactive species of a 
MWt corresponding to the GR became detectable with either of the antisera in the 
transfected COS cells (figure A.9.).
A.5. Re-coupling o f peptides to the carrier molecule KLH
To address the possibility that the previous conjugation of the peptides to the carrier 
molecule, KLH, may have been ineffective, the work undertaken by a previous worker 
in our laboratory was repeated. The peptides corresponding to sequences within the C- 
terminal tail of the GR (peptides 4 and 5) were chosen to undergo this process. This
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conjugation was done using a modification (as described in section 2.3.2.2.) of the 
protocol utilised previously in order to allow more time for the coupling of the hapten to 
the carrier.
The coupled peptides was then injected into male New Zealand White rabbits in 
complete Freund's adjuvant, and again, 10 and 21 days later, in incomplete Freund's 
adjuvant. The antisera obtained 10 days later were tested by immunoblotting. While 
these antisera detected a number of immunoreactive species in both GR-transfected and 
untransfected COS cell, no species was detected in the transfected cells with the intensity 
predicted for an over-expressed protein (figure A. 10.A and B).
but some other cross-reacting protein.
Discussion
In testing the antisera raised against peptides corresponding to regions of the GR 
amino acid sequence, it was found that the antisemm derived from rabbit YE627 detected 
an immunoreactive species in hepatocytes of an apparent MWt similar to that of the GR.
It could, perhaps, be envisaged that the inability to block the detection of this species by 
the prior incubation of the antiserum with the peptide against which the antisemm was 
raised, was the result of the possible adoption of a different conformation by this peptide 
in solution from that which it adopts when conjugated to KLH. However, the pre­
incubation of an antisemm with the peptide against which it was raised prior to 
immunoblotting is a method which has been used, for example, to demonstrate the 
specificity of PKC isofoim-specific antisera in our laboratoiy (Tang et al, 1993) and by 
others (Wetsel et al, 1992).
Furthermore, the subsequent inability of this antisemm to detect the GR expressed 
in transfected COS cells more strongly than in untransfected COS cells, together with the
■inability of peptide competition to block the detection of the hepatocyte protein by this 
antisemm, suggests that the species detected by this antisemm was not, in fact, the GR i
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It is intriguing that none of the antisera raised against the peptides or the fusion 
protein was able to detect an immunoreactive species of the MWt of the GR more 
strongly in COS cells tr ansfected with the cDNA encoding the GR than in control COS 
cells. This may be due to one or more of a number of possible reasons. For instance it 
is conceivable that the antisera do recognise epitopes of the GR but that these antigenic 
determinants are masked by one or more post-translational modifications. One such 
modification, glycosylation of the receptor, is indeed known to occur, as evidenced by 
the step-wise increase in electrophoretic mobility of the GR which follows endo-p-N- 
acetylglucosaminidase F treatment of the receptor (Iyengar and Herberg, 1984) and by 
the presence of potential sites for glycosylation in the extracellular', N-terminal region of 
the amino acid sequence of the rat hepatic GR. While such glycosylation of the receptor, 
might prevent recognition of extracellular epitopes by antisera raised against peptides 1-3 
it should not have prevented those antisera raised against peptides 4, peptide 5 and the 
fusion protein, from interacting with the antigenic determinants located on the 
intracellular aspect of the receptor.
Altei'natively, phosphorylation of the receptor in a manner similar to that known to 
occur for other G-protein coupled receptors (GPCRs), might be envisaged to block 
recognition of epitopes located on the intracellular loops and C-tei'minal tail of the 
receptor. However, alkaline phosphatase treatment of hepatocyte membranes did not 
lead to the detection of the GR by either of the antisera raised against the fusion protein, 
implying that the failuie of these antisera to successfully immunoblot the GR was not a 
result of stearic hindrance of the interaction by phosphate groups. An additional manner 
in which antigenic determinants might be obscured is by lipid modification of the 
receptor. Indeed, it is believed that, in several GPCRs, palmitoylation of one or more 
cysteine residues in the C-tei'minal region of the receptor occurs, and that such lipid 
moieties may even insert themselves into the plasma membrane in such a manner as to 
create a fourth intracellular loop (Baldwin, 1994). The rat hepatic GR does, in fact, 
contain thiee cysteines in the C-terminal tail at positions 444,449 or 465 of the open 
reading frame, but they do not reside in sequences that confoim to the consensus for
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palmitoylation. Finally, as immunoblotting was performed under denaturing conditions, 
in the presence of the reducing agent, p-mercaptoethanol, it is unlikely that the epitopes 
were masked by secondary or tertiaiy protein structure, nor by any possible complex 
formation with, for example, the G protein, Gs.
Rather than the epitopes of the GR being masked, it is possible that the peptides 
failed to act as effective immunogens. This is unlikely to be due to inadequate length of 
the sequences as although four of the peptides were 12 amino acids or less, the other was 
of 16 residues in length. One possibility is that the peptide synthesis was incomplete, 
resulting in two or more species of individual peptides, of vaiying lengths. However, 
HPLC analysis performed recently on these peptides at the author’s request, indicated 
that this was not the case, with only a single peak recorded for each peptide. 
Alternatively, it is conceivable that the coupling process, itself, failed to result in effective 
conjugation of the peptide to the cairier molecule, KLH, resulting in the presence of only 
unconjugated hapten.
It was, perhaps, not surprising that none of the antisera raised against the peptides 
or the fusion protein was able to detect the glucagon receptor effectively, in view of the 
paucity of available antisera to any GPCR. In fact, in instances when the successful 
immunodetection of such receptors has been described this has been by virtue of the 
incorporation of epitope tags into the respective coding sequences (Oppermann et al, 
1996). This strategy was employed in the work described in chapter 3.
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Table A.I. Amino acid sequences and corresponding locations of the 
synthetic peptides based on the primary sequence of the glucagon receptor
Peptide Length Sequence (residues) Location on GR R abbit
1 12 YSQKIGDDLSVS(C) (203-214) extracellular loop 619+620
2 12 WTSNDNMGFWWI(C) (296-307) extracellular loop 2 621+622
3 9 AQGTLRSTK(C) (374-382) extracellular loop 3 623+624
4 10 SLPRLADSPT(C) (476-485) C terminal tail (distal) 625+626
5 16 AELLRRWRRWQEGKAL(C) (410-425) C terminal tall (proximal) 627+628
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,'ÿ‘"Figure A.I. Immunoblot of liver membranes using as primary antibody 
either pre-immune serum or an antiserum raised against peptide 4 of the 
glucagon receptor
100 pg (lane 1) or 400 jiig (lane 2) of liver plasma membrane proteins were boiled 
in Laemmli sample buffer and subjected to electrophoresis on an 8% polyacrylamide SDS 
gel prior to transfer to niti ocellulose and blocking in 5% (w/v) diied milk protein. The 
nitrocellulose blots were then incubated for 2  hours at room temperature with either pre- 
immune (A) or immune (B) serum of rabbit YE625, diluted 1 in 100. Following the 
removal of unhybridised antibodies by successive washing, the blots were incubated in 
HRP-conjugated anti-rabbit IgG, and detection performed by enhanced 
chemiluminescence.
2 6 1
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Figure A.2. Immunoblot of liver membranes using as primary antibody 
either pre-immune serum or an antiserum raised against peptide 5 of the 
glucagon receptor
100 jxg (lane 1) or 400 pg (lane 2) of liver plasma membrane proteins were boiled 
in Laemmli sample buffer and subjected to electrophoresis on an 8% polyacrylamide SDS 
gel prior to transfer to nitrocellulose and blocking in 5% (w/v) dried milk protein. The 
nitrocellulose blots were then incubated for 2  hours at room temperature with either pre- 
immune (A) or immune (B) serum of rabbit YE627, diluted 1 in 100. Following the 
removal of unhybridised antibodies by successive washing, the blots were incubated in 
HRP-conjugated anti-rabbit IgG, and detection performed by enhanced 
chemiluminescence. The arrow indicates the immunoreactive species considered to 
possibly represent the glucagon receptor.
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Figure A.3, The effect of peptide competition on immunodetection by
YE627 antiserum
400 pg (lane 1) or 100 pg (lane 2) of liver plasma membrane proteins were boiled 
in Laemmli sample buffer and subjected to electrophoresis on an 8% polyacrylamide SDS 
gel prior to transfer to nitrocellulose and blocking in 5% (w/v) dried milk protein. The 
nitrocellulose blots were then incubated for 2 hours at room temperature with the immune 
serum of rabbit YE627 following pre-incubation of the anti-serum with either peptide 4 
(A) or the peptide against which the antisemm was raised, peptide 5 (B). Such pre­
incubations were done by mixing the anti-semm with a 1 mg/ml solution of the peptide in 
the ratio 1:1, and leaving for 1 hour, as described previously (Tang et al, 1993). 
Following incubation of the nitrocellulose with the primary antibody, unhybridised 
antibodies were removed by successive washing, the blots were incubated in HRP- 
conjugated anti-rabbit IgG, and detection was performed by enhanced 
chemiluminescence. The arrow indicates the immuno-reactive species which was 
detected despite the pre-incubation with the specific peptide.
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Figure A.4. Iramunoblot of COS cell extracts using as primary antibody 
either pre-immune serum or an antiserum raised against peptide 5 of the 
glucagon receptor
From COS-7 cells which were either glucagon receptor cDNA-transfected (lanes 1, 
3 and 5) or mock-transfected (lanes 2 ,4  and 6), 100 }ig of protein of crude lysate (lanes 
1 and 2), membranes (lanes 3 and 4) or cytosol (lanes 5 and 6) were boiled in Laemmli 
sample buffer and subjected to electrophoresis on an 8% polyacrylamide SDS gel. 
Subsequently, the proteins were transferred to nitrocellulose and blocking was performed 
by incubation in 5% (w/v) dried milk protein. The nitrocellulose blots were then 
incubated for 2 hours at room temperature with either immune (A) or pre-immune (B) 
semm of rabbit YE627, diluted 1 in 100. Following the removal of unhybridised 
antibodies by successive washing, the blots were incubated in HRP-conjugated anti­
rabbit IgG, and detection performed by enhanced chemiluminescence. The arrow 
indicates the immuno-reactive species discussed in the text, which was detected more 
strongly by the immune than the pre-immune serum, but was equally intense in the 
extracts of the transfected and control COS cells.
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Figure A.5. Immunoblots of COS cell extracts using as primary 
antibodies, antisera YE621, YE622, YE625 and YE628
From COS-7 cells which were either mock-transfected (lanes 1) or glucagon 
receptor cDNA-transfected (lanes 2), 100 |Xg of protein of crude lysate was boiled in 
Laemmli sample buffer and subjected to electrophoresis on an 8% polyacrylamide SDS 
gel. Subsequently, the proteins were transferred to nitrocellulose and blocking was 
performed by incubation in 5% (w/v) dried milk protein. The nitrocellulose blots were 
then incubated for 2 hours at room temperature with antisemm from rabbit YE621 (A), 
YE622 (B), YE625 (C) or YE628 (D), diluted 1 in 100. These antisera had been raised 
against GR peptides 2, 2, 4 and 5, respectively. Following the removal of unhybridised 
antibodies by successive washing, the blots were incubated in HRP-conjugated anti­
rabbit IgG, and detection performed by enhanced chemiluminescence. In each case, the 
immuno-reactive species were observed to be of equal intensity in the exti acts of the 
transfected and control COS cells.
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Figure A.6. Protein-staining of hepatocyte membranes and COS cell 
extracts, confirming the expression of transfected glucagon receptor 
cDNA
From crude lysates of COS-7 cells which had been either mock-transfected (lanes 
2) or transfected with the glucagon receptor cDNA (lane 3), and from a plasma 
membrane preparation of rat hepatocytes (lane 1), 100 pg of protein was boiled in 
Laemmli sample buffer and subjected to electrophoresis on an 8% polyacrylamide SDS
,gel. Subsequently, the proteins were transferred to nitrocellulose, which was then rinsed
with water, and stained with Ponceau solution. The aiTow indicates the only protein 
species to be detected in transfected but not in control COS cells.
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Figure A.7. Immunoblots of hepatocyte and COS ceil extracts using as 
primary antibody an antiserum raised against a GST-GR fusion protein
A 12% polyacrylamide SDS gel was loaded with samples of hepatocyte membranes 
(lane 1), transfected (lane 2) and control (lane 3) COS-7 cells lysates, purified GST (lane 
4) and GST-GR fusion protein (lane 5), the P2 fraction of control (lane 7) and transfected 
COS cells (lane 8), and the Pi fraction of control (lane 9) and transfected cells (lane 10), 
In each case an aliquot containing 100 |Lig of protein (but only 30 p,g of the purified 
GST proteins) was boiled in Laemmli sample buffer prior to loading. 10 jxg of protein 
molecular weight markers was also loaded (lane 6). Following electrophoresis, the 
proteins were transferred to nitrocellulose and blocking was performed by incubation in 
5% (w/v) dried milk protein. The nitrocellulose blots were then incubated for 2 hours at 
room temperature with GST-purified antiserum from rabbit Ig7 (A) or IgS (B), diluted 1 
in 200. Following the removal of unhybridised antibodies by successive washing, the 
blots were incubated in HRP-conjugated anti-rabbit IgG, and detection performed by 
enhanced chemiluminescence. The arrows indicate the 34 kDa GST-GR species 
discussed in the text, which was detected much more strongly than the 28 kDa GST 
protein species, by both antisera.
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Figure A.8. [l^^Ij-glucagon specific binding following 
immunoprécipitation from hepatocyte membranes using the antisera raised 
against a GST-GR fusion protein
The source material for the specific immunoprécipitation of -glucagon binding 
activity was a hepatocyte membrane fraction (1.75 mg of starting material) solubilised by 
CHAPS detergent. The solubilisation mixture comprised 25 mM HEPES pH 7.5,
137 mM NaCl, 2 mM EDTA pH 8.0, 6 mM CHAPS and Ix protease inhibitor 
"cocktail" (see section 2.3.3.). After a period of 30 min on ice, during which the 
constituents were agitated every 10 min, any unsolubilised membranes were pelleted by 
centrifugation at 245,000 gav for 30 min at 4  °C. Antiserum (either pre-immune serum, 
or the Ig7 or IgS antiserum raised against the GST-GR fusion protein) was added to each 
sample of the supernatant at a dilution of 1:50 and the samples briefly vortexed before 
being left overnight at 4 °C in order to allow conjugation to occur. Pansorbin was then 
added to a final concentration of 2% w/v, and the resultant suspension gently mixed at 
4 ®C for 2 h. The preparations were then centrifuged at 14,000g for 2 min and the 
pellets were resuspended in the immunoprécipitation buffer (25 mM HEPES pH 7.5,
137 mM NaCl, 2 mM EDTA pH 8.0 and Ix protease inhibitors) before being 
recentrifuged as before. The resultant pellets were then washed twice more.
The final pellet was resuspended in binding assay buffer and assayed immediately 
for specific glucagon binding as described previously (Houslay et al, 1977). Briefly,
40 p,l of each immunoprecipitate was incubated in a final reaction volume of 100 pi 
containing 0.1% (w/v) BSA, 1 mM-EDTA, 20 mM-Tris.HCl pH 7.5 (binding buffer), 
and 0.2 nM [125i]_giucagon. Non-specific binding was determined by the addition of 
1 pM unlabelled glucagon. Incubations were undertaken for 20 min at 32 °C. The 
reactions were teiminated by the addition of 3 ml ice-cold binding buffer and the diluted 
samples immediately filtered through 0.45-pm cellulose acetate filters which had been 
soaked in 10% BSA overnight and washed with 2 ml ice-cold binding buffer. The tubes 
were rinsed twice with 3 ml ice-cold binding buffer and the rinses filtered. The filters 
were then washed finally with 6 ml ice-cold binding buffer and the radioactivity bound 
to them was measured using a y counter.
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Figure A.9. Immunoblots of COS cell membrane fractions following 
phosphatase treatment using an antiserum raised against a GST-GR fusion 
protein
200 pg of membrane proteins prepared from either untransfected (lanes 1, 2, 6 and 
7) or GR cDNA-transfected COS cells (lanes 3,4, 8 and 9) were treated in a total volume 
of 100 pi with 20 units of alkaline phosphatase for 1 hour (lanes 2, 4 ,7  and 9) or in 
buffer alone (lanes 1, 3, 6 and 8). This was done following a 15 min pre-incubation at 
70 °C to inactivate any kinases isolated with the membranes (lanes 1-4), or on ice (lanes 
6-9).
After boiling in Laennnli sample buffer, these samples were loaded on an 8% 
polyacrylamide SDS gel. 10 pg of protein molecular weight markers was loaded in lane 
5. Following electrophoresis, the proteins were transfeiTed to nitrocellulose and 
blocking was performed by incubation in 5% (w/v) dried milk protein. The 
nitrocellulose blots were then incubated for 2 hours at room temperature with GST- 
purified antiserum from rabbit IgS, diluted 1 in 200. Following the removal of 
unhybridised antibodies by successive washing, the blots were incubated in HRP- 
conjugated anti-rabbit IgG, and detection performed by enhanced chemiluminescence. A 
similar blot was also probed with the antiserum from rabbit Ig7, but no immunoreactive 
species were detected.
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Figure A. 10. Immunoblots of COS cell extracts using antisera raised 
against re-conjugated peptide 4 and peptide 5 of the glucagon receptor
From COS-7 cells which were either glucagon receptor cDNA-transfected (lanes 2) 
or mock-tiansfected (lanes 1), 100 pg of protein of crude lysate was boiled in Laemmli 
sample buffer and subjected to electrophoresis on an 8% polyacrylamide SDS gel. 
Subsequently, the proteins were transferred to nitrocellulose and blocking was performed 
by incubation in 5% (w/v) dried milk protein. The nitrocellulose blots were then 
incubated for 2 hours at room temperature with an antisemm raised against either re­
conjugated peptide 4 (A) or peptide 5 (B) of the glucagon receptor, diluted 1 in 100. 
Following the removal of unhybridised antibodies by successive washing, the blots were 
incubated in HRP-conjugated anti-rabbit IgG, and detection performed by enhanced 
chemiluminescence.
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MIVlESÏÏf I UBRABY IAPPENDIX B
Amino acid sequence of the rat hepatic glucagon receptor
MLLTQLHCPY LLLLLWLSC LPKAPSAQVM DFLFEKWKLY SDQCHHNLSL 50
*
LPPPTELVCN RTFDKYSCWP DTPPNTTANI SCPWYLPWYH KVQHRLVFKR 100* * *
CGPDGQWVRG PRGQSWRDAS QCQMDDDEIE VQKGVAKMYS SYOVMYTVGY 150
TMl
SLSLGALLLA LVILLGLRKL HCTRNYIHGN LFASFVLKAG SVLVIDWLLK 200
TM2
TRYSQKIGDD LSVSVWLSDG AVAGCRVATV IMOYGIIANY CWLLVEGVYL 250
TM3
YSLLSITTFS EKSFFSLYLC IGWGSPLLFV IPWWVKCLF ENVQCWTSND 300
TM4
NMGFWWILRI PVLLAILINF FIFVRITHLL VAKLRAHOMH YADYKFRLAR 350
TM5
STLTLIPLLG VHEWFAFVT DEHAQGTLRS TKLFFDLFFS SFQGLLVAVL 400
TM6 TM7
YCFLNKEVOA ELLRRWRRWQ EGKALQEERM ASSHGSHMAP AGTCHGDPCE 450
#
KLQLMSAGSS SGTGCEPSAK TSLASSLPRL ADSPT 485 |
The peptide sequence of the rat hepatic glucagon receptor (Genbank Accession No. L04796) is 
shown. The ammo acids contained within the seven putative transmembrane domains (TMl-7) are 
underlined. The four sites of asparagine-linked glycosylation in the amino-terminal domain are 
indicated with asterisks while the putative PKD phosphorylation site at serine 432 in the carboxy- 
terminal tail is indicated by a hadi symbol.
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